

**2026 ANNUAL REPORT OF  
THE BOARDS OF TRUSTEES OF THE  
FEDERAL HOSPITAL INSURANCE AND  
FEDERAL SUPPLEMENTARY MEDICAL INSURANCE  
TRUST FUNDS**

**COMMUNICATION**

**From**

**THE BOARDS OF TRUSTEES,  
FEDERAL HOSPITAL INSURANCE AND  
FEDERAL SUPPLEMENTARY MEDICAL INSURANCE  
TRUST FUNDS**

**Transmitting**

**THE 2026 ANNUAL REPORT OF  
THE BOARDS OF TRUSTEES OF THE  
FEDERAL HOSPITAL INSURANCE AND  
FEDERAL SUPPLEMENTARY MEDICAL INSURANCE  
TRUST FUNDS**



**LETTER OF TRANSMITTAL**

---

**BOARDS OF TRUSTEES OF THE  
FEDERAL HOSPITAL INSURANCE AND  
FEDERAL SUPPLEMENTARY MEDICAL INSURANCE TRUST FUNDS,  
Washington, D.C., June 9, 2026**

HONORABLE MIKE JOHNSON,  
*Speaker of the House of Representatives*

HONORABLE JD VANCE,  
*President of the Senate*

DEAR MR. SPEAKER AND MR. PRESIDENT:

We have the honor of transmitting to you the 2026 Annual Report of the Boards of Trustees of the Federal Hospital Insurance Trust Fund and the Federal Supplementary Medical Insurance Trust Fund, the 61st such report.

Respectfully,

SCOTT BESSENT,  
*Secretary of the Treasury,  
and Managing Trustee of the Trust Funds.*

KEITH E. SONDERLING,  
*Acting Secretary of Labor,  
and Trustee.*

ROBERT F. KENNEDY, JR.,  
*Secretary of Health and Human Services,  
and Trustee.*

FRANK J. BISIGNANO,  
*Commissioner of Social Security,  
and Trustee.*

VACANT,  
*Public Trustee.*

VACANT,  
*Public Trustee.*

MEHMET C. OZ, MD,  
*Administrator,  
Centers for Medicare & Medicaid Services,  
and Secretary, Boards of Trustees.*



## CONTENTS

I. INTRODUCTION.....	1
II. OVERVIEW .....	6
A. Highlights.....	6
B. Medicare Data for Calendar Year 2025.....	12
C. Medicare Assumptions .....	14
D. Financial Outlook for the Medicare Program .....	21
E. Financial Status of the HI Trust Fund .....	27
F. Financial Status of the SMI Trust Fund .....	34
G. Conclusion .....	44
III. ACTUARIAL ANALYSIS .....	47
A. Introduction.....	47
B. HI Financial Status .....	48
1. Financial Operations in Calendar Year 2025.....	48
2. 10-Year Actuarial Estimates (2026–2035) .....	54
3. Long-Range Estimates.....	63
4. Long-Range Sensitivity Analysis .....	75
C. Part B Financial Status.....	80
1. Financial Operations in Calendar Year 2025.....	80
2. 10-Year Actuarial Estimates (2026–2035) .....	87
3. Long-Range Estimates.....	100
D. Part D Financial Status .....	102
1. Financial Operations in Calendar Year 2025.....	102
2. 10-Year Actuarial Estimates (2026–2035) .....	106
3. Long-Range Estimates.....	116
IV. ACTUARIAL METHODOLOGY AND PRINCIPAL ASSUMPTIONS	119
A. Hospital Insurance .....	119
B. Supplementary Medical Insurance.....	131
1. Part B.....	131
2. Part D.....	144
C. Private Health Plans .....	155
D. Long-Range Medicare Cost Growth Assumptions.....	166
V. APPENDICES.....	175
A. Medicare Amendments since the 2025 Report .....	175
B. Total Medicare Financial Projections.....	185
C. Illustrative Alternative Projections.....	197
D. Average Medicare Expenditures per Beneficiary.....	202
E. Medicare Cost-Sharing and Premium Amounts.....	205
F. Medicare and Social Security Trust Funds and the Federal Budget.....	214
G. Infinite Horizon Projections.....	221
H. Fiscal Year Historical Data and Projections through 2035.....	228
I. Glossary .....	239
List of Tables .....	260
List of Figures.....	264
Statement of Actuarial Opinion .....	265



## I. INTRODUCTION

The Medicare program helps pay for health care services for people aged 65 and older, as well as individuals with a disability, end-stage renal disease (ESRD), or Amyotrophic Lateral Sclerosis (also called ALS or Lou Gehrig's disease). It has two separate trust funds, the Hospital Insurance trust fund (HI) and the Supplementary Medical Insurance trust fund (SMI).

HI, otherwise known as Medicare Part A, helps pay for inpatient hospital services, hospice care, and skilled nursing facility (SNF) and home health services following hospital stays. SMI consists of Medicare Part B and Part D. Part B helps pay for physician, outpatient hospital, home health, and other services for individuals who have voluntarily enrolled. Part D provides subsidized access to drug insurance coverage on a voluntary basis for all beneficiaries. It also provides premium and cost-sharing subsidies for low-income enrollees.

Medicare also has a Part C, which serves as an alternative to traditional Part A and Part B coverage. Under this option, beneficiaries can choose to enroll in and receive care from private Medicare Advantage and certain other health insurance plans. Medicare Advantage and Program of All-Inclusive Care for the Elderly (PACE) plans receive prospective, *capitated payments*<sup>1</sup> for these beneficiaries from the HI and SMI Part B trust fund accounts. The other plans are paid from the accounts on the basis of their costs.

The Social Security Act established the Medicare Board of Trustees to oversee the HI and SMI trust funds' financial operations.<sup>2</sup> The Board has six members. Four members serve by virtue of their positions in the Federal Government:

- The Secretary of the Treasury, who is the Managing Trustee;
- The Secretary of Labor;
- The Secretary of Health and Human Services; and
- The Commissioner of Social Security.

Two other members are public representatives whom the President appoints and the Senate confirms. These positions have been vacant

---

<sup>1</sup>Any term that appears in the glossary is italicized the first time it is used in the text.

<sup>2</sup>The Social Security Act established separate boards for HI and SMI. Both boards have the same membership, so they are collectively referred to as the Medicare Board of Trustees in this report.

## *Introduction*

since 2015. The Administrator of the Centers for Medicare & Medicaid Services (CMS) serves as Secretary of the Board.

The Social Security Act requires that the Board report annually to Congress on the financial and actuarial status of the HI and SMI trust funds. The 2026 report is the 61st that the Board has submitted.

## **Exceptions to Current Law in Projections**

With two exceptions, the projections in this report are based on the Social Security Act's current-law provisions.

The first exception is that the Part A projections disregard payment reductions that would occur if the Medicare HI trust fund became depleted. Under current law, payments would be reduced to levels that could be covered by incoming tax and premium revenues when the HI trust fund was depleted. If the projections reflected such payment reductions, then any imbalances between payments and revenues would be automatically eliminated, and this report would not fulfill one of its critical functions, which is to inform policymakers and the public about the size of any trust fund deficits that would need to be resolved to avert program insolvency. To date, lawmakers have never allowed the Medicare HI trust fund to become depleted.

The second exception is that the elimination of the safe harbor protection for manufacturer rebates, which was finalized in a rule released in November 2020, is not reflected in the Part D projections. This final rule imposed a January 1, 2022, effective date. However, implementation was initially delayed until January 1, 2023. Since then, legislation has delayed implementation three times, and it is currently delayed until January 1, 2032. Therefore, the likelihood of this rule taking effect is highly uncertain.

## **COVID-19 Pandemic Effects**

The COVID-19 pandemic is no longer projected to have a significant impact on the Medicare program. Fee-for-service per capita spending has stabilized and the Trustees rely more on recent experience when developing the cost projections. The only remaining adjustment is to account for the surviving population's morbidity improvement, which is expected to continue to affect spending levels through 2029.

## **Uncertainty of Projections and Other Challenges**

Projections of Medicare costs are highly uncertain, especially when looking out more than several decades, partially because scientific

## Introduction

advances will make new interventions, procedures, and therapies possible. Some conditions that are untreatable today may be handled routinely in the future. Spurred by economic incentives, the institutions through which care is delivered will evolve, possibly becoming more efficient. While most health care technological advances to date have increased expenditures, the health care landscape is shifting. No one knows whether future developments will increase or decrease costs.

Certain features of current law may result in some challenges for the Medicare program. For example, physician payment update amounts are specified for all future years. These amounts do not vary based on underlying economic conditions, and they are not expected to keep pace with the average rate of physician cost increases. These rate updates could be an issue in years when levels of inflation are high and would be problematic when the cumulative gap between the price updates and physician costs becomes large. Payment rate updates for most non-physician Medicare provider categories are reduced by the growth in economy-wide private nonfarm business total factor productivity.<sup>3</sup> However, these health providers have historically achieved lower levels of productivity growth.

If the health sector cannot transition to more efficient care delivery and if the provider reimbursement rates paid by commercial insurers continue to be based on the same negotiated process, then the availability, particularly with respect to physician services, and quality of health care received by Medicare beneficiaries will, under current law, fall over time compared to that received by those with private health insurance.

Additionally, the difference in the rate of growth in health care costs and the rate of growth in the overall economy presents uncertainty. Since 1960, U.S. national health expenditure growth rates have typically outpaced economic growth rates. However, the magnitude of the differences has been declining, particularly over the last 15 years. There is some debate on whether this recent narrowing reflects the impact of factors that are mostly cyclical in nature, such as economic growth, or factors that are more permanent, such as structural changes to the health sector. The Trustees assume that the long-range national health expenditure growth differential will continue to narrow,

---

<sup>3</sup>The term *economy-wide private nonfarm business total factor productivity* will now be referred to as *economy-wide productivity*. Beginning with the November 18, 2021, release of the productivity data, the Bureau of Labor Statistics (BLS) replaced the term *multifactor productivity* with the term *total factor productivity*, a change in name only, as the underlying methods and data were unchanged.

*Introduction*


consistent with the trajectory observed over the past half century. They also assume that the cost-reduction provisions required under current law will further decrease this gap.

**Summary of Projections**

Current-law projections indicate that Medicare still faces a substantial financial shortfall that needs to be addressed with further legislation. Such legislation should be enacted sooner rather than later to minimize the impact on beneficiaries, providers, and taxpayers.

Figure I.1 shows Medicare’s projected expenditures as a percentage of the Gross Domestic Product (GDP) under two sets of assumptions: current law and an illustrative alternative, described below.<sup>4</sup>

**Figure I.1.—Medicare Expenditures as a Percentage of the Gross Domestic Product under Current Law and Illustrative Alternative Projections**



Note: Percentages are affected by economic cycles.

<sup>4</sup>A set of illustrative alternative Medicare projections has been prepared under a hypothetical modification to current law. A summary of the projections under the illustrative alternative is contained in section V.C of this report, and a more detailed discussion is available at <https://www.cms.gov/files/document/illustrative-alternative-scenario-2026.pdf>. Readers should not infer any endorsement of the policies represented by the illustrative alternative by the Trustees, CMS, or the Office of the Actuary. Section V.C also provides additional information on the uncertainties associated with productivity adjustments to specific provider payment updates and the scheduled physician payment updates.

## Introduction

The expenditure projections reflect the cost-reduction provisions required under current law but not the payment reductions and/or delays that would result from the HI trust fund depletion, which is projected in this report to occur in 2033. At that point, HI revenues are projected to cover 89 percent of incurred program costs.

The illustrative alternative shown in the top line of figure I.1 assumes the following:

- There would be a transition from current-law<sup>5</sup> payment updates for providers affected by the economy-wide productivity adjustments to payment updates that reflect adjustments for health care productivity; and
- The average physician payment updates would transition from current law<sup>6</sup> to payment updates that reflect the *Medicare Economic Index*.

The difference between the illustrative alternative and the current-law projections continues to demonstrate that the long-range costs could be substantially higher than shown throughout much of the report if the cost-reduction measures prove problematic and new legislation scales them back.

As figure I.1 shows, Medicare's costs under current law rise steadily from their current level of 3.9 percent of GDP in 2025 to 6.5 percent in 2050. Costs then rise more slowly before leveling off at around 7.5 percent in the projection period's final 25 years. Under the illustrative alternative, projected costs would continue rising steadily throughout the projection period, reaching 7.0 percent of GDP in 2050 and 9.8 percent in 2100.

Medicare's actual future costs are highly uncertain for reasons apart from the inherent challenges in projecting health care cost growth over time. The Board recommends that readers interpret the current-law estimates in the report as the financial outcome under the Trustees' economic and demographic assumptions if the required cost-reduction provisions can be sustained. Readers should review section V.C for more information on this important subject. The key financial outcomes under the illustrative alternative scenario are shown with the current-law projections throughout this report.

---

<sup>5</sup>Medicare's annual payment rate updates for most categories of provider services would be reduced below the increase in providers' input prices by the growth in economy-wide productivity (1.0 percent over the long range).

<sup>6</sup>The law specifies physician payment rate updates of 0.75 percent or 0.25 percent annually thereafter for physicians in advanced alternative payment models (advanced APMs) or the merit-based incentive payment system (MIPS), respectively. These updates are notably lower than the projected physician cost increases, which are assumed to average 2.05 percent per year in the long range.

## II. OVERVIEW

### A. HIGHLIGHTS

The major findings of this report under the intermediate set of assumptions appear below. The rest of the overview and the following actuarial analysis section describe these findings in more detail.

The non-health-specific intermediate assumptions for this report were set in February 2026. The Trustees will continue to monitor developments, reevaluate the assumptions, and modify the projections in later reports.

#### *Notable Assumption, Policy, and Law Changes*

The economic and demographic assumptions underlying the projections of HI and SMI costs shown in this report are consistent with those in the 2026 Annual Report of the Board of Trustees of the Federal Old-Age and Survivors Insurance and Federal Disability Insurance (OASDI) Trust Funds. Section II.A of that report describes notable assumption changes in more detail.

Part B spending for skin substitutes increased from \$0.8 billion in 2021 to \$14.1 billion in 2025 because of much higher average prices and increased utilization. The 2026 physician fee schedule final rule includes significant policy changes to skin substitute payments starting in 2026. The Trustees project that spending for skin substitutes will decline by more than 90 percent in 2026 as a result of the policy changes in this rule.

The Part D expenditures are significantly higher than those in last year's report in all years. This is mainly due to increases in the utilization of *GLP-1* and expensive specialty drugs in 2025. Additionally, projected growth is higher than in last year's report because of higher cost trends and lower projected direct and indirect remuneration (DIR) through the short-range period.

Three laws have been enacted that have an effect on the Medicare trust funds. See section V.A for more information on the relevant provisions.

The One Big Beautiful Bill Act (OBBBA) makes permanent the lower income tax rates and adjusted tax brackets originally enacted under the 2017 Tax Cuts and Jobs Act and both increases and makes permanent the larger standard deduction of the 2017 Act. The OBBBA also adds a temporary additional standard deduction for taxpayers over age 65. As a result, less income tax will be paid on Social Security

## *Highlights*

benefits, and the HI trust fund will receive lower levels of revenue in the future from income taxation of Social Security benefits. The Trustees will continue to consider effects of OBBBA or any other legislation on trust fund finances and adjust projections in future reports as necessary.

### ***2025 in Review***

During 2025, an estimated 69.3 million people were enrolled in Medicare: 62.2 million aged 65 and older, and 7.1 million disabled. About 51 percent of these beneficiaries have chosen to enroll in Part C private health plans that contract with Medicare to provide Part A and Part B health services.

Total Medicare expenditures were \$1,210.1 billion and income was \$1,226.2 billion in 2025.

Total HI income in 2025 was \$462.4 billion and exceeded expenditures by \$18.2 billion. The assets were \$255.7 billion at the beginning of 2026.

Total SMI income in 2025 was \$763.8 billion and expenditures were \$765.8 billion, resulting in a net decrease in assets of \$2.1 billion.

More details on these operations are available in the following section.

### ***Actuarial Estimates***

The Trustees make actuarial estimates for a 75-year period (2026 through 2100 for this year's report), which fully allows for the presentation of anticipated future developments, such as the impact of the large increase in enrollees from 2010 through 2031. This increase in the number of beneficiaries will occur because the relatively large number of persons born during the period between the end of World War II and the mid-1960s (known as the baby boom generation) will reach eligibility age and begin to receive benefits. Moreover, as this generation ages, these individuals will experience greater health care utilization and costs, thereby adding further to growth in program expenditures.

### ***HI Key Results***

Table II.A1 presents the key results for the HI program. These results are explained in more detail later in this report.

## Overview

**Table II.A1.—HI Key Results**  
[Under intermediate assumptions]

Year of projected trust fund reserve depletion	2033
Percent of annual cost payable after reserve depletion:	
For year of reserve depletion	89
For 2100	93
75-year actuarial balance (percentage of taxable payroll)	-0.56

Note: Under the illustrative alternative scenario, the annual cost payable after reserve depletion in 2100 is 62 percent and the actuarial balance is -1.38 percent of taxable payroll.

### ***a) Trust Fund Reserves and Reserve Depletion***

Trust fund reserves for the HI program, along with projected program income, are sufficient to cover the projected costs of the program over the next 7 years under the intermediate (best estimate) assumptions.

The HI trust fund is projected to become depleted in the second quarter of 2033, which is one quarter earlier than projected in last year's report. Upon reserve depletion in 2033, projected income is sufficient to pay 89 percent of scheduled benefits. This percentage increases gradually to 93 percent by 2100. Details are provided in section II.E.

### ***b) Trust Fund Ratios***

The annual trust fund ratio is equal to trust fund reserves at the beginning of a year expressed as a percentage of program cost during that year. The HI trust fund ratio is projected to decline from 53 percent at the beginning of 2026 until reserves become depleted in 2033.

Two tests, both involving trust fund ratios, are used to assess the financial adequacy of the trust funds: the short-range test of financial adequacy and long-range test of close actuarial balance. The Trustees project that HI tax income and other non-interest income will fall short of HI incurred expenditures beginning in 2027. The HI trust fund does not meet either the Trustees' test of short-range financial adequacy or their test of long-range close actuarial balance. See section III.B for full explanations of the tests and these results.

### ***c) Income and Cost Rates***

The income rate is defined as the ratio of a program's non-interest income to its taxable payroll. The projected HI income rate is 3.49 percent of taxable payroll for 2026. After 2026, the income rate generally increases very gradually, reaching 4.51 percent for 2100.

The cost rate is defined as the ratio of a program's cost to its taxable payroll. The projected cost rate is 3.49 percent of taxable payroll for

## *Highlights*

2026 and increases steadily to 4.54 percent in 2045 due to rising per beneficiary spending and the impact of demographic shifts—notably, the aging of the baby boom population. After 2045, the projected cost rate increases to 4.86 percent in 2100 as subsequent demographic shifts reduce the growth. (Under the illustrative alternative projections, the HI cost rate in 2100 is projected to be 7.35 percent of taxable payroll.)

### ***d) Actuarial Balance and Actuarial Deficit***

The actuarial balance is a summary measure of a program's financial status over a given projection period. The actuarial balance, which is expressed as a percentage of the program's taxable payroll over the projection period, includes:

- trust fund reserves at the beginning of the period
- all cost and income during the period
- a target trust fund reserve of 1 year's cost at the end of the period

A negative actuarial balance is called an actuarial deficit. Simply put, the actuarial deficit represents the average amount of change in income or cost that is needed throughout the projection period to achieve an actuarial balance of zero.

The HI actuarial deficit for the 75-year projection period (2026-2100) is 0.56 percent of taxable payroll. (Under the illustrative alternative projections, the HI actuarial deficit would be 1.38 percent of taxable payroll.) In last year's report, the HI actuarial deficit was 0.42 percent of taxable payroll. Section III.B explains why the actuarial balance estimates changed from last year's report.

### ***e) Size of the Solvency Gap***

A program is considered solvent if it can pay scheduled benefits when due with scheduled financing. The HI program will not be solvent once its reserves become depleted in 2033.

To illustrate the magnitude of the solvency gap, if the following changes were made in 2026, then the combined HI program would be solvent for the full 75-year period ending in 2100:

- Increase the payroll tax rate from 2.90 percent to 3.46 percent starting in January 2026, or

## Overview

- Reduce scheduled benefits by 12.0 percent for all current and future beneficiaries starting in January 2026.

If substantial actions are deferred until the HI program reaches reserve depletion, significantly larger changes would be concentrated on fewer years and fewer generations.

## ***SMI Key Results***

Table II.A2 presents the key results for Parts B and D of the SMI program. These results are explained in more detail later in this report.

**Table II.A2.—SMI Key Results**  
[Under intermediate assumptions]

	Part B	Part D
Average annual growth rate (2026-2030) <sup>1</sup>	8.5%	9.4%
Expenditures as a percentage of GDP		
2025	1.90%	0.59%
2035	2.90	0.76
2100	4.48	1.01

<sup>1</sup>Average annual growth in GDP over this same period is 4.0 percent.

Note: Under the illustrative alternative scenario, Part B expenditures as a share of GDP would be 2.94 percent in 2035 and 5.70 percent in 2100.

The SMI trust fund is expected to be adequately financed over the next 10 years and beyond because income from premiums and Federal Government contributions for Parts B and D are reset each year to cover expected costs and ensure a reserve for Part B contingencies. However, this financing would have to increase faster than the economy to cover expected expenditure growth.

## ***Medicare Funding Warning***

As required by law, the Trustees are issuing a determination of projected *excess general revenue Medicare funding* in this report because the difference between Medicare's total expenditures and its dedicated financing sources<sup>7</sup> is projected to exceed 45 percent of expenditures within 7 years. For this year's report, this ratio is expected to exceed 45 percent in fiscal year 2026, which is the first year of the projection. Since this determination was made last year as well, this year's determination triggers a *Medicare funding warning*, which requires the following:

---

<sup>7</sup>Dedicated financing sources consist of HI payroll taxes, the HI share of income taxes on Social Security benefits, Part D State payments, Part B drug fees, and beneficiary premiums.

### *Highlights*

- The President to submit to Congress proposed legislation to respond to the warning within 15 days after the Fiscal Year 2028 Budget submission; and
- Congress to consider the legislation on an expedited basis.

This is the tenth consecutive year that a determination of excess general revenue Medicare funding has been issued, and the ninth consecutive year that a Medicare funding warning has been issued.

### ***Unfunded Obligation***

The unfunded obligation represents the cumulative present value of scheduled income less cost. Expressed in present-value dollars discounted to January 1, 2026, the 75-year open-group unfunded obligation for HI is \$4.2 trillion, or 0.2 percent of GDP, and is \$0 for SMI.

### **Conclusion**

Based on the intermediate set of assumptions, the Trustees project that Medicare expenditures will increase at a faster pace in future years than either aggregate workers' earnings or the economy overall. Spending as a percentage of GDP is projected to increase from 3.9 percent in 2025 to 7.5 percent by 2100. Under the relatively higher price increases for physicians and other health services assumed for the illustrative alternative projection, Medicare spending would represent roughly 9.8 percent of GDP in 2100. Growth under either of these scenarios would substantially increase the strain on the nation's workers, the economy, Medicare beneficiaries, and the Federal budget.

The projections in this report show that change is needed to address Medicare's financial challenges. If elements of current law are not adhered to, even more substantial changes could be needed, as shown in the illustrative alternative scenario. The sooner solutions are enacted, the more flexible and gradual they can be. Introducing reforms early would give affected individuals and organizations—including health care providers, beneficiaries, and taxpayers—more time to adjust their expectations and behavior. The Trustees recommend that Congress and the executive branch work closely together to quickly address these challenges.

Overview

**B. MEDICARE DATA FOR CALENDAR YEAR 2025**

HI (Part A) and SMI (Parts B and D) have separate trust funds, revenue sources, and expenditure categories. Table II.B1 presents Medicare data for calendar year 2025 in total and for each part of the program. For additional information, see section III.B for HI and sections III.C and III.D for SMI.

For fee-for-service<sup>8</sup> Medicare, the largest Part A expenditure category is inpatient hospital services. The largest Part B expenditure categories are outpatient hospital and physician services. Payments to private health plans for providing Part A and Part B services represented roughly 52 percent of total A and B benefit costs in 2025.

**Table II.B1.—Medicare Data for Calendar Year 2025**

	HI or Part A	SMI		Total
		Part B	Part D	
Assets at end of 2024 (billions)	\$237.5	\$151.7	\$18.8	\$407.9
Total income	\$462.4	\$580.5	\$183.3	\$1,226.2
Payroll taxes	403.2	—	—	403.2
Interest	9.1	3.6	0.3	13.0
Taxation of benefits	41.1	—	—	41.1
Premiums	6.0	150.7	14.9	171.5
Government contributions	1.1	422.9	148.8	572.9
Payments from States	—	—	19.1	19.1
Other	1.9	3.2	0.3	5.4
Total expenditures	\$444.2	\$584.3	\$181.5	\$1,210.1
Benefits	438.3	578.4	181.0	1,197.8
Hospital	159.8	77.8	—	237.7
Skilled nursing facility	30.7	—	—	30.7
Home health care	6.2	10.4	—	16.6
Physician fee schedule services	—	72.4	—	72.4
Private health plans (Part C)	209.6	321.3	—	530.9
Prescription drugs	—	—	181.0	181.0
Other	31.9	96.5	—	128.4
Administrative expenses	5.9	5.9	0.5	12.3
Net change in assets	\$18.2	-\$3.8	\$1.8	\$16.2
Assets at end of 2025	\$255.7	\$147.8	\$20.6	\$424.1
Enrollment (millions)				
Aged	62.0	56.8	50.8	62.2
Disabled	7.1	6.6	6.0	7.1
Total	69.1	63.4	56.8	69.3
Average benefit per enrollee	\$6,344	\$9,117	\$3,190	\$18,650 <sup>1</sup>

<sup>1</sup>Calculated as the sum of the Part A, Part B, and Part D amounts.

Note: Totals do not necessarily equal the sums of rounded components.

For HI, the primary financing source is the payroll tax on covered earnings. Employers and employees each pay 1.45 percent of a worker's wages, while self-employed workers pay 2.9 percent of their net

<sup>8</sup>The Centers for Medicare & Medicaid Services uses the phrase "Original Medicare" or "OM" in lieu of "Fee-for-Service Medicare" or "FFS." The term FFS is used in this report to maintain consistency with terminology used in current law.

### *Medicare Data*

earnings. High-income workers pay an additional 0.9-percent tax on their earnings above an unindexed threshold (\$200,000 for single taxpayers and \$250,000 for married couples).

Other HI revenue sources include a portion of the Federal income taxes that Social Security recipients with incomes above certain unindexed thresholds pay on their benefits, as well as interest earned on the securities held in the HI trust fund.

For SMI, government contributions represent the largest source of income. These contributions covered about 75 percent of program costs in 2025. Also, beneficiaries pay monthly premiums for Parts B and D. Those premiums financed roughly 22 percent of the total cost in 2025. As with HI, the securities held in the SMI trust fund earn interest.

### C. MEDICARE ASSUMPTIONS

Future Medicare expenditures will depend on a number of factors, including the size and composition of the population eligible for benefits, changes in the volume and intensity of services, and increases in the price per service. Future HI trust fund income will depend on the size of the covered workforce and the level of workers' earnings. Future SMI trust fund income will depend on projected program costs. These workforce and program cost factors will depend in turn upon future birth rates, death rates, labor force participation rates, wage increases, and many other economic and demographic factors affecting Medicare.

To illustrate the uncertainty and sensitivity inherent in estimates of future Medicare trust fund operations, the Board has prepared current-law projections under a low-cost, high-cost, and intermediate set of economic and demographic assumptions. In addition, the Trustees asked the CMS Office of the Actuary to develop the illustrative alternative projections to demonstrate the potential effect on the Medicare financial status if certain current-law features are not fully implemented in the future.

Table II.C1 summarizes the key assumptions used in this report. Many of the demographic and economic variables that determine Medicare costs and income are common to the Old-Age, Survivors, and Disability Insurance (OASDI) program, and the OASDI annual report explains these variables in detail.<sup>9</sup> These variables include changes in the Consumer Price Index (CPI), wages, real interest rates,<sup>10</sup> fertility rates, mortality rates, and net immigration levels. In most cases, the assumptions vary from year to year during the first 5 to 25 years before reaching their ultimate assumed values<sup>11</sup> for the remainder of the 75-year projection period.

---

<sup>9</sup>The non-health-specific intermediate assumptions for this report were set in February 2026. The Trustees will continue to monitor developments, reevaluate the assumptions, and modify the projections in later reports.

<sup>10</sup>*Real* indicates that the effects of inflation have been removed.

<sup>11</sup>The assumptions do not include economic cycles beyond the first 10 years.

*Medicare Assumptions*

**Table II.C1.—Key Assumptions, 2050–2100**

	Intermediate	Low-Cost	High-Cost
<b>Economic:</b>			
Annual percentage change in:			
Gross Domestic Product (GDP) per capita <sup>1</sup> .....	3.6	4.8	2.4
Average wage in covered employment .....	3.57	4.79	2.34
Private nonfarm business total factor productivity <sup>2</sup> .....	1.0	—	—
Consumer Price Index (CPI) .....	2.4	3.0	1.8
Real-wage growth (percent) .....	1.14	1.74	0.53
Real interest rate (percent) .....	2.3	2.8	1.8
<b>Demographic:</b>			
Total fertility rate (children per woman) .....	1.75	2.10	1.40
Annual percentage reduction in total age-sex adjusted death rates .....	0.73	0.27	1.24
Net lawful permanent resident (LPR) immigration .....	788,000	1,000,000	595,000
Net temporary or unlawfully present immigration .....	389,000	624,000	154,000
<b>Health cost growth:</b>			
Annual percentage change in per beneficiary Medicare expenditures (excluding demographic impacts) <sup>1</sup>			
HI (Part A) .....	3.5	3	3
SMI Part B .....	3.8	3	3
SMI Part D .....	4.0	3	3
Total Medicare .....	3.7	3	3

<sup>1</sup>The assumed ultimate increases in per capita GDP and per beneficiary Medicare expenditures can also be expressed in real terms, adjusted to remove the impact of assumed inflation. When adjusted by the chain-weighted GDP price index, assumed real per capita GDP growth under the intermediate assumptions is 1.6 percent, and real per beneficiary Medicare cost growth is 1.4 percent, 1.7 percent, and 1.9 percent for Parts A, B, and D, respectively.

<sup>2</sup>Private nonfarm business total factor productivity is published by the Bureau of Labor Statistics and is used as the economy-wide private nonfarm business total factor productivity to adjust certain provider payment updates.

<sup>3</sup>See section III.B3 for further explanation of the Part A alternative (low-cost and high-cost) assumptions. Long-range alternative projections are not prepared for Parts B and D.

Other assumptions are specific to Medicare. As with all the assumptions underlying the financial projections, the Trustees review the Medicare-specific assumptions annually and update them based on the latest available data and analysis of trends. The assumptions and projection methodology are also subject to periodic review by independent panels of expert actuaries and economists. The most recent review was completed by the 2016–2017 Technical Review Panel on the Medicare Trustees Report.<sup>12</sup>

Section IV.D describes the methodology used to derive the long-range Medicare cost growth assumptions.<sup>13</sup> These assumptions reflect the annual percent change in per beneficiary Medicare expenditures (excluding demographic effects) for the following five categories of provider services:

<sup>12</sup>The Panel’s final report is available at <https://aspe.hhs.gov/system/files/pdf/257821/MedicareTechPanelFinalReport2017.pdf>.

<sup>13</sup>When Medicare cost growth rates are compared with the per capita increase in GDP, they are characterized as *GDP plus X percent*.

## Overview

- (i) *All HI, and some SMI Part B, services that are updated annually by provider input price increases less the increase in economy-wide productivity.*

HI services are inpatient hospital, SNF, home health, and hospice. The primary Part B services affected are outpatient hospital, home health, and dialysis.

Under the Trustees' intermediate economic assumptions, the year-by-year cost growth rates for these provider services start at 3.6 percent in 2050, or GDP plus 0.0 percent, declining gradually to 3.4 percent in 2100, or GDP minus 0.3 percent.

- (ii) *Physician services.*

Payment rate updates are 0.75 percent per year for qualified physicians assumed to be participating in advanced alternative payment models (advanced APMs) and 0.25 percent for those assumed to be participating in the merit-based incentive payment system (MIPS). The year-by-year cost growth rates for physician payments are assumed to decline from 3.1 percent in 2050, or GDP minus 0.5 percent, to 2.8 percent in 2100, or GDP minus 0.9 percent.

- (iii) *Certain SMI Part B services that are updated annually by the CPI increase less the increase in productivity.*

Such services include durable medical equipment that is not subject to competitive bidding,<sup>14</sup> care at ambulatory surgical centers, ambulance services, and medical supplies.

The Trustees assume the year-by-year cost growth rates for these services to decline from 2.8 percent in 2050, or GDP minus 0.8 percent, to 2.6 percent in 2100, or GDP minus 1.1 percent.

- (iv) *The remaining Part B services, which consist mostly of physician-administered drugs, laboratory tests, and small facility services.*

Payments for these Part B services are established through market processes and are not affected by the productivity adjustments. For physician-administered Part B drugs, the

---

<sup>14</sup>The portion of durable medical equipment that is subject to competitive bidding is included with all other Medicare services since the price is determined by a competitive bidding process. For more information on the bidding process, see section IV.B.

### *Medicare Assumptions*

Inflation Reduction Act's key inflation provisions are not anticipated to affect such payments over the long range.

The long-range cost growth rates for these services are assumed to equal the growth rates as determined from the "factors contributing to growth" model. The corresponding year-by-year cost growth rates decline from 4.3 percent in 2050, or GDP plus 0.7 percent, to 4.1 percent by 2100, or GDP plus 0.4 percent.

(v) *Prescription drugs provided through Part D.*

Medicare payments to Part D plans are based on a competitive bidding process but are influenced by key Inflation Reduction Act provisions that link drug price growth to the overall inflation rate. As a result, they are assumed to grow slightly more slowly over the long range than would be the case if they were determined strictly through market processes.

The corresponding year-by-year cost growth rates decline from 4.1 percent in 2050, or GDP plus 0.5 percent, to 3.9 percent by 2100, or GDP plus 0.2 percent.

After combining the growth rates from the four long-range assumptions, the weighted average cost growth rate for Part B is 3.8 percent in 2050,<sup>15</sup> or GDP plus 0.2 percent, remaining at 3.8 percent by 2100, or GDP plus 0.1 percent. When Parts A, B, and D are combined, the weighted average cost growth rate for Medicare is 3.8 percent, or GDP plus 0.2 percent in 2050, declining to 3.7 percent, or GDP plus 0.0 percent by 2100.

These cost growth rates must be modified to account for demographic impacts, which reflect the Medicare population's changing distribution by age, sex, and time-to-death.<sup>16</sup> Those who are closer to death have higher health spending, regardless of age. The Trustees assume that as mortality rates for Medicare beneficiaries continue to improve in the future, a smaller portion of the population will be closer to death at a given age, which somewhat offsets the effect of individuals getting older and spending more on health care.

---

<sup>15</sup>In 2050, the shares of Part B spending are 27 percent for services updated by input price indexes, 15 percent for physician services, 6 percent for services updated by the CPI, and 52 percent for the remaining Part B services.

<sup>16</sup>More information on the time-to-death adjustment is available at <https://www.cms.gov/files/document/incorporation-time-death-medicare-demographic-assumptions.pdf>.

## *Overview*

This is particularly the case for Part A services—such as inpatient hospital, SNF, and home health services—for which the distribution of spending is more concentrated in the period right before death. For Part B services and Part D, incorporating the time-to-death adjustment has a smaller effect.

As in the past, the Trustees establish detailed growth rate assumptions for the initial 10 years (2026 through 2035) by individual type of service (for example, inpatient hospital care and physician services). These assumptions reflect recent trends and the impact of all applicable statutory provisions. For each of Parts A, B, and D, the assumed cost growth rates for years 11 through 25 of the projection period (adjusted to reflect discontinuities in yearly payment policies) are set by interpolating between the rate at the end of the short-range projection period and the rate at the start of the last 50 years of the long-range period.

The 2016–2017 Medicare Technical Review Panel concluded that both the current length of the transition period and the current approach to the transition are reasonable. They recommended that the Trustees continue to use the same approach to transition between short-range and long-range projections for both HI and SMI.<sup>17</sup>

The basis for the Medicare cost growth rate assumptions described above has been chosen primarily to incorporate the productivity adjustments and the physician payment structure in a relatively simple, straightforward manner and with the assumption that these elements of current law will operate as specified in all future years. The Trustees use this approach in part because of the uncertainty associated with these provisions and in part because of the difficulty of modeling the consequences for access to care, health status, and utilization if these provisions of current law do not operate as intended.<sup>18</sup> This approach incorporates the effects of changes in payment mechanisms, delivery systems, and other aspects of health care that have been implemented recently, including modest savings from accountable care organizations.

However, the Trustees have considered neither the possible effects of future changes that could arise in response to the payment limitations or future innovative payment models nor the potential effects of

---

<sup>17</sup>See Findings 6-2 and 6-3 and Recommendation 6-1.

<sup>18</sup>For a detailed discussion of uncertainty, see section V.C.

### *Medicare Assumptions*

sustained slower payment increases on provider participation, beneficiary access to care, quality of services, and other factors.<sup>19</sup>

Consistent with the practice in recent reports, a set of illustrative alternative Medicare projections has been developed. This information is presented in section V.C. An actuarial memorandum on the illustrative alternative is available on the CMS website.<sup>20</sup> The illustrative alternative projection assumes the following:

- There would be a transition from current-law payment updates for providers affected by the economy-wide productivity adjustments to payment updates that reflect adjustments for health care productivity; and
- The average physician payment updates would transition from current law to payment updates that reflect the Medicare Economic Index.

The transition from current law to the ultimate illustrative alternative assumptions starts at the same dates that were assumed in last year's report. Under the illustrative alternative projections, the year-by-year cost growth rate assumptions for HI and SMI Part B decline from approximately 4.3 percent in 2050, or GDP plus 0.7 percent, to 4.1 percent by 2100, or GDP plus 0.4 percent. On average over this period, the growth rate of per beneficiary expenditures for these services is equal to the growth rate for per capita national health expenditures, as described previously for other Medicare services for which price updates are based on market processes.

For the HI low-cost and high-cost projections, Medicare expenditures are determined by changing the assumption for the ratio of aggregate costs to taxable payroll (the cost rate). These changes are intended to show how Medicare expenditures could vary in the future as a result of different economic, demographic, and health care trends.<sup>21</sup>

For the HI high-cost assumptions, the assumed annual increase in the cost rate during the initial 25-year period is 2 percentage points greater than under the intermediate assumptions. Under the low-cost assumptions, the assumed annual increase in the cost rate for the

---

<sup>19</sup>The 2016–2017 Medicare Technical Review Panel considered these issues at some length. Their final report contains a discussion of the delivery system changes to date and the impact on the Medicare projections.

<sup>20</sup>See <https://www.cms.gov/files/document/illustrative-alternative-scenario-2026.pdf>.

<sup>21</sup>Under the automatic financing provisions for the SMI programs, Parts B and D will be adequately financed. Accordingly, the Trustees have not conducted high-cost and low-cost analyses of the general fund transfers.

### *Overview*

initial period is 2 percentage points less than under the intermediate assumptions. The Trustees assume that, after 25 years, the 2-percentage-point differentials will gradually decline to zero in 2075, after which the growth in cost rates is the same under all three sets of assumptions.

While it is possible that actual economic, demographic, and health cost-growth experience will fall within the range defined by the three alternative sets of assumptions, there can be no assurances that it will do so in light of the wide variations in these factors over past decades. In general, readers can place a greater degree of confidence in the assumptions and estimates for the earlier years than for the later years. Nonetheless, the estimates in total are only an indication of the expected trends and the general ranges of future Medicare experience.

Also, because of uncertain long-range adequacy of physician payments and payments affected by the statutory productivity adjustments, actual future Medicare expenditures could exceed the intermediate projections shown in this report, possibly by large amounts. Reference to key results under the illustrative alternative projections demonstrates this potential understatement.

***D. FINANCIAL OUTLOOK FOR THE MEDICARE PROGRAM***

This report evaluates the HI and SMI trust funds' financial status. For HI, the Trustees apply formal tests of financial status for both the short range and the long range. For SMI, the Trustees assess the trust fund's ability to meet costs incurred over the period for which financing has been set.

HI and SMI are financed in very different ways. Within SMI, current law provides for the annual determination of Part B and Part D beneficiary premiums and government contributions to cover expected costs for the following year. In contrast, HI is subject to substantially greater variation in asset growth, as employee and employer tax rates under current law do not change or adjust to meet expenditures except through new legislation.

Despite the significant differences in benefit provisions and financing, the two components of Medicare are closely related. HI and SMI operate in an interdependent health care system. Most Medicare beneficiaries are enrolled in HI and SMI Parts B and D, and many receive services from all three.


Accordingly, efforts to improve and reform either component have repercussions for the other component. With the anticipated growth in Medicare expenditures, it is also important to consider the distribution among the various sources of revenues for financing Medicare and the manner in which this distribution will change over time.

This section reviews the projected total expenditures for the Medicare program, along with the primary sources of financing.

Figure II.D1 shows projected costs as a percentage of GDP. Medicare expenditures represented 3.9 percent of GDP in 2025 and will increase to 6.5 percent of GDP by 2050. Costs then increase to 7.5 percent of GDP in 2100, with growth in health care cost per beneficiary becoming the larger factor later in the valuation period, particularly for Part D costs, which are not affected by legislated price reductions. (If the payment update constraints were phased down as in the illustrative alternative projections, then Medicare expenditures would reach an estimated 9.8 percent of GDP in 2100.)

Overview

Figure II.D1.—Medicare Expenditures as a Percentage of the Gross Domestic Product



Note: Percentages are affected by economic cycles.

Table II.D1 shows five components of Medicare expenditure growth:

- Growth of overall prices as measured by the CPI;
- Growth of Medicare prices relative to growth in the CPI;
- Growth in the number of beneficiaries;
- Change in the demographic composition of the beneficiaries; and
- Change in the volume and intensity of services.

The table presents these components over three valuation periods. The price growth for Part A is projected to be below CPI growth initially, close to CPI growth in the 2036–2050 period, and below in the long run. For Part B, price growth is projected to be below CPI growth during each valuation period. As discussed in section IV.D, prices for all of Part A and some of Part B are constrained by the provider payment updates specified under current law. Part B prices are further constrained by the current-law physician payment updates.

For all parts of Medicare, growth in the number of beneficiaries is highest over the next 10 years as the baby boom generation continues to enter Medicare. Beneficiary growth slows continually thereafter.

**Table II.D1.—Components of Increase in Medicare Incurred Expenditures by Part**  
[In percent]

Valuation period	Average annual percentage change						Total increase
	Prices		Overall Medicare	Number of beneficiaries	Beneficiary demographic mix	Volume and intensity	
	CPI	Medicare relative to CPI					
Part A:							
2026–2035	3.2%	-0.4%	2.8%	1.5%	0.5%	2.0%	7.0%
2036–2050	2.4	-0.1	2.3	0.4	0.2	1.3	4.2
2051–2100	2.4	-0.1	2.2	0.4	-0.1	1.2	3.7
Part B:							
2026–2035	3.2	-1.1	2.0	1.7	0.1	4.4	8.5
2036–2050	2.4	-0.5	1.9	0.4	-0.1	3.2	5.6
2051–2100	2.4	-0.2	2.1	0.4	-0.1	1.6	4.1
Part D:							
2026–2035	3.2	-2.0	1.1	1.9	-0.2	3.7	6.7
2036–2050	2.4	-0.2	2.2	0.4	-0.2	1.4	3.9
2051–2100	2.4	0.2	2.6	0.4	-0.1	1.3	4.3

Notes: 1. Price reflects annual updates, total factor productivity reductions, and any other reductions required by law or regulation.  
2. Volume and intensity is the residual after the other four factors shown in the table (CPI, excess Medicare price, number of beneficiaries, and beneficiary demographic mix) are removed.  
3. Totals do not necessarily equal the sums of rounded components.

Most beneficiaries have the option to enroll in private health insurance plans that contract with Medicare to provide Part A and Part B medical services. The share of Medicare beneficiaries in such plans has risen steadily in recent years. It reached 51 percent in 2025 from 12.8 percent in 2004. The Trustees project that the overall participation rate for private health plans will continue to increase—from about 51 percent in 2026 to about 56 percent in 2035 and thereafter.<sup>22</sup>

Figure II.D2 shows the past and projected amounts of Medicare revenues under current law excluding interest income, which will not be a significant part of program financing in the long range as trust fund assets decline. The figure compares total Medicare expenditures with Medicare non-interest income from these sources:

- HI payroll taxes;
- HI income from the taxation of Social Security benefits;
- HI and SMI premiums;
- SMI Part D State payments for certain Medicaid beneficiaries;
- Fees on manufacturers and importers of brand-name prescription drugs (allocated to Part B); and


<sup>22</sup>For more detail on the Medicare Advantage program, see section IV.C.

*Overview*

- HI and SMI general fund transfers.

The Trustees expect total Medicare expenditures to exceed non-interest revenue for all future years.

**Figure II.D2.—Medicare Sources of Non-Interest Income and Expenditures as a Percentage of the Gross Domestic Product**



Note: Percentages are affected by economic cycles.

As shown in figure II.D2, for much of the early historical period, payroll tax revenues increased steadily as a percentage of GDP because of increases in the HI payroll tax rate and in the limit on taxable earnings, the latter of which lawmakers eliminated in 1994.

Beginning in 2013, the HI trust fund receives an additional 0.9-percent tax on earnings in excess of a threshold amount.<sup>23</sup> The Trustees project that, as a result of this provision, payroll taxes will grow slightly faster

<sup>23</sup>Current law also specifies that individuals with incomes greater than \$200,000 per year and couples above \$250,000 pay an additional Medicare contribution of 3.8 percent on some or all of their non-work income (such as investment earnings). However, the revenues from this tax are not allocated to the Medicare trust funds.

than GDP.<sup>24</sup> HI revenue from income taxes on Social Security benefits is expected to gradually increase as a share of GDP as the share of benefits subject to such taxes increases.<sup>25</sup>

The Trustees expect growth in SMI Part B and Part D premiums and government contributions to continue to outpace GDP growth and HI payroll tax growth in the future. This phenomenon occurs primarily because SMI revenue increases at the same rate as expenditures, whereas HI revenue does not. Accordingly, as the HI revenue sources become increasingly inadequate to cover HI costs, SMI revenues will represent a growing share of total Medicare revenues. Government contributions are projected to gradually increase from 47 percent of Medicare financing in 2025 to about 50 percent in 2035, stabilizing thereafter. Growth in these contributions as a share of GDP adds significantly to the Federal budget pressures. SMI premiums will also increase at the same rate as SMI expenditure growth, placing a growing burden on beneficiaries. High-income beneficiaries have paid an income-related premium for Part B since 2007 and for Part D since 2011.

### **Medicare and the Federal Budget**

The interrelationship between the Medicare program and the Federal budget is an important topic—one that will become increasingly critical over time as the general fund requirements for SMI continue to grow.

Government contributions are the major source of financing for the SMI trust fund. They are central to the automatic financial balance of the fund's two accounts, while representing a large and growing requirement for the Federal budget. SMI government contributions equaled 1.9 percent of GDP in 2025 and will increase to an estimated 3.7 percent in 2100 under current law. For the HI trust fund, without legislation to address the financial imbalance, interest earnings on trust fund assets and redemption of those assets will cover the difference between HI dedicated revenues and expenditures until

---

<sup>24</sup>Although the Trustees expect total worker compensation to grow at the same rate as GDP after the first 10 years of the projection, wages and salaries are projected to increase more slowly than fringe benefits (health insurance costs in particular). Thus, projected taxable earnings (wages and salaries) gradually decline as a percentage of GDP. Absent any change to the tax rate scheduled under current law, HI payroll tax revenue would similarly decrease as a percentage of GDP. Over time, however, a growing proportion of workers will have earnings that exceed the fixed earnings thresholds specified in the law (\$200,000 for individuals and \$250,000 for couples), and an increasing portion of taxable earnings will therefore become subject to the additional 0.9-percent HI payroll tax. The net effect of these factors is an increasing trend in payroll taxes as a percentage of GDP.

<sup>25</sup>See section V.C7 of the 2026 OASDI Trustees Report for more detailed information on the projection of income from taxation of Social Security benefits.

## *Overview*

2033.<sup>26</sup> In 2032, this funding shortfall for the HI trust fund represents 0.2 percent of GDP.

Section V.F describes the interrelationship between the Federal budget and the Medicare and Social Security trust funds. It illustrates the programs' long-range financial outlook from both a trust fund perspective and a budget perspective.

### **Federal Reporting Requirements on Medicare Funding**

Federal law requires that the Trustees make a determination of excess general revenue Medicare funding if they project that under current law the difference between program expenditures and dedicated financing sources<sup>27</sup> will exceed 45 percent of Medicare costs within the first 7 fiscal years of the projection. For this year's report, the difference between program expenditures and dedicated revenues is expected to exceed 45 percent in fiscal year 2026, which is the first year of the projection. Therefore, the Trustees are issuing this determination.<sup>28</sup>

Because this determination was made last year as well, this year's determination results in a Medicare funding warning, which requires the following:

- The President to submit to Congress proposed legislation to respond to the warning within 15 days after the Fiscal Year 2028 Budget submission; and
- Congress to consider the legislation on an expedited basis.

Such funding warnings were previously made in each of the 2007 through 2013 reports and in the 2018 through 2025 reports.

While this section has summarized the total financial obligation posed by Medicare and the manner in which it is financed, the HI and SMI components of Medicare have separate and distinct trust funds, each with its own revenue sources and mandated expenditures. Sections II.E and II.F present assessments for the financial status of the HI trust fund and the SMI trust fund, respectively.

---

<sup>26</sup>After asset depletion in 2033, as described in section II.E, no provision exists to use transfers from the general fund of the Treasury or any other means to cover the HI deficit.

<sup>27</sup>The dedicated financing sources are HI payroll taxes, the HI share of income taxes on Social Security benefits, Part B receipts from the fees on manufacturers and importers of brand-name prescription drugs, Part D State payments, and beneficiary premiums. These sources are the first four layers depicted in figure II.D2.

<sup>28</sup>Section V.B contains additional details on these tests.

***E. FINANCIAL STATUS OF THE HI TRUST FUND***

**1. 10-Year Actuarial Estimates (2026–2035)**

Over the past 20 years, the HI trust fund experienced various periods of surpluses and deficits. Expenditures exceeded income each year from 2008 through 2015. However, in 2016 and 2017, there were fund surpluses amounting to \$5.4 billion and \$2.8 billion, respectively. In 2018, 2019, and 2020, expenditures again exceeded income, with trust fund deficits of \$1.6 billion, \$5.8 billion, and \$60.4 billion, respectively. The large deficit in 2020 was mostly due to accelerated and advance payments to providers from the trust fund. In 2021, there was a small surplus of \$8.5 billion as these payments began to be repaid to the trust fund, and this continued repayment resulted in a larger surplus in 2022 of \$53.9 billion. In 2023, 2024, and 2025 there were surpluses of \$12.2 billion, \$28.7 billion, and \$18.2 billion, respectively.

After a small projected surplus in 2026, deficits are projected to return in 2027 and persist for the remainder of the projection period, requiring redemption of trust fund assets until the trust fund's depletion in 2033.

Table II.E1 presents the HI trust fund's projected operations under the intermediate assumptions for the next decade. At the beginning of 2026, HI assets represented 53 percent of annual expenditures. This ratio has declined from 150 percent since 2007. The Board has recommended an asset level at least equal to annual expenditures to serve as an adequate contingency reserve in case of adverse economic or other conditions.

The Trustees apply an explicit test of short-range financial adequacy.<sup>29</sup> Based on the 10-year projection shown in table II.E1, the HI trust fund does not meet this test because estimated assets are below 100 percent of annual expenditures and are not projected to attain this level under the intermediate assumptions. Prompt legislative action is needed to achieve financial adequacy for the HI trust fund throughout the short-range period.

---

<sup>29</sup>This test is described in section III.B2 of this report.

Overview

**Table II.E1.—Estimated Operations of the HI Trust Fund  
under Intermediate Assumptions, Calendar Years 2025–2035**

[Dollar amounts in billions]					
Calendar year	Total income <sup>1</sup>	Total expenditures	Change in fund	Fund at year end	Ratio of assets to expenditures <sup>2</sup>
2025 <sup>3</sup>	\$462.4	\$444.2	\$18.2	\$255.7	53%
2026	486.7	480.5	6.2	261.9	53
2027	514.5	524.9	-10.5	251.4	50
2028	542.4	563.6	-21.3	230.1	45
2029	570.5	603.3	-32.8	197.4	38
2030	599.6	643.5	-43.9	153.5	31
2031	629.1	685.3	-56.2	97.3	22
2032	658.4	727.5	-69.2	28.1	13
2033 <sup>4</sup>	690.0	775.1	-85.0	-56.9	4
2034 <sup>4</sup>	720.2	831.7	-111.6	-168.5	— <sup>5</sup>
2035 <sup>4</sup>	749.2	877.3	-128.1	-296.5	— <sup>5</sup>

<sup>1</sup>Includes interest income.

<sup>2</sup>Ratio of assets in the fund at the beginning of the year to expenditures during the year.

<sup>3</sup>Figures for 2025 represent actual experience.

<sup>4</sup>Estimates for 2033 and later are hypothetical since the HI trust fund would be depleted in these years.

<sup>5</sup>Trust fund reserves would be depleted at the beginning of this year


Note: Totals do not necessarily equal the sums of rounded components.

This year's short-range financial outlook for the HI trust fund is slightly less favorable than last year's projections. HI income is projected to be lower throughout the projection period due to lower taxation of Social Security benefits resulting from the One Big Beautiful Bill Act. HI expenditures are projected to be relatively close to last year's projections through the short-range period.

Under the intermediate assumptions, after 2026 the assets of the HI trust fund would steadily decrease as a percentage of annual expenditures throughout the remainder of the short-range projection period, as illustrated in figure II.E1. The ratio declines until the fund is depleted in the second quarter of 2033, one quarter earlier than projected last year.

If assets were depleted, Medicare could pay health plans and providers of Part A services only to the extent allowed by ongoing tax revenues—and these revenues would be inadequate to fully cover costs. Beneficiary access to health care services could be rapidly reduced. To date, Congress has never allowed the HI trust fund to become depleted.

**Figure II.E1.—HI Trust Fund Balance at Beginning of Year as a Percentage of Annual Expenditures**



There is substantial uncertainty in the economic, demographic, and health care projection factors for HI trust fund expenditures and revenues. Accordingly, the date of HI trust fund depletion could differ substantially in either direction from the 2033 intermediate estimate. As shown in greater detail in section III.B, trust fund assets would increase throughout the entire projection period under the low-cost assumptions. However, under the high-cost assumptions, asset depletion would occur in 2030.

**2. 75-Year Actuarial Estimates (2026–2100)**

Each year, the Board prepares 75-year estimates of the HI trust fund’s financial and actuarial status. Although financial outcomes are inherently uncertain, particularly over periods as long as 75 years, such estimates are helpful for assessing the trust fund’s long-term financial condition.

Because of the difficulty in comparing dollar values for different periods without some type of relative scale, the Trustees show income and expenditure amounts relative to the earnings in covered employment that are taxable under HI (referred to as *taxable payroll*).

## Overview

The ratio of HI income<sup>30</sup> to taxable payroll is called the *income rate*. The ratio of expenditures to taxable payroll is the *cost rate*.<sup>31</sup>

The standard HI payroll tax rate is scheduled to remain constant at 2.9 percent for employees and employers, combined. High-income workers also pay an additional 0.9 percent of their earnings above \$200,000 (for single workers) or \$250,000 (for married couples filing joint income tax returns).

Because income thresholds for determining eligibility for the additional HI tax are not indexed, over time an increasing proportion of workers and their earnings will become subject to a higher HI tax rate. (By the end of the long-range projection period, an estimated 80 percent of workers would be subject to this additional tax.) Thus, HI payroll tax revenues will increase steadily as a percentage of taxable payroll.

Similarly, HI income from taxation of Social Security benefits will also increase faster than taxable payroll because the income thresholds determining taxable benefits are not indexed for inflation and the income tax brackets are indexed to the chained CPI, which increases at a slower rate than average wages. After the 10th year of the projection period, income tax brackets are assumed to rise with average wages, rather than with the chained CPI as specified in the Internal Revenue Code. As a result of this assumption, income from the taxation of Social Security benefits increases at a similar rate as taxable payroll.<sup>32</sup>

The cost rate has mostly been declining over the last decade largely because of expenditure growth that was constrained in part by low utilization and low payment updates. The cost rate increased in 2019, as taxable payroll growth slowed, and in 2020 because of the pandemic. The rate then declined again in 2021 and 2022 because of a decrease in expenditures attributable to the pandemic's impact.

After remaining steady in 2023, 2024, and increasing slightly in 2025, the cost rate is projected to rise in 2026 and beyond primarily as a result of an acceleration of health services cost growth. This cost rate increase is moderated by the productivity adjustments to provider

---

<sup>30</sup>HI income here includes payroll taxes, income from taxation of Social Security benefits, premiums, general fund transfers for uninsured beneficiaries, and monies from fraud and abuse control activities, but it excludes interest income.

<sup>31</sup>The Trustees estimate these costs on an incurred basis.

<sup>32</sup>See section V.C7 of the 2026 OASDI Trustees Report for more detailed information on the projection of income from taxation of Social Security benefits.

### *HI Financial Outlook*

price updates, which are estimated to reduce annual HI per capita cost growth by an average of 0.9 percent through 2035 and 1.0 percent thereafter. For example, after 25, 50, and 75 years, the prices paid to HI providers under current law would be 20 percent, 38 percent, and 52 percent lower, respectively, than prices without the productivity reductions.

Figure II.E2 shows projected income and cost rates under the intermediate assumptions. As indicated, estimated HI incurred expenditures continue to exceed non-interest income for all projected years. (The projected excess of costs over non-interest income until 2033 is covered by interest earnings and trust fund asset redemption.)


The HI cost rate increases more rapidly than the income rate for most years through about 2043. The projected annual deficits expressed as a share of taxable payroll increase from 0.14 percent in 2027 to a high of 0.71 percent in 2042 and then gradually decrease to 0.35 percent by the end of the projection period. The convergence of growth rates for income and costs reflects the following:

- The continuing effects of slower payment rate updates;
- Assumed decelerating growth in the volume and intensity of services; and
- The increasing portion of earnings that are subjected to the additional 0.9-percent payroll tax.

The percentage of expenditures covered by non-interest income is projected to be 89 percent in 2033 (year of depletion), 85 percent in 2050 (25th projection year), and about 93 percent in 2100 (end of the projection period). (Under the illustrative alternative, the expenditures covered by non-interest income are projected to decline from 89 percent in 2033 to 80 percent in 2050 and then to about 62 percent by the end of the projection period.)

Overview

**Figure II.E2.—Long-Range HI Non-Interest Income and Cost as a Percentage of Taxable Payroll, Intermediate Assumptions**



It is possible to summarize the year-by-year cost rates and income rates shown in figure II.E2 into single values<sup>33</sup> representing, in effect, the average value over a given period. Based on the intermediate assumptions, the Trustees project an HI actuarial deficit of 0.56 percent of taxable payroll for the 75-year period under current law. This value represents the difference between the summarized income rate of 4.06 percent and the corresponding cost rate of 4.63 percent.<sup>34</sup>

As a result, the HI trust fund fails the Trustees’ test for long-range financial balance, as it has every year since 1991, when this test was first applied. (Under the illustrative alternative projections, the long-range HI deficit would be 1.38 percent of payroll.)

The projected HI cost rates shown in this report are mostly consistent with last year’s projection through 2050 and then higher through 2100. The cost rate projections are ultimately higher than in last year’s report due to changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower taxable payroll projections.

<sup>33</sup>See section III.B3 for details on the summarized income and cost rates.

<sup>34</sup>Totals do not necessarily equal the sums of rounded components.

### **Addressing the Long-Range Financial Imbalance**

Lawmakers have many options to address the long-range financial imbalance and keep the HI trust fund solvent throughout the 75-year projection period. Two potential approaches—with either immediate or gradual implementation—illustrate the magnitude of the changes needed to eliminate the deficit:

- The standard 2.90-percent payroll tax could be immediately increased by the amount of the actuarial deficit to 3.46 percent, or expenditures could be reduced immediately by 12 percent.<sup>35,36</sup>
- The tax and/or benefit changes could occur gradually but would require ultimate adjustments that would be higher than adjustments that were done immediately.

---

<sup>35</sup>Under the illustrative alternative projection, the corresponding immediate changes would be an increase from 2.90 percent to 4.28 percent in the standard tax rate or a decrease in expenditure levels of 25 percent.

<sup>36</sup>Under the two approaches for addressing the actuarial deficit, tax income would initially be substantially greater than expenditures, and trust fund assets would accumulate rapidly. However, tax income would be inadequate, and assets would subsequently be drawn down to cover the difference. This approach shows that if lawmakers designed legislative solutions to eliminate only the 75-year actuarial deficit, without consideration of such year-by-year patterns, then a substantial financial imbalance could still remain at the end of the period, and the program's long-range sustainability could still be in doubt.

*Overview*

***F. FINANCIAL STATUS OF THE SMI TRUST FUND***

SMI is composed of two parts, Part B and Part D, each with its own separate account within the SMI trust fund. The Trustees must evaluate the financial status of each account separately to determine the SMI trust fund's financial status because there is no provision in the law for transferring assets or income between the Part B and Part D accounts.

The nature of the financing for both parts of SMI is similar in that the law establishes a mechanism by which income from the Part B premium and the Part D premium, and the corresponding general fund transfers for each part, are sufficient to cover the following year's estimated expenditures. Accordingly, each account within SMI is automatically in financial balance under current law.

Parts B and D differ fundamentally from HI and OASDI in regard to the nature of their financing and the method by which their financial status is evaluated. Both parts of SMI are voluntary and are mostly financed by premiums from participants and contributions from the general fund of the Treasury. OASDI and HI are generally compulsory and are primarily financed from payroll taxes. The financial assessment of the SMI program therefore differs in important ways.

**1. 10-Year Actuarial Estimates (2026–2035)**

Table II.F1 shows the estimated operations of the Part B account, the Part D account, and the total SMI trust fund under the intermediate assumptions during calendar years 2025 through 2035.

For Part B, expenditures grew at an average annual rate of 6.9 percent over the past 5 years, less than average annual GDP growth of 7.6 percent. Estimated Part B cost increases average about 8.5 percent over the next 5 years, faster than the GDP growth rate of 4.0 percent. Compared with last year's report, income and expenditures are lower in the short range mainly because of the assumed impact of policy changes for skin substitute payments.

**Table II.F1.—Estimated Operations of the SMI Trust Fund  
under Intermediate Assumptions, Calendar Years 2025–2035**

[Dollar amounts in billions]				
Calendar year	Total income <sup>1</sup>	Total expenditures	Change in fund	Fund at year end
<b>Part B account:</b>				
2025 <sup>2</sup>	\$580.5	\$584.3	-\$3.8	\$147.8
2026	662.6 <sup>3</sup>	626.0	36.6	184.5
2027	672.2 <sup>3</sup>	679.8	-7.6	176.8
2028	757.6	743.5	14.1	190.9
2029	821.4	806.2	15.2	206.2
2030	895.0	878.9	16.1	222.3
2031	966.7	950.8	16.0	238.2
2032	1,043.7	1,024.9	18.8	257.0
2033	1,140.2	1,117.1	23.1	280.1
2034	1,244.1	1,222.4	21.7	301.8
2035	1,341.6	1,319.1	22.5	324.4
<b>Part D account:</b>				
2025 <sup>2</sup>	183.3	181.5	1.8	20.6
2026	224.6 <sup>3</sup>	222.4	2.2	22.7
2027	237.9 <sup>3</sup>	236.2	1.7	24.5
2028	261.6	259.9	1.7	26.1
2029	273.6	273.5	0.1	26.2
2030	286.0	284.8	1.2	27.4
2031	300.1	299.7	0.4	27.8
2032	306.8	305.6	1.2	29.0
2033	321.7	320.8	1.0	30.0
2034	334.9	333.7	1.1	31.1
2035	348.2	346.7	1.5	32.6
<b>Total SMI:</b>				
2025 <sup>2</sup>	763.8	765.8	-2.0	168.4
2026	887.2 <sup>3</sup>	848.4	38.8	207.2
2027	910.1 <sup>3</sup>	916.0	-5.9	201.3
2028	1,019.2	1,003.4	15.7	217.1
2029	1,095.0	1,079.7	15.3	232.4
2030	1,181.0	1,163.7	17.3	249.7
2031	1,266.8	1,250.5	16.4	266.1
2032	1,350.5	1,330.5	20.0	286.0
2033	1,461.9	1,437.9	24.0	310.1
2034	1,579.0	1,556.1	22.9	333.0
2035	1,689.8	1,665.8	24.0	357.0

<sup>1</sup>Includes interest income.

<sup>2</sup>Figures for 2025 represent actual experience.

<sup>3</sup>Section 708 of the Social Security Act modifies the provisions for the payment of Social Security benefits when the regularly designated day falls on a Saturday, Sunday, or legal public holiday. Payment of those benefits normally due January 3, 2027, will occur on December 31, 2026. Consequently, the Part B and Part D premiums withheld from these benefits and the associated Part B government contributions will be added to the respective Part B (about \$5.8 billion) or Part D (about \$0.2 billion) account on December 31, 2026.

Because of the nature of Part B financing, Part B income growth is normally quite close to expenditure growth. The financing for 2026 was

## *Overview*

set to maintain the Part B account within the customary range during 2026.<sup>37</sup>

For the Part D account, the Trustees project that income and expenditures will grow at an average annual rate of 9.3 percent and 9.4 percent, respectively, over the 5-year period 2026–2030. Compared with last year’s report, income and expenditures are projected to be higher. This is mainly due to increases in the utilization of GLP-1 and expensive specialty drugs in 2025. Additionally, projected growth is higher than in last year’s report because of higher cost trends and lower projected direct and indirect remuneration (DIR) through the short-range period.

As with Part B, income and expenditures would remain in balance because income from premiums and general fund transfers is adjusted annually to cover costs. The appropriation for Part D government contributions has generally been set so that amounts can be transferred to the Part D account on an as-needed basis. Under this process, there is no need to maintain a contingency reserve. The Part D account reflects a policy to transfer amounts from the Treasury into the account 5 business days before the benefit payments to the plans.

The primary financial adequacy test for Parts B and D pertains to the financing level established for a given period (normally, through the end of the current calendar year). The financing for each part of SMI is considered satisfactory if it is sufficient to fund all services, including benefits and administrative expenses, provided through a given period. To protect against the possibility that cost increases under either part of SMI will be higher than expected, the trust fund accounts would normally need assets adequate to cover a reasonable degree of variation between actual and projected costs.

For Part B, the Trustees estimate that the financing established through December 2026 will be sufficient to cover benefits and administrative costs incurred through 2026. They estimate that assets will be adequate to cover potential variations in costs if there is new legislation or if cost growth factors exceed expectations. The estimated financing established for Part D, together with the flexible

---

<sup>37</sup>The traditional measure used to evaluate the status of the SMI trust fund’s Part B account is defined as the ratio of the excess of Part B assets over Part B liabilities to the next year’s Part B incurred expenditures. The customary range for this ratio is 15 to 20 percent, and the minimally financially adequate level is 14 percent; the CMS Office of the Actuary developed these amounts based on private health insurance standards and past studies indicating that this asset reserve level is sufficient to protect against adverse events.

appropriation authority for this trust fund account, would be sufficient to cover benefits and administrative costs incurred through 2026.

The contingency reserve amount needed in Part B is normally much smaller (both in absolute dollars and as a fraction of annual costs) than in HI or OASDI. A smaller reserve is adequate because the premium rate and corresponding general fund transfers for Part B are determined annually based on estimated future costs, while the HI and OASDI payroll tax rates are fixed under law and are therefore much more difficult to adjust if circumstances change. A statutory competitive bidding process establishes Part D revenues annually to cover estimated costs.<sup>38</sup> Additionally, lawmakers have established a flexible appropriation authority for Part D, which allows additional general fund financing if costs are higher than anticipated.

## **2. 75-Year Actuarial Estimates (2026–2100)**

Figure II.F1 shows past and projected total SMI expenditures and premium income as a percentage of GDP. Total SMI expenditures amounted to 2.5 percent of GDP in 2025 and are projected to grow to about 5.0 percent of GDP within 40 years and to 5.5 percent by the end of the projection period. (Under the illustrative alternative, total SMI expenditures in 2100 would be 6.7 percent of GDP.)


Compared with the projections in the 2025 Trustees Report, the projected Part B and Part D expenditures as a share of GDP shown in figure II.F1 are higher. The Part B differences after the short-range period are due to faster projected growth for Part B drugs, resulting in expenditures as a percentage of GDP being higher than in last year's report by 2048. Thereafter, for both Part B and Part D, expenditures as a percentage of GDP grow faster than in last year's report due to changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower GDP projections.

---

<sup>38</sup>For more information on the bidding process, see section IV.B.

Overview

Figure II.F1.—SMI Expenditures and Premiums as a Percentage of the Gross Domestic Product



Note: Percentages are affected by economic cycles.

### 3. Implications of SMI Cost Growth

Financing for the SMI trust fund is adequate because beneficiary premiums and government contributions for both Part B and Part D are established annually to cover the expected costs for the upcoming year. If actual costs exceed those anticipated when the financing is determined, future financing rates can include adjustments to recover the shortfall. Likewise, if actual costs are less than those anticipated, the savings will result in lower future financing rates. As long as the future financing rates continue to cover the following year's estimated costs, both parts of the SMI trust fund will remain financially solvent.

A critical issue for the SMI program is the impact of the rapid growth of SMI costs, which places steadily increasing demands on beneficiaries and taxpayers. This section compares the past and projected growth in SMI costs with GDP growth. It also assesses the implications of the rapid growth for beneficiaries and the budget of the Federal Government.

Table II.F2 compares the growth in SMI expenditures with that of the economy as a whole. SMI cost growth is expected to continue to outpace growth in GDP throughout the projection period, but at a slower rate compared with the last 10 years or prior periods.

*SMI Financial Outlook*

The relatively high growth during 2026–2035 is due to the continuing retirement of the baby boom generation and increases in cost trends. Growth rates are projected to decline during 2036–2050 as beneficiary population growth slows. For the projection period’s last 50 years, cost growth moderates further because of the continued deceleration in beneficiary population growth and lower health care cost growth rate assumptions.

On a per capita basis, SMI expenditure growth was somewhat faster than GDP growth for the 2016–2025 period, though it substantially exceeded GDP growth in a number of years that were not affected by the COVID-19 pandemic. Per capita SMI expenditure growth for 2026–2035 is projected to again significantly exceed growth in GDP. Then it is expected to slow and increase only slightly faster than GDP growth after 2050 because of several legislatively specified payment updates, including those for physician prices.

**Table II.F2.—Average Annual Rates of Growth in SMI and the Economy**  
[In percent]

Calendar years	SMI			U.S. Economy			Growth differential <sup>1</sup>
	Beneficiary population	Per capita expenditures	Total expenditures	Total population	Per capita GDP	Total GDP	
Historical data:							
1968–2004	2.1%	10.8%	13.2%	1.0%	6.4%	7.4%	5.4%
2005–2015	2.5	6.5 <sup>2</sup>	9.2 <sup>2</sup>	0.8	2.6	3.4	5.5 <sup>2</sup>
2016–2025	2.3	5.1	7.5	0.6	4.7	5.3	2.1
Intermediate estimates:							
2026–2035	1.7	6.3	8.1	0.3	3.7	4.0	3.9
2036–2050	0.4	4.8	5.3	0.2	3.6	3.9	1.4
2051–2075	0.6	3.7	4.4	0.2	3.6	3.7	0.6
2076–2100	0.2	3.7	3.9	0.1	3.6	3.7	0.2

<sup>1</sup>Excess of total SMI expenditure growth above total GDP growth, calculated as a multiplicative differential.

<sup>2</sup>Includes the addition of the prescription drug benefit to the SMI program in 2006. Excluding 2006, the average annual per capita expenditure increase is 3.6 percent, the total expenditure increase is 6.3 percent, and the growth differential is 3.0 percent.

The availability of SMI Part B and Part D benefits greatly reduces the costs that beneficiaries would otherwise pay for health care services. The introduction of the prescription drug benefit increased beneficiaries’ costs for SMI premiums and cost sharing, but it reduced their costs for previously uncovered services by substantially more.

As SMI per capita benefits grow faster than average income or per capita GDP, the premiums and coinsurance amounts paid by beneficiaries represent a growing share of their total income. Figure II.F2 compares past and projected growth in average benefits for SMI versus Social Security. The figure also shows amounts for the standard premium and average cost sharing for Part B, as well as the

### *Overview*

average basic premium and basic cost sharing for Part D.<sup>39</sup> To facilitate comparison across long time periods, all values are in constant 2025 dollars.

Over time, the average Social Security benefit tends to increase at about the rate of growth in average earnings. Health care costs generally reflect increases in the earnings of health care professionals, growth in the utilization and intensity of services, and other medical cost inflation.

As indicated in figure II.F2, average SMI benefits were only about one-twelfth the level of average Social Security benefits in 1970 but grew to more than one-third by 2005. With the introduction of the Part D prescription drug benefit in 2006, this ratio grew to almost one-half. Under the intermediate projections, SMI benefits would continue increasing at a faster rate and would represent more than 85 percent of the average Social Security retired-worker benefit in 2100.


Average beneficiary premiums and cost-sharing payments for SMI will increase at about the same rate as average SMI benefits.<sup>40</sup> Therefore, over time, a growing proportion of most beneficiaries' Social Security benefit may be needed to pay their SMI premiums and cost-sharing amounts.

---

<sup>39</sup>Average cost sharing for Part B is based on its defined benefits, while basic premiums and cost sharing for Part D reflect the defined standard benefit or actuarially equivalent benefits.

<sup>40</sup>As a result, the projected ratio of average SMI out-of-pocket payments to average SMI benefits is nearly constant over time.

**Figure II.F2.—Comparison of Average Monthly SMI Benefits, Premiums, and Cost Sharing to the Average Monthly Social Security Benefit**  
 [Amounts in constant 2025 dollars]



Most SMI enrollees have other income in addition to Social Security benefits. Other possible sources include earnings from employment, employer-sponsored pension benefits, and investment earnings. In addition, most draw down their accumulated assets to supplement their income in retirement.

For simplicity, the comparisons in figure II.F2 apply to Social Security benefits only. A comparison of average SMI premiums and cost-sharing amounts to average total beneficiary income would likely lead to similar conclusions.

The Trustees estimate that the average Part B plus Part D premium would equal about 12 percent of the average Social Security benefit in 2026 but would increase to almost 21 percent in 2100. Similarly, an average cost-sharing amount in 2026 would be equivalent to about 15 percent of the Social Security benefit but would increase to about 20 percent in 2100. The combination of premium and cost-sharing amounts for Parts B and D would equal about 27 percent of the average Social Security benefit in 2026 and would increase to an estimated 41 percent in 2100.

The average OASI benefit amount for all retired workers is the basis for the Social Security benefits shown in figure II.F2. Individual retirees may receive significantly more or less than the average,

### *Overview*

depending on their past earnings and other factors. For purposes of illustration, the figure shows the average SMI benefit value and cost-sharing liability for all beneficiaries.

The value of SMI benefits and the cost-sharing payments of individual enrollees both vary more substantially than OASI benefits, depending on the enrollees' income, assets, and use of covered health services in a given year.

Medicaid pays Part B premiums and cost-sharing amounts for beneficiaries with very low incomes, and the Medicare low-income drug subsidy pays the corresponding Part D amounts (except for nominal copayments). Moreover, high-income beneficiaries have paid an income-related premium for Part B since 2007 and for Part D since 2011. Further information on this comparison and the variations from the average results is available in a memorandum by the CMS Office of the Actuary at <http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Beneficiaryoop.html>.

Another way to evaluate the implications of rapid SMI cost growth is to compare transfers from the general fund of the Treasury to the SMI trust fund with total Federal income taxes (personal and corporate income taxes). Table II.F3 shows SMI government contributions as a percentage of total Federal income taxes. If these taxes in the future maintain their historical average level of the last 50 years relative to the national economy, then, based on the intermediate assumptions, SMI government contributions in 2100 will represent about 38.3 percent of total income taxes.

**Table II.F3.—SMI Government Contributions as a Percentage of Personal and Corporate Federal Income Taxes**

Fiscal year	Percentage of income taxes <sup>1</sup>
Historical data:	
1970	0.8%
1980	2.2
1990	5.9
2000	5.4
2010	19.6
2015	14.0
2016	16.2
2017	16.4
2018	16.8
2019	17.0
2020	19.6
2021	18.5
2022	13.3
2023	16.9
2024	16.1
2025	17.6
Intermediate Estimates:	
2030	22.0
2040	28.6
2050	31.5
2060	33.5
2070	35.8
2080	37.5
2090	38.3
2100	38.3

<sup>1</sup>Includes the Part D prescription drug benefit beginning in 2006.

These examples illustrate the significant impact of SMI expenditure growth on beneficiaries, taxpayers, and the Federal budget. The projected SMI expenditure increases associated with the cost of providing health care, plus the impact of the baby boom generation reaching eligibility age, would continue to require a growing share of available economic resources to finance these costs. This outlook reinforces the Trustees' recommendation to develop and enact further reforms to address the SMI expenditure growth rate.

### ***G. CONCLUSION***

Total Medicare expenditures were \$1,210.1 billion in 2025, and the Board projects that they will increase in most future years at a somewhat faster pace than either aggregate workers' earnings or the economy overall. The faster increase is primarily due to the number of beneficiaries increasing more rapidly than the number of workers, coupled with an increase in the volume and intensity of services delivered. Based on the intermediate set of assumptions under current law, Medicare expenditures as a percentage of GDP would increase from the current 3.9 percent to a projected 7.5 percent by 2100.

As it has since 2004, the HI trust fund fails to meet the Board of Trustees' short-range test of financial adequacy. In addition, as in all past reports, the HI trust fund fails to meet the Trustees' long-range test of close actuarial balance.

HI has experienced surpluses since 2021, and they are expected to continue through 2026 and then turn to deficits for the remainder of the 75-year projection period. The projected trust fund depletion date is in the second quarter of 2033, one quarter earlier than estimated in last year's report.

The HI actuarial deficit in this year's report is 0.56 percent of taxable payroll, up from 0.42 percent in last year's report. The cost rate projections in this year's report are mostly consistent with last year's projection through 2050 and then higher through 2100, and the projected income rates are lower than those in the 2025 report. The cost rate projections are ultimately higher than in last year's report due to changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower taxable payroll projections.

The financial outlook for SMI is fundamentally different than for HI as a result of the statutory differences in the methods of financing for these two components of Medicare.

The Trustees project that both the Part B and Part D accounts of the SMI trust fund will remain in financial balance for all future years because beneficiary premiums and general fund transfers are assumed to be set at a level to meet expected costs each year. However, SMI costs are projected to increase significantly as a share of GDP over the next 75 years, from 2.5 percent to 5.1 percent under current law.

## *Conclusion*

The projected Part B costs as a share of GDP in this report are lower in the short range than the Part B costs in the 2025 report mainly because of the assumed impact of policy changes for skin substitutes, which are categorized as physician-administered drugs. Faster projected growth for other Part B drugs cause expenditures as a percentage of GDP to be higher than in last year's report by 2048. Thereafter, expenditures as a percentage of GDP grow faster than in last year's report due to lower GDP projections that result from the changes in demographic assumptions mentioned previously.

For Part D, the expenditure share of GDP is significantly higher than the share in last year's report in all years. This is mainly due to increases in the utilization of GLP-1 and expensive specialty drugs in 2025. Additionally, projected growth is higher than in last year's report because of higher cost trends and lower projected DIR through the short-range period. In the long-range period, this difference grows due to the changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower GDP projections.

The financial projections shown for the Medicare program in this report reflect current-law payment updates. These payment updates would probably not be viable indefinitely for most health care provider categories without fundamental changes in the current delivery system.

Considering these issues with provider payment rates, the Trustees note that the actual future costs for Medicare could exceed those shown in this report. Projections under an alternative scenario, as provided in section V.C and in a memorandum from the Office of the Actuary,<sup>41</sup> can help illustrate the potential magnitude of the understatement. For example, the total cost of Medicare in 2100 would be 9.8 percent of GDP under the alternative projections (versus 7.5 percent under current law), and the HI actuarial deficit would be 1.38 percent of taxable payroll (versus 0.56 percent). The projected depletion date for the HI trust fund would be unchanged.

Readers should interpret the current law projections shown in this report as illustrations of the very favorable impact of permanently slower growth in health care costs within Medicare, relative to the assumed costs for the rest of the health sector, if such slower growth is achieved over the projection period. The illustrative alternative

---

<sup>41</sup>See <https://www.cms.gov/files/document/illustrative-alternative-scenario-2026.pdf>.

## *Overview*

projections show the assumed higher costs if slower growth cannot be achieved under current law.

Policymakers should determine effective solutions to the long-range HI financial imbalance. Even assuming that the provider payment rates will be adequate, HI revenues would cover 89 percent of estimated expenditures in 2033 and 85 percent in 2050. Policymakers should also consider the likelihood that the price adjustments in current law may prove difficult to adhere to fully and may require even more changes to address the financial imbalance.

The projections in this year's report continue to demonstrate the need for timely and effective action to address Medicare's remaining financial challenges—including the HI trust fund's projected depletion, this fund's long-range financial imbalance, and the rapid growth in Medicare expenditures. Furthermore, if the growth in Medicare costs is comparable to growth under the illustrative alternative projections, then policy reforms will have to address much larger financial challenges than those assumed under current law.

The Board of Trustees believes that solutions can and must be found to ensure the financial integrity of HI and reduce the rate of growth in Medicare costs. The sooner solutions are enacted, the more flexible and gradual they can be. The early introduction of reforms also increases the time available for affected individuals and organizations—including health care providers, beneficiaries, and taxpayers—to adjust their expectations and behavior. The Board recommends that Congress and the executive branch work together to quickly address these challenges.

### III. ACTUARIAL ANALYSIS

#### A. INTRODUCTION

The Actuarial Analysis section focuses on the costs and financing of the individual HI and SMI trust fund accounts. The Trustees perform an analysis for each trust fund individually, to determine whether each account's income and expenditures are balanced as necessary to maintain solvency. (It is also valuable to consider Medicare's total expenditures and the sources and relative magnitudes of the program's revenues. Section V.B presents such information for Medicare overall.)

For this report, projections are shown in two different ways. The cash basis reflects the date when payment for the service was made, whereas the incurred basis reflects the date when the service was performed. The projections are first prepared on an incurred basis, and then adjustments are made to account for costs on a cash basis. Generally, trust fund operations show the actual or projected income and expenditures on a cash basis, while analysis and methodology are presented on an incurred basis.

The HI and SMI trust funds are separate and distinct, each with its own sources of financing. There are no provisions for using HI revenues to finance SMI expenditures, or vice versa, or for lending assets between the two trust funds. Moreover, the benefit provisions, financing methods, and, to a lesser degree, eligibility rules are very different between these Medicare components. In particular, both accounts of the SMI trust fund are automatically in financial balance, whereas the HI fund is not.

For these reasons, the Trustees can evaluate the financial status of the Medicare trust funds only by separately assessing the status of each fund. Sections III.B, III.C, and III.D of this report present such assessments for HI (Part A), SMI Part B, and SMI Part D, respectively. The Trustees also provide key results based on an illustrative alternative scenario in section V.C.

**B. HI FINANCIAL STATUS**

This section presents actual HI trust fund operations in 2025 and HI trust fund projections for the next 75 years. Section III.B1 discusses HI financial results for 2025, and sections III.B2 and III.B3 discuss the short-range HI projections and the long-range projections, respectively. The projections shown in sections III.B2 and III.B3 assume no changes will occur in the statutory provisions and regulations under which HI now operates.<sup>42</sup>

**1. Financial Operations in Calendar Year 2025**

On July 30, 1965, the Social Security Act established the Federal Hospital Insurance Trust Fund as a separate account in the U.S. Treasury. All the HI financial operations occur within this fund.

Table III.B1 presents a statement of the revenue and expenditures of the fund in calendar year 2025, and of its assets at the beginning and end of the calendar year.

The total assets of the trust fund amounted to \$237.5 billion on December 31, 2024. During calendar year 2025, total revenue amounted to \$462.4 billion, and total expenditures were \$444.2 billion. Total assets thus increased by \$18.2 billion during the year to \$255.7 billion on December 31, 2025.

---

<sup>42</sup>The one exception is that the projections disregard payment reductions that would result from the projected depletion of the HI trust fund.

**Table III.B1.—Statement of Operations of the HI Trust Fund  
during Calendar Year 2025**  
[In thousands]

Total assets of the trust fund, beginning of period .....	\$237,496,412
Revenue:	
Payroll taxes .....	\$403,211,638
Income from taxation of OASDI benefits.....	41,054,000
Interest on investments .....	9,101,036
Premiums collected from voluntary participants .....	5,726,522
Premiums collected from Medicare Advantage participants.....	251,908
ACA Medicare shared savings program receipts.....	435,541
Transfer from Railroad Retirement account.....	686,200
Reimbursement, transitional uninsured coverage.....	44,000
Reimbursement, program management general fund .....	573,403
Interfund interest payments to OASDI <sup>1</sup> .....	-1,712
Interest on reimbursements, Railroad Retirement .....	30,092
Other .....	603
Reimbursement, union activity .....	1,286
Fraud and abuse control receipts:	
Criminal fines .....	10,523
Civil monetary penalties.....	33,493
Civil penalties and damages, Department of Justice .....	564,375
Asset forfeitures, Department of Justice.....	161,588
3% administrative expense reimbursement, Department of Justice .....	25,282
General fund appropriation fraud and abuse, FBI.....	173,565
General fund transfer, Discretionary.....	334,977
Total revenue.....	<u>\$462,418,321</u>
Expenditures:	
Net benefit payments .....	\$438,338,836
Administrative expenses:	
Treasury administrative expenses .....	164,729
Salaries and expenses, SSA <sup>2</sup> .....	1,322,609
Salaries and expenses, CMS <sup>3</sup> .....	1,770,858
Salaries and expenses, Office of the Secretary, HHS .....	96,104
Medicare Payment Advisory Commission .....	8,294
Medicare Access Children's Health Insurance Program (CHIP) .....	-352
Fraud and abuse control expenses:	
HHS Medicare integrity program.....	1,085,178
HHS Office of Inspector General .....	262,447
Department of Justice .....	84,392
FBI .....	119,788
HCFAC Discretionary, CMS.....	904,888
HCFAC Department of Justice Discretionary, CMS .....	32,954
HCFAC Office of Inspector General Discretionary, CMS .....	24,320
Total administrative expenses .....	<u>5,876,208</u>
Total expenditures .....	<u>\$444,215,044</u>
Net addition to the trust fund.....	18,203,276
Total assets of the trust fund, end of period .....	<u>\$255,699,688</u>

<sup>1</sup>Reflects interest adjustments on the reallocation of administrative expenses among the Medicare trust funds, the OASDI trust funds, and the general fund of the Treasury. Estimated payments are made from the trust funds and then are reconciled, with interest, the next year when the actual costs are known. A positive figure represents a transfer to the HI trust fund from the other trust funds. A negative figure represents a transfer from the HI trust fund to the other funds.

<sup>2</sup>For facilities, goods, and services provided by the Social Security Administration (SSA).

<sup>3</sup>Includes expenses of the Medicare Administrative Contractors.

Note: Totals do not necessarily equal the sums of rounded components.

### ***a. Revenues***

The trust fund's primary source of income consists of amounts appropriated to it, under permanent authority, on the basis of taxes paid by workers, their employers, and individuals with

*Actuarial Analysis*

self-employment earnings, in work covered by HI. Included in HI are workers covered under the OASDI program, those covered under the Railroad Retirement program, and certain Federal, State, and local employees not otherwise covered under the OASDI program.

HI taxes are payable without limit on a covered individual's total wages and self-employment earnings. For calendar years prior to 1994, taxes were computed on a person's annual earnings up to a specified maximum annual amount called the *maximum tax base*. Table III.B2 presents the maximum tax bases for 1966–1993. Legislation enacted in 1993 removed the limit on taxable income beginning in calendar year 1994.

Table III.B2 also shows the HI tax rates applicable in each of calendar years 1966 and later. For 2027 and thereafter, the tax rates shown are the rates scheduled in current law. As indicated in the footnote to the table, in 2013 and later employees and self-employed individuals pay an additional HI tax of 0.9 percent on their earnings above certain thresholds.

**Table III.B2.—Tax Rates and Maximum Tax Bases**

Calendar years	Maximum tax base	Tax rate (Percentage of taxable earnings)	
		Employees and employers, each	Self-employed
Past experience:			
1966	\$6,600	0.35%	0.35%
1967	6,600	0.50	0.50
1968–71	7,800	0.60	0.60
1972	9,000	0.60	0.60
1973	10,800	1.00	1.00
1974	13,200	0.90	0.90
1975	14,100	0.90	0.90
1976	15,300	0.90	0.90
1977	16,500	0.90	0.90
1978	17,700	1.00	1.00
1979	22,900	1.05	1.05
1980	25,900	1.05	1.05
1981	29,700	1.30	1.30
1982	32,400	1.30	1.30
1983	35,700	1.30	1.30
1984	37,800	1.30	2.60
1985	39,600	1.35	2.70
1986	42,000	1.45	2.90
1987	43,800	1.45	2.90
1988	45,000	1.45	2.90
1989	48,000	1.45	2.90
1990	51,300	1.45	2.90
1991	125,000	1.45	2.90
1992	130,200	1.45	2.90
1993	135,000	1.45	2.90
1994–2012	no limit	1.45	2.90
2013–2026	no limit	1.45 <sup>1</sup>	2.90 <sup>1</sup>
Scheduled in current law:			
2027 & later	no limit	1.45 <sup>1</sup>	2.90 <sup>1</sup>

<sup>1</sup>Beginning in 2013, workers pay an additional 0.9 percent of their earnings above \$200,000 (for those who file an individual tax return) or \$250,000 (for those who file a joint income tax return).

### *HI Financial Status*

Total HI payroll tax income in calendar year 2025 amounted to \$403.2 billion—an increase of 1.7 percent over the amount of \$396.4 billion for the preceding 12-month period. This increase occurred primarily because both the number of covered workers and average wages were higher.

Up to 85 percent of an individual's or couple's OASDI benefits may be subject to Federal income taxation if their income exceeds certain thresholds. The income tax revenue attributable to the first 50 percent of OASDI benefits is allocated to the OASI and DI trust funds. The revenue associated with the amount between 50 and 85 percent of benefits is allocated to the HI trust fund. Income from the taxation of OASDI benefits amounted to \$41.1 billion in calendar year 2025.

Another substantial source of trust fund income is interest credited from investments in government securities held by the fund. In calendar year 2025, the fund received \$9.1 billion in such interest. A description of the trust fund's investment procedures appears later in this section.

Section 1818 of the Social Security Act provides that certain persons not otherwise eligible for HI protection may obtain coverage by enrolling in HI and paying a monthly premium. In 2025, premiums collected from such voluntary participants (or paid on their behalf by Medicaid) amounted to about \$5.7 billion.

The Railroad Retirement Act provides for a system of coordination and financial interchange between the Railroad Retirement program and the HI trust fund. This financial interchange requires a transfer that would place the HI trust fund in the same position in which it would have been if the Social Security Act had always covered railroad employment. In accordance with these provisions, a transfer of \$686 million in principal and about \$15 million in interest from the Railroad Retirement program's Social Security Equivalent Benefit Account to the HI trust fund balanced the two systems as of September 30, 2024. The trust fund received this transfer, together with interest to the date of transfer totaling about \$15 million, in June 2025.

Legislation in 1982 added transitional entitlement for those Federal employees who retire before having had a chance to earn sufficient quarters of Medicare-qualified Federal employment. The general fund of the Treasury provides reimbursement for the costs of this coverage, including administrative expenses. In calendar year 2025, such

### *Actuarial Analysis*

reimbursement amounted to \$44 million for estimated benefit payments for these beneficiaries.

Legislation in 1996 established a health care fraud and abuse control account within the HI trust fund. Monies derived from the fraud and abuse control program are transferred from the general fund of the Treasury to the HI trust fund. During calendar year 2025, the trust fund received about \$1,304 million from this program.

#### ***b. Expenditures***

The HI trust fund pays expenditures for HI benefit payments and administrative expenses. All HI administrative expenses incurred by the Department of Health and Human Services, the Social Security Administration, the Department of the Treasury (including the Internal Revenue Service), and the Department of Justice in administering HI are charged to the trust fund. Such administrative duties include payment of benefits, the collection of taxes, fraud and abuse control activities, and experiments and demonstration projects designed to determine various methods of increasing efficiency and economy in providing health care services, while maintaining the quality of such services, under HI and SMI.

In addition, Congress has authorized expenditures from the trust funds for construction, rental and lease, or purchase contracts of office buildings and related facilities for use in connection with the administration of HI. Although trust fund expenditures include these costs, the statement of trust fund assets presented in this report does not carry the net worth of facilities and other fixed capital assets because the proceeds of sales of such assets revert to the General Services Administration. Since the value of fixed capital assets does not represent funds available for benefit or administrative expenditures, the Trustees do not consider it in assessing the actuarial status of the funds.

Of the \$444.2 billion in total HI expenditures, \$438.3 billion represented net benefits paid from the trust fund for health services.<sup>43</sup> Net benefit payments increased 5.3 percent in calendar year 2025 over the corresponding amount of \$416.3 billion paid during the preceding calendar year. These payments reflect the change in the number of beneficiaries, the price of health services, and the volume and intensity

---

<sup>43</sup>Net benefits equal the total gross amounts initially paid from the trust fund during the year, less recoveries of overpayments identified through fraud and abuse control activities.

*HI Financial Status*

of services. Further information on HI benefits by type of service is available in section IV.A.

The remaining \$5.9 billion in expenditures was for net HI administrative expenses, after adjustments to the preliminary allocation of administrative costs among the Social Security and Medicare trust funds and the general fund of the Treasury. The expenditure amount of \$5.9 billion also included \$2.5 billion for the health care fraud and abuse control program.

***c. Actual experience versus prior estimates***

Table III.B3 compares the actual experience in calendar year 2025 with the estimates presented in the 2024 and 2025 annual reports. A number of factors can contribute to differences between estimates and subsequent actual experience. In particular, actual values for key economic and other variables can differ from assumed levels, and legislative and regulatory changes may occur after a report’s preparation.

As shown in table III.B3, actual HI payroll tax income in 2025 was slightly higher than estimated in the 2024 and 2025 reports because of higher levels of covered wages. Actual HI benefit payments in calendar year 2025 were lower than projected in the 2025 report and higher than those projected in the 2024 report.

**Table III.B3.—Comparison of Actual and Estimated Operations of the HI Trust Fund, Calendar Year 2025**  
[Dollar amounts in millions]

Item	Comparison of actual experience with estimates for calendar year 2025 published in—					
	Actual amount	Estimated amount <sup>1</sup>	2025 report		2024 report	
			Actual as a percentage of estimate	Estimated amount <sup>1</sup>	Actual as a percentage of estimate	
Payroll taxes	\$403,212	\$399,877	101%	\$397,980	101%	
Benefit payments <sup>2</sup>	438,339	443,174	99	426,702	103	

<sup>1</sup>Under the intermediate assumptions.

<sup>2</sup>Benefit payments include (i) additional premiums for Medicare Advantage plans that are deducted from beneficiaries’ Social Security benefits, (ii) costs of Quality Improvement Organizations, and (iii) health information technology payments.

***d. Assets***

The Department of the Treasury invests, on a daily basis, the portion of the trust fund not needed to meet current expenditures for benefits and administration in interest-bearing obligations of the U.S. Government. The Social Security Act authorizes the issuance of special public-debt obligations for purchase exclusively by the trust fund. The law requires that these special public-debt obligations bear interest at

### *Actuarial Analysis*

a rate based on the average market yield (computed on the basis of market quotations as of the end of the calendar month immediately preceding the date of such issue) for all marketable interest-bearing obligations of the United States forming a part of the public debt that are not due or callable until after 4 years from the end of that month. Currently, all invested assets of the HI trust fund are in the form of such special-issue securities.<sup>44</sup> Table V.H9, presented in section V.H, shows the assets of the HI trust fund at the end of fiscal years 2024 and 2025.

#### **2. 10-Year Actuarial Estimates (2026–2035)**

This section provides detailed information concerning the short-range financial status of the trust fund, including projected annual income, expenditures, differences between income and expenditures, and trust fund balances. Also discussed is the Trustees' test of short-range financial adequacy.


To illustrate the sensitivity of future costs to different economic and demographic factors and to portray a reasonable range of possible future trends, the Trustees show estimates under three alternative sets of economic and demographic assumptions—intermediate, low-cost, and high-cost assumptions. Because of the uncertainty inherent in such projections, however, the actual operations of the HI trust fund in the future could differ significantly from these estimates.

Figure III.B1 shows past and projected income and expenditures for the HI trust fund under the Trustees' intermediate assumptions. Following the Balanced Budget Act of 1997, the fund experienced annual surpluses through 2007. Beginning in 2008, expenditures exceeded total income, and this situation continued through 2015. In 2016 and 2017, the fund experienced small surpluses. In 2018 through 2019 there were deficits, and in 2020 there was a very large deficit because of the accelerated and advance payments made to providers. There was a small surplus in 2021, and a larger one in 2022, as these payments began to be repaid. Small surpluses occurred again in 2023, 2024, and 2025, with a small projected surplus expected in 2026. After 2026 annual deficits are expected to return and continue throughout the rest of the projection period.

---

<sup>44</sup>The Department of the Treasury may also make investments in obligations guaranteed as to both principal and interest by the United States, including certain federally sponsored agency obligations.

**Figure III.B1.—HI Expenditures and Income**  
[In billions]



The impact of the December 2007 through June 2009 recession on HI payroll tax income is apparent in figure III.B1. In 2009 and 2010, payroll taxes decreased substantially as a result of higher unemployment and slow growth in wages along with collection lags; these factors contributed to the \$32.3 billion trust fund deficit in 2010. For 2011 through 2015, revenues rebounded somewhat but not enough to reach the level of expenditures, which continued to grow because of increased enrollment and the regular updating of the payment rates. Together these factors resulted in a decline in trust fund deficits from \$27.7 billion in 2011 to \$3.5 billion in 2015.

In 2016 and 2017, a lower level of growth in expenditures combined with higher growth in payroll taxes led to surpluses of \$5.4 billion and \$2.8 billion, respectively, in the trust fund. In 2018 and 2019 the trend reversed, with a higher level of growth in expenditures and lower growth in payroll taxes leading to trust fund deficits of \$1.6 billion and \$5.8 billion, respectively. In 2020, a very large deficit of \$60.4 billion was reached because of the accelerated and advance payments to providers, which amounted to \$63.5 billion net of repayments and which were paid from the trust fund. The net repayments of about \$29.0 billion and \$33.8 billion of these payments were completed in 2021 and 2022, resulting in surpluses of \$8.5 billion and \$53.9 billion, respectively. In 2023, 2024, and 2025, there were surpluses of \$12.2 billion, \$28.7 billion, and \$18.2 billion, respectively.

### *Actuarial Analysis*

Despite the significant increase in the number of beneficiaries since 2010, expenditure growth has been slower than observed throughout the history of the program because of a reduction in price updates and low growth in the utilization of services. For example, since 2012, price updates for all HI providers have been reduced by the growth in economy-wide productivity.

HI expenditures are further affected by the *sequestration* required by current law, which reduces benefit payments by the following percentages: 2 percent from April 1, 2013, through April 30, 2020; 1 percent from April 1, 2022, through June 30, 2022; and 2 percent from July 1, 2022, through August 31, 2033.

Because of sequestration, non-salary administrative expenses are reduced by an estimated 5 to 7 percent from March 1, 2013, through August 31, 2033, excluding May 1, 2020, through March 31, 2022. (See section V.A for recent legislative changes affecting the sequestration of Medicare expenditures.)

As figure III.B1 illustrates, HI income increased at a faster rate during 2011–2016 than HI expenditures, in contrast to the situation that has prevailed during most of the program’s history. The recovery from the economic recession that ended in 2009 accelerated income growth during this period. At the same time, the provider payment updates mentioned previously slowed expenditure growth significantly. From 2017 through 2020, expenditures increased more rapidly than income; however, a reversal occurred in 2021 and 2022 that was attributable to repayment of the accelerated and advance payments and the slower rebound in utilization in those years, along with higher payroll tax income in 2022. In 2023, expenditures once again increased more rapidly than income. Although income grew more rapidly than expenditures in 2024, expenditure growth was faster in 2025 and is expected to be faster than income growth for most of the short-range projection period.

Table III.B4 shows the expected operations of the HI trust fund during calendar years 2026–2035 based on the intermediate set of assumptions, together with the past experience. Section IV.A of this report presents the detailed assumptions underlying the intermediate projections.

The increases in estimated income shown in table III.B4 primarily reflect increases in payroll tax income to the trust fund since such taxes are the main source of HI financing. As noted, payroll tax revenues increase in 2013 and later as a result of the additional 0.9-percent tax

### *HI Financial Status*

rate on earnings for high-income workers. For all other workers, while the payroll tax rate will remain constant under current law, covered earnings will increase every year under the intermediate assumptions because of projected increases in both the number of HI workers covered and the average earnings of these workers.

The income from taxation of Social Security benefits is affected by the 2017 Tax Cuts and Jobs Act that reduced individual income tax rates beginning in 2018. This provision was originally set to expire in 2026, but the One Big Beautiful Bill Act (OBBBA) made these reductions permanent.

Interest earnings have been a source of income to the trust fund for many years, surpassed only by payroll taxes and income from the taxation of OASDI benefits. As the trust fund balance continues to decrease, interest earnings will follow the same pattern.

The Trustees project that over the next 10 years most of the remaining sources of financing for the HI trust fund will increase along with payroll tax revenues and covered earnings. More detailed descriptions of these sources of income were discussed earlier in this section.

Table III.B4.—Operations of the HI Trust Fund during Calendar Years 1970–2035

Calendar year	Income								Expenditures			Trust fund	
	Payroll taxes	Income from taxation of benefits	Railroad Retirement account transfers	Reimbursement for uninsured persons	Premiums from voluntary enrollees	Payments for military wage credits	Interest and other <sup>1,2</sup>	Total	Benefit payments <sup>2,3</sup>	Administrative expenses <sup>4</sup>	Total	Net change	Fund at end of year
Historical data:													
1970	\$4.9	—	\$0.1	\$0.9	—	\$0.0	\$0.2	\$6.0	\$5.1	\$0.2	\$5.3	\$0.7	\$3.2
1975	11.5	—	0.1	0.6	\$0.0	0.0	0.7	13.0	11.3	0.3	11.6	1.4	10.5
1980	23.8	—	0.2	0.7	0.0	0.1	1.1	26.1	25.1	0.5	25.6	0.5	13.7
1985	47.6	—	0.4	0.8	0.0	-0.7 <sup>5</sup>	3.4	51.4	47.6	0.8	48.4	4.8 <sup>6</sup>	20.5
1990	72.0	—	0.4	0.4	0.1	-1.0 <sup>7</sup>	8.5	80.4	66.2	0.8	67.0	13.4	98.9
1995	98.4	\$3.9	0.4	0.5	1.0	0.1	10.8	115.0	116.4	1.2	117.6	-2.6	130.3
2000	144.4	8.8	0.5	0.5	1.4	0.0	11.7	167.2	128.5 <sup>8</sup>	2.6	131.1	36.1	177.5
2005	171.4	8.8	0.4	0.3	2.4	0.0	16.1	199.4	180.0	2.9	182.9	16.4	285.8
2010	182.0	13.8	0.5	-0.1	3.3	0.0	16.1	215.6	244.5	3.5	247.9	-32.3	271.9
2015	241.1	20.2	0.6	0.2	3.2	0.0	10.1	275.4	273.4	5.5	278.9	-3.5	193.8
2016	253.5	23.0	0.7	0.2	3.3	0.0	10.1	290.8	280.5	4.9	285.4	5.4	199.1
2017	261.5	24.2	0.6	0.1	3.5	0.0	9.4	299.4	293.3	3.2 <sup>9</sup>	296.5	2.8	202.0
2018	268.3	24.2	0.6	0.1	3.6	0.0	9.8	306.6	303.0	5.2	308.2	-1.6	200.4
2019	285.1	23.8	0.6	0.1	3.9	0.0	9.0	322.5	322.8	5.4	328.3	-5.8	194.6
2020	303.3	26.9	0.6	0.1	4.0	0.0	6.7	341.7	397.7 <sup>10</sup>	4.5	402.2	-60.4	134.1
2021	302.5	25.0	0.6	0.1	4.2	0.0	5.1	337.4	323.6 <sup>10</sup>	5.3	328.9	8.5	142.7
2022	352.8	32.8	0.5	0.1	4.5	0.0	5.9	396.6	337.4 <sup>10</sup>	5.3	342.7	53.9	196.6
2023	367.2	35.0	0.6	0.1	4.7	0.0	7.9	415.3	397.5 <sup>10</sup>	5.6	403.1	12.2	208.8
2024	396.4	39.8	0.7	0.0	4.8	0.0	9.4	451.2	416.3	6.2	422.5	28.7	237.5
2025	403.2	41.1	0.7	0.0	5.7	0.0	11.7	462.4	438.3	5.9	444.2	18.2	255.7
Intermediate estimates:													
2026	419.6	47.0	0.7	0.0	6.9	0.0	12.5	486.7	474.3	6.2	480.5	6.2	261.9
2027	441.6	52.1	0.7	0.0	7.4	0.0	12.6	514.5	518.4	6.5	524.9	-10.5	251.4
2028	464.5	56.8	0.7	0.0	7.9	0.0	12.3	542.4	556.8	6.9	563.6	-21.3	230.1
2029	488.0	61.6	0.8	0.0	8.5	0.0	11.7	570.5	596.1	7.2	603.3	-32.8	197.4
2030	512.7	66.6	0.8	0.0	9.0	0.0	10.5	599.6	636.0	7.5	643.5	-43.9	153.5
2031	538.5	71.6	0.8	0.0	9.7	0.0	8.6	629.1	677.5	7.9	685.3	-56.2	97.3
2032	564.4	76.9	0.8	0.0	10.3	0.0	5.9	658.4	719.3	8.2	727.5	-69.2	28.1
2033 <sup>11</sup>	591.6	83.0	0.8	0.0	11.1	0.0	3.6	690.0	766.4	8.7	775.1	-85.0	-56.9
2034 <sup>11</sup>	617.4	89.0	0.9	0.0	11.9	0.0	1.0	720.2	822.4	9.4	831.7	-111.6	-168.5
2035 <sup>11</sup>	644.2	94.9	0.9	0.0	12.6	0.0	-3.5	749.2	867.5	9.8	877.3	-128.1	-296.5

<sup>1</sup>Other income includes recoveries of amounts reimbursed from the trust fund that are not obligations of the trust fund, receipts from the fraud and abuse control program, and a small amount of miscellaneous income. These receipts amount to \$2.0–\$3.1 billion each year for the 10-year projection period.

<sup>2</sup>Values after 2005 include additional premiums for Medicare Advantage (MA) plans that are deducted from beneficiaries' Social Security benefits. These additional premiums are beneficiary obligations and occur when a beneficiary chooses an MA plan whose monthly plan payment exceeds the benchmark amount. Beneficiaries subject to such premiums may choose to either reimburse the plans directly or have the premiums deducted from their Social Security benefits. The premiums deducted from the Social Security benefits are transferred to the HI and SMI trust funds and then transferred from the trust funds to the plans.

<sup>3</sup>Includes costs of Peer Review Organizations from 1983 through 2001 (beginning with the implementation of the prospective payment system on October 1, 1983) and costs of Quality Improvement Organizations beginning in 2002.

<sup>4</sup>Includes costs of experiments and demonstration projects. Beginning in 1997, includes fraud and abuse control expenses.

<sup>5</sup>Includes a lump-sum adjustment of –\$0.8 billion transferred from the HI trust fund to the general fund of the Treasury.

<sup>6</sup>Includes repayment of loan principal, from the OASI trust fund, of \$1.8 billion.

<sup>7</sup>Includes a lump-sum adjustment of –\$1.1 billion transferred from the HI trust fund to the general fund of the Treasury.

<sup>8</sup>For 1998 through 2003, includes monies transferred to the SMI trust fund for home health agency costs.

<sup>9</sup>Reflects a larger-than-usual downward adjustment of \$1.8 billion for prior-year allocations among Part A, Part B, and Part D.

<sup>10</sup>Includes net payments of \$63.5 billion made through the Medicare Accelerated and Advance Payments Program in calendar year 2020 and subsequent net repayments of \$29.0 billion, \$33.8 billion, and \$0.5 billion in calendar years 2021 through 2023, respectively.

<sup>11</sup>Estimates for 2033 and later are hypothetical since the HI trust fund would be depleted in those years.

Note: Totals do not necessarily equal the sums of rounded components.

*Actuarial Analysis*

The Trustees have recommended maintenance of HI trust fund assets at a level of at least 100 percent of annual expenditures throughout the projection period. Such a level would provide a cushion of several years in the event that income falls short of expenditures, thereby allowing time for policymakers to implement legislative corrections. The trust fund balance has been below 1 year's expenditures in every year since 2012 and is not projected to reach that level under the intermediate assumptions.

The Trustees have also prepared projections using two alternative sets of assumptions. Table III.B5 summarizes the estimated operations under all three alternatives. Section IV.A presents in substantial detail the assumptions underlying the intermediate assumptions, as well as the assumptions used in preparing estimates under the low-cost and high-cost alternatives.

**Table III.B5.—Estimated Operations of the HI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions**  
[Dollar amounts in billions]

Calendar year	Total income	Total expenditures	Net increase in fund	Fund at end of year	Ratio of assets to expenditures <sup>1</sup> (percent)	Expenditures as a percentage of taxable payroll
Intermediate:						
2025 <sup>2</sup>	\$462.4	\$444.2	\$18.2	\$255.7	53%	3.37%
2026	486.7	480.5	6.2	261.9	53	3.49
2027	514.5	524.9	-10.5	251.4	50	3.65
2028	542.4	563.6	-21.3	230.1	45	3.74
2029	570.5	603.3	-32.8	197.4	38	3.82
2030	599.6	643.5	-43.9	153.5	31	3.88
2031	629.1	685.3	-56.2	97.3	22	3.95
2032	658.4	727.5	-69.2	28.1	13	4.00
2033 <sup>3</sup>	690.0	775.1	-85.0	-56.9	4	4.09
2034 <sup>3</sup>	720.2	831.7	-111.6	-168.5	— <sup>4</sup>	4.21
2035 <sup>3</sup>	749.2	877.3	-128.1	-296.5	— <sup>4</sup>	4.27
Low-cost:						
2025 <sup>2</sup>	462.4	444.2	18.2	255.7	53	3.35
2026	492.5	472.8	19.7	275.4	54	3.37
2027	535.5	508.9	26.5	301.9	54	3.40
2028	572.8	544.8	28.0	330.0	55	3.42
2029	612.4	579.4	33.0	363.0	57	3.42
2030	653.9	613.3	40.6	403.6	59	3.41
2031	698.3	648.4	49.9	453.5	62	3.40
2032	745.6	683.6	62.0	515.5	66	3.38
2033	797.3	724.4	72.9	588.4	71	3.38
2034	850.1	774.0	76.0	664.4	76	3.41
2035	904.7	812.2	92.5	756.9	82	3.39
High-cost:						
2025 <sup>2</sup>	462.4	444.2	18.2	255.7	53	3.38
2026	478.5	487.6	-9.1	246.6	52	3.62
2027	480.8	528.8	-47.9	198.7	47	3.95
2028	500.1	566.9	-66.8	131.9	35	4.10
2029	519.5	612.2	-92.7	39.2	22	4.27
2030 <sup>3</sup>	540.5	661.1	-120.6	-81.3	6	4.43
2031 <sup>3</sup>	563.1	713.6	-150.5	-231.9	— <sup>4</sup>	4.59
2032 <sup>3</sup>	583.7	766.7	-183.0	-414.9	— <sup>4</sup>	4.75
2033 <sup>3</sup>	603.1	824.6	-221.5	-636.4	— <sup>4</sup>	4.95
2034 <sup>3</sup>	619.3	892.0	-272.7	-909.0	— <sup>4</sup>	5.19
2035 <sup>3</sup>	633.8	948.4	-314.5	-1,223.6	— <sup>4</sup>	5.37

## *HI Financial Status*

<sup>1</sup>Ratio of assets in the fund at the beginning of the year to expenditures during the year.

<sup>2</sup>Figures for 2025 represent actual experience.

<sup>3</sup>Estimates are hypothetical for 2033 and later under the intermediate assumptions, and for 2030 and later under the high-cost assumptions, since the HI trust fund would be depleted in those years.

<sup>4</sup>Trust fund reserves would be depleted at the beginning of this year.

Note: Totals do not necessarily equal the sums of rounded components.

Because of the price assumptions for these alternative scenarios, the expenditures presented in these scenarios represent a narrow range of outcomes, and actual experience could easily fall outside of this range. For the low-cost scenario, the Trustees assume higher price inflation, which leads to higher spending. Similarly, under the high-cost scenario, the Trustees assume lower price inflation, which leads to lower spending. These price inflation assumptions partially offset the effects of the other assumptions in the high-cost and low-cost scenarios, resulting in a narrow range of expenditures. Given the considerable variation in the factors affecting health care spending, actual Part A experience could easily fall outside of this range. Because the taxable payroll assumptions in these scenarios are similarly affected by the price inflation assumptions, Part A expenditures as a percent of taxable payroll provide better insight into the variability of spending than the nominal dollar amounts, as shown in table III.B5.

The Board of Trustees has established an explicit test of short-range financial adequacy. The requirements of this test are conditional on the initial status of the HI trust fund ratio. If the fund ratio is at least 100 percent at the beginning of the projection period, the test requires that the ratio remain at or above 100 percent throughout the 10-year projection period. Alternatively, if the fund ratio is initially less than 100 percent, the test requires that the ratio reach a level of at least 100 percent within 5 years (with no depletion of the trust fund at any time during this period) and then remain at or above 100 percent throughout the rest of the 10-year period. The Trustees apply this test based on the intermediate projections.

The HI trust fund does not meet this short-range test. Failure of the trust fund to meet this test is an indication that HI solvency over the next 10 years is in question and that action is necessary to improve the short-range financial adequacy of the fund. While the short-range test is stringent, its purpose is to ensure that health care benefits continue to be available without interruption to the millions of aged and disabled Americans who rely on such coverage.

Table III.B6 shows the ratios of assets in the HI trust fund at the beginning of a calendar year to total expenditures during that year. As table III.B6 shows, the Trustees project that the trust fund ratio, which was below the 100-percent level at the beginning of 2025 and is

*Actuarial Analysis*

projected to decrease until the fund is depleted in 2033. Accordingly, the financing for HI is not considered adequate in the short range (2026–2035).

The projected trust fund depletion date is in the second quarter of 2033, one quarter earlier than estimated in last year’s report. HI income is projected to be lower than last year’s estimates due to lower taxation of Social Security benefits resulting from the OBBBA changes. HI expenditures are projected to be relatively close to last year’s estimates.

In total, for the period 2026–2035, income is \$51.6 billion (or about 0.8 percent) lower, and expenditures are \$4.3 billion (or about 0.1 percent) higher than projected in last year’s report.

**Table III.B6.—Ratio of Assets at the Beginning of the Year to Expenditures during the Year for the HI Trust Fund**

Calendar year	Ratio
Historical data:	
1967	28%
1970	47
1975	79
1980	52
1985	32
1990	128
1995	113
2000	108
2005	147
2010	123
2015	71
2016	68
2017	67
2018	66
2019	61
2020	48
2021	41
2022	42
2023	49
2024	49
2025	53
Intermediate Estimates:	
2026	53
2027	50
2028	45
2029	38
2030	31
2031	22
2032	13
2033	4
2034	— <sup>1</sup>
2035	— <sup>1</sup>


<sup>1</sup>Trust fund reserves would be depleted at the beginning of this year.

Figure III.B2 shows the historical trust fund ratios and the projected ratios under the three sets of assumptions. It also shows the declining level of assets (as a percentage of expenditures) through 2021, after

*HI Financial Status*

which the level of assets rises in 2022 and 2023. After remaining steady in 2024, the fund ratio rose in 2025 and declines afterward under the intermediate assumptions. Similarly, the fund ratio would rise until 2025 and subsequently decline under the high-cost assumptions. Only under conditions of robust economic growth and extremely low health care cost increases, as assumed in the low-cost alternative, would HI assets grow significantly relative to expenditures under current law.

**Figure III.B2.—HI Trust Fund Balance at the Beginning of the Year as a Percentage of Annual Expenditures**



The HI trust fund is projected to be depleted in 2033 under the intermediate assumptions. Under the low-cost assumptions, trust fund assets are projected to increase throughout the entire projection period, while asset depletion would occur in 2030 under the high-cost assumptions.

**3. Long-Range Estimates**

This section examines the long-range actuarial status of the trust fund under the three alternative sets of economic and demographic assumptions, while section IV.A summarizes the assumptions used in preparing projections.

The Trustees measure the long-range actuarial status of the HI trust fund by comparing, on a year-by-year basis, the non-interest income (from payroll taxes, taxation of OASDI benefits, premiums, general fund transfers for uninsured persons, and monies derived from the

### *Actuarial Analysis*

fraud and abuse control program) with the corresponding incurred costs, expressed as percentages of taxable payroll.<sup>45</sup> These percentages are referred to as *income rates* and *cost rates*, respectively.

Table III.B7 shows historical and projected HI costs and income under the intermediate assumptions, expressed as percentages of taxable payroll. The ratio of expenditures to taxable payroll has generally increased over time; it rose from 1.11 percent in 1967 to 3.46 percent in 1996—an increase that reflected rapid growth in HI expenditures, which more than offset growth in average earnings per worker, and increases in (and eventual elimination of) the maximum taxable wage base for HI.

Cost rates declined significantly during 1997–2000 to 2.63 percent because of favorable economic performance, the impact of legislation, and efforts to curb fraud and abuse in the Medicare program. The cost rate increased to 3.17 percent by 2005 as a result of legislation and, after remaining about level through 2007, increased rapidly to 3.75 percent in 2010, reflecting the impact of the recession, which lowered taxable payroll. The resulting deficit in 2010 as a percentage of taxable payroll was the largest since the program began (0.55 percent). Cost rates generally decreased from 2011 through 2015 as the economy recovered, while health care cost growth rates were low. Cost rates remained fairly level until 2020, when there was a slight increase that was attributable to very low growth in taxable payroll as a result of the pandemic. In 2021 and 2022, cost rates declined as utilization remained low during the pandemic. There was a very small rebound in 2023 as expenditures grew slightly faster than taxable payroll. The cost rate remained stable in 2024 as expenditures and taxable payroll grew at a nearly identical rate. The cost rate increased slightly in 2025 as expenditures grew faster than taxable payroll.

---

<sup>45</sup>Taxable payroll is the total amount of wages, salaries, tips, self-employment income, and other earnings subject to the HI payroll tax.

**Table III.B7.—HI Cost and Income Rates<sup>1</sup>**

Calendar year	Cost rates	Income rates	Difference <sup>2</sup>
Historical data:			
1967	1.11%	1.09%	-0.01%
1970	1.35	1.41	+0.07
1975	1.79	1.90	+0.11
1980	2.26	2.16	-0.10
1985	2.68	2.74	+0.06
1990	2.72	2.92	+0.21
1995	3.36	3.05	-0.30
2000	2.63	3.11	+0.49
2005	3.17	3.12	-0.05
2010	3.75	3.20	-0.55
2015	3.43	3.35	-0.09
2016	3.48	3.35	-0.12
2017	3.45	3.36	-0.09
2018	3.41	3.33	-0.08
2019	3.47	3.35	-0.12
2020	3.54	3.37	-0.17
2021	3.34	3.39	+0.05
2022	3.31	3.38	+0.07
2023	3.34	3.41	+0.07
2024	3.33	3.41	+0.08
2025	3.37	3.47	+0.10
Intermediate estimates:			
2026	3.49	3.49	0.00
2027	3.65	3.52	-0.14
2028	3.74	3.54	-0.20
2029	3.82	3.56	-0.26
2030	3.88	3.58	-0.31
2031	3.95	3.60	-0.35
2032	4.00	3.62	-0.39
2033	4.09	3.64	-0.45
2034	4.21	3.66	-0.55
2035	4.27	3.68	-0.58
2040	4.47	3.77	-0.70
2045	4.54	3.84	-0.70
2050	4.58	3.92	-0.66
2055	4.59	4.00	-0.60
2060	4.64	4.08	-0.55
2065	4.72	4.16	-0.56
2070	4.83	4.24	-0.59
2075	4.93	4.32	-0.61
2080	4.98	4.38	-0.60
2085	4.99	4.43	-0.56
2090	4.98	4.46	-0.52
2095	4.94	4.49	-0.45
2100	4.86	4.51	-0.35

<sup>1</sup>Based on the Trustees' intermediate assumptions and expressed as a percentage of taxable payroll. Taxable payroll includes statutory wage credits for military service for 1957–2001.

<sup>2</sup>Difference between the income rates and cost rates. Negative values represent deficits.


The Trustees expect growing deficits through about 2045, as cost rates grow faster than income rates. The increase in cost rates during this period is mostly attributable to rising per beneficiary spending and the impact of demographic shifts—notably, the aging of the baby boom population. After 2045, the size of the projected deficits decreases as subsequent demographic shifts reduce the growth in cost rates, resulting in cost-rate growth that is lower than income-rate growth. Projected HI expenditures are 4.58 and 4.86 percent of taxable payroll in 2050 and 2100, respectively. (Under the illustrative alternative

*Actuarial Analysis*

projections, the HI cost rates for 2050 and 2100 would equal 4.93 and 7.35 percent, respectively.)

Figure III.B3 shows the year-by-year costs as a percentage of taxable payroll for each of the three sets of assumptions. It also shows the income rates, but only for the intermediate assumptions in order to simplify the presentation.

**Figure III.B3.—Estimated HI Cost and Income Rates as a Percentage of Taxable Payroll**



Based on the intermediate assumptions, the Trustees project that cost rates will continue to exceed income rates in all years starting in 2027. By the end of the 75 years, the income rates and cost rates would be roughly equal. Throughout the period, cost rate growth is constrained by the productivity reductions in provider payments, and income rates continue to increase as a larger share of earnings becomes subject to the additional 0.9-percent payroll tax and a larger share of Social Security benefits becomes subject to income tax that is credited to the HI trust fund.

Under the more favorable economic and demographic conditions assumed in the low-cost assumptions, HI costs would be lower than scheduled income and surpluses would steadily grow throughout the entire 75-year projection period. This very favorable result is due in large part to HI expenditure growth rates that would average only about 5 percent per year, reflecting the combined effects of (i) slower

### *HI Financial Status*

growth in utilization and intensity of services and (ii) lower Medicare enrollment.

The high-cost projections illustrate the large financial imbalance that could occur if future economic conditions resemble those of the 1973–1995 period, if HI expenditure growth accelerates toward pre-1997 levels, and if fertility rates decline.<sup>46</sup>

The Trustees project costs beyond the initial 25-year period for the intermediate estimate based on the assumption that average HI expenditures per beneficiary will increase at a rate determined by the economic model described in sections II.C and IV.D, less the price update adjustments based on economy-wide productivity gains. This net rate is roughly the same as the increase in Gross Domestic Product (GDP) per capita in 2050 and declines to about 0.3 percentage point *slower* than the growth in GDP by 2100. Beyond the initial 25-year projection period, the low-cost and high-cost alternatives assume that HI cost increases, relative to taxable payroll increases, are initially 2 percentage points less rapid and 2 percentage points more rapid, respectively, than the results under the intermediate assumptions. The assumed initial 2-percentage-point differentials decrease gradually until the year 2075, when HI cost increases (relative to taxable payroll) are assumed to be the same as under the intermediate assumptions.

Figure III.B3 shows the cost rates over a 75-year valuation period in order to present fully the future economic and demographic developments that one may reasonably expect to occur, such as the impact of the large increase in the number of people over age 65 that began to take place in 2011. Growth occurs in part because the ratio of workers to beneficiaries will decrease as persons born during the period between the end of World War II and the mid-1960s (known as the baby boom generation) reach eligibility age and begin to receive benefits.


Figure III.B4 shows the projected ratio of workers per HI beneficiary from 1980 to 2100. As figure III.B4 indicates, the ratio was about 4 workers per beneficiary from 1980 through 2008. It began to decline initially because of the recession but then declined further because of the retirement of the baby boom generation.

---

<sup>46</sup>Actual experience during these periods was similar on average to the high-cost economic and programmatic assumptions for the future.

Actuarial Analysis

**Figure III.B4.—Workers per HI Beneficiary**  
[Based on intermediate assumptions]



While every beneficiary in 2025 had about 2.7 workers to pay for his or her HI benefit, in 2030 under the intermediate demographic assumptions there would be only about 2.5 workers for each beneficiary. This ratio would then continue to decline until there were only 2.0 workers per beneficiary in 2100. This reduction implies an increase in the HI cost rate of about 35 percent by 2100, relative to its current level, solely because of this demographic factor.<sup>47</sup>

While year-by-year comparisons of revenues and costs are necessary to measure the adequacy of HI financing, the financial status of the trust fund is often summarized, over a specific valuation period, by a single measure known as the *actuarial balance*. The actuarial balance of the HI trust fund is defined as the difference between the summarized income rate for the valuation period and the summarized cost rate for the same period.

The summarized income rates, cost rates, and actuarial balance are based upon the present values of future income, costs, and taxable payroll. The Trustees calculate the present values, as of the beginning of the valuation period, by discounting the future annual amounts of

---

<sup>47</sup>In addition to this factor, the projected increase in the HI cost rate reflects greater use of health care services as the beneficiary population ages and higher average costs per service because of medical price inflation and technological advances in care. The slower growth in Medicare payment rates to HI providers substantially offsets these increases.

### *HI Financial Status*

income and expenditures using the projected effective rates of interest credited to the HI trust fund for the first 10 years and transition to the ultimate interest rate assumption by year 15. They then determine the summarized income and cost rates over the projection period by dividing the present value of income and cost, respectively, by the present value of taxable payroll. The difference between the summarized income rate and cost rate over the long-range projection period (after an adjustment to take into account the fund balance at the valuation date and a target trust fund balance at the end of the valuation period) is the actuarial balance.

The summarized cost rate includes the cost of maintaining a trust fund balance at the end of the period equal to the following year's estimated costs. While a zero or positive actuarial balance implies that the end-of-period trust fund balance is at least as large as the target trust fund balance, there is no such implication for the trust fund balance at other times during the projection period.

Table III.B8 shows the actuarial balances based on the Trustees' three sets of economic and demographic assumptions, for the next 25, 50, and 75 years. Based on the intermediate set of assumptions, the summarized income rate for the entire 75-year period is 4.06 percent of taxable payroll and the summarized cost rate is 4.63 percent. As a result, the actuarial balance is -0.56 percent, and the HI trust fund fails to meet the Trustees' long-range test of close actuarial balance.<sup>48</sup>

One can interpret the actuarial balance as the percentage that could be added to the income rates and/or subtracted from the cost rates immediately and throughout the entire valuation period in order for the financing to support HI costs and provide for the targeted trust fund balance at the end of the projection period. The income rate increase according to this method is 0.56 percent of taxable payroll. However, if no such changes occurred until 2033, when the trust fund would be depleted, then the required increase would be 0.65 percent of taxable payroll under the intermediate assumptions.<sup>49</sup>

---

<sup>48</sup>This test is defined in section V.I.

<sup>49</sup>Actuarial balance could also be reached by reducing benefits by 12 percent every year immediately, or by making no change until 2033 and then reducing benefits by 16 percent.

*Actuarial Analysis*

**Table III.B8.—HI Actuarial Balances under Three Sets of Assumptions**

	Intermediate assumptions	Alternative	
		Low-Cost	High-Cost
Valuation periods: <sup>1</sup>			
25 years, 2026–2050:			
Summarized income rate	3.80	3.75	3.86
Summarized cost rate	4.42	3.29	6.03
Actuarial balance	-0.62	0.47	-2.17
50 years, 2026–2075:			
Summarized income rate	3.94	3.90	4.02
Summarized cost rate	4.53	2.81	7.44
Actuarial balance	-0.59	1.09	-3.42
75 years, 2026–2100:			
Summarized income rate	4.06	4.02	4.16
Summarized cost rate	4.63	2.64	8.11
Actuarial balance	-0.56	1.37	-3.95

<sup>1</sup>Income rates include beginning trust fund balances, and cost rates include the cost of attaining a trust fund balance at the end of the period equal to 100 percent of the following year's estimated expenditures.

Note: Totals do not necessarily equal the sums of rounded components.

The divergence in outcomes among the three sets of assumptions is apparent both in the estimated operations of the trust fund on a cash basis (as discussed in section III.B2) and in the 75-year summarized costs. Under the low-cost economic and demographic assumptions, the summarized cost rate for the 75-year valuation period is 2.64 percent of taxable payroll, the summarized income rate is 4.02 percent of taxable payroll, and the actuarial balance is 1.37 percent of taxable payroll; therefore, HI income rates would be adequate under the highly favorable conditions assumed in the low-cost alternative. Under the high-cost assumptions, the summarized cost rate for the 75-year projection period is 8.11 percent of taxable payroll, which is nearly twice the summarized income rate of 4.16 percent of taxable payroll, resulting in an actuarial balance of -3.95 percent of taxable payroll.

As suggested earlier, past experience has indicated that economic and demographic conditions that are as financially adverse as those assumed under the high-cost alternative can, in fact, occur over many years. Readers should view all of the alternative sets of economic and demographic assumptions as plausible. The wide range of results under the three sets of assumptions is indicative of the uncertainty of HI's future cost and its sensitivity to future economic and demographic conditions. Accordingly, it is important to maintain an adequate balance in the HI trust fund as a reserve for contingencies and to promptly address financial imbalances through corrective legislation.

Table III.B9 shows the long-range actuarial balance under the intermediate projections with its component parts—the present values of tax income, expenditures, and asset requirement of the HI program over the next 75 years.

**Table III.B9.—Components of 75-Year HI Actuarial Balance under Intermediate Assumptions (2026–2100)**

<b>Present value as of January 1, 2026 (in billions):</b>	
a. Payroll tax income .....	\$27,203
b. Taxation of benefits income .....	4,814
c. Fraud and abuse control receipts .....	131
d. Other Income.....	542
e. Total income (a + b + c + d).....	32,691
f. Expenditures .....	37,136
g. Expenditures minus income (f - e).....	4,446
h. Trust fund assets at start of period .....	256
i. Open-group unfunded obligation (g - h).....	4,190
j. Ending target trust fund <sup>1</sup> .....	359
k. Present value of actuarial balance (e - f + h - j).....	-4,549
l. Taxable payroll.....	810,511
<b>Percent of taxable payroll:</b>	
Actuarial balance (k ÷ l).....	-0.56%

<sup>1</sup>The calculation of the actuarial balance includes the cost of accumulating a target trust fund balance equal to 100 percent of annual expenditures by the end of the period.

Note: Totals do not necessarily equal the sums of rounded components.


The present value of future expenditures less future tax income, decreased by the amount of HI trust fund assets on hand at the beginning of the projection, amounts to \$4.2 trillion. This value is referred to as the 75-year *unfunded obligation* for the HI trust fund, and it is higher than last year’s value of \$3.1 trillion because of higher expenditures and lower income, as explained in more detail later in this section. The actuarial balance is like the unfunded obligation but with three differences. The first is that it is a measure of the degree to which the program is funded rather than unfunded and so is opposite in sign. The second is that it includes the target trust fund balance at the end of 75 years as a cost. The third difference is that it is expressed as a percentage of taxable payroll. Specifically, the actuarial balance is -0.56 percent of taxable payroll and is calculated as the trust fund balance plus the present value of revenues less the present value of costs (-\$4.2 trillion), less the present value of the target trust fund balance (\$359 billion), all divided by the present value of future taxable payroll (\$811 trillion).

Figure III.B5 shows the present values, as of January 1, 2026, of cumulative HI taxes less expenditures (plus the 2026 trust fund) through each of the next 75 years. The Trustees estimate these values under current-law expenditures and tax rates.

*Actuarial Analysis*

**Figure III.B5.—Present Value of Cumulative HI Taxes Less Expenditures through Year Shown, Evaluated under Current-Law Tax Rates and Legislated Expenditures**

[Present value as of January 1, 2026; in trillions]



The cumulative annual balance of the trust fund at the beginning of 2026 is about \$0.3 trillion. The cumulative present value steadily declines after 2027 because of the anticipated shortfall of tax revenues, relative to expenditures. The projected depletion date of the trust fund is 2033, at which time cumulative expenditures would have exceeded cumulative tax revenues by enough to equal the initial fund assets accumulated with interest. The downward slope over the next 50 years further illustrates the difference between the HI expenditures projected under current law and the financing currently scheduled to support these expenditures. The slope flattens at the end of the projection period because of the continuing effects of the slower payment rate updates that are required under current law.


As noted previously, over the full 75-year period, the fund has a projected present value unfunded obligation of \$4.2 trillion. This unfunded obligation indicates that if \$4.2 trillion were added to the trust fund at the beginning of 2026, the program would meet the projected cost of expenditures over the next 75 years. More realistically, additional annual revenues and/or reductions in expenditures, with a present value totaling \$4.2 trillion, would be necessary to reach financial balance (but with zero trust fund assets at the end of 2100).

### HI Financial Status

The estimated unfunded obligation of \$4.2 trillion and the closely associated present value of the actuarial deficit (\$4.5 trillion) are useful indicators of the sizable financial burden facing the American public. In other words, increases in revenues and/or reductions in benefit expenditures—equivalent to a lump-sum amount today of \$4.5 trillion—would be necessary to bring the HI trust fund into long-range financial balance. At the same time, long-range measures expressed in dollar amounts can be difficult to interpret, even when calculated as present values, which are sensitive to the underlying discount rate assumptions. For this reason, the Board of Trustees has customarily emphasized relative measures, such as the income rate and cost rate comparisons shown earlier in this section, and comparisons with the present value of future taxable payroll or GDP.

Figure III.B6 compares the year-by-year HI cost and income rates for the current annual report with the corresponding projections from the 2025 report.

**Figure III.B6.—Comparison of HI Cost and Income Rate Projections:  
Current versus Prior Year's Reports**



As figure III.B6 indicates, the intermediate HI cost rate projections in this year's report are mostly consistent with last year's projection through 2050 and then higher through 2100, and the projected income rates are lower than those in the 2025 report. The cost rate projections are ultimately higher than in last year's report due to changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower taxable payroll projections.

### *Actuarial Analysis*

The Trustees' estimate of the 75-year HI actuarial balance under the intermediate assumptions,  $-0.56$  percent of taxable payroll, is  $0.14$  percentage point less favorable than estimated in the 2025 annual report. The reasons for this change, which are listed in table III.B10, are explained below:

- (1) Change in valuation period: Updating the valuation period from 2025–2099 to 2026–2100 results in no change in the actuarial balance.
- (2) Updating the projection base: Actual 2025 incurred HI expenditures were lower than previously estimated, resulting in a  $0.06$ -percent increase in the actuarial balance.
- (3) Private health plan assumptions: Per capita expenditures for private health plans are higher than those estimated in last year's report. A technical correction increased the projection of MA benchmarks. In addition, higher projected enrollment in Medicare Advantage plans among higher-cost populations, including Special Needs Plans (SNPs), contributed to an increase in average MA per capita expenditures. The net effect of these modifications is a  $0.08$ -percent decrease in the actuarial balance.
- (4) Provider Assumptions: The primary change in hospital assumptions in this year's report is increased projections of Disproportionate Share (DSH) payments. In addition, there was lower utilization than assumed in last year's report. The combined impact of these changes for hospitals is a  $0.04$ -percent decrease in the actuarial balance. Higher assumed utilization for SNF and hospice services result in a  $0.05$ -percent decrease in the actuarial balance. Overall, the net impact of these and other provider changes is a  $0.09$ -percent decrease in the actuarial balance.
- (5) Other economic and demographic assumptions: The net effect of several adjustments to the economic and demographic assumptions is a  $0.05$ -percent increase in the actuarial balance. Several key economic assumptions lead to a  $0.08$ -percent increase in the actuarial balance, including lower short-range payment updates associated with faster productivity assumptions ( $0.02$ -percent increase) and lower health spending growth assumptions thereafter associated with slower per capita GDP growth ( $0.06$ -percent increase). This is somewhat offset by the net demographic assumptions ( $0.03$ -percent decrease), which is attributable to assumptions for fertility and immigration that impact taxable payroll ( $0.08$ -percent decrease) and demographic assumptions that affect enrollment, morbidity, and the age-sex-time to death factors that cumulatively increases the actuarial balance by  $0.05$  percent.

- (6) Legislative changes: The OBBBA permanently extended the 2017 Tax Cut and Jobs Act individual tax rate reductions, which lowered income from the taxation of Social Security benefits. This impact results in a 0.09-percent decrease in the actuarial balance.

**Table III.B10.—Change in the 75-Year Actuarial Balance since the 2025 Report**

1. Actuarial balance, intermediate assumptions, 2025 report	-0.42%
2. Changes:	
a. Valuation period	0.00
b. Base estimate	0.06
c. Private health plan assumptions	-0.08
d. Provider assumptions	-0.09
e. Other economic and demographic assumptions	0.05
f. Legislative Changes	-0.09
Net effect, above changes	-0.14
3. Actuarial balance, intermediate assumptions, 2026 report	-0.56

Note: Totals do not necessarily equal the sums of rounded components.

#### 4. Long-Range Sensitivity Analysis

The low-cost and high-cost estimates discussed in previous sections demonstrate the effects of varying all the principal assumptions simultaneously in order to portray a generally more optimistic or pessimistic future for the projected financial status of the HI trust fund. In contrast, this section presents estimates that illustrate the sensitivity of the long-range HI cost rate, income rate, and actuarial balance to changes in selected individual assumptions. In this sensitivity analysis, the intermediate set of assumptions is the reference point, and only one assumption at a time varies within that alternative. In each case, the Trustees assume that the provisions of current law remain unchanged throughout the 75-year projection period.

Each table that follows shows the effects of changing a particular assumption on the HI summarized income rates, summarized cost rates, and actuarial balances for 25-year, 50-year, and 75-year valuation periods. The discussion of the tables generally does not include the income rate, since it varies only slightly with changes in assumptions. The change in each of the actuarial balances is approximately equal to the change in the corresponding cost rate, but in the opposite direction. For example, a lower projected cost rate would result in an improvement or increase in the corresponding projected actuarial balance.

##### *a. Real-Wage Growth*

Table III.B11 shows the sensitivity of projected HI income rates, cost rates, and actuarial balances to the real-wage growth. The ultimate

*Actuarial Analysis*

real-wage growth will be 0.53 percentage point (high-cost alternative), 1.14 percentage points (intermediate projections), and 1.74 percentage points (low-cost alternative). In each case, the assumed ultimate annual increase in the CPI is 2.4 percent (as assumed for the intermediate projections).

Projected HI cost rates are fairly sensitive to the assumed growth rates in real wages. For the 75-year period 2026–2100, the summarized cost rate decreases from 5.03 percent (for real-wage growth of 0.53 percentage point) to 4.23 percent (for growth of 1.74 percentage points). The HI actuarial balance over this period shows an improvement for faster rates of growth in real wages.

**Table III.B11—Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various Real-Wage Growth Assumptions**  
[As a percentage of taxable payroll]

Valuation period	Average annual real-wage growth		
	0.53	1.14	1.74
Summarized income rate:			
25-year: 2026–2050	3.81	3.80	3.80
50-year: 2026–2075	3.91	3.94	3.98
75-year: 2026–2100	3.99	4.06	4.13
Summarized cost rate:			
25-year: 2026–2050	4.61	4.42	4.25
50-year: 2026–2075	4.83	4.53	4.25
75-year: 2026–2100	5.03	4.63	4.23
Actuarial balance:			
25-year: 2026–2050	-0.80	-0.62	-0.46
50-year: 2026–2075	-0.92	-0.59	-0.26
75-year: 2026–2100	-1.03	-0.56	-0.10

The sensitivity of the HI actuarial balance to different real-wage growth assumptions is significant, but not as substantial as one might intuitively expect. Higher real-wage growth immediately increases both HI expenditures for health care and wages for all workers. Though there is a full effect on wages and payroll taxes, the effect on benefits is only partial, since not all health care costs are wage related. The HI cost rate decreases with increasing real-wage growth because the higher real-wage levels increase the taxable payroll to a greater extent than they increase HI benefits. In particular, each 0.5-percentage-point increase in the assumed real-wage growth increases the long-range HI actuarial balance, on average, by about 0.38 percent of taxable payroll.

**b. Consumer Price Index**

Table III.B12 shows the sensitivity of projected HI income rates, cost rates, and actuarial balances to the rate of increase for the CPI. The ultimate annual increase in the CPI will be 3.0 percent (low-cost alternative), 2.4 percent (intermediate projections), and 1.8 percent (high-cost alternative).<sup>50</sup> In each case, the assumed ultimate real-wage growth is 1.14 percent (as assumed for the intermediate projections).

**Table III.B12.—Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various CPI-Increase Assumptions**  
[As a percentage of taxable payroll]

Valuation period	Ultimate percentage increase in the CPI		
	3.00	2.40	1.80
Summarized income rate:			
25-year: 2026–2050	3.86	3.80	3.74
50-year: 2026–2075	4.08	3.94	3.79
75-year: 2026–2100	4.21	4.06	3.85
Summarized cost rate:			
25-year: 2026–2050	4.41	4.42	4.43
50-year: 2026–2075	4.52	4.53	4.54
75-year: 2026–2100	4.62	4.63	4.64
Actuarial balance:			
25-year: 2026–2050	-0.55	-0.62	-0.69
50-year: 2026–2075	-0.44	-0.59	-0.75
75-year: 2026–2100	-0.41	-0.56	-0.79

The variation in the rate of change assumed for the CPI has only a small impact on the actuarial balance, as the summarized income rates are slightly affected while the summarized cost rates are virtually unchanged.

Faster assumed growth in the CPI results in a somewhat larger HI income rate because the income thresholds for the taxation of Social Security benefits and for the additional 0.9-percent payroll tax rate are not indexed. Therefore, the share of Social Security benefits subject to income tax, as well as the share of earnings subject to the additional tax, increases over time. This impact accelerates under conditions of faster CPI growth.

After the 10th year of the projection period, income tax brackets are assumed to rise with average wages, rather than with the C-CPI-U as specified in the Internal Revenue Code. As a result of this assumption, income for the taxation of Social Security benefits increases at a similar rate as taxable payroll. In contrast, the cost rate remains about the same with greater assumed rates of increase in the CPI. HI cost rates are relatively insensitive to the assumed level of general price

<sup>50</sup>Prior to the 2015 report, the Trustees used the lower CPI growth rate for the low-cost alternative and the higher CPI growth rate for the high-cost alternative.

*Actuarial Analysis*

inflation because price inflation has about the same proportionate effect on taxable payroll of workers as it does on medical care costs.

In practice, differing rates of inflation could occur between the economy in general and the medical-care sector. Readers can judge the effect of such a difference from the sensitivity analysis shown in section III.B4d on health care cost factors.

***c. Real-Interest Rate***

Table III.B13 shows the sensitivity of projected HI income rates, cost rates, and actuarial balances to the annual real-interest rate for special public-debt obligations issuable to the trust fund. The ultimate annual real-interest rate will be 1.8 percent (high-cost alternative), 2.3 percent (intermediate projections), and 2.8 percent (low-cost alternative). In each case, the assumed ultimate annual increase in the CPI is 2.4 percent (as assumed for the intermediate projections), which results in ultimate annual yields of 4.2, 4.8, and 5.2 percent under the three illustrations.

**Table III.B13.—Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various Real-Interest Assumptions**  
[As a percentage of taxable payroll]

Valuation period	Ultimate annual real-interest rate		
	1.8 percent	2.3 percent	2.8 percent
Summarized income rate:			
25-year: 2026–2050	3.80	3.80	3.79
50-year: 2026–2075	3.95	3.94	3.93
75-year: 2026–2100	4.09	4.06	4.04
Summarized cost rate:			
25-year: 2026–2050	4.44	4.42	4.40
50-year: 2026–2075	4.56	4.53	4.50
75-year: 2026–2100	4.67	4.63	4.58
Actuarial balance:			
25-year: 2026–2050	-0.64	-0.62	-0.60
50-year: 2026–2075	-0.61	-0.59	-0.57
75-year: 2026–2100	-0.58	-0.56	-0.55

For all periods, the cost rate decreases slightly with increasing real-interest rates. Over 2026–2100, for example, the summarized HI cost rate would decline from 4.67 percent (for an ultimate real-interest rate of 1.8 percent) to 4.58 percent (for an ultimate real-interest rate of 2.8 percent). Accordingly, each 1.0-percentage-point increase in the assumed real-interest rate increases the long-range actuarial balance, on average, by about 0.03 percent of taxable payroll.

***d. Health Care Cost Factors***

Table III.B14 shows the sensitivity of projected HI income rates, cost rates, and actuarial balances to two variations on the relative annual

*HI Financial Status*

growth rate in the aggregate cost of providing covered health care services to HI beneficiaries. For this sensitivity analysis, the ratio of costs to taxable payroll will grow 1 percentage point more slowly than the intermediate projections, the same as the intermediate projections, and 1 percentage point faster than the intermediate projections. In each case, the taxable payroll will be the same as assumed for the intermediate projections.<sup>51</sup>

As noted previously, factors such as wage and price increases may simultaneously affect HI tax income and the costs incurred by hospitals and other providers of medical care to HI beneficiaries. (Sections III.B4a and III.B4b evaluate the sensitivity of the trust fund’s financial status to these factors.) Other factors, such as the utilization of services by beneficiaries or the relative complexity of the services provided, can have an impact on provider costs without affecting HI tax income. The sensitivity analysis shown in table III.B14 illustrates the financial effect of any combination of these factors that results in the ratio of cost to payroll taxes increasing by 1 percentage point faster or slower than the intermediate assumptions.

**Table III.B14.—Estimated HI Income Rates, Cost Rates, and Actuarial Balances,  
Based on Intermediate Estimates  
with Various Health Care Cost Growth Rate Assumptions**  
[As a percentage of taxable payroll]

Valuation period	Annual cost/payroll relative growth rate		
	-1 percentage point	0 percentage point	+1 percentage point
Summarized income rate:			
25-year: 2026–2050	3.80	3.80	3.80
50-year: 2026–2075	3.94	3.94	3.94
75-year: 2026–2100	4.06	4.06	4.08
Summarized cost rate:			
25-year: 2026–2050	3.87	4.42	5.07
50-year: 2026–2075	3.56	4.53	5.86
75-year: 2026–2100	3.32	4.63	6.72
Actuarial balance:			
25-year: 2026–2050	-0.07	-0.62	-1.27
50-year: 2026–2075	0.37	-0.59	-1.92
75-year: 2026–2100	0.73	-0.56	-2.64

As illustrated in table III.B14, the financial status of the HI trust fund is extremely sensitive to the relative growth rates for health care service costs versus taxable payroll. For the 75-year period, the cost rate increases from 3.32 percent (for an annual cost/payroll growth rate of 1 percentage point less than the intermediate assumptions) to 6.72 percent (for an annual cost/payroll growth rate of 1 percentage point more than the intermediate assumptions). Each 1.0-percentage-point increase in the assumed cost/payroll relative

<sup>51</sup>These variations in HI cost growth rates are not equivalent to the high- and low-cost alternative assumptions, which use a different level and pattern of growth differentials and vary other assumptions in addition to the cost growth factors.

*Actuarial Analysis*

growth rate decreases the long-range actuarial balance, on average, by about 1.69 percent of taxable payroll.

**C. PART B FINANCIAL STATUS**

This section presents actual operations of the Part B account in the SMI trust fund in 2025 and Part B projections for the next 75 years. Section III.C1 discusses Part B financial results for 2025, and sections III.C2 and III.C3 discuss the short-range Part B projections and the long-range projections, respectively. The projections shown in sections III.C2 and III.C3 assume no changes will occur in the statutory provisions and regulations under which Part B now operates.

**1. Financial Operations in Calendar Year 2025**

Table III.C1 presents a statement of the revenue and expenditures of the Part B account of the SMI trust fund in calendar year 2025, and of its assets at the beginning and end of the year.

Part B Financial Status

**Table III.C1.—Statement of Operations of the Part B Account  
in the SMI Trust Fund during Calendar Year 2025**

[In thousands]	
Total assets of the Part B account in the trust fund, beginning of period	\$151,663,621
Revenue:	
Premiums from enrollees:	
Enrollees aged 65 and over .....	\$135,636,089
Disabled enrollees under age 65 .....	<u>14,682,129</u>
Total premiums .....	150,318,218
Premiums collected from Medicare Advantage participants .....	387,807
Government contributions:	
Enrollees aged 65 and over .....	364,060,078
Disabled enrollees under age 65 .....	64,007,500
Repayment amount <sup>1</sup> .....	-485,780
Adjustment for exempted amounts <sup>2</sup> .....	-4,624,646
Repayment of the Medicare Accelerated and Advance Payments (AAP) Program transfer <sup>3</sup> .....	-24,115
Union activity .....	<u>1,915</u>
Total government contributions .....	422,934,951
Other .....	299
Interest on investments .....	3,615,673
Interfund interest receipts & payments <sup>4</sup> .....	-5,646
Annual fees—branded Rx manufacturers and importers .....	2,795,039
ACA Medicare shared savings program receipts .....	434,368
Total revenue .....	<u>\$580,480,710</u>
Expenditures:	
Net Part B benefit payments .....	\$578,426,247
Administrative expenses:	
Transfer to Medicaid <sup>5</sup> .....	1,370,746
Treasury administrative expenses .....	257
Salaries and expenses, CMS <sup>6</sup> .....	2,433,638
Salaries and expenses, Office of the Secretary, HHS .....	96,104
Salaries and expenses, SSA .....	1,961,137
Medicare Payment Advisory Commission .....	5,530
Railroad Retirement administrative expenses .....	13,670
Railroad Retirement administrative expenses, OIG .....	79
Railroad Retirement administrative expenses, SMAC .....	9,661
MACRA <sup>7</sup> .....	<u>-339</u>
Total administrative expenses .....	5,890,483
Total expenditures .....	<u>\$584,316,730</u>
Net addition to the trust fund .....	-3,836,020
Total assets of the Part B account in the trust fund, end of period .....	<u>\$147,827,601</u>

<sup>1</sup>Represents transfers from Part B to the general fund of the Treasury of amounts collected from beneficiaries for repayment of (i) the 2016 and 2021 transfers for the premium income lost and (ii) the forgone income-related premium income in those years as a result of the specification of the aged actuarial rate. The repayment amounts reflect the \$3.00 that is added to the Part B premium otherwise determined. This addition will continue until the total amount of the forgone income-related premium income plus transfers is fully repaid.

<sup>2</sup>The additional premium repayment amounts (footnote 1 repayment amounts) are not to be matched by government contributions; however, since CMS is not able to separate the additional repayment premium amounts from the standard premium amounts, the additional repayment premium amounts are matched. An adjustment for exempted amounts is therefore necessary to transfer these erroneous Federal matching amounts back to the general fund.

<sup>3</sup>Represents transfers from Part B to the general fund of the Treasury of amounts recovered from providers for repayment of AAP program payments, as required by the Continuing Appropriations Act, 2021 and Other Extensions Act.

<sup>4</sup>Reflects interest adjustments on the reallocation of administrative expenses among the Medicare trust funds, the OASDI trust funds, and the general fund of the Treasury. Estimated payments are made from the trust funds and then are reconciled, with interest, the next year when the actual costs are known. A positive figure represents a transfer to the Part B account in the SMI trust fund from the other trust funds. A negative figure represents a transfer from the Part B account of the SMI trust fund to the other funds.

## *Actuarial Analysis*

<sup>5</sup>Represents amount transferred from the Part B account in the SMI trust fund to Medicaid to pay the Part B premium for certain qualified individuals.

<sup>6</sup>Includes expenses of the Medicare Administrative Contractors.

<sup>7</sup>Represents amounts transferred from the Part B account of the SMI trust fund for administration of provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

Note: Totals do not necessarily equal the sums of rounded components.

The total assets of the account amounted to \$151.7 billion on December 31, 2024. During calendar year 2025, total revenue amounted to \$580.5 billion, and total expenditures were \$584.3 billion. Total assets were \$147.8 billion as of December 31, 2025. The asset level decreased during 2025 by approximately \$3.8 billion.

### ***a. Revenues***

The major sources of revenue for the Part B account are (i) contributions of the Federal Government that the law authorizes to be appropriated and transferred from the general fund of the Treasury and (ii) premiums paid by (or on behalf of) eligible persons who voluntarily enroll.

Of the total Part B revenue in calendar year 2025, \$150.3 billion represented premium payments by (or on behalf of) enrollees—an increase of 7.5 percent over the amount of \$139.8 billion for the preceding year.

Government contributions matched the premiums paid for fiscal years 1967 through 1973 dollar for dollar. Beginning July 1973, disabled persons who are under age 65 and who have met certain other conditions became eligible to enroll in Medicare, and the calculation of the premium-matching government contributions was changed. The amount of government contributions corresponding to premiums paid is determined by applying a matching rate to the amount of premiums received.<sup>52</sup> By law, a matching rate is determined for each of two groups of Part B enrollees—one for those aged 65 and older and one for the disabled. The matching rate is equal to twice the monthly actuarial rate applicable to the particular group of enrollees, minus the standard monthly premium rate, divided by the standard monthly premium rate.

---

<sup>52</sup>For 2016 through 2026, under the intermediate assumptions, the standard premium includes an additional amount (\$3.00 through 2024, \$0.90 in 2025, and \$0.20 in 2026) to repay the balance due resulting from general fund transfers in 2016 and 2021 to the Part B account of the SMI trust fund, in accordance with the Bipartisan Budget Act of 2015 and the Continuing Appropriations Act, 2021 and Other Extensions Act. This additional amount is not included in the determination of the matching rates and is not to be matched by government contributions.

*Part B Financial Status*

The Secretary of Health and Human Services (HHS) promulgates standard monthly premium rates and actuarial rates each year. Table III.C2 shows past monthly premium rates and actuarial rates together with the corresponding percentages of Part B costs covered by the premium rate. Estimated future premium amounts under the intermediate set of assumptions appear in tables V.E2 and V.E3.

**Table III.C2.—Standard Part B Monthly Premium Rates, Actuarial Rates, and Premium Rates as a Percentage of Part B Cost**

	Standard monthly premium rate <sup>1</sup>	Monthly actuarial rate		Premium rates as a percentage of Part B cost	
		Enrollees aged 65 and over	Disabled enrollees under age 65	Enrollees aged 65 and over	Disabled enrollees under age 65
July 1966–March 1968	\$3.00	—	—	50.0%	—
April 1968–June 1970	4.00	—	—	50.0	—
12-month period ending June 30 of					
1975	6.70	\$6.70	\$18.00	50.0	18.6%
1980	8.70	13.40	25.00	32.5	17.4
Calendar year					
1985	15.50	31.00	52.70	25.0	14.7
1990	28.60	57.20	44.10	25.0	32.4
1991	29.90	62.60	56.00	23.9	26.7
1992	31.80	60.80	80.80	26.2	19.7
1993	36.60	70.50	82.90	26.0	22.1
1994	41.10	61.80	76.10	33.3	27.0
1995	46.10	73.10	105.80	31.5	21.8
1996	42.50	84.90	105.10	25.0	20.2
1997	43.80	87.60	110.40	25.0	19.8
1998	43.80	87.90	97.10	24.9	22.6
1999	45.50	92.30	103.00	24.6	22.1
2000	45.50	91.90	121.10	24.8	18.8
2001	50.00	101.00	132.20	24.8	18.9
2002	54.00	109.30	123.10	24.7	21.9
2003	58.70	118.70	141.00	24.7	20.8
2004	66.60	133.20	175.50	25.0	19.0
2005	78.20	156.40	191.80	25.0	20.4
2006	88.50	176.90	203.70	25.0	21.7
2007	93.50	187.00	197.30	25.0	23.7
2008	96.40	192.70	209.70	25.0	23.0
2009	96.40	192.70	224.20	25.0	21.5
2010	110.50	221.00	270.40	25.0	20.4
2011	115.40	230.70	266.30	25.0	21.7
2012	99.90	199.80	192.50	25.0	25.9
2013	104.90	209.80	235.50	25.0	22.3
2014	104.90	209.80	218.90	25.0	24.0
2015	104.90	209.80	254.80	25.0	20.6
2016	121.80	237.60	282.60	25.6	21.5
2017	134.00	261.90	254.20	25.6	26.4
2018	134.00	261.90	295.00	25.6	22.7
2019	135.50	264.90	315.40	25.6	21.5
2020	144.60	283.20	343.60	25.5	21.0
2021	148.50	291.00	349.90	25.5	21.2
2022	170.10	334.20	368.90	25.4	23.1
2023	164.90	323.70	357.90	25.4	22.9
2024	174.70	343.40	427.20	25.0	20.1
2025	185.00	368.10	487.80	25.0	18.9
2026	202.90	405.40	548.60	25.0	18.5


<sup>1</sup>The amount shown for each year represents the standard Part B premium paid by, or on behalf of, most Part B enrollees. It does not reflect other amounts that certain beneficiaries must pay, such as the income-related monthly adjustment amount for beneficiaries with high incomes and the premium surcharge for

*Actuarial Analysis*

beneficiaries who enroll late. In addition, it does not reflect a reduction in premium for beneficiaries covered by the hold-harmless provision. As a result of this provision, most Part B beneficiaries had their 2010 and 2011 monthly premium held to the 2009 rate of \$96.40, had their 2016 monthly premium held to the 2015 rate of \$104.90, and had the increase in their 2017 monthly premium limited to about \$4.00, on average. Section V.E describes these amounts in more detail.

Figure III.C1 is a graph of the monthly per capita financing rates in all financing periods after 1983 for enrollees aged 65 and over and for disabled individuals under age 65. The graph shows the portion of the financing contributed by the beneficiaries and by government contributions. As indicated, government contributions are the largest income source for Part B.

**Figure III.C1.—Part B Aged and Disabled Monthly Per Capita Trust Fund Income**



Note: The amounts shown do not include the catastrophic coverage monthly premium rate for 1989.

In calendar year 2025, contributions received from the general fund of the Treasury amounted to \$422.9 billion, which accounted for 72.9 percent of total revenue. The Bipartisan Budget Act of 2015 and the Continuing Appropriations Act, 2021 and Other Extensions Act require that payments be made from the Part B account of the SMI trust fund to the general fund of the Treasury, and these amounts totaled \$0.5 billion in 2025. Transfers amounting to \$4.6 billion were made from the Part B account to the general fund in order to adjust for certain transfers made for exempted amounts.<sup>53</sup> In accordance with the Continuing Appropriations Act, 2021 and Other Extensions Act,

<sup>53</sup>See footnote 4 of table III.C1.

### *Part B Financial Status*

\$24 million of the government contributions represent a transfer from the Part B account to the general fund to partially repay the outstanding balance of the Accelerated and Advance Payments (AAP) Program. The balance of the general fund transfers consisted almost entirely of premium-matching contributions.

Another source of Part B revenue is interest received on investments held by the Part B account. A description of the investment procedures of the Part B account appears later in this section. In calendar year 2025, \$3.6 billion of revenue was from interest on the investments of the account. One more source of Part B revenue is the annual fees assessed on manufacturers and importers of brand-name prescription drugs, which amounted to \$2.8 billion in 2025.

#### ***b. Expenditures***

The account pays expenditures for Part B benefit payments and administrative expenses. All expenses incurred by the Department of Health and Human Services, the Social Security Administration, and the Department of the Treasury in administering Part B are charged to the account. Such administrative duties include payment of benefits, fraud and abuse control activities, and experiments and demonstration projects designed to determine various methods of increasing efficiency and economy in providing health care services while maintaining the quality of these services.

In addition, Congress has authorized expenditures from the trust funds for construction, rental and lease, or purchase contracts of office buildings and related facilities for use in connection with the administration of Part B. The account expenditures include such costs. The net worth of facilities and other fixed capital assets, however, does not appear in the statement of Part B assets presented in this report, since the value of fixed capital assets does not represent funds available for benefit or administrative expenditures and is not, therefore, pertinent in assessing the actuarial status of the funds.

Of total Part B expenditures, \$578.4 billion represented net benefits paid from the account for health services.<sup>54</sup> Net benefits increased 5.6 percent compared with the corresponding amount of \$547.8 billion paid during the preceding calendar year. The change in net benefits paid reflects the net change in both the number of beneficiaries and the

---

<sup>54</sup>Net benefits equal the total gross amounts initially paid from the trust fund during the year less recoveries of overpayments identified through fraud and abuse control activities.

*Actuarial Analysis*

price, volume, and intensity of services. Additional information on Part B benefits by type of service is available in section IV.B1.

The remaining \$5.9 billion of expenditures was for administrative expenses and represented 1.0 percent of total Part B expenditures in 2025. Administrative expenses are shown on a net basis, after adjustments to the preliminary allocation of such costs among the Social Security and Medicare trust funds and the general fund of the Treasury.

***c. Actual experience versus prior estimates***

Table III.C3 compares the actual experience in calendar year 2025 with the estimates presented in the 2024 and 2025 annual reports. A number of factors can contribute to differences between estimates and subsequent actual experience. In particular, actual values for key economic and other variables can differ from assumed levels, and lawmakers may adopt legislative and regulatory changes after a report’s preparation.

As shown in table III.C3, actual Part B benefit payments were somewhat higher than the estimates in the 2024 and 2025 reports. Spending on skin substitutes was higher in 2025 than had been projected in prior reports. For both of these reports, actual government contributions were nearly the same as the estimates, but premiums from enrollees were lower.

**Table III.C3.—Comparison of Actual and Estimated Operations of the Part B Account in the SMI Trust Fund, Calendar Year 2025**

[Dollar amounts in millions]

Item	Comparison of actual experience with estimates for calendar year 2025 published in:					
			2025 report		2024 report	
	Actual amount	Estimated amount <sup>1</sup>	Actual as a percentage of estimate	Estimated amount <sup>1</sup>	Actual as a percentage of estimate	
Premiums from enrollees	\$150,318	\$154,844	97%	\$155,046	97%	
Government contributions	422,935 <sup>2</sup>	423,450	100	423,380	100	
Benefit payments <sup>3</sup>	578,426	573,050	101	564,843	102	

<sup>1</sup>Under the intermediate assumptions.

<sup>2</sup>See footnotes 1–3 of table III.C1.

<sup>3</sup>Benefit payments include (i) additional premiums for Medicare Advantage plans that are deducted from beneficiaries’ Social Security benefits and (ii) costs of Quality Improvement Organizations.

***d. Assets***

The Department of the Treasury invests the portion of the Part B account not needed to meet current expenditures for benefits and administration in interest-bearing obligations of the U.S. Government.

## *Part B Financial Status*

The Social Security Act authorizes the issuance of special public-debt obligations for purchase exclusively by the account. The law requires that these special public-debt obligations shall bear interest at a rate based on the average market yield (computed on the basis of market quotations as of the end of the calendar month immediately preceding the date of such issue) for all marketable interest-bearing obligations of the United States forming a part of the public debt that are not due or callable until after 4 years from the end of that month. Since the inception of the SMI trust fund, the Department of the Treasury has always invested the assets in special public-debt obligations.<sup>55</sup> Table V.H10, presented in section V.H, shows the assets of the SMI trust fund (Parts B and D) at the end of fiscal years 2024 and 2025.

### **2. 10-Year Actuarial Estimates (2026–2035)**

This section provides detailed information concerning the short-range financial status of the Part B account, including projected annual income, expenditures, differences between income and expenditures, and trust fund balances. Section IV.B1 presents an explanation of the effects of these assumptions on the estimates in this report. The Trustees also assume that financing for future periods will be determined according to the statutory provisions described in section III.C1a, although Part B financing rates have been set only through December 31, 2026.

In 2026 the monthly Part B premium rate is \$202.90, which is higher than the 2025 monthly premium of \$185.00. The estimated monthly premium for 2027 is \$209.50. This premium, paid by affected enrollees and Medicaid and matched by general fund transfers, would maintain a contingency reserve at the level necessary to accommodate typical financial variation, plus the possibility of legislative action that would raise costs after the establishment of financing rates.

For determining an individual's monthly premium rate, there is a hold-harmless provision in the law that limits the dollar increase in the premium to the dollar increase in an individual's Social Security benefit. This provision applies to most beneficiaries who have their

---

<sup>55</sup>The Department of the Treasury may also make investments in obligations guaranteed as to both principal and interest by the United States, including certain federally sponsored agency obligations.

### *Actuarial Analysis*

premiums deducted from their Social Security benefits, or roughly 70 percent of Part B enrollees.<sup>56</sup>

In 2016, the cost-of-living adjustment (COLA) for Social Security benefits was 0 percent, and premiums did not increase from the 2015 level for beneficiaries to whom the hold-harmless provision applies. Without the Bipartisan Budget Act of 2015 (BBA 2015), Part B premiums for other beneficiaries would have been raised substantially to offset premiums forgone as a result of the hold-harmless provision. However, BBA 2015 specified that the Part B premium for 2016 be determined as if the hold-harmless provision did not apply and that a transfer be made from the general fund of the Treasury to the Part B account of the SMI trust fund in the amount of the estimated forgone premiums (and that the transfer be treated as premiums for matching purposes).

BBA 2015 further requires that, starting in 2016, the Part B premium otherwise determined be increased by \$3.00, which is to be collected and repaid to the general fund of the Treasury.

Similarly, the Continuing Appropriations Act, 2021 and Other Extensions Act specified that the 2021 actuarial rate for enrollees aged 65 and older be determined as the sum of the 2020 actuarial rate for enrollees aged 65 and older and one-fourth of the difference between the 2020 actuarial rate and the preliminary 2021 actuarial rate (as determined by the Secretary of HHS) for such enrollees. The premium revenue lost by using the resulting lower premium (excluding the forgone income-related premium revenue) was replaced by a transfer from the general fund of the Treasury, which will be repaid over time by increasing the balance due and continuing the additional repayment premium amounts.

The additional repayment premium amounts will continue until the balance due (defined in BBA 2015 and the Continuing Appropriations Act, 2021 and Other Extensions Act as the sum of the two transfers to the Part B account from the general fund plus forgone income-related premiums) has been repaid.<sup>57</sup> The 2026 premium of \$202.90 includes \$0.20 for this purpose.

---

<sup>56</sup>About 30 percent of Part B enrollees are not eligible for the hold-harmless provision. This group consists of new enrollees during the year, enrollees who do not receive Social Security benefit checks, enrollees with high incomes who are subject to the income-related premium adjustment, and dual Medicare-Medicaid beneficiaries (whose premiums are paid by State Medicaid programs).

<sup>57</sup>In the final repayment year, the additional amount may be less than \$3.00 in order to avoid overpayments.

*Part B Financial Status*

The initial balance due, which includes the amount transferred to the Part B account in 2016 and the estimated forgone income-related premiums, was \$9.1 billion. The balance due on January 1, 2020, was \$3.7 billion. In 2021, the balance due was increased by \$8.8 billion, which consists of the amount transferred to the Part B account in 2021 plus the estimated forgone income-related premiums. The balance due on January 1, 2026, was \$98 million. The Trustees estimate that the last repayment will be made by the end of 2026.

Projected Part B expenditures are affected by the sequestration required by current law, which reduces benefit payments by the following percentages: 2 percent from April 1, 2013, through April 30, 2020; 1 percent from April 1, 2022, through June 30, 2022; and 2 percent from July 1, 2022, through August 31, 2033.

Because of sequestration, non-salary administrative expenses are reduced by an estimated 5 to 7 percent from March 1, 2013, through August 31, 2033, excluding May 1, 2020, through March 31, 2022. (See section V.A for recent legislative changes affecting the sequestration of Medicare expenditures.)

Table III.C4 shows the estimated operations of the Part B account under the intermediate assumptions on a calendar-year basis through 2035.

Actuarial Analysis

**Table III.C4.—Operations of the Part B Account in the SMI Trust Fund (Cash Basis) during Calendar Years 1970–2035**

[In billions]									
Calendar year	Income				Expenditures			Account	
	Premium income	Government contribution <sup>1</sup>	Interest and other <sup>2,3</sup>	Total	Benefit payments <sup>3,4</sup>	Administrative expenses	Total	Net change	Balance at end of year <sup>5</sup>
Historical data:									
1970	\$1.1	\$1.1	\$0.0	\$2.2	\$2.0	\$0.2	\$2.2	-\$0.0	\$0.2
1975	1.9	2.6	0.1	4.7	4.3	0.5	4.7	-0.1	1.4
1980	3.0	7.5	0.4	10.9	10.6	0.6	11.2	-0.4	4.5
1985	5.6	18.3	1.2	25.1	22.9	0.9	23.9	1.2	10.9
1990	11.3	33.0	1.6	45.9	42.5	1.5	44.0	1.9	15.5
1995	19.7	39.0	1.6	60.3	65.0	1.6	66.6	-6.3	13.1
2000	20.6	65.9	3.4	89.9	88.9 <sup>6</sup>	1.8	90.7	-0.8	44.0
2005	37.5	118.1	1.4	157.0	149.2	3.2	152.4	4.6	24.0
2010	52.0 <sup>7</sup>	153.5 <sup>7</sup>	3.3	208.8	209.7	3.2	212.9	-4.1	71.4
2015	69.4 <sup>7</sup>	203.9 <sup>7</sup>	5.7	279.0	275.8	3.1	279.0	0.1	68.2
2016	72.1 <sup>7</sup>	235.6 <sup>7</sup>	5.5	313.2	289.5	3.9	293.4	19.8	88.0
2017	81.5	217.3	6.8	305.6	308.6	5.0 <sup>8</sup>	313.7	-8.1	79.9
2018	93.3	253.2	7.1	353.7	333.0	4.2	337.2	16.5	96.3
2019	99.4	268.2	5.9	373.6	365.7	4.6	370.3	3.3	99.6
2020	111.2 <sup>7</sup>	336.0 <sup>7,9</sup>	5.1	452.3	414.1 <sup>10</sup>	4.5	418.6	33.7	133.3
2021	111.0 <sup>7</sup>	318.6 <sup>7,9</sup>	6.0	435.5	400.5 <sup>10</sup>	5.0	405.5	30.1	163.3
2022	130.9	329.7 <sup>9</sup>	6.9	467.6	431.6 <sup>10</sup>	5.1	436.7	30.9	194.2
2023	131.2	342.1 <sup>9</sup>	7.6	480.9	497.4 <sup>10</sup>	5.4	502.9	-22.0	172.2
2024	139.8	386.0	7.1	532.9	547.8	5.6	553.4	-20.5	151.7
2025	150.3	422.2	8.0	580.5	578.4	5.9	584.3	-3.8	147.8
Intermediate estimates:									
2026	174.8 <sup>7</sup>	478.9 <sup>7</sup>	8.9	662.6	619.2	6.8	626.0	36.6	184.5
2027	182.8 <sup>7</sup>	478.7 <sup>7</sup>	10.6	672.2	672.6	7.2	679.8	-7.6	176.8
2028	204.0	542.7	10.9	757.6	735.8	7.7	743.5	14.1	190.9
2029	222.3	587.6	11.6	821.4	798.0	8.2	806.2	15.2	206.2
2030	243.5	639.1	12.3	895.0	870.2	8.7	878.9	16.1	222.3
2031	264.3	689.3	13.1	966.7	941.6	9.2	950.8	16.0	238.2
2032	286.9	742.8	14.0	1,043.7	1,015.2	9.7	1,024.9	18.8	257.0
2033	315.1	810.1	15.0	1,140.2	1,106.8	10.3	1,117.1	23.1	280.1
2034	346.0	882.0	16.1	1,244.1	1,211.4	11.0	1,222.4	21.7	301.8
2035	375.1	949.2	17.3	1,341.6	1,307.6	11.5	1,319.1	22.5	324.4

<sup>1</sup>General fund matching payments, plus certain interest-adjustment items.

<sup>2</sup>Other income includes recoveries of amounts reimbursed from the trust fund that are not obligations of the trust fund and other miscellaneous income. In 2008, includes an adjustment of \$0.8 billion for interest earned as a result of Part A hospice costs that were misallocated to the Part B trust fund account.

<sup>3</sup>See footnote 2 of table III.B4.

<sup>4</sup>Includes costs of Peer Review Organizations from 1983 through 2001 and costs of Quality Improvement Organizations beginning in 2002.

<sup>5</sup>The financial status of Part B depends on both the assets and the liabilities of the trust fund (see table III.C8).

<sup>6</sup>Benefit payments less monies transferred from the HI trust fund for home health agency costs.

<sup>7</sup>Section 708 of the Social Security Act modifies the provisions for the payment of Social Security benefits when the regularly designated day falls on a Saturday, Sunday, or legal public holiday. Payment of those benefits normally due January 3, 2010, actually occurred on December 31, 2009, payment of benefits normally due January 3, 2016, occurred on December 31, 2015, and payment of benefits normally due January 3, 2021, occurred on December 31, 2020. Consequently, the Part B premiums withheld from these benefits and the associated government contributions were added to the Part B account on December 31, 2009 (about \$13.8 billion), December 31, 2015 (about \$7.9 billion), and December 31, 2020 (about \$10.0 billion), respectively. Similarly, the payment date for those benefits normally due on January 3, 2027, will be December 31, 2026. Accordingly, an estimated \$5.8 billion will be added to the Part B account on December 31, 2026.

<sup>8</sup>Reflects a larger-than-usual upward adjustment of \$1.7 billion for prior-year allocations among Part A, Part B, and Part D.

<sup>9</sup>Includes (i) a transfer of \$37.8 billion in calendar year 2020 from the general fund of the Treasury to Part B, which occurred in November of 2020 for the outstanding balance of the Medicare Accelerated and Advance Payments (AAP) Program, as required by the Continuing Appropriations Act, 2021 and Other Extensions Act, and (ii) subsequent recoveries from providers that were transferred from Part B to the

### Part B Financial Status

general fund of the Treasury in the amounts of \$14.3 billion, \$21.7 billion, and \$1.7 billion in calendar years 2021 through 2023, respectively.


<sup>10</sup>Includes net payments of \$37.0 billion made through the AAP program in calendar year 2020 and subsequent net repayments of \$18.9 billion, \$17.6 billion, and \$0.3 billion in calendar years 2021 through 2023, respectively.

Note: Totals do not necessarily equal the sums of rounded components.

As shown in table III.C4, the Part B account would increase by the end of 2026 to an estimated \$184.5 billion. The financing for 2026 was set to maintain Part B assets at a fully sufficient level.

The statutory provisions governing Part B financing have changed over time. Under current law, the standard Part B premium is set at the level of about 25 percent of average expenditures for beneficiaries aged 65 and over. As discussed previously, the Bipartisan Budget Act of 2015 and the Continuing Appropriations Act, 2021 and Other Extensions Act specify that the Part B premium otherwise estimated be increased by \$3.00, starting with 2016, until the balance due (which is the sum of the government contributions transferred in 2016 and 2021 plus the forgone income-related premium income) is repaid. In addition, Part B beneficiaries with high incomes pay a higher income-related premium. Figure III.C2 shows historical and projected ratios of premium income to Part B expenditures.

**Figure III.C2.—Premium Income as a Percentage of Part B Expenditures**



Beneficiary premiums are also affected by fees on the manufacturers and importers of brand-name prescription drugs that are allocated to the Part B account of the SMI trust fund. Because of these fees there

### Actuarial Analysis

is a reduction in the premium margin such that total revenues from premiums, matching government contributions, and the earmarked fees relating to brand-name prescription drugs will equal the appropriate level needed for program financing.

The amount and rate of growth of benefit payments have caused concern for many years. Table III.C5 shows payment amounts in the aggregate, on a per capita basis, and relative to the Gross Domestic Product (GDP). Rates of growth appear historically and for the next 10 years based on the intermediate assumptions.

Aggregate Part B benefit growth has averaged 6.9 percent annually over the past 5 years. During 2025, Part B benefits increased 5.6 percent and constituted 1.88 percent of GDP.

The Part B expenditures are affected by the sequestration of Medicare benefits required under current law. Projected Part B costs continue to increase faster than GDP, as indicated in table III.C5.

**Table III.C5.—Growth in Part B Benefits (Cash Basis) through December 31, 2035**

Calendar year	Aggregate benefits [billions]	Percent change	Per capita benefits	Percent change	Part B benefits as a percentage of GDP
Historical data:					
1970	\$2.0	5.9%	\$101	3.5%	0.18%
1975	4.3	28.8	180	24.6	0.25
1980	10.6	22.1	390	19.3	0.37
1985	22.9	16.7	768	14.5	0.53
1990	42.5	10.9	1,304	9.1	0.71
1995	65.0	10.8	1,823	9.2	0.85
2000	88.9 <sup>1</sup>	10.1	2,381	9.2	0.87
2005	149.9	10.9	3,771	9.1	1.15
2010	209.7	3.5	4,779	1.2	1.39
2015	274.4	5.9	5,406	3.1	1.50
2016	288.8	5.2	5,543	2.5	1.54
2017	308.5	6.8	5,772	4.1	1.57
2018	333.2	8.0	6,095	5.6	1.61
2019	365.7	9.7	6,528	7.1	1.70
2020	414.1 <sup>2</sup>	13.2	7,224	10.7	1.94
2021	400.5 <sup>2</sup>	-3.3	6,858	-5.1	1.69
2022	431.6 <sup>2</sup>	7.8	7,253	5.8	1.66
2023	497.4 <sup>2</sup>	15.3	8,181	12.8	1.79
2024	547.8	10.1	8,821	7.8	1.88
2025	578.4	5.6	9,117	3.3	1.88
Intermediate estimates:					
2026	619.2	7.0	9,555	4.8	1.92
2027	672.6	8.6	10,129	6.0	2.01
2028	735.8	9.4	10,803	6.7	2.12
2029	798.0	8.5	11,476	6.2	2.21
2030	870.2	9.0	12,301	7.2	2.32
2031	941.6	8.2	13,124	6.7	2.42
2032	1,015.2	7.8	13,975	6.5	2.51
2033	1,106.8	9.0	15,066	7.8	2.63
2034	1,211.4	9.4	16,304	8.2	2.76
2035	1,307.6	7.9	17,401	6.7	2.87

<sup>1</sup>See footnote 6 of table III.C4.

<sup>2</sup>See footnote 10 of table III.C4.

Note: Percentages are affected by economic cycles.

*Part B Financial Status*

The Trustees have prepared the estimates shown throughout the report using the intermediate set of assumptions. They have also prepared estimates using two alternative sets of assumptions. Table III.C6 summarizes the estimated operations of the Part B account for all three alternatives. Section IV.B1 presents in substantial detail the assumptions underlying the intermediate estimates, as well as the assumptions used in preparing estimates under the low-cost and high-cost alternatives.

**Table III.C6.—Estimated Operations of the Part B Account in the SMI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions**  
[Dollar amounts in billions]

Calendar year	Premiums from enrollees	Other income <sup>1</sup>	Total income	Total expenditures	Balance in fund at end of year	Expenditures as a percentage of GDP
Intermediate:						
2025 <sup>2</sup>	\$150.3	\$430.2	\$580.5	\$584.3	\$147.8	1.90%
2026	174.8 <sup>3</sup>	487.8 <sup>3</sup>	662.6	626.0	184.5	1.94
2027	182.8 <sup>3</sup>	489.3 <sup>3</sup>	672.2	679.8	176.8	2.03
2028	204.0	553.6	757.6	743.5	190.9	2.14
2029	222.3	599.2	821.4	806.2	206.2	2.24
2030	243.5	651.5	895.0	878.9	222.3	2.35
2031	264.3	702.4	966.7	950.8	238.2	2.44
2032	286.9	756.8	1,043.7	1,024.9	257.0	2.53
2033	315.1	825.0	1,140.2	1,117.1	280.1	2.65
2034	346.0	898.1	1,244.1	1,222.4	301.8	2.79
2035	375.1	966.5	1,341.6	1,319.1	324.4	2.89
Low-cost:						
2025 <sup>2</sup>	150.3	430.2	580.5	584.3	147.8	1.90
2026	174.8 <sup>3</sup>	487.8 <sup>3</sup>	662.6	622.1	188.3	1.90
2027	179.6 <sup>3</sup>	480.8 <sup>3</sup>	660.4	673.4	175.3	1.95
2028	201.2	545.8	747.0	734.0	188.4	2.02
2029	217.9	587.3	805.2	791.3	202.3	2.06
2030	236.7	633.4	870.2	856.1	216.4	2.12
2031	255.1	678.0	933.1	919.1	230.4	2.16
2032	275.0	725.5	1,000.5	983.4	247.5	2.20
2033	299.9	784.9	1,084.8	1,063.9	268.4	2.26
2034	326.4	847.3	1,173.7	1,155.7	286.4	2.33
2035	350.9	904.2	1,255.0	1,236.3	305.2	2.37
High-cost:						
2025 <sup>2</sup>	150.3	430.2	580.5	584.3	147.8	1.90
2026	174.8 <sup>3</sup>	487.7 <sup>3</sup>	662.5	624.9	185.4	1.98
2027	177.8 <sup>3</sup>	476.1 <sup>3</sup>	654.0	663.8	175.6	2.11
2028	201.7	547.5	749.2	734.3	190.5	2.27
2029	223.3	602.1	825.4	807.6	208.3	2.42
2030	247.7	662.8	910.5	892.5	226.2	2.59
2031	272.4	723.6	996.0	977.4	244.8	2.75
2032	298.9	788.0	1,086.8	1,064.7	267.0	2.90
2033	330.5	865.0	1,195.5	1,169.7	292.8	3.10
2034	365.1	947.6	1,312.7	1,289.3	316.3	3.33
2035	399.2	1,028.1	1,427.3	1,401.4	342.1	3.52

<sup>1</sup>Other income contains government contributions, fees on manufacturers and importers of brand-name prescription drugs, and interest.

<sup>2</sup>Figures for 2025 represent actual experience.

<sup>3</sup>See footnote 7 of table III.C4.

Notes: 1. Totals do not necessarily equal the sums of rounded components.  
2. Percentages are affected by economic cycles.

### *Actuarial Analysis*

Because of the price assumptions for these alternative scenarios, the expenditures presented in these scenarios represent a narrow range of outcomes, and actual experience could easily fall outside of this range. For the low-cost scenario, the Trustees assume higher price inflation, which leads to higher spending. Similarly, under the high-cost scenario, the Trustees assume lower price inflation, which leads to lower spending. These price inflation assumptions partially offset the effects of the other assumptions in the high-cost and low-cost scenarios, resulting in a narrow range of expenditures. Given the considerable variation in the factors affecting health care spending, actual Part B experience could easily fall outside of this range. Because the GDP assumptions in these scenarios are similarly affected by the price inflation assumptions, Part B expenditures as a percent of GDP provide better insight into the variability of spending than the nominal dollar amounts, as shown in table III.C6.

The alternative projections shown in table III.C6 illustrate two important aspects of the financial operations of the Part B account:

- Despite the differing assumptions underlying the three alternatives, the balance between Part B income and expenditures remains relatively stable. This result occurs because the Secretary of HHS annually reestablishes the premiums and government contributions underlying Part B financing to cover each year's anticipated incurred benefit costs and other expenditures and then increases these amounts by a margin that reflects the uncertainty of the projection. Thus, Part B income automatically tracks Part B expenditures fairly closely, regardless of the specific economic and other conditions.
- As a result of the close matching of income and expenditures described above, projected account assets show similar, stable patterns of change under all three sets of assumptions.

### *Adequacy of Part B Financing Established for Calendar Year 2025*

The traditional concept of financial adequacy, as it applies to Part B, is closely related to the concept as it applies to many private group insurance plans. Part B is somewhat similar to private yearly renewable term insurance, with financing established each year based on estimated costs for the year. For Part B, premium income paid by the enrollees and contributions from the Federal Government provide financing. As with private plans, the income during a 12-month period for which financing is being established should be sufficient to cover the costs of services expected to be rendered during that period

### *Part B Financial Status*

(including associated administrative costs), even though payment for some of these services will not occur until after the period closes. The portion of income required to cover those benefits not paid until after the end of the year is added to the account; thus assets in the account at any time should not be less than the costs of the benefits and the administrative expenses incurred but not yet paid.

Because the Secretary of HHS establishes the income per enrollee (premium plus government contribution) prospectively each year, it is subject to projection error. Additionally, legislation enacted after the financing has been established, but effective for the period for which financing has been set, may affect costs. Account assets, therefore, need to be maintained at a level that is adequate to cover not only the value of incurred-but-unpaid expenses but also a reasonable degree of variation between actual and projected costs (in case actual costs exceed projected).

The Trustees traditionally evaluate the actuarial status or financial adequacy of the Part B account over the period for which the enrollee premium rates and level of government contribution have been established. There are two primary tests that are used for this evaluation. The first is that the assets and income for years for which financing has been established should be sufficient to meet the projected benefits and associated administrative expenses incurred for that period. The second primary test is that the assets should be sufficient to cover projected liabilities for benefits that have not yet been paid as of the end of the period.

If Part B does not meet these adequacy tests, it can still continue to operate if the account remains at a level adequate to permit the payment of claims as presented. However, to protect against the possibility that costs will be higher than assumed, assets should be sufficient to include contingency levels that cover a reasonable degree of variation between actual and projected costs.

As noted above, the tests of financial adequacy for Part B rely on the incurred experience of the account, including a liability for the costs of services performed in a particular year but not yet paid in that year. Table III.C7 shows the estimated transactions of the account on an

## Actuarial Analysis

incurred basis. Readers should view the incurred experience as an estimate, even for historical years.<sup>58</sup>

**Table III.C7.—Estimated Part B Income and Expenditures (Incurred Basis) for Financing Periods through December 31, 2026**

[In millions]								
Financing period	Income				Expenditures			Net operations in year
	Premium income	Government contribution	Interest and other	Total	Benefit payments	Administrative expenses	Total	
Historical data:								
12-month period ending June 30,								
1970	\$936	\$936	\$12	\$1,884	\$1,928	\$213	\$2,141	-\$257
1975	1,887	2,396	105	4,388	3,957	438	4,395	-7
1980	2,823	6,627	421	9,871	9,840	645	10,485	-614
Calendar year								
1985	5,613	18,243	1,248	25,104	22,750	986	23,736	1,368
1990	11,320	33,035	1,558	45,913	42,577	1,541	44,118	1,795
1995	19,717	45,743	1,739	67,199	64,923	1,607	66,531	668
2000	20,555	65,898	3,450	89,903	91,059 <sup>1</sup>	1,770	92,828	-2,925
2005	37,535	118,091	1,365	156,992	151,430	3,185	154,615	2,376
2010	55,580	163,660	3,281	222,520	212,093	3,153	215,245	7,275
2015	67,515	197,931	5,727	271,172	279,048	3,145	282,193	-11,021
2016	73,986	241,582	5,496	321,064	292,135	3,909	296,044	25,020
2017	81,522	217,253	6,796	305,571	309,587	5,014	314,601	-9,030
2018	93,312	253,237	7,147	353,697	338,578	4,203	342,781	10,916
2019	99,413	268,241	5,919	373,573	368,729	4,628	373,357	216
2020	108,746	328,446	5,148	442,340	381,133	4,541	385,674	56,665
2021	113,411	326,125	5,975	445,511	424,643	5,018	429,661	15,850
2022	130,941	329,712	6,913	467,567	451,378	5,098	456,476	11,091
2023	131,166	342,127	7,563	480,855	498,278	5,422	503,700	-22,845
2024	139,837	385,980	7,074	532,890	536,842	5,588	542,430	-9,539
2025	150,318	422,162	8,000	580,481	579,892	5,890	585,782	-5,302
Intermediate estimates:								
2026	173,228	474,662	8,896	656,786	626,677	6,798	633,475	23,310

<sup>1</sup>See footnote 6 of table III.C4.

Estimates of the liability amounts for benefits incurred but unpaid as of the end of each financing period, and of the administrative expenses related to processing these benefits, appear in table III.C8. In some years, account assets have not been as large as liabilities. Nonetheless, the fund has remained positive, which has allowed payment of all claims.

<sup>58</sup>Part B experience is more difficult to determine on an incurred basis than on a cash basis. For some services, reporting of payment occurs only on a cash basis, and it is necessary to infer the incurred experience from the cash payment information. Moreover, for recent time periods the tabulations of bills are incomplete because of normal processing time lags.

Part B Financial Status

**Table III.C8.—Summary of Estimated Part B Assets and Liabilities  
as of the End of the Financing Period, for Periods through December 31, 2026**  
[Dollar amounts in millions]

	Balance in trust fund	Government contribution due but unpaid	Total assets	Benefits incurred but unpaid	Administrative costs incurred but unpaid	Liabilities <sup>1</sup>	Excess of assets over liabilities	Ratio <sup>2</sup>
Historical data:								
As of June 30,								
1970	\$57	\$15	\$72	\$567	—	\$567	-\$495	-0.21
1975	1,424	67	1,491	1,257	\$14	1,271	—	0.04
1980	4,657	—	4,657	2,621	188	2,809	1,848	0.15
As of December 31,								
1985	10,924	—	10,924	3,142	-38	3,104	7,820	0.28
1990	15,482	—	15,482	4,060	20	4,080	11,402	0.24
1995	13,130	6,893 <sup>3</sup>	20,023	4,298	-214	4,084	15,939	0.23
2000	44,027	—	44,027	8,715	-285	8,430	35,597	0.35
2005	24,008	—	24,008	13,556	—	13,556	10,452	0.06
2010	71,435	—	71,435	18,394	—	18,394	53,042	0.23
2015	68,157	—	68,157	25,197	—	25,197	42,961	0.15
2016	87,964	—	87,964	27,882	—	27,882	60,082	0.19
2017	79,882	—	79,882	28,748	—	28,748	51,134	0.15
2018	96,343	—	96,343	34,293	—	34,293	62,049	0.17
2019	99,602	—	99,602	37,313	—	37,313	62,289	0.16
2020	133,283	—	133,283	41,356	—	41,356	91,927	0.21
2021	163,333	—	163,333	46,619	—	46,619	116,714	0.26
2022	194,215	—	194,215	48,776	—	48,776	145,440	0.29
2023	172,210	—	172,210	49,291	—	49,291	122,919	0.23
2024	151,664	—	151,664	38,228	—	38,228	113,435	0.19
2025	147,828	—	147,828	39,694	—	39,694	108,134	0.17
Intermediate estimates:								
2026	178,615	—	178,615	47,171	—	47,171	131,444	0.19

<sup>1</sup>These amounts include only items incurred but not paid. They do not include the amounts that are to be paid back to the general fund of the Treasury over time or the AAP amounts paid to providers that are to be paid back to the trust fund over time.

<sup>2</sup>Ratio of the excess of assets over liabilities to the following year's total incurred expenditures.

<sup>3</sup>This amount includes both the principal of \$6,736 million and the accumulated interest through December 31, 1995, for the shortfall in the fiscal year 1995 appropriation for government contributions. Normally, this transfer would have occurred on December 31, 1995, and the trust fund balance would have reflected it. However, because of absence of funding, there was a delay in the transfer of the principal and the appropriate interest until March 1, 1996.

The amount of assets minus liabilities, compared with the estimated incurred expenditures for the following calendar year, forms a relative measure of the Part B account's financial status. The last column in table III.C8 shows such ratios for past years and the estimated ratio at the end of 2026. Actuarial analysis has indicated that a ratio of roughly 15 to 20 percent is sufficient to protect against unforeseen contingencies, such as unusually large increases in Part B expenditures.

The Secretary of HHS established Part B financing through December 31, 2026. Estimated income exceeds estimated incurred expenditures in 2026, as shown in table III.C7. The excess of assets over liabilities increases by an estimated \$23.0 billion by the end of December 2026, as indicated in table III.C8. This increase occurs

### *Actuarial Analysis*

because the 2026 Part B financing was set to maintain the contingency reserve at a fully adequate level.

Since the financing rates are set prospectively, variations between assumed cost increases and subsequent actual experience could affect the actuarial status of the Part B account. To test the status of the account under varying assumptions, the Trustees prepared a lower-growth-range projection and an upper-growth-range projection by varying the key assumptions for 2025 and 2026. These two alternative sets of assumptions provide a range of financial outcomes within which one might reasonably expect the actual experience of Part B to fall. The Trustees determined the values for the lower- and upper-growth-range assumptions from a statistical analysis of the historical variation in the respective increase factors.

The methods underlying this sensitivity analysis are fundamentally different from the methods underlying the low-cost and high-cost projections discussed previously in this section. This sensitivity analysis is based on stochastic modeling and is shown for the period for which the financing has been established (through 2026 for this report), whereas the low-cost and high-cost projections illustrate the financial impact of slower or faster growth trends throughout the entire short-range (10-year) projection period.

Table III.C9 indicates that, under the lower-growth-range scenario, account assets would exceed liabilities at the end of December 2026 by a margin equivalent to 25.4 percent of the following year's incurred expenditures. Under the upper-growth-range scenario, account assets would still exceed liabilities, but by a margin of 14.2 percent of incurred expenditures in 2026. Figure III.C3 shows the reserve ratio for historical years and for 2026 under the three cost-growth scenarios.


Part B Financial Status

**Table III.C9.—Actuarial Status of the Part B Account in the SMI Trust Fund under Three Cost Sensitivity Scenarios for Financing Periods through December 31, 2026**

As of December 31,	2024	2025	2026
Intermediate scenario:			
Actuarial status (in millions)			
Assets	\$151,664	\$147,828	\$178,615
Liabilities	38,228	39,694	47,171
Assets less liabilities	113,435	108,134	131,444
Ratio <sup>1</sup>	19.4%	17.1%	19.3%
Lower-range scenario:			
Actuarial status (in millions)			
Assets	\$151,664	\$147,828	\$200,899
Liabilities	38,228	38,773	44,718
Assets less liabilities	113,435	109,054	156,181
Ratio <sup>1</sup>	19.7%	18.2%	25.4%
Upper-range scenario:			
Actuarial status (in millions)			
Assets	\$151,664	\$147,828	\$156,250
Liabilities	38,228	40,611	49,629
Assets less liabilities	113,435	107,216	106,621
Ratio <sup>1</sup>	19.1%	16.1%	14.2%

<sup>1</sup>Ratio of assets less liabilities at the end of the year to the total incurred expenditures during the following year, expressed as a percent.

**Figure III.C3.—Actuarial Status of the Part B Account in the SMI Trust Fund through Calendar Year 2026**



Note: The Trustees measure the actuarial status of the Part B account in the SMI trust fund by the ratio of (i) assets minus liabilities at the end of the year to (ii) the following year's incurred expenditures.

Based on the test described above, the Trustees conclude that the financing established for the Part B account for calendar year 2026 is adequate to cover 2026 expected expenditures.

*Actuarial Analysis*

**3. Long-Range Estimates**

Section III.C2 presented the expected operations of the Part B account over the next 10 years. This section examines the long-range expenditures of the account under the intermediate assumptions. Because of its automatic financing provisions, the Trustees expect the Part B account to be adequately financed into the indefinite future and so have not conducted a long-range analysis using high-cost and low-cost assumptions.

Table III.C10 shows the estimated Part B incurred expenditures under the intermediate assumptions expressed as a percentage of GDP for selected years over the calendar-year period 2025–2100.<sup>59</sup> (The intermediate assumptions are discussed in sections II.C and IV.D.)

**Table III.C10.—Part B Expenditures (Incurred Basis) as a Percentage of the Gross Domestic Product<sup>1</sup>**

Calendar year	Part B expenditures as a percentage of GDP
2025	1.90%
2026	1.96
2027	2.04
2028	2.15
2029	2.24
2030	2.36
2031	2.45
2032	2.54
2033	2.66
2034	2.80
2035	2.90
2040	3.33
2045	3.60
2050	3.73
2055	3.83
2060	3.96
2065	4.10
2070	4.22
2075	4.33
2080	4.42
2085	4.47
2090	4.49
2095	4.49
2100	4.48

<sup>1</sup>Expenditures are the sum of benefit payments and administrative expenses.

Note: Percentages are affected by economic cycles.

Under the intermediate assumptions, incurred Part B expenditures as a percentage of GDP increase from 1.90 percent in 2025 to 4.49 percent in 2090 before declining to 4.48 percent in 2100. (Part B expenditures


<sup>59</sup>These estimated incurred expenditures are for benefit payments and administrative expenses combined, unlike the values in table III.C5, which express only benefit payments on a cash basis as a percentage of GDP.

*Part B Financial Status*

instead increase to 5.7 percent in 2100 under the illustrative alternative scenario.)

Figure III.C4 compares the year-by-year Part B expenditures as a percentage of GDP for the 2026 report with the projections from the 2025 report. Both reports show a projected leveling off of the share of Part B spending as a percentage of GDP because of legislated updates, including those for physician payments. The expenditures as a percentage of GDP in this year's report are lower in the short range mainly because of the assumed impact of policy changes for skin substitutes, which are categorized as physician-administered drugs. Faster projected growth for other Part B drugs cause expenditures as a percentage of GDP to be higher than in last year's report by 2048. Thereafter, expenditures as a percentage of GDP grow faster than in last year's report due to changes in demographic assumptions, most notably the lower fertility rate assumptions, that result in lower GDP projections.

**Figure III.C4.—Comparison of Part B Projections as a Percentage of the Gross Domestic Product: Current versus Prior Year's Reports**



Note: Percentages are affected by economic cycles.

***D. PART D FINANCIAL STATUS***

This section presents actual operations of the Part D account in the SMI trust fund in 2025 and Part D projections for the next 75 years. Section III.D1 discusses Part D financial results for 2025, and sections III.D2 and III.D3 discuss the short-range Part D projections and the long-range projections, respectively. The projections shown in sections III.D2 and III.D3 assume no changes will occur in the statutory provisions and regulations under which Part D currently operates.

**1. Financial Operations in Calendar Year 2025**

The total assets of the account amounted to approximately \$18.8 billion on December 31, 2024. During calendar year 2025, total Part D expenditures were approximately \$181.5 billion. Government contributions were provided on an as-needed basis to cover the portion of expenditures that Medicare subsidies support. Total Part D receipts were \$183.3 billion. As a result, total assets in the Part D account increased to \$20.6 billion as of December 31, 2025.

Table III.D1 presents a statement of the revenue and expenditures of the Part D account of the SMI trust fund in calendar year 2025, and of its assets at the beginning and end of the calendar year.

*Part D Financial Status*

**Table III.D1—Statement of Operations of the Part D Account  
in the SMI Trust Fund during Calendar Year 2025**

[In thousands]	
Total assets of the Part D account in the trust fund, beginning of period	\$18,782,179
Revenue:	
Premiums from enrollees:	
Premiums deducted from Social Security benefits.....	\$6,007,333
Premiums paid directly to plans <sup>1</sup> .....	8,854,858
Total premiums .....	14,862,191
Government contributions:	
Prescription drug benefits .....	148,304,934
Prescription drug administrative expenses.....	538,742
Total government contributions .....	148,843,676
Payments from States .....	19,086,703
Interest on investments .....	266,818
DOJ/OIG/MA settlements <sup>2</sup> .....	258,043
Total revenue .....	\$183,317,430
Expenditures:	
Part D benefit payments <sup>1</sup> .....	\$181,021,319
Part D administrative expenses.....	509,891
Total expenditures.....	\$181,531,211
Net addition to the trust fund.....	1,786,220
Total assets of the Part D account in the trust fund, end of period .....	\$20,568,399

<sup>1</sup>Premiums paid directly to plans are not displayed on the Treasury statement and are estimated. These premiums have been added to the benefit payments reported on the Treasury statement to obtain an estimate of total Part D benefits. Direct data on such benefit amounts are not yet available.

<sup>2</sup>Reflects amounts transferred to the Part D account for settlements related to Department of Justice (DOJ) civil and criminal court cases, Office of the Inspector General (OIG) civil monetary penalties, and Medicare Advantage (MA) civil monetary penalties.

Note: Totals do not necessarily equal the sums of rounded components.

***a. Revenues***

The major sources of revenue for the Part D account are contributions of the Federal Government authorized to be apportioned and transferred from the general fund of the Treasury, premiums paid by eligible persons who voluntarily enroll, and payments from States.

Of the total Part D revenue in 2025, \$6.0 billion represented premium amounts withheld from Social Security benefits or other Federal benefit payments. Total premium payments, including those paid directly to Part D plans, amounted to an estimated \$14.9 billion or 8.1 percent of total revenue. The premium payments decreased substantially from 2024 due to the voluntary Part D premium demonstration program that reduced the premium amounts for stand-alone prescription drug plans (PDPs).

In calendar year 2025, contributions received from the general fund of the Treasury amounted to \$148.8 billion, which accounted for 81.2 percent of total revenue. The payments from States were \$19.1 billion.

### *Actuarial Analysis*

Another source of Part D revenue is interest received on investments held by the Part D account. Because this account holds a very low amount of assets, and only for brief periods of time, the interest on the investments of the account in calendar year 2025 was \$0.3 billion. Finally, law enforcement and other settlements were \$0.3 billion.

#### ***b. Expenditures***

Part D expenditures include both the costs of prescription drug benefits provided by Part D plans to enrollees and Medicare payments to retiree drug subsidy (RDS) plans on behalf of beneficiaries who obtain their primary drug coverage through such plans. Unlike Parts A and B of Medicare, the Part D account in the SMI trust fund does not directly support all Part D expenditures. In particular, enrollee premiums that are paid directly to Part D plans, and thus do not flow through the Part D account, finance a portion of these expenditures. However, these premium amounts are included in the Part D account operations (both income and expenditures) presented in this report. Total expenditures are characterized as either benefits (representing the gross cost of enrollees' prescription drug coverage plus RDS amounts) or Federal administrative expenses.

All expenses incurred by the Department of Health and Human Services, the Social Security Administration (SSA), and the Department of the Treasury in administering Part D are charged to the account. These administrative duties include making payments to Part D plans, fraud and abuse control activities, and experiments and demonstration projects designed to improve the quality, efficiency, and economy of health care services.

In addition, Congress has authorized expenditures from the trust funds for construction, rental and lease, or purchase contracts of office buildings and related facilities for use in connection with the administration of Part D. The account expenditures include such costs. However, the statement of Part D assets presented in this report does not carry the net worth of facilities and other fixed capital assets because the value of fixed capital assets does not represent funds available for benefit or administrative expenditures and is not, therefore, pertinent in assessing the actuarial status of the funds.

Of the \$181.5 billion in total Part D expenditures in 2025, \$181.0 billion represented benefits, as defined above, and the remaining \$0.5 billion reflected Federal administrative expenses. The Medicare direct premium subsidy payments and enrollee premiums implicitly cover administrative expenses incurred by Part D plans.

### *Part D Financial Status*

The total assets of the Part D account as of December 31, 2025, were higher than in 2024 primarily because of the larger advanced payments to Part D plans required in 2026 as a result of the increased bid amounts in 2026.

#### ***c. Actual experience versus prior estimates***

Table III.D2 compares the actual experience in calendar year 2025 with the estimates presented in the 2024 and 2025 annual reports. A number of factors can contribute to differences between estimates and subsequent actual experience. In particular, actual values for key economic variables can differ from assumed levels, lawmakers may adopt legislative and regulatory changes after a report's preparation, and the utilization of high-impact drugs could be higher than projected.

As shown in table III.D2, compared with the 2025 report, actual premiums from enrollees were lower than projected and payments from States were higher than projected due to a higher-than-estimated number of low-income beneficiaries. The government contributions were higher than projected mainly because (i) increased drug spending in 2024 resulted in substantial payments of reinsurance and risk corridor reconciliation payments in 2025, and (ii) the higher 2026 bid amounts required larger advanced payments for January to be transferred to the Part D trust fund in December 2025. Benefit payments were higher because of the larger than expected reconciliation payments for the 2024 policy year.

Compared with the 2024 report, the substantially lower actual premiums from enrollees were a result of the voluntary PDP premium demonstration program for 2025 instituted after the 2024 report. The smaller payments from States were due to fewer Medicaid recipients than projected. The increased government contributions were due to (i) the larger benefits payments, (ii) smaller payments from States, and (iii) higher 2026 bid amounts required larger advanced payments for January to be transferred to the Part D trust fund in December. The larger benefit payments for calendar year 2025 were mainly due to significantly higher than expected bid amounts for 2025 and the unexpected increase in drug spending in 2024 that resulted in substantial payments of reinsurance and risk corridor reconciliation payments.

*Actuarial Analysis*

**Table III.D2.—Comparison of Actual and Estimated Operations of the Part D Account in the SMI Trust Fund, Calendar Year 2025**

[Dollar amounts in millions]

Item	Comparison of actual experience with estimates for calendar year 2025 published in:					
	Actual amount	2025 report			2024 report	
		Estimated amount <sup>1</sup>	Actual as a percentage of estimate	Estimated amount <sup>1</sup>	Actual as a percentage of estimate	
Premiums from enrollees	\$14,862	\$14,953	98%	\$23,157	64%	
Payments from States	19,087	18,389	104	22,398	85	
Government contributions	148,844	142,996	104	116,583	128	
Benefit payments	181,021	177,512	102	161,168	112	

<sup>1</sup>Under the intermediate assumptions.

***d. Assets***

The Department of the Treasury invests the portion of the Part D account not needed to meet current expenditures for benefits and administration in interest-bearing obligations of the U.S. Government.

The Social Security Act authorizes the issuance of special public-debt obligations for purchase exclusively by the account. The law requires that these special public-debt obligations shall bear interest at a rate based on the average market yield (computed on the basis of market quotations as of the end of the calendar month immediately preceding the date of such issue) for all marketable interest-bearing obligations of the United States forming a part of the public debt that are not due or callable until after 4 years from the end of that month. Since the inception of the SMI trust fund, the Department of the Treasury has always invested the assets in special public-debt obligations.<sup>60</sup> Table V.H10, presented in section V.H, shows the assets of the SMI trust fund (Parts B and D) at the end of fiscal years 2024 and 2025.

As explained in section III.D2, the flexible apportionment of government contributions for Part D eliminates the need to maintain a contingency reserve. As a general rule, Part D assets are very low and are held only briefly in anticipation of immediate expenditures. However, in recent years, a reserve has accumulated in the Part D account for the future settlement of the portion of administrative expenses incurred by SSA on behalf of Medicare.

**2. 10-Year Actuarial Estimates (2026–2035)**

This section provides detailed information concerning the short-range financial status of the Part D account, including projected annual

<sup>60</sup>The Department of the Treasury may also make investments in obligations guaranteed for both principal and interest by the United States, including certain federally sponsored agency obligations.

### *Part D Financial Status*

income, expenditures, differences between income and expenditures, and trust fund balances. Section IV.B2 presents an explanation of the effects of the Trustees' intermediate assumptions and other assumptions unique to Part D on the estimates in this report.

Generally, the income to the Part D account includes the beneficiary premiums described previously and transfers from the general fund of the Treasury to cover each year's incurred benefit costs and other expenditures. The language that has been included in the Part D appropriation provides, without further Congressional action, resources for benefit payments under the Part D drug benefit program on an as-needed basis. The transfers from the Treasury reflect the direct premium subsidy payments, government subsidies,<sup>61</sup> amounts of reinsurance payments, RDS amounts, low-income subsidies, net risk-sharing payments, administrative expenses, drug manufacturer discount payments, and demonstration program costs. This income requirement is reduced by both inflation rebates<sup>62</sup> and State payments for the full-benefit dually eligible beneficiaries who were covered under Medicaid prior to the implementation of Part D.

Since 2015, the Treasury transfers into the Part D account amounts needed to pay benefit payments to plans five business days before they are to be paid, typically the first business day of a month. In addition, the account balance carries an accumulated reserve for the future settlement of the portion of administrative expenses incurred by SSA on behalf of Medicare.

The beneficiary premiums and direct subsidy rate are calculated based on the national average monthly bid amounts and defined prior to each year's operations. Starting in 2024, the base beneficiary premium constitutes the lesser of 25.5 percent<sup>63</sup> of the expected total plan costs for basic Part D coverage or the prior year's base beneficiary premium increased by 6 percent. The actual premium a beneficiary pays is calculated as the difference between the plan bid and the national

---

<sup>61</sup>Under the Inflation Reduction Act of 2022, the drug manufacturers' discount for costs below the catastrophic threshold will be replaced by government subsidies if the drugs are selected for price negotiation. In addition, there will be a one-time temporary retrospective subsidy to reduce cost sharing for vaccines and covered insulins for the 2023 plan year.

<sup>62</sup>The Inflation Reduction Act provided for the assessment of inflation rebates for those drugs for which prices are increasing more rapidly than the Consumer Price Index (CPI-U). However, the Trustees project that the inflation rebates will be modest while other price growth constraints will be more effective.

<sup>63</sup>Beginning in 2030, the base beneficiary premium percentage will be reset according to the specifications of the Inflation Reduction Act of 2022. Currently, we expect the percentage in 2030 will be set at 20 percent, causing a substantial premium increase.

### *Actuarial Analysis*

average monthly bid amount, which is then applied to the base beneficiary premium. Beginning in 2011, beneficiaries with modified adjusted gross incomes exceeding a specified threshold pay income-related premiums in addition to the premiums charged by the plans in which the individuals have enrolled. The extra premiums are credited to the Part D trust fund account and reduce the government contribution.

Starting in 2011, the drug manufacturers provide a 50-percent ingredient cost discount for brand-name drugs in the coverage gap that reduces beneficiary out-of-pocket expenses. In 2019, the Bipartisan Budget Act of 2018 increased the brand-name drug discount in the coverage gap to 70 percent, with a corresponding decrease in plan benefits. As of January 1, 2025, as a result of the altered Part D benefit structure under the Inflation Reduction Act, the brand-name discount from manufacturers has been revised to instead provide a 10-percent discount<sup>64</sup> in the initial coverage phase and a 20-percent discount in the catastrophic phase<sup>65</sup>. Medicare Part D pays advanced discount payments prospectively to the non-employer Part D plans and will be reimbursed for these amounts once the plans receive the discounts from the drug manufacturers. Although the net cashflow for this arrangement is zero, the timing of the cashflow has an impact on the yearly financing amounts.

Expenditures from the account include the premiums withheld from beneficiaries' Social Security benefits and transferred to the Part D drug plans, the direct premium subsidy payments, reinsurance payments, RDS amounts, low-income subsidy payments, net risk-sharing payments, other government subsidies, administrative expenses, drug manufacturer discount payments, and demonstration program costs. As noted previously, the Trustees supplement these expenditures to include the amount of enrollee premiums paid directly to Part D plans, thereby providing an estimate of total Part D benefit payments and other expenditures.

Part D expenditures on direct premium subsidy payments, RDS amounts, drug manufacturer discount payments, government subsidies, and administrative expenses are affected by the sequestration required by current law, which reduces benefit payments by the following percentages: 2 percent from April 1, 2013, through

---

<sup>64</sup>The 10-percent discount will be replaced by a government subsidy following the negotiation of a selected drug.

<sup>65</sup>The 20-percent discount will be replaced by a government reinsurance following the negotiation of a selected drug.

*Part D Financial Status*

April 30, 2020; 1 percent from April 1, 2022, through June 30, 2022; and 2 percent from July 1, 2022, through August 31, 2033.

Reinsurance, the low-income cost-sharing subsidy, and net risk-sharing payments are not affected by sequestration. (See section V.A for recent legislative changes affecting the sequestration of Medicare expenditures.)

Premiums for PDPs would have increased substantially in 2025 because of certain factors, including the new Part D benefit structure under the Inflation Reduction Act. However, to limit the increase in premiums and stabilize the year-by-year changes for these plans, a 3-year voluntary demonstration was implemented beginning with contract year 2025. These premium reductions result in a corresponding increase in the direct premium subsidies paid by Medicare.

A Medicare GLP-1 Bridge demonstration program will be implemented in the second half of 2026 to increase access of weight-loss drugs for beneficiaries. This program will operate outside of the Medicare Part D plan benefit coverage and will result in additional government contributions.

Table III.D3 shows the estimated operations of the Part D account under the intermediate assumptions on a calendar-year basis through 2035.

Actuarial Analysis

**Table III.D3.—Operations of the Part D Account in the SMI Trust Fund (Cash Basis) during Calendar Years 2004–2035**

[In billions]

Calendar year	Income				Expenditures			Account		
	Premium income <sup>1</sup>	Government contribution <sup>2</sup>	Payments from States <sup>3</sup>	Interest and other	Total	Benefit payments <sup>4</sup>	Administrative expense	Total	Net change	Balance at end of year <sup>5</sup>
Historical data:										
2004	—	\$0.4	—	—	\$0.4	\$0.4	—	\$0.4	—	—
2005	—	1.1	—	—	1.1	1.1	—	1.1	—	—
2006	\$3.5	39.2	\$5.5	\$0.0	48.2	47.1	\$0.3	47.4	\$0.8	\$0.8
2007	4.1	38.8	6.9	0.0	49.7	48.8	0.9	49.7	0.0	0.8
2008	5.0	37.3	7.1	0.0	49.4	49.0	0.3	49.3	0.1	0.9
2009	6.3 <sup>6</sup>	47.1	7.6	0.0	61.0	60.5	0.3	60.8	0.1	1.1
2010	6.5 <sup>6</sup>	51.1	4.0	0.0	61.7	61.7	0.4	62.1	-0.4	0.7
2011	7.7	52.6	7.1	0.0	67.4	66.7	0.4	67.1	0.3	1.0
2012	8.3	50.1	8.4	0.0	66.9	66.5	0.4	66.9	0.0	1.0
2013	9.9	51.0	8.8	0.0	69.7	69.3	0.4	69.7	-0.0	1.0
2014	11.4	58.1	8.7	0.0	78.2	77.7	0.4	78.1	0.1	1.1
2015	12.7 <sup>6</sup>	68.4	8.9	0.0	90.0	89.4	0.3	89.8	0.3	1.3
2016	13.8 <sup>6</sup>	82.4	10.0	0.0	106.2	99.5	0.5	99.9	6.3	7.6
2017	15.5	73.2	11.4	0.1	100.2	100.1	-0.1 <sup>7</sup>	100.0	0.2	7.8
2018	15.9	67.8	11.7	0.1	95.4	94.7	0.5	95.2	0.2	8.0
2019	15.7	70.2	12.3	0.5	98.7	97.0	0.5	97.5	1.2	9.2
2020	15.8 <sup>6</sup>	77.7	11.6	0.7	105.8	104.6	0.4	105.0	0.8	10.0
2021	17.0 <sup>6</sup>	85.3	12.1	0.3	114.7	104.5	0.5	105.0	9.7	19.7
2022	17.6	92.4	13.7	0.7	124.3	125.2	0.5	125.7	-1.4	18.3
2023	18.3	93.7	15.8	0.2	128.1	130.2	0.5	130.7	-2.6	15.7
2024	19.2	111.6	18.0	0.4	149.2	145.6	0.5	146.1	3.1	18.8
2025	14.9	148.8	19.1	0.5	183.3	181.0	0.5	181.5	1.8	20.6
Intermediate estimates:										
2026	20.1 <sup>6</sup>	183.2	20.6	0.6	224.6	221.8	0.6	222.4	2.2	22.7
2027	25.6 <sup>6</sup>	188.6	23.2	0.6	237.9	235.5	0.7	236.2	1.7	24.5
2028	28.8	208.5	23.7	0.7	261.6	259.3	0.7	259.9	1.7	26.1
2029	30.5	218.2	24.2	0.7	273.6	272.8	0.7	273.5	0.1	26.2
2030	51.7	208.3	25.3	0.7	286.0	284.0	0.7	284.8	1.2	27.4
2031	54.9	217.9	26.6	0.7	300.1	298.9	0.8	299.7	0.4	27.8
2032	56.4	221.9	27.8	0.8	306.8	304.8	0.8	305.6	1.2	29.0
2033	59.5	233.3	28.2	0.8	321.7	319.9	0.8	320.8	1.0	30.0
2034	62.0	243.5	28.5	0.8	334.9	332.8	0.9	333.7	1.1	31.1
2035	65.3	252.7	29.4	0.8	348.2	345.8	0.9	346.7	1.5	32.6

<sup>1</sup>Premiums include both amounts withheld from Social Security benefits or other Federal payments, direct payments to the Federal government, and those paid directly to Part D plans.

<sup>2</sup>Includes, net of payments from States, all government transfers required to fund benefit payments, inflation rebates as specified under the Inflation Reduction Act of 2022, administrative expenses, and State expenses for making low-income eligibility determinations.

<sup>3</sup>Payments from States with respect to the Federal assumption of Medicaid responsibility for drug expenditures for full-benefit dually eligible individuals.

<sup>4</sup>Includes payments to Part D plans, government subsidies corresponding to both the Inflation Reduction Act of 2022 and demonstration program costs, payments to retiree drug subsidy plans, payments to States for making low-income eligibility determinations, Part D drug premiums collected from beneficiaries, and transfers to Medicare Advantage plans and stand-alone prescription drug plans. Includes amounts for the Transitional Assistance program of \$0.4 billion, \$1.0 billion, and \$0.1 billion in 2004–2006, respectively.

<sup>5</sup>As noted in section III.D.2, a new policy was developed in 2015 under which amounts from the Treasury are transferred into the Part D account 5 business days before the benefit payments to the plans, rather than on the day the benefit payments are due—typically the first business day of a month—as had previously been the case. Accordingly, the Part D account includes a balance at the end of the previous year that is more substantial than it would have been prior to implementation of the new policy. For 2021, 2022, and 2023, the balances were larger than in prior years because of delayed settlement of the year-end reconciliation amounts from November to January. In addition, the balances since 2019 have also included an accumulated reserve for the administrative costs incurred by SSA on behalf of Medicare. The account balances were further increased in 2024 due to the larger monthly payments to plans starting in 2025 under the Inflation Reduction Act of 2022.

### *Part D Financial Status*

<sup>6</sup>Section 708 of the Social Security Act modifies the provisions for the payment of Social Security benefits when the regularly designated day falls on a Saturday, Sunday, or legal public holiday. Payment of those benefits normally due January 3, 2010, actually occurred on December 31, 2009, payment of benefits normally due January 3, 2016, occurred on December 31, 2015, and payment of benefits normally due January 3, 2021, occurred on December 31, 2020. Consequently, the Part D premiums withheld from these benefits were added to the Part D account on December 31, 2009 (about \$0.2 billion), December 31, 2015 (about \$0.2 billion), and December 31, 2020 (about \$0.1 billion), respectively. Similarly, the expected payment date for those benefits normally due January 3, 2027, is December 31, 2026. Accordingly, an estimated \$0.2 billion will be added to the Part D account on December 31, 2026.

<sup>7</sup>Reflects a larger-than-usual downward adjustment of \$0.3 billion for prior-year allocations among Part A, Part B, and Part D.

Note: Totals do not necessarily equal the sums of rounded components.

Table III.D4 shows prescription drug payment amounts in the aggregate, on a per capita basis, and relative to the Gross Domestic Product (GDP). The benefit amounts are shown on a cash basis and reflect net reconciliation payments that are made to adjust for prior-year differences between prospective payments made to plans and actual prescription drug expenditures.

The magnitude and timing of the year-end reconciliation payments can cause a volatile pattern of annual growth rates. This was the case during the COVID-19 pandemic, when the payments were delayed to the following calendar year because of deadline extensions for plans to submit risk-adjustment data.

*Actuarial Analysis*

**Table III.D4.—Growth in Part D Benefits (Cash Basis) through December 31, 2035**

Calendar year	Aggregate benefits [billions]	Percent change	Per capita benefits	Percent change	Part D benefits as a percentage of GDP
Historical data:					
2004	\$0.4	—	\$362	—	0.00%
2005	1.1	—	596	—	0.01
2006	47.1	—	1,708	—	0.34
2007	48.8	3.7%	1,556	-8.9%	0.34
2008	49.0	0.4	1,504	-3.3	0.33
2009	60.5	23.4	1,798	19.6	0.42
2010	61.7	2.0	1,775	-1.3	0.41
2011	66.7	8.1	1,868	5.3	0.43
2012	66.5	-0.4	1,776	-5.0	0.41
2013	69.3	4.2	1,772	-0.2	0.41
2014	77.7	12.1	1,919	8.3	0.44
2015	89.4	15.1	2,140	11.5	0.49
2016	99.5	11.2	2,302	7.6	0.53
2017	100.1	0.7	2,251	-2.2	0.51
2018	94.7	-5.4	2,068	-8.1	0.46
2019	97.0	2.5	2,057	-0.5	0.45
2020	104.6	7.7	2,147	4.4	0.49
2021	104.5	-0.1	2,091	-2.6	0.44
2022	125.2	19.8	2,436	16.5	0.48
2023	130.2	4.0	2,462	1.1	0.47
2024	145.6	11.9	2,636	7.1	0.50
2025	181.0	24.3	3,190	21.0	0.59
Intermediate estimates:					
2026	221.8	22.5	3,825	19.9	0.69
2027	235.5	6.2	3,945	3.1	0.70
2028	259.3	10.1	4,219	6.9	0.75
2029	272.8	5.2	4,332	2.7	0.76
2030	284.0	4.1	4,424	2.1	0.76
2031	298.9	5.2	4,583	3.6	0.77
2032	304.8	2.0	4,611	0.6	0.75
2033	319.9	4.9	4,782	3.7	0.76
2034	332.8	4.0	4,919	2.9	0.76
2035	345.8	3.9	5,054	2.7	0.76

Note: Percentages are affected by economic cycles.

Part D benefit payments have experienced an erratic growth pattern throughout the history of the program. Expenditures have been increasing substantially, reflecting not only rapid growth in enrollment but also multiple prescription drug cost and utilization trends that have varying effects on underlying costs. For example, while drug costs have been increasing more rapidly than other categories of medical spending, there has been a substantial increase in the proportion of prescriptions filled with low-cost generic drugs that has helped constrain cost growth and, at the same time, a significant increase in the cost of specialty drugs that has increased cost growth. Additionally, direct and indirect remuneration (DIR) as a percentage of gross drug spending has increased since the inception of the Part D program, a factor that has significantly slowed Part D spending growth.

New drugs or expanded uses for existing drugs can also increase overall growth in drug expenditures and result in higher program costs. In 2024, actual drug expenditures were significantly higher

### *Part D Financial Status*

because of the unanticipated rapid increase in the use of antidiabetic drugs. The utilization of these drugs has continued to increase through 2025 and is projected to continue due to new indication approvals, availability of pill formulations, and new drug releases. Meanwhile, the rapid increases in price and utilization of expensive cancer drugs has also contributed to significantly higher drug expenditures.

Legislation and policy changes also contribute to the volatility of the annual growth rates. For example, the coverage gap gradually closed from 2012 through 2020, increasing plan benefits and resulting in higher Part D expenditures and premiums. In addition, the policy to pay advanced reinsurance amounts to the employer/union-only group waiver plans, beginning in 2017, affects the timing of the reinsurance payments, which were previously provided exclusively through the reconciliation process.

Two recent legislation and policy changes have significantly affected Part D expenditures. First, a pharmacy price concessions policy (published in a May 9, 2022, CMS final rule) shifts pharmacy rebates to reduce point-of-sale drug prices, effective January 1, 2024. The reduction in rebates results in increased Medicare expenditures.

Second, the Inflation Reduction Act of 2022 has redesigned the standard Part D benefit to provide reduced beneficiary out-of-pocket costs while increasing Federal spending beginning in 2023, with the full effects of the benefit redesign implemented in 2025. Partially offsetting these additional costs by the end of the short-range projection are program savings resulting from the lowering of drug price growth through price negotiation and inflation rebates. The impact of negotiated prices begins in 2026 and will phase in over several years as the prices for more drugs are negotiated. While the price negotiations will lower drug prices at the point of sale, drug manufacturers are expected to reduce rebates offered to plan sponsors.

More recently, OBBBA had small effects on the negotiation selections for Part D while the Consolidated Appropriations Act of 2026 eliminated generic cost-sharing for some low-income populations.

Accordingly, over the next 10 years, aggregate benefits are projected to increase at a rate of 6.7 percent annually, on average, while the average per capita rate of growth is projected to be 4.7 percent.

The Trustees have also prepared estimates using two alternative sets of assumptions. Table III.D5 summarizes the estimated operations of the Part D account under the intermediate assumptions and under the

### Actuarial Analysis

two alternative sets of assumptions. Section IV.B2 presents the assumptions underlying the intermediate estimates in substantial detail, and it outlines the assumptions used in preparing estimates under the low-cost and high-cost alternatives.

**Table III.D5.—Estimated Operations of the Part D Account in the SMI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions**

[Dollar amounts in billions]						
Calendar year	Premiums from enrollees	Other income <sup>1</sup>	Total income	Total expenditures	Balance in account at end of year	Expenditures as a percentage of GDP
Intermediate:						
2025 <sup>2</sup>	\$14.9	\$168.5	\$183.3	\$181.5	\$20.6	0.59%
2026	20.1 <sup>3</sup>	204.4	224.6	222.4	22.7	0.69
2027	25.6 <sup>3</sup>	212.4	237.9	236.2	24.5	0.71
2028	28.8	232.8	261.6	259.9	26.1	0.75
2029	30.5	243.0	273.6	273.5	26.2	0.76
2030	51.7	234.3	286.0	284.8	27.4	0.76
2031	54.9	245.2	300.1	299.7	27.8	0.77
2032	56.4	250.5	306.8	305.6	29.0	0.75
2033	59.5	262.2	321.7	320.8	30.0	0.76
2034	62.0	272.8	334.9	333.7	31.1	0.76
2035	65.3	282.9	348.2	346.7	32.6	0.76
Low-cost:						
2025 <sup>2</sup>	14.9	168.5	183.3	181.5	20.6	0.59
2026	20.1 <sup>3</sup>	197.5	217.6	216.9	21.3	0.66
2027	25.2 <sup>3</sup>	189.0	214.2	213.0	22.5	0.62
2028	27.9	209.6	237.5	236.3	23.7	0.65
2029	29.7	217.0	246.7	246.8	23.6	0.64
2030	47.0	207.9	254.8	254.0	24.5	0.63
2031	49.7	214.9	264.5	264.4	24.6	0.62
2032	50.9	216.9	267.8	267.0	25.4	0.60
2033	53.6	224.3	277.9	277.3	26.0	0.59
2034	55.7	230.7	286.4	285.7	26.7	0.58
2035	58.3	236.2	294.5	293.6	27.7	0.56
High-cost:						
2025 <sup>2</sup>	14.9	168.5	183.3	181.5	20.6	0.59
2026	20.1 <sup>3</sup>	211.8	232.0	228.9	23.6	0.72
2027	26.0 <sup>3</sup>	229.9	255.9	253.4	26.1	0.81
2028	29.8	252.4	282.2	279.9	28.4	0.87
2029	31.5	268.3	299.8	299.3	28.9	0.90
2030	56.7	262.2	318.9	317.1	30.8	0.92
2031	60.6	279.6	340.2	339.3	31.6	0.95
2032	62.6	290.1	352.7	350.9	33.4	0.96
2033	66.4	308.1	374.5	372.9	34.9	0.99
2034	69.3	325.1	394.4	392.7	36.7	1.01
2035	73.1	341.9	415.0	412.8	38.9	1.04

<sup>1</sup>Other income contains government contributions, payments from States, inflation rebates as specified under the Inflation Reduction Act of 2022, interest, and settlement collections.

<sup>2</sup>Figures for 2025 represent actual experience.

<sup>3</sup>See footnote 6 of table III.D3.

Notes: 1. Totals do not necessarily equal the sums of rounded components.

2. Percentages are affected by economic cycles.

Because of the price assumptions for these alternative scenarios, the expenditures presented in these scenarios represent a narrow range of outcomes, and actual experience could easily fall outside of this range. For the low-cost scenario, the Trustees assume higher price inflation, which leads to higher spending. Similarly, under the high-cost

### *Part D Financial Status*

scenario, the Trustees assume lower price inflation, which leads to lower spending. These price inflation assumptions partially offset the effects of the other assumptions in the high-cost and low-cost scenarios, resulting in a narrow range of expenditures. Given the considerable variation in the factors affecting health care spending, actual Part D experience could easily fall outside of this range. Because the GDP assumptions in these scenarios are similarly affected by the price inflation assumptions, Part D expenditures as a percent of GDP provide better insight into the variability of spending than the nominal dollar amounts, as shown in table III.D5.

The alternative projections shown in table III.D5 illustrate two important aspects of the financial operations of the Part D account:

- Despite the differing assumptions underlying the three alternatives, the balance between Part D income and expenditures remains relatively stable. This result occurs because the premiums and government contributions underlying the Part D financing are reestablished annually. Thus, Part D income automatically tracks Part D expenditures fairly closely, regardless of the specific economic and other conditions.
- As a result of the close matching of income and expenditures described above, together with anticipated continuing flexibility in the apportionment of government contributions, the need for a contingency reserve to handle unanticipated fluctuations is minimal.

### *Adequacy of Part D Financing Established for Calendar Year 2025*

As noted previously, the Part D account in the SMI trust fund will be in financial balance indefinitely because the premiums paid by enrollees and the amounts apportioned from the general fund of the Treasury are determined each year so as to adequately finance Part D expenditures. Moreover, the appropriation for Part D government contributions has included an indefinite authority provision allowing for amounts to be transferred to the Part D account on an as-needed basis. This provision allows previously apportioned amounts to change without additional Congressional action if those amounts are later determined to be insufficient. Consequently, once an appropriation with this provision has been made, no deficit will occur in the Part D account, and no contingency fund will be necessary to cover deficits.<sup>66</sup>

---

<sup>66</sup>The indefinite authority applies to all Part D expenditures other than Federal administrative expenses, which are specifically appropriated each year.

### *Actuarial Analysis*

One exception for the unnecessary contingency fund in recent years is that a reserve has accumulated for the future settlement of the portion of administrative expenses incurred by SSA on behalf of Medicare.

As described in section III.C on the financial status of the Part B account, it is important to maintain an appropriate level of assets to cover the liability for claims that have been incurred but not yet reported or paid. In the case of Part D, however, most such claims are the responsibility of the prescription drug plans rather than the Part D program. Accordingly, the Part D account is generally not at risk for incurred-but-unreported claim amounts, and no asset reserve is necessary for this purpose.

Another potential Part D liability exists to the extent that Part D reinsurance payments and low-income cost-sharing subsidy payments are based on plan estimates.<sup>67</sup> Since actual Part D costs, as subsequently determined, will generally differ from plan bids, payment adjustments are made after the close of the year as needed to reconcile the accounts. When plan bids have been below actual costs, Medicare has made reconciliation payments to the plans from the following year's appropriated government contributions; thus, creation of a reserve for payment of such settlement amounts is not required.

For these reasons, the Trustees have concluded that maintenance of Part D account assets for drug plan contingency or liability purposes is unnecessary at this time. Accordingly, evaluation of the adequacy of Part D assets is also unnecessary, and the Part D account is considered to be in satisfactory financial condition for 2026 and all future years as a consequence of its basis for financing.

### **3. Long-Range Estimates**

Section III.D2 presented the expected operations of the Part D account over the next 10 years. This section describes the long-range expenditures of the account under the intermediate assumptions. Because of its automatic financing provisions, the Trustees expect adequate financing of the Part D account into the indefinite future and so have not conducted a long-range analysis using high-cost and low-cost assumptions.

---

<sup>67</sup>These estimates are subject to actuarial review by the CMS Office of the Actuary.

*Part D Financial Status*

Table III.D6 shows the estimated Part D incurred expenditures under the intermediate assumptions expressed as a percentage of GDP, for selected years over the calendar-year period 2025–2100.<sup>68</sup>

**Table III.D6.—Part D Expenditures (Incurred Basis) as a Percentage of the Gross Domestic Product<sup>1</sup>**

Calendar year	Part D expenditures as a percentage of GDP
2025	0.59%
2026	0.68
2027	0.69
2028	0.73
2029	0.76
2030	0.76
2031	0.77
2032	0.75
2033	0.76
2034	0.76
2035	0.76
2040	0.76
2045	0.75
2050	0.77
2055	0.80
2060	0.84
2065	0.88
2070	0.91
2075	0.94
2080	0.97
2085	0.99
2090	1.00
2095	1.00
2100	1.01

<sup>1</sup>Expenditures are the sum of benefit payments and administrative expenses.

Note: Percentages are affected by economic cycles.

The Trustees assume that, during the initial 25-year period, increases in Part D costs per enrollee will vary while gradually converging to the growth rates described in sections II.C and IV.D. Based on these assumptions and projected demographic changes, incurred Part D expenditures as a percentage of GDP would increase from 0.59 percent in 2025 to 1.01 percent in 2100.


Figure III.D1 compares the year-by-year Part D expenditures as a percentage of GDP for the current annual report with the corresponding projections from 2025. For Part D, the expenditure share of GDP is significantly higher than the share in last year’s report in all years. This is mainly due to increases in the utilization of GLP-1 and expensive specialty drugs in 2025. Additionally, projected growth is higher than in last year’s report because of higher cost trends and lower projected DIR through the short-range period. In the long-range period, this difference grows due to the changes in demographic

<sup>68</sup>These estimated incurred expenditures are for benefit payments and administrative expenses combined, unlike the values in table III.D4, which express only benefit payments on a cash basis as a percentage of GDP.

*Actuarial Analysis*

assumptions, most notably the lower fertility rate assumptions, that result in lower GDP projections.

**Figure III.D1.—Comparison of Part D Projections as a Percentage of the Gross Domestic Product: Current versus Prior Year's Reports**



Note: Percentages are affected by economic cycles.

#### **IV. ACTUARIAL METHODOLOGY AND PRINCIPAL ASSUMPTIONS FOR COST ESTIMATES FOR THE HOSPITAL INSURANCE AND SUPPLEMENTARY MEDICAL INSURANCE TRUST FUNDS**

This section describes the basic methodology and assumptions used in the estimates for the HI and SMI trust funds under the intermediate assumptions and presents projections of HI and SMI costs under two alternative sets of assumptions.

The economic and demographic assumptions underlying the projections of HI and SMI costs shown in this report are consistent with those in the 2026 Annual Report of the Board of Trustees of the Federal Old-Age and Survivors Insurance and Federal Disability Insurance (OASDI) Trust Funds.<sup>69</sup> That report describes these assumptions in more detail.

##### ***A. HOSPITAL INSURANCE***

###### **1. Cost Projection Methodology**

The principal steps involved in projecting future HI costs are as follows: (i) establishing the present cost of services provided to beneficiaries, by type of service, to serve as a projection base; (ii) projecting increases in HI payments for inpatient hospital services; (iii) projecting increases in HI payments for skilled nursing, home health, and hospice services covered; (iv) projecting increases in payments to private health plans; and (v) projecting increases in administrative costs.

###### ***a. Projection Base***

To establish a suitable base from which to project future HI costs, the incurred payments for services provided must be constructed for the most recent period for which a reliable determination can be made. Accordingly, payments to providers must be attributed to dates of service, rather than to payment dates; in addition, the nonrecurring effects of any changes in regulations, legislation, or administration, and of any items affecting only the timing and flow of payments to providers, must be eliminated. As a result, the rates of increase in the HI incurred costs differ from the increases in cash expenditures shown in the tables in section III.B.

---

<sup>69</sup>The non-health-specific intermediate assumptions for this report were set in February 2026. The Trustees will continue to monitor developments, reevaluate the assumptions, and modify the projections in later reports.

### *Actuarial Methodology*

For those expenses still reimbursed on a reasonable-cost basis, the costs for covered services are determined on the basis of provider cost reports. Because of the time required to obtain cost reports from providers, to verify these reports, and to perform audits (where appropriate), final settlements have lagged behind the original costs by as much as several years for some providers. Additional complications arise from legislative, regulatory, and administrative changes, the effects of which cannot always be determined precisely.

The process of allocating the various types of HI payments made to the proper incurred period—using incomplete data and estimates of the impact of administrative actions—presents difficult problems, and the solutions to these problems can be only approximate. Under the circumstances, the best that one can expect is that the actual HI incurred cost for a recent period can be estimated within a few percent. This process increases the projection error directly by incorporating any error in estimating the base year into all future years.

#### ***b. Fee-for-Service Payments for Inpatient Hospital Costs***

Payment for almost all inpatient hospital services for fee-for-service beneficiaries occurs under a prospective payment system. The law stipulates that the annual increase in the payment rate for each admission relate to a hospital input price index (also known as the hospital market basket), which measures the increase in prices for goods and services purchased by hospitals for use in providing care to hospital inpatients.

For fiscal year 2026, the prospective payment rates have already been determined. For fiscal years 2027 and later, the statute mandates that the annual increase in the payment rate per admission equal the annual increase in the hospital input price index (for those hospitals submitting required quality measure data), minus a specified percentage. For this report, the Trustees assume that all hospitals will submit these data.

Increases in aggregate payments for inpatient hospital care covered under HI can be analyzed in five broad categories, presented in table IV.A1:

- (1) Hospital input price index—the increase in prices for goods and services purchased by the hospital;

*Hospital Insurance*

- (2) Update factor adjustment—an amount added to or subtracted from the input price index (generally called for in legislation) to yield the prospective payment update factor;
- (3) Volume of services—the increase in total output of units of service (as measured by covered HI hospital admissions);
- (4) Case mix—the financial effect of changes in the average complexity of hospital admissions; and
- (5) Other sources—a residual category reflecting all other factors affecting hospital cost increases (such as enacted legislative changes).

Table IV.A1 shows the estimated historical values of these principal components, as well as the projected trends used in the estimates. The impact of sequestration during April 1, 2013, through August 31, 2013, with the exception of May 1, 2020, through March 31, 2022, when it was suspended, is reflected in the table. Unless otherwise indicated, the following discussions apply to projections under the intermediate assumptions.

**Table IV.A1.—Components of Historical and Projected Increases in HI Inpatient Hospital Payments<sup>1</sup>**

Calendar year	Input price index	Update factor adjustment <sup>2</sup>	Volume of services				Other sources	HI inpatient hospital payments
			HI enrollment	Managed care shift effect	Admission incidence	Case mix		
Historical data:								
2016	2.5%	-0.8%	2.7%	-1.1%	-1.6%	3.1%	-0.5%	4.2%
2017	2.7	-1.1	5.5	-2.2	-0.6	0.4	-3.7	0.8
2018	2.8	-1.4	-0.3	-2.8	-1.4	1.8	2.6	1.2
2019	2.9	-1.3	2.5	-2.8	-3.2	1.0	2.7	1.8
2020	2.9	-0.3	2.2	-4.2	-14.2	3.8	7.3	-4.0
2021	2.5	-0.2	1.8	-5.2	1.1	2.9	-1.5	1.0
2022	3.1	-0.6	1.9	-4.8	0.8	-0.3	-1.3	-1.4
2023	3.9	-0.3	2.2	-4.7	2.0	-1.0	-1.0	0.9
2024	3.3	-0.3	2.2	-3.6	1.7	0.0	0.8	4.1
2025	3.4	-0.6	2.0	-0.5	0.7	0.9	0.3	6.3
Intermediate estimates:								
2026	3.3	-0.8	1.8	0.2	0.5	0.75	2.0	7.9
2027	3.3	-1.0	2.2	-0.4	0.3	0.5	0.2	5.1
2028	3.5	-1.0	2.3	-0.8	0.0	0.5	0.4	5.0
2029	3.6	-0.9	1.9	-0.9	0.0	0.5	0.5	4.6
2030	3.7	-0.9	1.5	-0.9	0.0	0.5	0.3	4.3
2031	3.7	-0.8	1.2	-1.0	0.0	0.5	0.4	4.1
2032	3.6	-0.9	1.0	-0.9	0.0	0.5	0.4	3.8
2033	3.5	-0.8	0.9	-0.7	0.0	0.5	1.0	4.4
2034	3.4	-0.8	1.0	-0.6	0.0	0.5	1.6	5.1
2035	3.3	-0.8	1.0	-0.4	0.0	0.5	0.1	3.8

<sup>1</sup>Percent increase in year indicated over previous year, on an incurred basis.

<sup>2</sup>Reflects the adjustments to the prospective payment update for the 10-year moving average of economy-wide productivity growth and additional decreases in updates ranging from 0.1 percentage point to 0.75 percentage point through 2019.

### *Actuarial Methodology*

The input price index is a weighted average of the price proxies (prices of specific inputs) used in delivery of HI inpatient services. The first 2 years of the projection period are based on the methodology underlying the regulatory updates. Thereafter, the methodology uses the historical relationship of three macroeconomic series (average hourly compensation, GDP deflator, and CPI) to each price proxy and applies this relationship to the projected macroeconomic series.

The update factor adjustment is generally the amount subtracted from the input price index to yield the prospective payment update factor.<sup>70</sup> As indicated in table IV.A1, the negative adjustment throughout the first 10-year projection period is associated with the legislatively required adjustment for the 10-year moving average economy-wide productivity growth. While the law also requires that hospitals that do not submit quality measure data receive a reduced update, the Trustees assume that all hospitals will submit these data.

Increases in payments for inpatient hospital services also reflect growth in the number of inpatient hospital admissions covered under HI fee-for-service. As shown in table IV.A1, increases in admissions are attributable to growth in both HI enrollment and admission incidence (admissions per beneficiary). A very large decrease in admissions occurred in 2020 because of the pandemic, and some of these admissions returned over the next few years. Admissions are assumed to grow for the next few years until stabilizing by fiscal year 2028. The historical and projected growth in enrollment reflects a more rapid increase in the population aged 65 and over than in the total population of the United States, as well as trends in the number of disabled beneficiaries and persons with end-stage renal disease. Growth in enrollment is expected to continue and to mirror the ongoing demographic shift into categories of the population eligible for HI benefits and reduced by an increasing proportion of beneficiaries enrolling in private health plans.

The choice of more beneficiaries to join private health plans has been an offsetting factor to the HI enrollment growth, as shown in the “Managed care shift effect” column of table IV.A1. In other words, greater enrollment in private health plans reduced the number of beneficiaries with fee-for-service Medicare coverage and thereby reduced hospital admissions paid through fee-for-service. Private

---

<sup>70</sup>The update factors are generally prescribed on a fiscal-year basis, while table IV.A1 is on a calendar-year basis. Calculations have therefore been performed to estimate the update factor adjustment on the basis of calendar years. The sum of the input price index and the update factor adjustment generally reflects the prescribed prospective payment update factor, but on a calendar-year, rather than a fiscal-year, basis.

### *Hospital Insurance*

Medicare health plan membership is projected to continue to grow for most of the projection period.

Since the beginning of the prospective payment system (PPS), inpatient hospital payments have varied based on the complexity of admissions. These variations are primarily due to two factors. The first is the changes in diagnosis-related group (DRG) coding as hospitals continue to adjust to the PPS, and the second factor is the trend toward treating less complicated (and thus less expensive) cases in outpatient settings, which results in an increase in the average prospective payment per admission.

After increasing in fiscal year 2025, the increase in the average complexity of hospital admissions (case mix) is expected to slow gradually until reaching 0.5 percent annually in fiscal years 2027 through 2035. The projected growth in case mix is a result of an assumed continuation of the current trend toward treating less complicated cases in outpatient settings, ongoing changes in DRG coding, and the overall impact of new technology.

Hospital payments are also affected by other factors, as reflected in the “Other sources” column of table IV.A1. For example, statutory budget neutrality adjustments offset costs from significant increases in case mix that occurred when the new Medicare severity diagnosis-related group (MS-DRG) system was introduced in 2008. Although the law limited the size of these adjustments in 2008 and 2009, it allows subsequent recovery of any extra payments that resulted. The “Other sources” column reflects all of these actual and anticipated effects and adjustments.

In addition, one can attribute part of the increase from “other sources” to the increase in payments for certain costs, not included in the DRG payment, that are generally growing at a rate slower than the input price index. These other costs include capital, medical education (both direct and indirect), disproportionate share hospital (DSH) payments, and payments to hospitals not included in the PPS.

A particularly important change affecting these costs is the reduction in Medicare DSH payments. This change reflects the major coverage expansions that began in 2014 and that continue to result in significantly fewer uninsured hospital patients. In 2019, however, the elimination of the individual mandate increased the number of uninsured. Subsequently, the number of uninsured decreased beginning in 2020 because of the continuous eligibility provision that paused disenrollments from Medicaid during this time. Once the public

### *Actuarial Methodology*

health emergency ended in 2023, the number of uninsured increased when eligibility redeterminations were resumed.

The “Other sources” column also reflects the impact of the 20-percent add-on for COVID-19 admissions during the public health emergency.

Additional possible sources of changes in payments include the following: (i) a shift to higher-cost or lower-cost admissions because of changes in the demographic characteristics of the covered population; (ii) changes in medical practice patterns; and (iii) adjustments in the relative payment levels for various DRGs, or addition/deletion of DRGs, in response to changes in technology.

The “Other sources” column reflects, as appropriate, the impact of certain enacted legislation, including the sequestration process. Also reflected in this column is the impact of the estimated bonus payments and penalties for hospitals resulting from the health information technology incentives.

The increases in the input price index (less any intensity allowance specified in the law), units of service, and other sources are compounded to calculate the total increase in payments for inpatient hospital services. The last column of table IV.A1 shows these overall increases.

#### ***c. Fee-for-Service Payments for Skilled Nursing Facility, Home Health Agency, and Hospice Services***

To project fee-for-service payments for skilled nursing facilities (SNFs), a method similar to that for inpatient hospitals is used. First, the number of covered days is determined, and then the average reimbursement per day is calculated.

Historically, the number of days of care covered in SNFs under HI has varied widely. This extremely volatile experience has resulted, in part, from legislative and regulatory changes and from judicial decisions affecting the scope of coverage. Since 2015, there have been significant decreases in the number of covered SNF days, with the exception of 2022, when the effects of the waiver of the 3-day inpatient stay requirement are reflected. The intermediate projections assume that changes in covered SNF days will continue to reflect the aging of the population, but the underlying utilization rate will decline from 2026 through 2028 to be 0 percent in 2029 and beyond.

The methodology used to develop the market basket increases for SNFs is consistent with the methodology used to develop the hospital market

*Hospital Insurance*

basket increases. These market basket increases are reduced by the increase in economy-wide productivity beginning in 2012. Cost per day also increases by a case mix increase.

Case mix increases dropped from 0.5 percent in 2016 to 0.1 percent in 2019. In 2020, a new payment system was implemented, leading to an increase in case mix of 4.9 percent. This increase dropped afterward, and, for the projection, the case mix increases are assumed to remain at a level of 1.5 percent annually beginning in 2026. The required reduction in costs attributable to sequestration is also reflected in the projected expenditures. These assumed trends result in projected rates of increase in cost per day that are assumed to decline to a level slightly higher than increases in general earnings throughout the projection period.

Table IV.A2 shows the resulting increases in fee-for-service expenditures for SNF and other types of services. The sequestration impact is reflected in the table.

**Table IV.A2.—Comparison of Increases in HI Expenditures and Increases in Taxable Payroll<sup>1</sup>**

Calendar year	Inpatient hospital	Skilled nursing facility	Home health agency <sup>2</sup>	Hospice	Private plans	Weighted average	HI administrative costs <sup>3</sup>	HI expenditures <sup>3</sup>	HI taxable payroll	Growth rate differential <sup>4</sup>
Historical data:										
2016	4.3%	-2.2%	-1.0%	6.0%	7.2%	4.3%	-9.1%	4.1%	2.7%	1.3%
2017	0.7	-1.4	-0.7	6.4	10.5	3.8	4.2	3.8	4.6	-0.8
2018	1.2	-1.4	-0.4	7.3	9.1	3.8	4.4	3.8	5.0	-1.1
2019	1.8	-1.8	-2.1	8.4	15.4	6.4	3.0	6.3	4.5	1.7
2020	-4.0	5.3	-7.7	7.2	14.9	4.3	-18.2	3.9	1.8	2.1
2021	1.0	-4.8	-0.7	3.1	9.0	3.8	15.9	4.0	10.3	-5.7
2022	-1.4	6.5	-3.0	3.5	14.8	6.4	2.8	6.3	7.3	-0.9
2023	0.9	-6.0	-0.4	8.0	13.4	6.5	5.2	6.4	5.6	0.8
2024	4.1	3.4	2.6	10.1	4.5	4.6	11.1	4.7	4.8	-0.1
2025	6.3	8.8	2.0	9.3	4.4	5.7	-6.1	5.5	4.5	1.0
Intermediate estimates:										
2026	7.9	12.1	5.6	8.3	8.1	8.3	5.8	8.3	4.5	3.6
2027	5.1	8.8	11.2	8.5	12.7	9.4	5.2	9.3	4.4	4.7
2028	5.0	6.7	7.6	8.9	8.6	7.2	5.1	7.2	4.6	2.4
2029	4.6	6.2	7.0	8.8	8.5	7.0	4.7	7.0	4.8	2.1
2030	4.3	5.9	6.7	8.7	8.1	6.7	4.6	6.7	4.9	1.7
2031	4.1	5.8	6.8	8.9	7.8	6.5	4.3	6.4	4.8	1.6
2032	3.8	5.7	6.6	9.1	7.3	6.2	4.2	6.1	4.6	1.4
2033	4.4	6.3	7.2	9.6	7.7	6.7	6.1	6.7	4.4	2.2
2034	5.1	6.9	7.7	10.1	7.9	7.1	8.0	7.2	4.1	2.9
2035	3.8	5.7	6.3	8.4	5.9	5.5	4.1	5.4	4.0	1.4

<sup>1</sup>Percent increase in year indicated over previous year.

<sup>2</sup>Includes the declining share of costs drawn from HI for coverage of certain home health services transferred from HI to SMI Part B.

<sup>3</sup>Includes costs of Quality Improvement Organizations.

<sup>4</sup>The ratio of the increase in HI costs to the increase in taxable payroll. This ratio is equivalent to the percent increase in the ratio of HI expenditures to taxable payroll (the cost rate).

A methodology similar to the one for inpatient hospitals and SNFs is used to project home health agency (HHA) payments. For most

### *Actuarial Methodology*

historical years, HI experience with HHA payments had shown an upward trend, frequently with sharp increases in the number of visits from year to year. Following decreases in utilization in most previous years, there were decreases again for 2016 through 2019. Then utilization dropped significantly in 2020 because of the pandemic before rebounding beginning in 2021. Beginning in 2026 and throughout the rest of the short-range projection period, utilization increases are assumed to be equal to the growth and aging of the population plus 1 percent annually.

Reimbursement per episode of care<sup>71</sup> is assumed to increase at a slightly higher rate than increases in general earnings, but adjustments to reflect statutory limits on HHA reimbursement per episode are included where appropriate. As with other services, a least-squares regression model was used to develop market basket increases, which are reduced by the increase in economy-wide productivity beginning in 2015.

Costs also increase by a case mix increase factor. Case mix increases were modest from 2016 through 2019. There were decreases in 2020 and 2021, followed by slight rebounds in 2022 and 2023. Beginning in 2025, case mix increases are projected to grow at a rate of 1.5 percent annually.

HHA payment rates were rebased in 2014, and an estimated 14-percent reduction in payments was phased in over a 4-year period. Additionally, projected HHA costs reflect regulatory reductions that were made to the base payment rate from 2023 through 2027 in order to maintain budget neutrality for the switch to 30-day periods. Table IV.A2 shows the resulting increases in fee-for-service expenditures for HHA services.

HI covers certain hospice care for terminally ill beneficiaries. Hospice payments were originally very small relative to total HI benefit payments, but they have grown rapidly in most years and now substantially exceed the level of HI home health expenditures. This growth rate is composed of two factors. One is the price update, which is a function of the hospital market basket with an adjustment for economy-wide productivity, and the other is a residual, which reflects other factors excluding the impact of changes in enrollment. This residual was positive in 2016 through 2021. There was lower growth in the residual for 2022, a rebound in 2023, and then strong growth in

---

<sup>71</sup>Under the HHA prospective payment system, Medicare payments are made for each episode of care rather than for each individual home health visit.

## *Hospital Insurance*

2024 and 2025, which is assumed to phase down to an increase of 3 percent per year for the remainder of the short-range projection period. Estimates for hospice benefit payment increases are based on mandated daily payment rates and annual payment caps, and these estimates assume a deceleration in the growth in the number of covered days.

### ***d. Private Health Plan Costs***

HI payments to private health plans have generally increased significantly from the time that such plans began to participate in the Medicare program in the 1970s. Most of the growth in expenditures has been attributable to the increasing numbers of beneficiaries who have enrolled in these plans. Section IV.C of this report contains a description of the private health plan assumptions and methodology.

### ***e. Administrative Expenses***

Historically, the cost of administering the HI trust fund has remained relatively small in comparison with benefit amounts. The ratio of administrative expenses to benefit payments has generally fallen within the range of 1 to 3 percent. The short-range projection of administrative cost is based on estimates of workloads and approved budgets for Medicare Administrative Contractors and CMS. In addition, because of sequestration, the administrative costs reflect an estimated 5- to 7-percent reduction for the period April 1, 2013, through August 31, 2033, with the exception of May 1, 2020, through March 31, 2022, when it was suspended. In the long range, administrative cost increases are based on assumed increases in workloads, primarily as a result of growth and aging of the population, and on assumed unit cost increases equal to the increases in average annual covered wages.

## **2. Summary of Aggregate Reimbursement Amounts on an Incurred Basis under the Intermediate Assumptions**

Table IV.A3 shows aggregate historical and projected reimbursement amounts by type of service on an incurred basis under the intermediate assumptions. The sequestration impact is reflected in the table.

*Actuarial Methodology*

**Table IV.A3.—Aggregate Part A Reimbursement Amounts on an Incurred Basis**  
[In millions]

Calendar year	Inpatient hospital	Skilled nursing facility	Home health agency	Hospice	Total FFS	Private health plans	Total Part A
Historical data:							
2016	\$145,244	\$28,894	\$6,956	\$16,873	\$197,967	\$85,270	\$283,237
2017	146,248	28,494	6,907	17,947	199,596	94,246	293,842
2018	147,912	28,082	6,881	19,254	202,129	102,790	304,919
2019	150,253	27,573	6,737	20,879	205,443	118,620	324,063
2020	143,670	29,041	6,219	22,387	201,317	136,345	337,662
2021	145,524	27,656	6,177	23,082	202,439	148,602	351,041
2022	143,155	29,447	5,992	23,898	202,492	170,573	373,065
2023	144,073	27,675	5,969	25,819	203,537	193,350	396,887
2024	149,785	28,609	6,122	28,426	212,942	201,989	414,931
2025	159,191	31,122	6,244	31,081	227,638	210,901	438,539
Intermediate estimates:							
2026	171,870	34,882	6,593	33,657	247,003	227,975	474,978
2027	180,651	37,943	7,333	36,517	262,443	256,914	519,357
2028	189,554	40,489	7,888	39,756	277,687	279,044	556,731
2029	198,138	42,981	8,438	43,238	292,796	302,787	595,583
2030	206,657	45,517	9,005	47,015	308,194	327,375	635,569
2031	215,101	48,154	9,615	51,220	324,089	352,843	676,932
2032	223,276	50,883	10,245	55,866	340,270	378,475	718,745
2033	233,213	54,109	10,987	61,229	359,538	407,516	767,054
2034	245,200	57,862	11,831	67,443	382,336	439,660	821,996
2035	254,502	61,141	12,581	73,124	401,347	465,540	866,887

**3. Financing Analysis Methodology**

Because payroll taxes are the primary basis for financing the HI trust fund, HI costs can be compared on a year-by-year basis with the taxable payroll in order to analyze costs and evaluate the financing.

***a. Taxable Payroll***

Taxable payroll increases occur as a result of increases in both average covered earnings and the number of covered workers. The taxable payroll projection used in this report is based on the same economic assumptions used in the 2026 OASDI trustees report. Table IV.A2 shows the projected increases in taxable payroll for this report, under the intermediate assumptions.

***b. Relationship between HI Costs and Taxable Payroll***

The most meaningful measure of HI cost increases, with regard to the financing of the system, is the relationship between cost increases and taxable payroll increases. If costs increase more rapidly than taxable payroll, either income rates must be increased or costs reduced (or some combination thereof) to finance the system in the future. Table IV.A4 shows the projected increases in HI costs relative to taxable payroll over the 10-year projection period. For the intermediate assumption, these relative increases start at 3.6 percent per year in

*Hospital Insurance*

2026, increase to 4.7 percent in 2027, decrease gradually from 2.4 percent in 2028 to 1.4 percent in 2032, increase to 2.9 percent in 2034 because of sequestration, and decrease again to 1.4 percent in 2035.

**Table IV.A4.—Summary of HI Alternative Projections**

Changes in the relationship between expenditures and payroll <sup>1</sup>					
Calendar year	HI expenditures <sup>2,3</sup>	Taxable payroll	Ratio of expenditures to payroll	HI effective interest rate <sup>4</sup>	Nominal interest rate <sup>4</sup>
Intermediate estimates:					
2026	8.3%	4.5%	3.6%	3.983%	4.187%
2027	9.3	4.4	4.7	4.007	4.125
2028	7.2	4.6	2.4	4.083	4.125
2029	7.0	4.8	2.1	4.255	4.125
2030	6.7	4.9	1.7	4.452	4.125
2031	6.4	4.8	1.6	4.530	4.125
2032	6.1	4.6	1.4	4.562	4.125
2033	6.7	4.4	2.2	4.125	4.125
2034	7.2	4.1	2.9	4.125	4.125
2035	5.4	4.0	1.4	4.125	4.135
Low-cost:					
2026	6.9	6.4	0.4	4.071	4.604
2027	7.7	6.4	1.1	4.208	5.093
2028	6.8	6.4	0.4	4.388	5.229
2029	6.3	6.2	0.1	4.611	5.250
2030	5.8	6.1	-0.2	4.816	5.250
2031	5.7	6.1	-0.4	4.971	5.250
2032	5.4	6.1	-0.6	5.079	5.250
2033	6.1	6.0	0.1	5.143	5.250
2034	6.7	5.8	0.8	5.181	5.250
2035	4.9	5.5	-0.6	5.211	5.312
High-cost:					
2026	9.3	2.0	7.2	3.952	3.781
2027	8.6	-0.3	8.9	4.018	3.208
2028	7.1	3.2	3.8	4.331	3.000
2029	8.0	3.7	4.1	4.618	3.000
2030	8.0	4.1	3.7	3.000	3.000
2031	7.9	4.1	3.6	3.000	3.000
2032	7.4	3.8	3.4	3.000	3.000
2033	7.7	3.3	4.3	3.000	3.000
2034	8.0	2.9	4.9	3.000	3.000
2035	6.3	2.8	3.4	3.000	3.000

<sup>1</sup>Percent increase for the year indicated over the previous year.

<sup>2</sup>On an incurred basis.

<sup>3</sup>Includes hospital, SNF, HHA, private health plan, and hospice expenditures; administrative costs; and costs of Quality Improvement Organizations.

<sup>4</sup>The Trustees calculate present values by discounting the future annual amounts of income and expenditures using the projected effective rates of interest credited to the HI trust fund for the first 10 years and grade to the ultimate nominal interest rate assumption by year 15. The ultimate nominal interest rates for the intermediate, low-cost, and high-cost projections are 4.7, 5.8, and 3.6 percent, respectively.

#### 4. Projections under Alternative Assumptions

Projected HI expenditures under current law are subject to considerable uncertainty. To illustrate this uncertainty, HI costs have been projected under three alternative sets of assumptions.

### *Actuarial Methodology*

Under the low-cost and high-cost alternatives over the 10-year projection period, increases in HI expenditures relative to increases in taxable payroll vary for the first few years of the projection and, by 2050, reach 2.0 percentage points less than the intermediate scenario for the low-cost estimates and 2.0 percentage points more for the high-cost estimates.

Beyond the first 25-year projection period, HI costs under the intermediate assumptions are based on the assumption that average per beneficiary expenditures (excluding demographic impacts) will increase at the baseline rates determined by the economic model described in sections II.C and IV.D less the economy-wide productivity adjustments. This rate is assumed to be roughly the same as the increase in the Gross Domestic Product (GDP) per capita in 2050 but would decelerate to 0.3 percentage point slower than GDP per capita by 2100. HI expenditures, which were 3.4 percent of taxable payroll in 2025, increase to 4.6 percent by 2050 and averaging roughly 4.8 percent until 2100 under the intermediate assumptions. Accordingly, if all the projection assumptions were realized over time, the HI income rates (4.10 percent of taxable payroll summarized over 75 years) would be inadequate to support the HI cost.

For the HI low-cost and high-cost projections, Medicare expenditures are determined by changing the assumption for the ratio of aggregate costs to taxable payroll (the cost rate). These changes are intended to provide an indication of how Medicare expenditures could vary in the future as a result of different economic, demographic, and health care trends.

During the first 25-year projection period, the low-cost and high-cost alternatives contain assumptions that result in HI costs increasing, relative to taxable payroll increases, approximately 2 percentage points less rapidly and 2 percentage points more rapidly, respectively, than the results under the intermediate assumptions. Costs beyond the first 25-year projection period assume that the 2-percentage-point differential gradually decreases until 2074, when HI cost increases relative to taxable payroll are approximately the same as under the intermediate assumptions.

Assumptions regarding income to the HI trust fund—including payroll taxes, income from the taxation of benefits, interest, and other income items—and assumptions regarding administrative costs are consistent with those underlying the 2026 OASDI report.

**B. SUPPLEMENTARY MEDICAL INSURANCE**

SMI consists of Part B and, since 2004, Part D. The benefits provided by each part are quite different. The actuarial methodologies used to produce the estimates for each part reflect these differences and thus appear in separate sections (IV.B1 and IV.B2).

**1. Part B**

***a. Cost Projection Methodology***

Estimates under the intermediate assumptions are calculated separately for each category of enrollee and for each type of service. The estimates are prepared by establishing the allowed charges or costs incurred per enrollee for a recent year (to serve as a projection base) and then projecting these charges through the estimation period. The per enrollee charges are then converted to reimbursement amounts by subtracting the per enrollee values of the deductible and coinsurance. Aggregate reimbursement amounts are calculated by multiplying the per enrollee reimbursement amounts by the projected enrollment. In order to estimate cash expenditures, an allowance is made for the delay between receipt of, and payment for, the service.

(1) Projection Base

To establish a suitable base from which to project the future Part B costs, the incurred payments for services provided must be constructed for the most recent period for which a reliable determination can be made. Accordingly, payments to providers must be attributed to dates of service, rather than to payment dates; in addition, the nonrecurring effects of any changes in regulations, legislation, or administration, and of any items affecting only the timing and flow of payments to providers, must be eliminated. As a result, the rates of increase in the Part B incurred cost differ from the increases in cash expenditures. As a check on the validity of the projection base, incurred reimbursement amounts are compared with cash expenditures.

*(a) Practitioner Services*

Private contractors acting for the Centers for Medicare & Medicaid Services (CMS) pay reimbursement amounts for services billed by practitioners, including physician services, durable medical equipment (DME), laboratory tests performed in physician offices and independent laboratories, and other services (such as physician-administered drugs, free-standing ambulatory surgical center facility services, ambulance services, and supplies). These Medicare

### *Actuarial Methodology*

Administrative Contractors (MACs) use CMS guidelines to determine whether Part B covers billed services, establish the allowed charges for covered services, and transmit to CMS a record of the allowed charges, the applicable deductible and coinsurance, and the amount reimbursed after reduction for coinsurance and the deductible.

#### *(b) Institutional Services*

The same MACs also pay reimbursement amounts for institutional services covered under Part B. These include outpatient hospital services, home health agency services, laboratory services performed in hospital outpatient departments, and such services as renal dialysis performed in free-standing dialysis facilities, services in outpatient rehabilitation facilities, and services in rural health clinics.

Separate payment systems exist for almost all the Part B institutional services. For these systems, the MACs determine whether Part B covers billed services, establish the allowed payment for covered services, and send to CMS a record of the allowed payment, the applicable deductible and coinsurance, and the amount reimbursed after reduction for coinsurance and the deductible.

For those services still reimbursed on a reasonable-cost basis, the costs for covered services are determined on the basis of provider cost reports. Reimbursement for these services occurs in two stages. First, bills are submitted by providers to the MACs, and interim payments are made on the basis of these bills. The second stage takes place at the close of a provider's accounting period, when a cost report is submitted and lump-sum payments or recoveries are made to correct for the difference between interim payments and final settlement amounts for providing covered services (net of coinsurance and deductible amounts). Tabulations of the bills are prepared by date of service, and the lump-sum settlements, which are reported only on a cash basis, are adjusted (using approximations) to allocate them to the time of service.

#### *(c) Private Health Plan Services*

Private health plans with contracts to provide Part B services to Medicare beneficiaries are reimbursed directly by CMS on either a reasonable-cost or capitation basis. Section IV.C of this report contains a description of the assumptions and methodology used to estimate payments to private plans.

## *Supplementary Medical Insurance*

### (2) Projected Fee-for-Service Payments for Aged Enrollees and Disabled Enrollees without End-Stage Renal Disease (ESRD)

Part B enrollees with ESRD have per enrollee costs that are substantially higher and quite different in nature from those of most other beneficiaries. Accordingly, the analysis in this section excludes their Part B costs. Those costs, as well as costs associated with beneficiaries enrolled in private health plans, are discussed later in this section.

#### *(a) Practitioner Services*

##### i. Physician Services

Medicare payments for physician services are based on a fee schedule, which reflects the relative level of resources required for each service. The fee schedule amount is equal to the product of the procedure's relative value, a conversion factor, and a geographic adjustment factor. Payments are based on the lower of the actual charge and the fee schedule amount.

The physician fee schedule updates are specified by law for every future year. Prior to enactment of the Consolidated Appropriations Act, 2021, the Protecting Medicare and American Farmers from Sequester Cuts Act, the Consolidated Appropriations Act, 2023, and the Consolidated Appropriations Act, 2024, the update for 2021 through 2025 was statutorily set at 0 percent. Together these laws put in place the following updates: 3.75 percent for 2021, -0.7 percent for 2022, -0.5 percent for 2023, 0.1 percent for 2024, and -2.5 percent for 2025.

Starting in 2026, the annual update for qualified physicians in advanced alternative payment models (advanced APMs) will be higher than the update each year for all other physicians. The One Big Beautiful Bill Act set physician fee schedule updates to be 3.27 percent in 2026 and -1.71 percent in 2027 for qualified physicians in advanced APMs, and to be 2.76 percent in 2026 and -2.20 percent in 2027 for all other physicians. For 2028 and later, the annual update for qualified physicians in advanced APMs will be 0.75 percent, and, for all other physicians, the update each year will be 0.25 percent.

Per capita physician charges have also changed each year as a result of a number of other factors besides fee increases, including more physician visits and related services per enrollee, the demographic changes of the Medicare population, greater use of specialists and more expensive techniques, and certain administrative actions.

*Actuarial Methodology*

Table IV.B1 shows increases in total allowed charges per fee-for-service enrollee for the physician fee schedule and practitioner services. The sequestration of Medicare benefits during April 1, 2013, through August 31, 2033, with the exception of May 1, 2020, through March 31, 2022, when it was suspended, does not affect allowed charges and therefore is not reflected in table IV.B1; rather, that impact is included in table IV.B2.

**Table IV.B1.—Increases in Total Allowed Charges per Fee-for-Service Enrollee for Practitioner Services**  
[In percent]

Calendar year	Physician fee schedule	DME	Lab	Physician-administered drugs	Other
Aged:					
2016	-0.7%	-7.5%	-5.7%	9.1%	-0.4%
2017	1.2	-5.6	3.9	6.7	4.3
2018	1.6	17.7 <sup>1</sup>	11.3 <sup>2,3</sup>	12.1	2.2
2019	3.9 <sup>4</sup>	7.0	6.7	12.2	2.3
2020	-11.4	2.0	8.9	3.2	-0.8
2021	18.4	5.2	21.8	10.7	5.3
2022	1.7	13.1	-4.1	10.7	17.8
2023	3.8	8.2	7.7	24.1	20.6
2024	4.0	11.0	10.6	27.9	-3.3
2025	2.2	5.3	9.6	21.8	9.0
2026	6.3	7.0	9.2	-22.2	7.2
2027	1.0	6.0	4.9	8.4	6.5
2028	4.8	5.4	7.9	5.6	5.4
2029	2.5	5.5	7.4	5.8	5.5
2030	3.1	5.2	15.6	8.1	5.6
2031	3.2	5.2	6.3	7.1	5.2
2032	3.0	5.1	6.2	7.1	5.1
2033	3.2	5.1	14.1	8.3	5.1
2034	3.0	5.2	6.2	8.2	5.1
2035	3.0	5.1	6.1	8.1	5.0
Disabled (excluding ESRD):					
2016	-0.7	-6.3	-23.0	10.4	0.0
2017	-0.9	0.5	-2.1	4.0	8.6
2018	1.8	15.8 <sup>1</sup>	6.3 <sup>2,3</sup>	10.4	4.2
2019	2.9 <sup>4</sup>	2.4	9.2	9.7	2.6
2020	-8.9	-0.9	-7.6	8.8	7.5
2021	15.4	3.5	19.0	14.2	3.7
2022	-1.5	7.9	-5.4	15.0	10.9
2023	2.8	13.3	1.1	28.3	15.7
2024	3.4	6.2	7.2	37.7	-2.8
2025	2.7	6.1	6.9	59.6	6.6
2026	9.2	10.0	12.0	-52.1	10.1
2027	-1.0	4.3	2.8	4.6	4.4
2028	3.1	4.0	6.1	3.8	3.7
2029	2.9	6.1	7.8	6.1	5.9
2030	3.2	5.4	15.6	8.1	5.7
2031	3.0	5.2	6.1	7.0	5.0
2032	2.9	5.4	6.0	7.0	4.9
2033	2.8	5.1	13.7	7.9	4.8
2034	2.7	5.2	5.9	7.9	4.8
2035	2.9	5.3	6.0	8.0	4.9

<sup>1</sup>Reflects a significant increase in the utilization of certain orthotic braces beginning in 2018. This allegedly fraudulent utilization was stopped early in 2019.

<sup>2</sup>Beginning in 2018, payments under the laboratory fee schedule no longer include an adjustment for economy-wide productivity. Instead, payments reflect a survey of private sector lab payments and are updated every 3 years.

*Supplementary Medical Insurance*

<sup>3</sup>Reflects a significant increase in the utilization of genetic cancer testing services in 2018 and 2019. This allegedly fraudulent utilization was stopped late in 2019.

<sup>4</sup>For 2019–2026 and 2028, qualified physicians in an advanced APM will receive an incentive payment amounting to 5 percent of their Medicare payments for 2019–2024, 3.5 percent for 2025, 1.88 percent for 2026, and 3.1 percent for 2028. There are no incentive payments for qualified physicians in an advanced APM for 2027, and for 2029 and later. For 2019–2024, a total of \$500 million was available for additional payment adjustment under the merit-based incentive payment system (MIPS) for certain high-performing physicians.

Based on the increases in table IV.B1, and incorporating the sequestration of Medicare expenditures, table IV.B2 shows the estimates of the average incurred reimbursement for practitioner services per fee-for-service enrollee.

**Table IV.B2.—Incurred Reimbursement Amounts per Fee-for-Service Enrollee for Practitioner Services**

Calendar year	Fee-for-service enrollment [millions]	Physician fee schedule	DME	Lab	Physician-administered drugs	Other
Aged:						
2016	27.987	\$2,090.95	\$164.46	\$144.10	\$423.18	\$274.27
2017	28.056	2,103.31	155.13	149.78	450.72	286.28
2018	28.102	2,137.41	183.25	166.81	505.24	292.29
2019	28.195	2,238.78	195.90	177.52	566.30	298.49
2020	27.841	2,003.52	202.19	196.21	591.46	300.67
2021	26.973	2,411.18	213.84	240.24	658.30	318.83
2022	26.273	2,376.50	238.97	227.00	719.70	378.25
2023	25.667	2,447.40	257.92	242.08	891.34	460.75
2024	25.319	2,537.09	286.05	267.21	1,140.95	432.70
2025	25.560	2,563.00	303.62	291.74	1,388.16	470.96
2026	26.231	2,710.57	324.39	322.70	1,079.24	504.65
2027	26.664	2,730.56	344.17	338.54	1,169.70	537.40
2028	26.864	2,866.66	362.67	365.22	1,234.88	566.15
2029	27.058	2,920.57	382.38	392.08	1,306.13	597.36
2030	27.227	3,004.17	401.97	453.22	1,411.97	631.06
2031	27.326	3,091.64	422.63	481.87	1,512.59	663.56
2032	27.388	3,177.27	444.20	511.82	1,620.41	697.30
2033	27.422	3,289.04	469.99	588.11	1,768.07	738.34
2034	27.495	3,418.77	500.23	632.96	1,937.39	785.77
2035	27.645	3,509.23	525.66	671.78	2,095.13	825.12
Disabled (excluding ESRD):						
2016	5.503	1,775.81	286.39	197.76	353.80	274.48
2017	5.361	1,748.22	287.83	193.58	367.34	302.71
2018	5.027	1,778.27	333.25	205.66	404.42	314.99
2019	4.665	1,841.92	340.65	223.30	442.61	322.06
2020	4.202	1,697.37	341.56	209.17	486.71	354.67
2021	3.712	1,988.33	354.78	250.40	560.38	372.85
2022	3.253	1,897.98	377.20	233.60	637.87	412.44
2023	2.858	1,933.42	425.26	233.92	817.53	478.22
2024	2.575	1,992.02	451.95	250.36	1,133.36	454.33
2025	2.426	2,031.92	480.56	267.34	1,817.35	483.85
2026	2.256	2,210.41	528.40	303.28	868.07	532.74
2027	2.310	2,184.36	551.35	311.88	908.33	556.63
2028	2.435	2,255.81	573.35	331.05	943.21	576.97
2029	2.403	2,306.00	608.00	356.81	1,001.06	611.07
2030	2.333	2,371.61	640.75	412.55	1,082.44	645.69
2031	2.270	2,435.81	674.18	437.84	1,157.70	677.75
2032	2.232	2,498.87	710.55	464.24	1,238.38	711.01
2033	2.224	2,577.68	752.07	531.64	1,346.59	750.10
2034	2.228	2,671.76	801.31	570.74	1,472.17	796.38
2035	2.236	2,739.08	843.76	605.18	1,590.54	835.43

### *Actuarial Methodology*

Starting in 2019, qualified physicians who are part of an advanced APM receive payments that are different from those received by other physicians. Qualified physicians in an advanced APM will receive an annual incentive payment, which will be equal to 5 percent of their Medicare payments for 2019 through 2024, 3.5 percent of their Medicare payments for 2025, 1.88 percent of their Medicare payments for 2026, and 3.1 percent of their Medicare payments for 2028. There will be no incentive payments in 2027, and no incentive payments in 2029 and later. Most physicians who are not qualified physicians in an advanced APM will instead be under the merit-based incentive payment system (MIPS) and will receive a payment adjustment according to their performance. The payment adjustment ranges from -9 percent to 1.05 percent in 2026 and could range from -9 percent to 27 percent for 2027 and later. In total across all physicians to whom the payment adjustment applies, the impact is to be budget neutral.

For 2026 and later, qualified physicians in an advanced APM will receive a higher update than other physicians. Based on these payment mechanisms, the existing demonstration and payment models, and the requirements for becoming an advanced APM qualified physician, the Trustees assume that physician participation in advanced APMs will grow from 32 percent of spending in 2025 to 100 percent by 2065.

ii. Durable Medical Equipment (DME), Laboratory, Physician-Administered Drugs, and Other Practitioner Services

Unique fee schedules or reimbursement mechanisms have been established not only for physician services but also for virtually all other non-physician practitioner services. Table IV.B1 shows the increases in the allowed charges per fee-for-service enrollee for DME, laboratory services, and other services. As noted previously, allowed charges are not affected by the sequestration of Medicare expenditures. Based on the increases in table IV.B1, table IV.B2 shows the corresponding estimates of the average incurred reimbursement amounts for these services per fee-for-service enrollee; these amounts are affected by the sequestration.

Prior to 2011, DME items and laboratory services were updated by increases in the CPI, together with any applicable legislated limits on payment updates. Since 2011, these items and services have been updated by the increase in the CPI minus the increase in the 10-year moving average of economy-wide productivity.

### *Supplementary Medical Insurance*

A competitive-bidding program was implemented in 2011 to determine Medicare payment for a certain portion of DME items, and as a result this portion is no longer statutorily updated by the CPI or affected by the annual productivity adjustments. Round 1 of the competitive-bidding program was implemented on January 1, 2011, and it lowered total DME spending by less than 2 percent. Round 2 was effective on July 1, 2013 and lowered total DME spending by about 20 percent. The spending was lowered by an additional 4 percent by January 1, 2017, when national pricing for these services was fully implemented. CPI growth is used as a proxy for the updates for these items in the projections. The non-competitive-bidding portion of DME items continues to be updated by the increase in the CPI minus the increase in economy-wide productivity.

Beginning in 2018, Medicare payments for laboratory services are linked to private payment rates, and consequently these services are no longer updated by the CPI minus the productivity adjustments.<sup>72</sup> For laboratory services, as is the case with DME services, growth in the CPI is used as a proxy for updating the private payment rates for projected periods, a process that is to occur every 3 years. The initial survey was from 2016 and was implemented in 2018. The next survey implementation was delayed legislatively through 2026. The Consolidated Appropriations Act, 2026 specified that the next survey will be from 2025 and will be implemented in 2027.

Medicare pays average sales price plus 6 percent for most physician-administered drugs. Beginning in 2028, certain Part B drugs will have their Medicare price determined through negotiation, as specified in the Inflation Reduction Act of 2022. Because of generic or biosimilar versions of certain drugs becoming available, the estimated impact of drug price negotiations are somewhat lower than estimated in last year's report.

Part B spending for skin substitutes, which are included in physician-administered drugs, increased from \$0.8 billion in 2021 to \$14.1 billion in 2025 because of much higher average prices and increased utilization. The 2026 physician fee schedule final rule includes significant changes to skin substitute payments starting in 2026. The Trustees project that spending for skin substitutes will decline by more than 90 percent in 2026 as a result of the changes in this rule.

---

<sup>72</sup>Under the Protecting Access to Medicare Act of 2014, these changes were to be effective in 2017; however, CMS delayed implementation until 2018. These changes also apply to outpatient hospital laboratory services.

### *Actuarial Methodology*

Per capita charges for these expenditure categories have also grown as a result of other factors, including increased number of items and services provided, demographic change, more expensive items and services, and certain administrative actions. This expenditure growth is projected based on recent past trends in growth per enrollee.

#### *(b) Institutional Services*

Over the years, legislation has established new payment systems for virtually all Part B institutional services, including a fee schedule for tests performed in laboratories in hospital outpatient departments. A prospective payment system (PPS) was implemented on August 1, 2000, for services performed in the outpatient department of a hospital. Similarly, a PPS for home health agency services was implemented on October 1, 2000. Table IV.B3 shows the historical and projected increases in charges and costs per fee-for-service enrollee for institutional services, excluding the impact of sequestration.

Certain outpatient prospective payment system (OPPS) drugs are purchased at a significant discount under the 340B program. For 2018 through September 27, 2022, Medicare payments changed from average sales price (ASP) plus 6 percent generally for these 340B drugs to ASP minus 22.5 percent. This change was made on a budget-neutral basis by increasing payments for other OPPS services over this same period.

Effective September 28, 2022, the courts ruled that the differential 340B drug payment rates were unlawful because, prior to implementation, the Department of Health and Human Services failed to conduct a survey of hospital acquisition costs under the relevant statute. In response to this ruling and beginning September 28, 2022, Medicare is again paying 340B drugs ASP plus 6 percent generally, and payments for other OPPS services have been reduced to make this change budget neutral.

The remedy for the lower payments for 340B drugs for 2018 through September 27, 2022, and for the offsetting higher payments for other OPPS services over that same period, is being implemented in several parts. To offset the lower 340B drug payments, the 2022 claims were reprocessed. In addition, to remedy the lower 2018 through 2021 340B drug payments, a one-time payment to affected OPPS facilities was made in 2024 totaling \$9 billion. (This amount includes the cost sharing that would have otherwise been paid by Part B beneficiaries.) To offset the higher payments made for other OPPS services during 2018 through September 27, 2022, payments for these OPPS services

*Supplementary Medical Insurance*

to affected OPPS providers will be reduced by 0.5 percent starting in 2026 and continuing until a total of \$7.8 billion is recovered. These lower payments are expected to continue for roughly 16 years.

**Table IV.B3.—Increases in Costs per Fee-for-Service Enrollee for Institutional Services**

Calendar year	[In percent]			
	Outpatient hospital	Home health agency	Outpatient lab	Other
<b>Aged:</b>				
2016	5.2%	-0.9%	3.0%	2.4%
2017	7.4	-1.9	1.1	4.7
2018	11.4	1.5	-1.0 <sup>1</sup>	7.5
2019	5.2	0.6	-1.5	5.9
2020	-5.8	-2.3	7.4	-6.1
2021	19.7	4.0	16.2	6.1
2022	4.6	-1.3	-1.3	2.4
2023	8.4	0.8	-5.3	7.1
2024	9.0	1.9	3.2	6.8
2025	10.5	2.7	3.8	7.2
2026	9.4	3.3	2.9	7.1
2027	9.1	9.5	0.5	5.1
2028	8.5	6.7	2.5	6.2
2029	8.5	6.3	2.6	5.9
2030	9.1	6.3	6.7	5.7
2031	8.8	6.6	2.7	5.5
2032	8.4	6.5	2.6	5.2
2033	9.0	7.2	7.2	5.4
2034	8.9	7.4	2.6	5.3
2035	8.8	5.8	2.6	5.3
<b>Disabled (excluding ESRD):</b>				
2016	4.6	-5.4	3.1	5.9
2017	4.6	-3.4	-1.7	5.7
2018	11.0	3.3	2.1 <sup>1</sup>	6.6
2019	3.8	1.0	-1.8	9.9
2020	-8.1	10.1	6.4	-5.8
2021	12.7	5.4	19.5	8.0
2022	0.9	-0.4	-1.8	7.4
2023	5.8	3.0	-9.4	8.7
2024	7.0	5.3	1.5	9.7
2025	8.2	-0.9	4.1	7.8
2026	12.9	7.8	5.6	11.7
2027	7.6	6.9	-1.3	5.2
2028	7.2	3.3	1.0	5.7
2029	9.3	6.4	3.2	7.3
2030	9.6	6.3	6.9	6.5
2031	9.0	6.2	2.7	5.9
2032	8.7	5.7	2.7	5.8
2033	9.1	6.2	7.1	5.7
2034	9.2	6.5	2.6	5.7
2035	9.2	5.1	2.7	5.8

<sup>1</sup>See footnote 2 of table IV.B1.

Based on the increases in table IV.B3, table IV.B4 shows the estimates of the incurred reimbursement for the various institutional services per fee-for-service enrollee. Each of these expenditure categories is projected on the basis of recent trends in growth per enrollee, along with applicable legislated limits on payment updates. The sequestration impact is reflected in the table.

*Actuarial Methodology*

**Table IV.B4.—Incurred Reimbursement Amounts per Fee-for-Service Enrollee for Institutional Services**

Calendar year	Fee-for-service enrollment [millions]	Outpatient hospital	Home health agency	Outpatient lab	Other
<b>Aged:</b>					
2016	27.987	\$1,350.89	\$353.53	\$84.55	\$471.42
2017	28.056	1,460.01	346.89	85.45	490.90
2018	28.102	1,639.90	352.13	84.57	527.33
2019	28.195	1,738.43	354.21	83.28	556.71
2020	27.841	1,663.60	346.00	90.74	529.42
2021	26.973	2,021.62	359.83	106.02	561.25
2022	26.273	2,071.92	355.15	103.35	559.41
2023	25.667	2,229.36	358.09	97.13	587.68
2024	25.319	2,430.69	364.91	100.24	621.63
2025	25.560	2,713.56	374.89	104.04	658.34
2026	26.231	2,968.90	387.15	107.00	702.90
2027	26.664	3,243.67	424.02	107.58	735.83
2028	26.864	3,523.24	452.34	110.25	779.72
2029	27.058	3,825.99	480.91	113.06	824.52
2030	27.227	4,179.64	511.06	120.66	870.03
2031	27.326	4,549.83	544.72	123.92	916.67
2032	27.388	4,934.82	579.93	127.13	963.48
2033	27.422	5,417.95	621.76	137.14	1,020.90
2034	27.495	5,982.60	667.92	142.64	1,087.71
2035	27.645	6,518.18	706.72	146.34	1,143.91
<b>Disabled (excluding ESRD):</b>					
2016	5.503	1,597.90	246.53	90.15	350.91
2017	5.361	1,683.76	238.17	88.64	370.37
2018	5.027	1,901.85	246.01	90.53	393.47
2019	4.665	1,981.15	248.53	88.89	432.49
2020	4.202	1,833.72	273.62	95.93	412.91
2021	3.712	2,095.82	288.53	115.32	452.53
2022	3.253	2,066.31	287.25	111.90	474.75
2023	2.858	2,165.36	295.75	100.60	507.15
2024	2.575	2,334.45	311.55	102.09	553.92
2025	2.426	2,528.14	308.72	106.28	594.43
2026	2.256	2,882.38	332.82	112.28	661.30
2027	2.310	3,107.84	355.83	110.84	695.07
2028	2.435	3,337.06	367.70	111.98	733.91
2029	2.403	3,651.71	391.41	115.54	786.94
2030	2.333	4,009.15	415.92	123.54	837.49
2031	2.270	4,373.79	441.81	126.86	886.67
2032	2.232	4,761.76	466.94	130.30	937.90
2033	2.224	5,239.18	495.71	140.41	997.87
2034	2.228	5,800.32	527.89	146.00	1,068.18
2035	2.236	6,345.10	554.93	149.92	1,129.94

(3) Projected Fee-for-Service Payments for Persons with End-Stage Renal Disease (ESRD)

Most persons with ESRD are eligible to enroll for Part B coverage. For analytical purposes, this section includes two groups of enrollees. The first group comprises those who qualify for Medicare as a result of ESRD alone. The second group consists of those who qualify not only because they have ESRD but also because they are disabled.

*Supplementary Medical Insurance*

Enrollees in this latter group, who are eligible as Disability Insurance beneficiaries, are included in this section because their per enrollee costs are both higher and different in nature from those of most other disabled persons. Specifically, most of the Part B reimbursements for both groups are related to kidney transplants and renal dialysis.

The estimates under the intermediate assumptions reflect the payment mechanism for reimbursing ESRD services. Payment for dialysis services occurs through a bundled payment system, which began in 2011. The bundled payment rate is updated annually by an annual ESRD market basket less the increase in economy-wide productivity. Starting in 2021, eligible individuals with ESRD may enroll in a Medicare private health plan to obtain their Part A and Part B coverage. Table IV.B5 shows the historical and projected enrollment and costs for Part B benefits. The sequestration impact is reflected in the table.

**Table IV.B5.—Fee-for-Service Enrollment and Incurred Reimbursement for Beneficiaries under Age 65 with End-Stage Renal Disease**

Calendar year	Average enrollment [thousands]		Reimbursement [millions]	
	Disabled	Non-disabled	Disabled	Non-disabled
2016	130	82	\$5,869	\$2,615
2017	130	82	5,944	2,606
2018	129	82	6,451	2,804
2019	127	83	6,463	2,858
2020	121	82	6,170	2,794
2021	97	65	4,845	2,405
2022	80	57	3,975	2,108
2023	67	53	3,427	1,980
2024	59	50	3,131	1,974
2025	54	49	3,226	2,142
2026	51	47	3,243	2,140
2027	55	47	3,518	2,178
2028	62	45	4,045	2,201
2029	64	44	4,365	2,225
2030	64	43	4,599	2,272
2031	64	42	4,816	2,330
2032	65	41	5,062	2,395
2033	65	41	5,408	2,493
2034	67	40	5,812	2,605
2035	67	40	6,159	2,690

(4) Projected Payments for Persons with Immunosuppressive Drug Coverage Only

The Consolidated Appropriations Act, 2021 specifies that, in 2023 and later, Part B will provide coverage of immunosuppressive drug costs for individuals who previously were covered by Medicare Part B because they have permanent kidney failure and who received a kidney transplant that functioned for 3 years, resulting in a loss of Part B coverage. These individuals will pay a premium that is 15 percent of

### *Actuarial Methodology*

twice the aged actuarial rate instead of the standard Part B premium (which is 25 percent of twice the aged actuarial rate plus a repayment amount, if applicable). Transfers from the general fund of the Treasury will be made to Part B to make up the difference between the immunosuppressive drug premium and the standard Part B premium. (These transfers will be treated as premium income for general fund matching purposes.) In 2025, there were approximately 275 immunosuppressive drug coverage enrollees.

#### (5) Private Health Plan Costs

Part B payments to private health plans have generally increased significantly from the time that such plans began to participate in the Medicare program in the 1970s. Most of the growth in expenditures has been due to the increasing numbers of beneficiaries who have enrolled in these plans. Section IV.C of this report contains a description of the assumptions and methodology for the private health plans that provide coverage of Part B services for certain enrollees.

#### (6) Administrative Expenses

The ratio of Part B administrative expenses to total expenditures was 1.0 percent in 2025. Projections of administrative costs are based on estimates of changes in average annual wages, fee-for-service enrollment, and an estimated 5- to 7-percent reduction in expenditures resulting from sequestration for the period April 1, 2013, through August 31, 2033, with the exception of May 1, 2020, through March 31, 2022, when it was suspended.

#### ***b. Summary of Aggregate Reimbursement Amounts on an Incurred Basis under the Intermediate Assumptions***

Table IV.B6 shows aggregate historical and projected reimbursement amounts by type of service on an incurred basis under the intermediate assumptions.

**Table IV.B6.—Aggregate Part B Reimbursement Amounts on an Incurred Basis**

[In millions]

Calendar year	Practitioner					Institutional					Total FFS	Private health plans	Total Part B	
	Physician fee schedule	DME	Lab	Physician-administered drugs	Other	Total	Hospital	Lab	Home health agency	Other				Total
Historical data:														
2016	\$70,032	\$6,298	\$5,167	\$13,951	\$9,483	\$104,931	\$47,644	\$2,911	\$11,369	\$20,031	\$81,955	\$186,886	\$103,541	\$290,427
2017	70,061	6,016	5,290	14,782	9,964	106,113	51,125	2,923	11,123	20,683	85,854	191,967	114,854	306,821
2018	70,679	6,961	5,791	16,423	10,122	109,976	56,833	2,886	11,247	22,305	93,270	203,246	132,562	335,808
2019	73,415	7,257	6,135	18,223	10,267	115,297	59,446	2,818	11,262	23,207	96,732	212,029	154,193	366,222
2020	64,545	7,207	6,463	18,712	10,224	107,151	55,140	2,990	10,913	21,672	90,715	197,865	180,704	378,569
2021	73,812	7,201	7,564	20,049	10,247	118,873	63,316	3,347	10,869	20,770	98,301	217,175	203,482	420,656
2022	69,748	7,612	6,867	21,183	11,485	116,894	61,981	3,132	10,346	19,574	95,033	211,928	235,774	447,701
2023	69,326	7,937	6,979	25,427	13,393	123,062	64,145	2,826	10,106	19,496	96,573	219,635	275,625	495,260
2024	70,247	8,503	7,497	32,082	12,320	130,648	68,257	2,843	10,107	19,927	101,133	231,781	301,705	533,486
2025	71,267	9,022	8,205	40,247	13,414	142,154	76,211	2,958	10,394	21,235	110,799	252,953	323,499	576,452
Intermediate estimates:														
2026	76,934	9,799	9,259	30,441	14,653	141,087	85,143	3,101	10,970	23,000	122,214	263,301	359,722	623,023
2027	78,722	10,557	9,865	33,478	15,848	148,470	94,514	3,167	12,200	24,439	134,320	282,790	388,697	671,487
2028	83,460	11,258	10,750	35,685	16,874	158,028	103,736	3,280	13,128	26,200	146,344	304,372	429,891	734,263
2029	85,555	11,936	11,610	37,978	17,911	164,990	113,355	3,384	14,041	27,819	158,599	323,589	472,190	795,779
2030	88,343	12,575	13,467	41,219	18,983	174,587	124,299	3,623	14,978	29,356	172,257	346,843	521,396	868,239
2031	91,052	13,221	14,336	44,227	19,979	182,815	135,495	3,725	15,987	30,880	186,087	368,902	570,474	939,376
2032	93,670	13,902	15,239	47,431	21,009	191,251	147,130	3,825	17,030	32,418	200,404	391,655	621,359	1,013,014
2033	97,041	14,721	17,522	51,792	22,259	203,335	161,700	4,130	18,265	34,319	218,413	421,749	684,333	1,106,081
2034	101,123	15,712	18,905	56,895	23,749	216,384	179,054	4,307	19,661	36,595	239,618	456,001	753,826	1,209,828
2035	104,349	16,602	20,170	61,854	25,069	228,044	196,175	4,442	20,906	38,611	260,134	488,178	817,680	1,305,858

## *Actuarial Methodology*

### ***c. Projections under Alternative Assumptions***

Projections of Part B cash expenditures under the low-cost and high-cost alternatives were developed by modifying the growth rates estimated under the intermediate assumptions. Beginning in calendar year 2026, the low-cost and high-cost alternatives contain assumptions that result in benefits increasing, relative to the Gross Domestic Product (GDP), 2 percent less rapidly and 2 percent more rapidly, respectively, than the results under the intermediate assumptions. Administrative expenses under the low-cost and high-cost alternatives are projected on the basis of their respective wage series growth.

## **2. Part D**

Part D is a voluntary Medicare prescription drug benefit that offers beneficiaries a choice of private drug insurance plans. Low-income beneficiaries can receive additional assistance to reduce the cost sharing and premiums. Each year drug plan sponsors submit bids that include estimated total plan costs, reinsurance payments, low-income cost-sharing subsidies, and government subsidies for drugs selected for negotiations for the coming year. Upon approval of these bids, a national average monthly bid amount is calculated, and the result is used to determine the base beneficiary premium. The individual plan premium is calculated as the difference between the plan bid and the national average monthly bid amount, which is then applied to the base beneficiary premium.

Each drug plan receives monthly risk-adjusted direct subsidies, prospective reinsurance payments, and prospective low-income cost-sharing subsidies from Medicare, as well as premiums from the beneficiaries and premium subsidies from Medicare on behalf of low-income enrollees. At the end of the year, the prospective reinsurance and low-income cost-sharing subsidy payments are reconciled to match the plan's actual experience. During the annual reconciliation process, if actual experience differs from the plan's bid beyond specified risk corridors, Medicare shares in the plan's gain or loss.

Expenditures for this voluntary prescription drug benefit are determined by combining estimated Part D enrollment with projections of per capita spending. The base experience for the estimates consists of preliminary 2026 Part D enrollment data, 2025 Part D spending by enrollment category, and 2026 Part D plan bid information.

### *Supplementary Medical Insurance*

In addition, Medicare pays special subsidies on behalf of beneficiaries retaining primary drug coverage through retiree drug subsidy (RDS) plans. Total expenditures for these plans are determined by tabulating actual enrollment and per capita spending data separately and then projecting forward using both the enrollment and Part D expenditure growth rates throughout the estimation period.

Government contributions primarily finance the various Medicare drug subsidies. Since Medicaid is no longer the primary payer of drug costs for full-benefit dually eligible beneficiaries, States are required to pay the Part D account in the SMI trust fund a portion of their estimated forgone drug costs for this population. From 2006 through 2015, the percentage of estimated costs paid by States was phased down from 90 percent to the current 75 percent.

Beneficiaries can choose to have their drug insurance premiums withheld from their Social Security benefits and then forwarded to the drug plans on their behalf.<sup>73</sup> In 2025, around 29 percent of the non-low-income premium dollars were withheld and forwarded to Part D drug plans.

#### ***a. Participation Rates***

All individuals entitled to Medicare Part A or enrolled in Part B are eligible to enroll in the voluntary prescription drug benefit.

##### (1) Employer-Sponsored Plans

There are two ways that employer-sponsored plans can benefit from the Part D program. One way is the retiree drug subsidy (RDS), in which, for qualifying employer-sponsored plans, Medicare subsidizes a portion of their qualifying retiree drug expenses. As a result of tax deduction changes included in the Affordable Care Act, RDS program participation has declined significantly since 2012 and is assumed to decline further over the next several years. The Trustees expect that most of the retirees losing drug coverage through RDS plans will participate in other Part D plans.

The other way that an employer-sponsored plan can benefit from Part D is to enroll in an employer/union-only group waiver plan (EGWP) by either wrapping around an existing Part D plan or becoming a prescription drug plan itself. The subsidies for these types of arrangements are generally calculated in the same way as for other

---

<sup>73</sup>The Part D income-related premium adjustment amount for each beneficiary is deposited into the Part D account.

### *Actuarial Methodology*

Part D plans. The Trustees expect that such plans will offer additional benefits beyond the standard Part D benefit package.

Participation in EGWPs steadily increased from 2016 to 2023, with the enrollment increases occurring in Medicare Advantage Prescription Drug Plans (MA-PDs). Meanwhile, participation in Prescription Drug Plan (PDP) EGWPs was stagnant before declining slightly. In 2024 and 2025, enrollment increased sharply as two groups of beneficiaries joined Part D PDP EGWPs: approximately 1.3 million beneficiaries who had previously received creditable Part D coverage from Federal Employee Health Benefit (FEHB) plans, and approximately 0.5 million beneficiaries who enrolled under the Postal Service Health Benefits (PSHB) program, as required by the Postal Service Reform Act of 2022. Most of this enrollment transition occurred in 2024 while a residual shift continued in 2025.

#### (2) Low-Income Subsidy

Qualifying low-income beneficiaries can receive various degrees of additional Part D subsidies based on their resource levels to help finance premium and cost-sharing payments. Total low-income subsidy enrollment has increased year-over-year through 2024 at a rate largely in line with the overall Part D enrollment growth rate, but declined in 2025 because of the Medicaid unwinding from the ending of the COVID-19 public health emergency. The number of low-income enrollees constitutes a projected 25 percent of total Part D beneficiaries in 2026 and is assumed to grow at the same rate as that for Medicare beneficiaries who are enrolled in Part B.

#### (3) Other Part D Beneficiaries

Medicare beneficiaries not covered by employer-sponsored plans and not qualified for the low-income subsidy have the option to enroll in a Part D plan. Once enrolled, they pay for premiums and any applicable deductible, coinsurance, and/or copayment. Because of the influx of enrollment in Part D plans in 2024 and 2025 from beneficiaries who were formerly receiving coverage in FEHB plans, the participation rate for non-employer and non-low-income Medicare beneficiaries<sup>74</sup> rose from 69 percent in 2023 to 72 percent in 2025. In 2026, the participation rate is expected to increase slightly to 73 percent. After 2026, the participation rate for non-employer and non-low-income

---

<sup>74</sup>A significant portion of the remaining eligible beneficiaries who do not participate in Part D plans receive creditable coverage through another source (such as the Federal Employees Health Benefits Program, TRICARE for Life, the Department of Veterans Affairs, and the Indian Health Service).

*Supplementary Medical Insurance*

beneficiaries is projected to gradually increase to 77 percent throughout the short-range projection period.

(4) Medicare Advantage Prescription Drug Plan (MA-PD) versus Prescription Drug Plan (PDP) Beneficiaries

The enrollment growth in MA-PDs has been higher than in PDPs every year except 2013 and 2026. In 2013, MA-PD beneficiaries accounted for 37 percent of the enrollment in Part D plans. This ratio grew to 58 percent in 2025 but is projected to decrease to 56 percent in 2026, primarily due to a projected temporary shift in EGWP participation, before reaching 61 percent by 2035.

Table IV.B7 provides a summary of the estimated average enrollment in Part D, by category.

**Table IV.B7.—Part D Enrollment**  
[In millions]

Calendar year	Retiree drug subsidy <sup>1</sup>	EGWP	Low-income subsidy			Total	All others	Total	MA-PD share of Part D <sup>3</sup>
			Medicaid full-benefit dual eligible	Other, with full subsidy	Other, with partial subsidy <sup>2</sup>				
Historical data:									
2016	1.9	6.6	7.8	4.3	0.3	12.4	22.2	43.2	39.8
2017	1.7	6.7	8.0	4.4	0.3	12.7	23.4	44.5	41.0
2018	1.5	6.9	8.1	4.5	0.3	12.9	24.5	45.8	42.3
2019	1.4	7.0	8.2	4.5	0.3	13.1	25.7	47.2	44.3
2020	1.2	7.1	8.2	4.7	0.3	13.1	27.2	48.7	47.0
2021	1.1	7.3	8.3	4.7	0.3	13.2	28.4	50.0	50.6
2022	1.0	7.4	8.7	4.7	0.3	13.7	29.3	51.4	53.6
2023	0.9	7.6	9.3	4.8	0.3	14.3	30.1	52.9	56.7
2024	0.8	8.7	9.6	4.9	0.0	14.5	31.2	55.2	57.5
2025	0.7	9.1	9.1	5.0	—	14.2	32.9	56.8	58.1
Intermediate estimates:									
2026	0.6	9.1	9.4	5.1	—	14.4	33.8	58.0	56.1
2027	0.6	9.2	9.6	5.2	—	14.8	35.1	59.7	56.6
2028	0.5	9.4	9.8	5.3	—	15.2	36.3	61.4	57.9
2029	0.5	9.6	10.0	5.4	—	15.5	37.4	63.0	58.9
2030	0.5	9.7	10.2	5.5	—	15.8	38.2	64.2	59.4
2031	0.5	9.9	10.4	5.6	—	16.0	38.9	65.2	59.9
2032	0.5	10.0	10.5	5.7	—	16.2	39.4	66.1	60.3
2033	0.5	10.1	10.6	5.8	—	16.4	39.9	66.9	60.7
2034	0.5	10.2	10.7	5.8	—	16.6	40.4	67.7	61.0
2035	0.5	10.3	10.9	5.9	—	16.7	40.8	68.4	61.3

<sup>1</sup>Excludes Federal Government and military retirees covered by either the Federal Employees Health Benefit Program or the TRICARE for Life program. Such programs qualify for the retiree drug subsidy, but the subsidy will not be paid since it would amount to the Federal Government subsidizing itself.

<sup>2</sup>Low-income beneficiaries currently receiving partial subsidies have started receiving full subsidies effective January 1, 2024, as required by the Inflation Reduction Act of 2022.

<sup>3</sup>This calculation does not include retiree drug subsidy beneficiaries but does include EGWP, low-income subsidy, and all other beneficiaries.

*Actuarial Methodology*

***b. Cost Projection Methodology on an Incurred Basis***

(1) Drug Benefit Categories

Projected drug expenses are allocated to the beneficiary premium, direct subsidy, and reinsurance subsidy by the Part D premium formula based on the benefit formula specifications. Meanwhile, the additional premium and cost-sharing subsidies are projected for low-income beneficiaries. In addition, under the Inflation Reduction Act of 2022, for drugs that are selected for price negotiation, there will be government subsidies for expenditures that are below the catastrophic threshold to compensate for the exemption from the manufacturer discount program for negotiated drugs.

The statute specifies that the base beneficiary premium is equal to 25.5 percent of the sum of the national average monthly bid amount and the estimated catastrophic reinsurance. The average premium amount per enrollee is estimated using the base beneficiary premium with an adjustment to reflect enrollees' tendency to select plans with below-average premium costs.

Moreover, Part D collects income-related premiums for individuals whose modified adjusted gross income exceeds a specified threshold. The amount of the income-related premium depends upon the individual's income level. Before 2019, the extra premium amount was the difference between 35, 50, 65, or 80 percent and 25.5 percent applied to the national average monthly bid amount adjusted for reinsurance. Starting in 2019, the Bipartisan Budget Act of 2018 requires a portion of the beneficiaries currently in the 80-percent group to pay the difference between 85 percent and 25.5 percent.

Under the Inflation Reduction Act of 2022, the increase in base beneficiary premiums is limited to 6 percent per year from 2024 through 2029. For 2030, the base beneficiary premium will be set at the maximum of a) 6 percent increase from the prior year and b) 20 percent of the national average monthly bid amount and the estimated catastrophic reinsurance. Because of the rapid increase in drug expenditures, the Trustees anticipate the 2030 base beneficiary premium will be set to be 20 percent of the national average monthly bid amount and the estimated catastrophic reinsurance. This change in base beneficiary premium calculation is projected to result in a substantial premium increase from \$46.44 in 2029 to \$68.93 in 2030, as presented in table V.E2 of section V.E. For years 2031 and later, the base beneficiary premium will be set by the 20 percent formula as the 6 percent increase limitation will no longer apply.

### *Supplementary Medical Insurance*

Premiums for stand-alone prescription drug plans would have increased substantially in 2025 and 2026 because of certain factors, including the new Part D benefit structure under the Inflation Reduction Act and higher-than-expected drug spending. However, to limit the increase in premiums and stabilize the year-by-year changes for these plans, a 3-year voluntary Part D Premium Stabilization Demonstration was implemented beginning with contract year 2025. These premium reductions result in a corresponding increase in the direct premium subsidies paid by Medicare.

#### (2) Projections

The projections are based in part on actual Part D spending data through 2025. These data include amounts for total prescription drug costs, costs above the catastrophic threshold, plan payments, low-income cost-sharing payments, and government subsidies for drugs selected for negotiations.

The estimates under the intermediate assumptions are calculated by establishing the total prescription drug costs for 2025 and then projecting these costs with both Part D expenditure and enrollment growth rates through the estimation period. The growth rate assumptions for Part D costs are based on a Part D-specific, short-term model that provides the 2026 and 2027 drug-specific and therapeutic-class-specific growth rate projections. A transition factor is applied for 2028 and 2029 to converge to the long-term projection of Part D costs.

The growth in expensive specialty and GLP-1 drugs has been a major factor driving the increase in gross drug costs over time, which in turn has resulted in fast-growing overall spending and reinsurance in recent years. Therefore, the trend rates for the catastrophic portion of the Part D benefits are also assumed to generally grow slightly more rapidly than the overall growth rates. Table IV.B8 shows the historical and projected Part D per capita growth rates.

In addition, the Trustees incorporate the estimated impact from recent new legislation and policy. Effective January 1, 2024, a pharmacy price concessions policy (published in a May 9, 2022, CMS final rule) shifts the pharmacy-specific direct and indirect remuneration (DIR) to the point of sale, thus reducing total DIR, lowering drug prices for beneficiaries at the point of sale, and increasing Federal Part D spending. In addition, while the drug trend will slow because of drug price negotiations and inflation rebate assessments that are required by the Inflation Reduction Act of 2022, Part D plan benefits will increase because of the redesigned benefit structure under the new

*Actuarial Methodology*

legislation. Meanwhile, the Trustees project that DIR will be reduced in response to the lower negotiated drug prices. More recently, the One Big Beautiful Bill Act in 2025 has exempted certain orphan drugs from being selected for price negotiations. This exemption will lower the overall discounts from negotiations.

To determine the estimated benefits for Part D, the total per capita drug benefits are adjusted for two key factors. One is the projected total amount of DIR, and the other is the administrative costs that plans are projected to incur related to plan operations and profits.

Table IV.B8 displays these key factors affecting Part D expenditure estimates.

**Table IV.B8.—Key Factors for Part D Expenditure Estimates<sup>1</sup>**

Calendar year	Part D per capita cost trend	Direct and indirect remuneration <sup>2</sup>	Plan administrative expenses and profits <sup>3</sup>
Historical data:			
2016	1.9%	19.9%	11.4%
2017	2.2	21.9	10.3
2018	4.9	25.0	10.7
2019	5.2	26.5	9.3
2020	4.7	27.0	9.2
2021	5.5	29.1	8.1
2022	8.2	31.3	7.3
2023	11.2	33.5	6.7
2024	-0.1	26.5	7.0
Intermediate estimates:			
2025	18.3	27.7	9.4
2026	-1.6	19.5	9.9
2027	-2.9	16.8	10.2
2028	2.9	15.6	10.0
2029	3.3	15.0	9.9
2030	4.4	17.2	10.3
2031	2.3	16.6	10.4
2032	-2.7	14.9	10.8
2033	2.4	14.7	10.9
2034	2.0	14.7	11.1
2035	2.4	14.2	11.2

<sup>1</sup>These factors do not reflect the impact of the sequestration for years 2016–2033.

<sup>2</sup>Expressed as a percentage of total drug costs.

<sup>3</sup>Expressed as a percentage of total net plan benefit payments, which include plan benefits and administrative expenses with profits and which are reduced by DIR.

## *Supplementary Medical Insurance*

### (3) Direct and Indirect Remuneration

Until January 1, 2024, DIR primarily consisted of drug manufacturer rebates and pharmacy rebates that PDPs and MA-PDs negotiate.<sup>75</sup> The average projected DIR from plan bids increased substantially through 2023, but then, in 2024, pharmacy rebates were removed from DIR by the pharmacy price concessions policy, causing a DIR reduction. DIR is projected to decrease significantly in 2026 and beyond as a result of the following three factors:

- Implementation of the Inflation Reduction Act of 2022, which introduces changes to the Part D benefit structure;
- A gradual roll-out of government negotiated prices with manufacturers of high-impact drugs; and
- An inflation rebate from manufacturers to the government if drug prices increase above the CPI.

The Trustees expect that these cost pressures on brand-name drugs will considerably reduce the amount of DIR over the projection period, as shown in table IV.B8.<sup>76</sup>

### (4) Administrative Expenses

Administrative costs and profit margins are estimated from the 2026 plan bids. Future administrative expenses are projected to grow at the same rate as wages, while profit margins are projected to grow at the same rate as per capita drug cost trend rates prior to drug price negotiations. The level of administrative expenses as a percentage of benefits increased substantially in 2025, and it is expected to maintain at this higher percentage of benefits because of the cost for plans to undertake more benefit risks and the cost of the voluntary Medicare

---

<sup>75</sup>The safe harbor protection for manufacturer rebates was eliminated in a final rule released in November 2020. This final rule imposed a January 1, 2022, effective date; however, the implementation date was initially delayed until January 1, 2023. In 2021, the Infrastructure Investment and Jobs Act imposed a moratorium on implementation of this rule until January 1, 2026; in 2022, the Bipartisan Safer Communities Act extended the moratorium from 2026 to 2027; and most recently the Inflation Reduction Act of 2022 extended it until 2032. Since the likelihood of this rule taking effect is highly uncertain, the impact is not reflected in the Part D projections.

<sup>76</sup>These are average DIR percentages across all prescription drugs—including for EGWP plans, which do not submit bids. Generic drugs, which represent about 88 percent of all Part D drugs dispensed and 12 percent of drug spending in 2025, typically carry little to no rebates, while many brand-name prescription drugs carry substantial rebates.

*Actuarial Methodology*

Prescription Payment Plan, which helps beneficiaries manage their out-of-pocket costs.

(5) Incurred Per Capita Reimbursements

Table IV.B9 shows estimated enrollments and average per capita reimbursements for beneficiaries in private plans, low-income beneficiaries, and beneficiaries in RDS plans. The direct subsidy and retiree drug subsidy are affected by the 2 percent sequestration of Medicare benefit expenditures, which applies from April 1, 2013, through August 31, 2033, with the exception of May 1, 2020, through March 31, 2022, when it was suspended. Under the sequestration, Medicare administrative expenses are reduced by an estimated 5 to 7 percent for the period April 1, 2013, through August 31, 2033, with the exception of May 1, 2020, through March 31, 2022, when it was suspended.

**Table IV.B9.—Incurred Reimbursement Amounts per Enrollee for Part D Expenditures**

Calendar year	Private plans (PDPs and MA-PDs)				Low-income subsidy		Retiree drug subsidy	
	Enrollment (millions)	Direct subsidy	Reinsurance	Risk sharing and other <sup>1</sup>	Enrollment (millions)	Subsidy amount	Enrollment (millions)	Subsidy amount
Historical data:								
2016	41.2	\$441	\$861	-\$27	12.4	\$2,126	1.9	\$505
2017	42.8	352	878	-11	12.7	2,156	1.7	493
2018	44.2	305	918	-1	12.9	2,204	1.5	482
2019	45.8	247	1,004	10	13.1	2,273	1.4	490
2020	47.5	199	1,021	31	13.1	2,507	1.2	514
2021	48.9	121	1,065	25	13.2	2,646	1.1	516
2022	50.4	79	1,128	18	13.7	2,873	1.0	532
2023	52.0	54	1,214	32	14.3	3,092	0.9	574
2024	54.4	383	1,360	69	14.5	2,833	0.8	567
2025	56.1	1,869	651	171	14.2	1,226	0.7	672
Intermediate estimates:								
2026	57.3	2,405	716	77	14.4	1,254	0.6	660
2027	59.1	2,375	732	58	14.8	1,384	0.6	640
2028	60.9	2,490	825	62	15.2	1,459	0.5	657
2029	62.5	2,598	908	68	15.5	1,579	0.5	677
2030	63.7	2,372	947	53	15.8	1,833	0.5	706
2031	64.7	2,445	987	57	16.0	1,922	0.5	722
2032	65.6	2,463	981	68	16.2	1,956	0.5	700
2033	66.4	2,559	1,019	69	16.4	1,982	0.5	720
2034	67.1	2,652	1,034	70	16.6	2,014	0.5	742
2035	67.9	2,733	1,067	75	16.7	2,076	0.5	758

<sup>1</sup>Included in this category are government subsidies specified under the Inflation Reduction Act of 2022, which limit the out-of-pocket costs for insulins in 2023 and, starting in 2026, replace the discounts on negotiated drugs in the initial coverage phase. The projected cost of the GLP-1 Bridge demonstration program in 2026 is also included.

(6) Incurred Aggregate Reimbursements

Table IV.B10 shows the projected incurred aggregate reimbursements to plans and employers by type of payment.

*Supplementary Medical Insurance*

**Table IV.B10.—Aggregate Part D Reimbursement Amounts on an Incurred Basis**

[In billions]							
Calendar year	Premiums <sup>1</sup>	Direct subsidy	Reinsurance	Low-income subsidy	Retiree drug subsidy	Risk sharing and other <sup>2</sup>	Total
Historical data:							
2016	\$12.7	\$18.2	\$35.5	\$26.4	\$1.0	-\$1.1	92.7
2017	14.0	15.1	37.6	27.3	0.8	-0.5	94.4
2018	14.2	13.5	40.6	28.5	0.7	-0.0	97.4
2019	13.8	11.3	46.0	29.7	0.7	0.5	102.0
2020	13.6	9.4	48.5	33.0	0.6	1.5	106.6
2021	15.0	5.9	52.1	35.0	0.6	1.2	109.7
2022	15.5	4.0	56.8	39.4	0.5	0.9	117.1
2023	15.7	2.8	63.1	44.2	0.5	1.7	128.0
2024	16.6	20.8	74.0	41.2	0.5	3.7	156.9
2025	12.0	104.8	36.5	17.4	0.5	9.6	180.6
Intermediate estimates:							
2026	16.3	137.9	41.0	18.1	0.4	4.4	218.2
2027	21.6	140.5	43.3	20.5	0.4	3.4	229.6
2028	24.1	151.8	50.3	22.1	0.3	3.8	252.4
2029	25.2	162.3	56.7	24.5	0.3	4.2	273.3
2030	39.7	151.1	60.3	28.9	0.4	3.4	283.8
2031	41.8	158.2	63.9	30.7	0.4	3.7	298.7
2032	42.6	161.6	64.4	31.7	0.4	4.5	305.0
2033	44.6	169.9	67.6	32.4	0.4	4.6	319.5
2034	46.0	178.1	69.4	33.3	0.4	4.7	331.9
2035	48.0	185.5	72.4	34.8	0.4	5.1	346.2

<sup>1</sup>Total premiums paid to Part D plans by enrollees (directly, or indirectly through premium withholding from Social Security benefits), excluding late-enrollment penalties.

<sup>2</sup>Negative amounts are net gain-sharing receipts from plans, while positive amounts are net loss-sharing payments to plans. The government subsidies specified under the Inflation Reduction Act of 2022 are included in this category. The projected cost of the GLP-1 Bridge demonstration program in 2026 is also included.

***c. Projections under Alternative Assumptions***

Part D expenditures for the low-cost and high-cost alternatives were developed by modifying the estimates under the intermediate assumptions. Separate modifications were applied to the assumptions for the 2025 base projection and to the assumptions for projected years 2026–2035.

The 2025 base modifications include the following adjustments, since final data for 2025 will not be available until later in 2026:

- $\pm 2$  percent to account for the uncertainty of the completeness of the actual spending in 2025. The high-cost scenario increases the spending by 2 percent, and the low-cost scenario decreases the spending by 2 percent.
- $\pm 2$  percent for the average rebate that drug plans negotiate. The high-cost scenario decreases the average rebate by 2 percent, and the low-cost scenario increases the average rebate by 2 percent.

For the projections beyond 2025, the per capita drug costs for the high-cost and low-cost scenarios are increased, relative to GDP, 2 percent

*Actuarial Methodology*

more rapidly and 2 percent less rapidly, respectively, than under the intermediate assumptions. The 2-percent base-year modification to rebate percentage is also maintained throughout the short-range projection period. In addition, participation in the low-income subsidy and the participation rate for Part D-eligible individuals who do not qualify for the low-income subsidy or receive coverage through employer-sponsored plans assumptions vary in the alternative scenarios. Table IV.B11 compares these varying assumptions.

**Table IV.B11.—Part D Assumptions under Alternative Scenarios for Calendar Years 2025–2035<sup>1</sup>**

Calendar year	Intermediate assumptions	Alternatives	
		Low-cost	High-cost
Participation of retiree drug subsidy beneficiaries as a percentage of Part D enrollees			
2025	1.2%	1.2%	1.2%
2026	1.1	1.1	1.1
2027	0.9	1.2	0.7
2028	0.8	1.2	0.3
2029	0.8	1.2	—
2030	0.8	1.2	—
2031	0.8	1.2	—
2032	0.8	1.2	—
2033	0.8	1.2	—
2034	0.8	1.2	—
2035	0.8	1.2	—
Participation of low-income beneficiaries as a percentage of Part D enrollees			
2025	24.9%	24.9%	24.9%
2026	24.9	24.9	24.9
2027	24.8	24.7	24.8
2028	24.7	24.6	24.8
2029	24.6	24.0	25.2
2030	24.5	23.5	25.7
2031	24.5	23.0	26.1
2032	24.5	22.6	26.6
2033	24.5	22.1	27.1
2034	24.5	21.7	27.6
2035	24.5	21.3	28.2
Part D participation rate of the non-employer and non-low-income Part D-eligible individuals			
2025	72.4%	72.4%	72.4%
2026	72.6	72.6	72.6
2027	73.5	71.5	75.5
2028	74.3	70.3	78.3
2029	75.0	71.0	79.0
2030	75.5	71.5	79.5
2031	76.0	72.0	80.0
2032	76.3	72.3	80.3
2033	76.6	72.6	80.6
2034	76.8	72.8	80.8
2035	77.0	73.0	81.0

<sup>1</sup>The percentages for the presented categories are not intended to summate to 100 percent due to differing population pools.

### **C. PRIVATE HEALTH PLANS**

Dating back to the 1970s, some Medicare beneficiaries have chosen to receive their coverage for Part A and Part B services through private health plans. Over time, numerous changes have been made to these plans that have increased or decreased the attractiveness of private plan coverage.

The foundation of the current program was established in 2003, when most of the private plans were renamed as Medicare Advantage (MA) plans and all private health insurance coverage options available through Medicare were formally designated as Part C.<sup>77</sup> Since then, there has been a continuous increase in MA enrollment.

Beginning in 2006, payments are based on competitive bids and their relationship to corresponding benchmarks, which are based on an annually developed ratebook. Also, rebates were introduced to provide additional benefits not covered under Medicare, reduce cost sharing, and/or reduce Part B or Part D premiums. From 2006 through 2011, rebates were calculated as 75 percent of the difference, if any, between the benchmark and the bid.

In addition to the plan types that already existed, regional preferred provider organizations (RPPOs) and special needs plans (SNPs) were established in 2006. Unlike other MA plans, which define their own service areas, RPPOs operate in pre-defined service areas referred to as regions and have special rules for capitation payment benchmarks, and they received special incentives.

SNPs are products designed for, and marketed to, these special population groups: Medicaid dual-eligible beneficiaries, individuals with specialized chronic conditions, and institutionalized beneficiaries. The statutory authority for SNPs, which had been extended several times previously, was permanently extended under the Bipartisan Budget Act of 2018.

Beginning in 2012, the MA county-level benchmarks are based on a multiple of estimated fee-for-service costs in the county. The factor applied for a given county is based on the ranking of its fee-for-service cost relative to that for other counties. The 25 percent, or quartile, of counties with the highest fee-for-service costs have a factor of

---

<sup>77</sup>Of Medicare beneficiaries enrolled in private plans, about 98 percent are in MA plans. The remainder are in certain holdover plans reimbursed on a cost basis rather than through capitation payments or in Program of All-Inclusive Care for the Elderly (PACE) plans. Medicare-Medicaid Plans (MMPs) were discontinued at the end of 2025.

### *Actuarial Methodology*

95 percent of county fee-for-service costs; the second quartile, 100 percent; the third quartile, 107.5 percent; and the lowest quartile, 115 percent. Prior to 2012, most county benchmarks were in the range of 100 to 140 percent of local fee-for-service costs.

Plans are eligible to receive specified increases to their benchmark based on their quality rating scores. The statutory provisions call for a bonus of 5 percent for plans with at least a 4-star rating. The bonuses are doubled for health plans in a qualifying county, defined as a county that meets the following three criteria: per capita spending in original Medicare is lower than average; 25 percent or more of eligible<sup>78</sup> beneficiaries were enrolled in the MA program as of December 2009; and the benchmark rate in 2004 was based on the minimum amount applicable to an urban area.

There are special bonus provisions for newly established and low-enrollment plans. Additionally, the phased-in benchmarks, including bonuses, are capped at the pre-2012 benchmark level.

The share of the excess of benchmarks over bids, which is paid to the plan sponsors as rebates, varies based on quality. The highest quality plans (4.5 stars or higher) receive a 70 percent rebate, plans with a quality rating of at least 3.5 stars and less than 4.5 stars receive a 65 percent rebate, and plans with a rating of less than 3.5 stars receive a 50 percent rebate.

Beginning in 2014, private insurers were required to pay an assessment, or fee, based on their revenues from the prior year. There was a 1-year moratorium on the annual fee in 2017 and again in 2019. The fee was in place for calendar year 2020, with the assessment on MA sponsors expected to represent approximately 1.4 percent of plan revenues. The Further Consolidated Appropriations Act, 2020 permanently repealed the annual fee for calendar year 2021 and future years.

It is important to note that Medicare coverage provided through private health plans does not have separate financing or an associated trust fund. Rather, the Part A and Part B trust funds are the source for payments to such private health plans.

---

<sup>78</sup>Beneficiaries are eligible for the MA program if they are entitled to coverage in Medicare Part A and enrolled in Medicare Part B.

## **1. Participation Rates**

### ***a. Background***

To account for the distinct benefit, enrollment, and payment characteristics of private health plans, enrollment and spending trends for such plans are analyzed at the product level:

- Local coordinated care plans (LCCPs), which include health maintenance organizations (HMOs), HMOs with a point-of-service option, and local preferred provider organizations (PPOs).
- Private fee-for-service (PFFS) plans.
- Regional PPO (RPPO) plans.
- Special needs plans (SNPs).
- Other products, which include cost plans and Program of All-Inclusive Care for the Elderly (PACE) plans. Medicare-Medicaid plans (MMPs) were discontinued at the end of 2025 with the majority of the enrollment in those plans converted to a SNP.

In table IV.C1, all types of coverage except for those represented in the “Other” category are MA plans. Also, the values represented in each category include enrollment not only in plans available to all beneficiaries residing in the plan’s service area, but also in plans available only to members of employer or union groups.

### ***b. Historical***

Table IV.C1 shows historical and projected private health plan enrollment by type of plan. From 2016 through 2025, private plan enrollment grew by 17.0 million or 92 percent, compared with growth in the overall Medicare population of 21 percent for the same period.

PFFS enrollment dropped 83 percent during these years primarily because of plan reaction to new statutory provider network requirements beginning in 2011. Most of the enrollees in terminating PFFS plans transferred to LCCP or RPPO plans.

The 2025 enrollment includes 5.8 million beneficiaries with coverage through employer/union-only group waiver plans (EGWPs), the majority of whom are in LCCPs. Beginning in 2017, the bidding requirements for these types of plans have been waived, and payments

*Actuarial Methodology*

to these EGWPs, including RPPOs, are based on individual market bids.

**Table IV.C1.—Private Health Plan Enrollment<sup>1</sup>**  
[In thousands]

Calendar year	Local CCP		Regional				Total private health plan	Total Medicare	Ratio of private health plan to total Medicare
	HMO	PPO	PPO	PFFS	SNP	Other			
2016	9,630	4,158	1,086	231	2,231	1,058	18,393	57,073	32.2%
2017	10,051	4,943	1,085	184	2,421	1,133	19,817	58,683	33.8
2018	10,646	5,696	1,003	148	2,729	1,115	21,338	60,020	35.6
2019	11,325	6,880	866	111	3,065	701	22,949	61,535	37.3
2020	12,159	7,893	747	81	3,497	697	25,074	62,887	39.9
2021	12,802	9,282	625	57	4,077	702	27,546	63,980	43.1
2022	13,136	10,532	501	44	4,897	727	29,838	65,166	45.8
2023	13,203	11,833	386	35	6,092	611	32,159	66,606	48.3
2024	13,228	13,137	293	32	6,860	552	34,103	68,066	50.1
2025	13,547	13,522	170	40	7,568	513	35,359	69,289	51.0
2026	13,795	13,479	121	37	8,419	321	36,171	70,743	51.1 <sup>2</sup>
2027	14,173	13,808	99	36	8,882	329	37,327	72,322	51.6
2028	14,744	14,319	93	36	9,192	333	38,719	74,026	52.3
2029	15,274	14,810	89	36	9,437	337	39,983	75,436	53.0
2030	15,743	15,250	85	36	9,635	340	41,088	76,598	53.6
2031	16,157	15,644	80	36	9,796	342	42,056	77,521	54.3
2032	16,533	16,004	77	36	9,932	345	42,927	78,327	54.8
2033	16,878	16,332	73	36	10,054	347	43,721	79,058	55.3
2034	17,212	16,640	69	36	10,172	349	44,480	79,827	55.7
2035	17,509	16,911	66	36	10,290	351	45,164	80,632	56.0

<sup>1</sup>Most private plan enrollees are eligible for Medicare Part A and enrolled in Medicare Part B. Some enrollees have coverage for only Medicare Part B. For example, in 2024 the Part B-only private plan enrollment consisted of 26,000 in local CCPs and 53,000 in the “Other” coverage category.

<sup>2</sup>This table presents the ratio of private health plan to total Medicare enrollment. The ratio of private health plan enrollees to Medicare beneficiaries with both Part A and Part B coverage in 2026 is 56.3 percent.

***c. Projected***

The MA enrollment projection model groups counties by common characteristics and models each of these groups using 2015 through 2025 base data. Ten equally distributed groups (based on 2021 enrollment) are created, as defined by the 2020 rural-urban commuting area (RUCA) codes designation. The ten groups are sorted on 2021 enrollment-weighted RUCA scores with an approximately equal number of MA-eligible beneficiaries in each group. A separate group consists of enrollees residing in Puerto Rico.

The private health plan enrollment projections are based on three cohorts of beneficiaries: dual-eligible beneficiaries; beneficiaries with employer-sponsored coverage; and all others, including individual-market enrollees.

Private plan enrollment for the individual market and for dual-eligible beneficiaries is projected by calculating the penetration growth rates in years 2015 through 2025 for each category described above and extrapolating those results through 2035. These growth rates are

### *Private Health Plans*

applied to the enrollment distribution for each county's specific 2025 plan type (for example, LCCP, PFFS, and RPPO) and are adjusted to reflect applicable legislative changes to the program, as described in more detail below. Enrollment for dual-eligible beneficiaries has increased more rapidly in recent years than has enrollment for both EGWPs and the individual market, and for this reason dual-eligible enrollment has been projected separately.

The category of MA enrollees with employer coverage is modeled at the national level. Historically, EGWP enrollment has had much larger enrollment variation from year to year while individual-market enrollment has trended at a more consistent level. Because of the fluctuations in enrollment, the cohort method does not work as well for beneficiaries with employer-sponsored coverage.

The private Medicare health plan enrollment projections in this report are lower than those in the 2025 report. As shown in table IV.C1, the share of Medicare enrollees in private health plans is projected to increase from 51.0 percent in 2025 to 56.0 percent in 2035. The increases in private plan penetration rates over the projection period are partly attributable to higher relative rebates, which are used to lower beneficiary premiums and expand benefits. Growth is expected to be modest in the near term, increase somewhat later in the decade as rebate growth accelerates, and then moderate as the market matures.

SNP enrollment is expected to grow by 11 percent in 2026 after increasing by 10 percent in 2025. Part of the 2026 increase reflects the expiration of MMPs at the end of 2025, with most enrollees transitioning to SNPs in January 2026. Beginning in 2027, enrollment growth is expected to slow, ranging from 6 percent in 2027 to 1 percent in 2035.

Enrollment growth for LCCP-HMOs is projected to remain modest, increasing by 1.8 percent in 2026 following growth of 2.4 percent in 2025. For LCCP-PPOs, enrollment is expected to decrease by 0.3 percent in 2026, after increasing by 3 percent in 2025, reflecting a decline in the number of PPO plan offerings.

The "Other" category is expected to fluctuate over the next several years because of enrollment in the MMP capitated model and enrollment in cost plans. The MMP capitated model represents health plans that are capitated by CMS and States to provide comprehensive and coordinated care for Medicare-Medicaid enrollees. After the introduction of MMPs in October 2013, enrollment grew nationally

### *Actuarial Methodology*

from approximately 3,400 enrollees in a single State to over 227,000 enrollees across eight States in September 2025. Most contracts were originally set to expire in 2023 but were extended to 2025 as a way of transitioning from MMPs to SNPs, as described in a Medicare Advantage and Part D final rule that was published by CMS on May 9, 2022.<sup>79</sup> Preliminary 2026 data shows that the majority of MMP enrollees have remained in the MA program by switching to SNPs.

Additionally, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) amended the cost plan competition requirements specified in section 1876(h)(5)(C) of the Social Security Act. The amended competition requirements provide that CMS not renew cost plans in service areas where two or more competing local or regional MA coordinated care plans meet enrollment requirements over the course of the entire prior contract year. Under MACRA, cost plans were permitted to transition to the MA program until the beginning of calendar year 2019.

Enrollment in the “Other” category decreased by 37 percent in 2019 because of the reduction in the number of cost plans required by MACRA provisions. During the period 2020 through 2026, enrollment in the “Other” category is expected to decrease by 54 percent as a result of the expiration of the MMP contracts; for 2027 and later, it is expected to grow at a rate of less than 3 percent.

## **2. Cost Projection Methodology**

### ***a. Background***

Benchmarks form the foundation for payments to MA plans. Along with geographic, demographic, and risk characteristics of plan enrollees, these values determine the monthly prospective payments made to private health plans. MA benchmarks vary substantially by county. Benchmarks range between 95 and 115 percent of county-level fee-for-service costs, plus applicable quality bonuses.

For individual non-RPPO plans, a plan’s benchmark is an average of the statutory capitation ratebook values, weighted by projected plan enrollment in each county in the plan’s service area. For RPPOs, the benchmark is a blend of the weighted ratebook values for all Medicare-eligible beneficiaries in the region and an enrollment-weighted average of RPPO bids for the region. The weight applied to the bid component

---

<sup>79</sup>See <https://www.govinfo.gov/content/pkg/FR-2022-05-09/pdf/2022-09375.pdf>.

### *Private Health Plans*

to calculate the blended benchmark is the national MA participation rate.

Plans submit bids equal to their projected per enrollee cost of providing the standard Medicare Part A and Part B benefits. Plans with bids below the benchmark apply the rebate share of the *savings* to aid plan enrollees through coverage of Part A and Part B cost sharing, coverage of additional non-drug benefits, and/or reduction in the Part B or Part D premium. The rebate percentage is based on the quality rating of the health plan and ranges from 50 to 70 percent. Beneficiaries choosing plans with bids above the benchmark must pay for both the full amount of the difference between the bid and the benchmark and the projected cost of the plans' supplemental benefits.

Medicare capitation payments to an MA plan are a product of the standardized plan bid, which is equal to the bid divided by the plan's projected risk score, and the actual enrollee risk score, which is based on demographic characteristics and medical diagnosis data. The risk score for a given enrollee may be adjusted retrospectively since CMS receives diagnosis data after the payment date.

Rebate payments are based on the projected risk profile of the plan and are not adjusted based on subsequent actual risk scores.

#### ***b. Incurred Basis***

Private health plan expenditures are forecast on an incurred basis by coverage type. The bid-based expenditures for each quarter are a product of the average enrollment and the projected average per capita bid. Similarly, the rebate expenditures are a product of enrollment and projected average rebates.

Annual per capita benchmarks, bids, and rebates were determined on an incurred basis for calendar years 2007–2025 for each coverage category. These amounts include adjustments processed after the payment due date for retroactive enrollment and risk score updates.

From 2017 through 2024, following completion of the phase-in of the fee-for-service-based ratebook, benchmark growth exceeded bid growth (as shown in table IV.C4). Over the period 2018 through 2024, average benchmark growth was 1.7 percent higher than average bid growth, resulting in per capita rebates that increased by 119 percent during those years. Overall benchmark growth averaged 5.1 percent, and bid growth averaged 3.4 percent. Benchmark growth was higher than expenditure growth for beneficiaries enrolled in Medicare fee-for-

### *Actuarial Methodology*

service during this period partly reflecting increases in quality rating bonuses, and payment risk scores. The large increase in SNP enrollment from 2018 through 2024 (described in section IV.C1) contributed to higher payment risk scores and increased benchmark growth. Another factor leading to faster payment risk score growth is coding behavior by MA plans.<sup>80</sup> In 2025, however, bid growth was slightly higher than benchmark growth, resulting in marginally lower rebates compared with 2024.

Private health plan expenditures are affected by the sequestration required by current law, which will reduce benefit payments by specified percentages through August 2033.

#### ***c. Cash Basis***

Cash MA expenditures are largely identical to incurred amounts, since both arise primarily from the monthly capitation payments to plans. Small cash payment adjustments are developed from incurred spending by accounting for the payment lag that results from CMS' receipt of post-payment diagnosis data, retroactive enrollment notifications, and corrections in enrollees' demographic characteristics.

Table IV.C2 shows Medicare private plan expenditures on an incurred and cash basis. The incurred payments are reported separately for the bid-related and rebate expenditures. As noted, most payments to plans are made as they are incurred, and cash and incurred amounts are generally the same.

---

<sup>80</sup>See [https://www.medpac.gov/wp-content/uploads/202603/Mar26\\_Ch12\\_MedPAC\\_Report\\_To\\_Congress\\_SEC.pdf](https://www.medpac.gov/wp-content/uploads/202603/Mar26_Ch12_MedPAC_Report_To_Congress_SEC.pdf)

Private Health Plans

**Table IV.C2.—Medicare Payments to Private Health Plans, by Trust Fund**  
[Dollar amounts in billions]

Calendar year	Incurred basis <sup>1</sup>			Part A as a percentage of total <sup>2</sup>	Cash basis
	Bid	Rebate	Total		
2016	\$174.4	\$14.4	\$188.8	45.2%	\$188.6
2017	193.3	15.7	209.0	45.1	209.6
2018	217.3	18.1	235.4	43.7	232.7
2019	249.9	23.0	272.8	43.5	273.8
2020	288.3	28.7	317.0	43.0	317.1
2021	315.3	36.8	352.1	42.2	349.9
2022	359.9	46.5	406.4	42.0	403.3
2023	405.8	63.2	469.0	41.2	466.7
2024	436.0	67.7	503.7	40.1	503.7
2025	464.2	70.2	534.4	39.5	530.9
2026	511.0	76.7	587.7	38.8	586.0
2027	560.7	84.9	645.6	39.8	643.8
2028	616.1	92.8	708.9	39.4	707.0
2029	672.2	102.8	775.0	39.1	772.9
2030	734.0	114.8	848.8	38.6	846.5
2031	795.7	127.6	923.3	38.2	921.0
2032	858.9	141.0	999.9	37.9	997.4
2033	935.3	156.5	1,091.8	37.3	1,089.0
2034	1,020.0	173.5	1,193.5	36.8	1,190.3
2035	1,094.4	188.8	1,283.2	36.3	1,280.4

<sup>1</sup>The bid category includes all expenditures for non-MA coverage.

<sup>2</sup>The remaining percentage is paid from the Part B account of the SMI trust fund.

**d. Incurred Expenditures per Enrollee**

Table IV.C3 shows estimated incurred per enrollee expenditures for beneficiaries enrolled in private health plans. It combines the values for expenditures from the Part A and Part B trust funds.

**Table IV.C3.—Incurred Expenditures per Private Health Plan Enrollee<sup>1</sup>**

Calendar year	Local CCP		Regional PPO	PFFS	SNP	Other	Total
	HMO	PPO					
Bid-based expenditures <sup>2</sup>							
2016	\$8,891	\$9,272	\$9,029	\$10,254	\$13,158	\$8,394	\$9,495
2017	9,089	9,622	9,009	10,797	13,672	8,721	9,777
2018	9,419	10,000	9,464	11,123	14,340	9,029	10,202
2019	10,003	10,342	10,002	12,117	15,227	13,129	10,906
2020	10,482	10,825	10,603	13,096	16,275	14,513	11,519
2021	10,426	10,591	10,216	12,625	16,360	14,595	11,464
2022	10,893	11,015	10,567	13,322	17,208	15,286	12,075
2023	11,244	11,375	11,041	14,306	17,888	15,714	12,634
2024	11,296	11,556	11,269	13,946	17,843	16,337	12,795
2025	11,470	11,851	11,582	13,166	18,199	17,269	13,141
2026	12,216	12,630	12,410	14,105	19,678	15,389	14,138
2027	12,950	13,388	13,310	15,050	20,863	17,110	15,034
2028	13,714	14,192	14,186	15,976	22,085	18,519	15,922
2029	14,496	15,019	15,079	16,917	23,338	19,871	16,824
2030	15,407	15,986	16,114	18,004	24,791	21,385	17,875
2031	16,325	16,966	17,167	19,096	26,257	22,886	18,933
2032	17,271	17,975	18,257	20,217	27,760	24,412	20,021
2033	18,475	19,258	19,630	21,636	29,671	26,299	21,407
2034	19,813	20,673	21,165	23,216	31,797	28,416	22,947
2035	20,944	21,869	22,497	24,554	33,590	30,257	24,248

*Actuarial Methodology*

Calendar year	Local CCP		Regional PPO	PFFS	SNP	Other	Total
	HMO	PPO					
Rebate expenditures <sup>2</sup>							
2016	\$1,123	\$290	\$310	\$199	\$925	\$0	\$788
2017	1,120	281	403	194	1,082	0	796
2018	1,183	324	421	176	1,183	0	851
2019	1,327	445	535	198	1,448	0	1,004
2020	1,506	546	585	189	1,615	0	1,147
2021	1,708	706	692	524	1,941	0	1,337
2022	1,941	898	807	674	2,279	0	1,562
2023	2,358	1,183	1,117	1,032	2,887	0	1,967
2024	2,306	1,236	1,044	1,501	3,013	0	1,988
2025	2,188	1,244	1,015	2,024	3,099	0	1,986
2026	2,288	1,353	1,165	1,727	3,174	0	2,122
2027	2,438	1,385	1,114	2,240	3,490	0	2,275
2028	2,564	1,460	1,173	2,356	3,698	0	2,401
2029	2,756	1,574	1,277	2,540	3,939	0	2,572
2030	2,997	1,718	1,414	2,776	4,280	0	2,796
2031	3,261	1,873	1,564	3,033	4,634	0	3,036
2032	3,528	2,032	1,719	3,297	5,022	0	3,286
2033	3,851	2,222	1,897	3,611	5,466	0	3,582
2034	4,197	2,427	2,084	3,945	5,955	0	3,902
2035	4,487	2,599	2,238	4,224	6,411	0	4,182
Total expenditures <sup>2</sup>							
2016	\$10,014	\$9,562	\$9,339	\$10,453	\$14,083	\$8,394	\$10,283
2017	10,209	9,903	9,412	10,991	14,754	8,721	10,573
2018	10,602	10,324	9,885	11,299	15,524	9,029	11,053
2019	11,330	10,787	10,536	12,314	16,674	13,129	11,910
2020	11,988	11,371	11,188	13,285	17,890	14,513	12,667
2021	12,134	11,297	10,907	13,148	18,301	14,595	12,801
2022	12,834	11,913	11,374	13,996	19,486	15,286	13,637
2023	13,602	12,557	12,158	15,337	20,775	15,714	14,601
2024	13,602	12,792	12,313	15,448	20,856	16,337	14,784
2025	13,658	13,095	12,597	15,190	21,298	17,269	15,126
2026	14,503	13,984	13,575	15,832	22,852	15,389	16,260
2027	15,388	14,773	14,424	17,290	24,353	17,110	17,309
2028	16,279	15,652	15,359	18,333	25,783	18,519	18,323
2029	17,251	16,593	16,356	19,457	27,277	19,871	19,396
2030	18,404	17,704	17,528	20,779	29,071	21,385	20,671
2031	19,586	18,839	18,731	22,129	30,890	22,886	21,969
2032	20,799	20,007	19,976	23,514	32,782	24,412	23,307
2033	22,326	21,480	21,527	25,247	35,137	26,299	24,989
2034	24,010	23,101	23,250	27,161	37,752	28,416	26,849
2035	25,431	24,469	24,735	28,778	40,001	30,257	28,430

<sup>1</sup>Values represent the sum of per capita expenditures for Part A and Part B.

<sup>2</sup>The bid category includes all expenditures for non-MA coverage.

Average Medicare payments per private plan enrollee vary by geographic location of the plan, plan efficiency, and average reported health status of plan enrollees. LCCPs and SNPs tend to be located in urban areas where prevailing health care costs tend to be above average. Conversely, PFFS plans and RPPOs generally reflect a more rural enrollment. These factors complicate meaningful comparisons of average per capita costs by plan category.

Per capita bids are expected to increase from \$13,141 in 2025 to \$14,138 in 2026 (or by 7.6 percent), as shown in table IV.C3. For years 2027 through 2035, the per capita bid trend is expected to be equal to the average of growth in per capita Medicare fee-for-service

*Private Health Plans*

expenditures and benchmark growth for each specific coverage category. After 2035, average Medicare payments to private plans per enrollee are assumed to follow the aggregate growth trends of the HI and SMI Part B per capita benefits, as described in section IV.D of this report.

Per capita benchmarks are based on the fee-for-service United States Per Capita Cost (USPCC) growth rates, with adjustments for MA risk score patterns and quality rating bonus changes. Table IV.C4 shows the fee-for-service USPCC average amount per member per month (PMPM) and the MA benchmark PMPM for individual and SNP beneficiaries. MA benchmark growth for years 2027 and later is estimated to be higher than USPCC expenditure growth since benchmark growth includes adjustments to MA risk scores for differences in diagnosis coding between MA and fee-for-service beneficiaries, as well as other minor factors.

Two policy changes are assumed to be phased in over 3 years beginning in 2024. The first is a change to exclude medical education expenses associated with MA enrollees from the fee-for-service per capita costs that are used in the development of the MA benchmarks; this change will reduce Part A MA payments in all future years. The second policy change is an updated risk adjustment model that slows the growth in the MA benchmarks. Changes in rebates as a percentage of bids show that these additional benefits increased dramatically in recent years through 2024 and are projected to grow again after these policy changes are fully phased in.

**Table IV.C4.—Key Factors for Medicare Advantage Expenditure Estimates**

Calendar year	FFS USPCC PMPM <sup>1</sup>	Benchmark PMPM <sup>2</sup>	Bid PMPM <sup>2</sup>	Bid to benchmark ratio	Rebate PMPM <sup>2</sup>	Rebate to bid ratio	Average final risk scores
2016	800	\$900	\$778	86.4%	\$81	10.4%	1.108
2017	825	929	793	85.4	90	11.3	1.115
2018	848	975	829	85.0	96	11.6	1.142
2019	891	1,042	873	83.9	111	12.7	1.143
2020	941	1,097	911	83.0	123	13.5	1.154
2021	975	1,101	890	80.8	141	15.9	1.110
2022	1,028	1,194	943	79.0	166	17.6	1.149
2023	1,079	1,299	990	76.2	209	21.1	1.160
2024	1,105	1,316	999	75.9	211	21.1	1.156
2025	1,131	1,343	1,028	76.6	209	20.3	<sup>3</sup>
2026	1,231	1,448	1,111	76.8	221	19.9	<sup>3</sup>
2027	1,298	1,544	1,184	76.7	236	19.9	<sup>3</sup>
2028	1,369	1,639	1,255	76.6	249	19.8	<sup>3</sup>
2029	1,445	1,737	1,326	76.3	266	20.1	<sup>3</sup>
2030	1,522	1,855	1,409	75.9	289	20.5	<sup>3</sup>
2031	1,607	1,975	1,492	75.6	314	21.1	<sup>3</sup>
2032	1,695	2,099	1,578	75.2	340	21.5	<sup>3</sup>
2033	1,792	2,240	1,677	74.9	368	22.0	<sup>3</sup>
2034	1,890	2,378	1,774	74.6	396	22.3	<sup>3</sup>
2035	1,995	2,521	1,876	74.4	424	22.6	<sup>3</sup>

<sup>1</sup>For 2026 and earlier, the USPCC value is the amount that was included in the Medicare Advantage rate announcement for that year. Represents the average amount per member per month (PMPM).

<sup>2</sup>Individual and SNP coverages only (excludes EGWP, ESRD, and other enrollment and payments).

<sup>3</sup>The Trustees do not explicitly project average risk scores.

#### **D. LONG-RANGE MEDICARE COST GROWTH ASSUMPTIONS**

Sections IV.A, IV.B, and IV.C have described the detailed assumptions and methodology underlying the projected expenditures for HI (Part A), SMI (Parts B and D), and private health plans (Part C) during 2026 through 2035. These projections are made for individual categories of Medicare-covered services, such as inpatient hospital care and physician services.

As the projection horizon lengthens, it becomes increasingly difficult to anticipate changes in the delivery of health care, the development of new medical technologies, and other factors that will affect future health care cost increases. Accordingly, rather than extending the detailed projections by individual type of service for all future years, the Trustees use a more aggregated basis for setting cost growth assumptions in the long range. Such increases also reflect the substantial uncertainty associated with payments that are specified through statute, which may present challenges for the Medicare program.

Beginning with the 2013 report, the Trustees used the statutory price updates and the volume and intensity assumptions from the “factors contributing to growth” model to derive the year-by-year Medicare cost growth assumptions for the last 50 years of the projection period.<sup>81</sup> The Trustees assume that the productivity reductions to Medicare payment rate updates will reduce volume and intensity growth by 0.1 percent below the factors model projection.<sup>82</sup>

The output and key assumptions of the factors model that are used in this year’s report are similar to those used in the 2025 report. In subsequent reports, the Trustees will determine if additional historical data warrant a re-evaluation of these assumptions and a re-estimation of the factors model output. The remainder of section IV.D discusses the factors model and its role in the Medicare projections. Section V.C

---

<sup>81</sup>This assumed increase in the average expenditures per beneficiary excludes the impacts of the aging of the population, changes in the sex composition of the Medicare population, and changes in the distribution of the Medicare population on the basis of proximity to death, as the Trustees estimated these factors separately. For convenience, the increase in Medicare expenditures per beneficiary, before consideration of demographic impacts, is referred to as the Medicare cost growth rate.

<sup>82</sup>The Trustees’ methodology is consistent with Finding III-2 and Recommendation III-3 of the 2010–2011 Medicare Technical Review Panel and with Finding 3-2 of the 2016–2017 Medicare Technical Review Panel. The Panels’ final reports are available at <http://aspe.hhs.gov/health/reports/2013/MedicareTech/TechnicalPanelReport2010-2011.pdf> and at <https://aspe.hhs.gov/system/files/pdf/257821/MedicareTechPanelFinalReport2017.pdf>.

explains the methods used to derive the long-range cost growth assumptions underlying the illustrative alternative projection.

### **1. Long-Range Growth Assumptions for the Overall Health Sector**

The first step to estimate the long-range Medicare trends is to determine the long-range assumptions affecting the overall health sector. The Trustees use the factors model to determine the year-by-year growth rates for the overall health sector over the last 50 years of the projection. Based on the factors model, the Trustees assume that the long-range per capita overall health spending growth is GDP plus 0.7 percent (or 4.3 percent) for 2050, gradually declining to GDP plus 0.4 percent by 2100 (or 4.1 percent).<sup>83</sup> The per capita increase in overall health care costs is due to the combined effects of general inflation, medical-specific *excess* price inflation (above general price growth), and changes in the utilization of services per person and the intensity or average complexity per service. The Trustees assume the following for years beginning in 2050: (i) price inflation for goods and services produced in the U.S., as measured by the GDP deflator, will remain constant at 2.05 percent per year; (ii) excess medical price inflation will remain constant at 0.75 percent per year; and (iii) the annual increase in the volume and intensity of services per person will decline gradually from approximately 1.5 percent in 2050 to 1.3 percent in 2100 based on the key economic assumptions and elasticity estimates from the factors model, as described below.

Excess medical price inflation for the overall health sector is assumed to grow at 0.75 percent annually from 2050 through 2100. This assumption is roughly equivalent to the difference between the growth in the personal health care deflator over the past three decades and the growth in the GDP deflator over this same period.<sup>84</sup> Combining this assumption with the ultimate assumed growth rate of 2.05 percent per year in the GDP deflator yields the Trustees' estimate of the long-range rate of medical price growth of 2.8 percent annually. Using the relationship between medical price growth and resource-based health

---

<sup>83</sup>These growth rate assumptions are described relative to the per capita increase in GDP and characterized simply as *GDP plus X percent*.

<sup>84</sup>Calculated through 2019. Information on the personal health care deflator is available at <http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html>.

### *Actuarial Methodology*

sector productivity growth<sup>85</sup> allows for the determination of medical input price growth.<sup>86</sup> For resource-based health sector productivity, the Trustees assume that the rate of growth will be equivalent to published research<sup>87</sup> of 0.4 percent per year. Hence, the Trustees' estimate of the long-range rate of growth of medical input prices is 3.2 percent.

As stated earlier, the factors model is based on economic research that separates health spending growth into its major drivers—income growth, relative medical price inflation, insurance coverage, and a residual that primarily reflects the impact of technological development.<sup>88</sup> The factors model provides the ability to model the expected behavioral effects associated with a continuing increase in the share of national income devoted to consumption of health care services. In particular, this approach is based on historically estimated income and price elasticities and uses measurable key variables, providing a foundation for developing the long-range growth assumptions.<sup>89</sup>

In the factors model, the sensitivity of health cost growth to each of the three factors must be estimated. Each sensitivity is measured as an elasticity, which is the percentage change in cost growth that is caused by a 1-percent change in a factor. The first elasticity, the income-technology elasticity, reflects the increase in demand for health care and new medical technologies in response to growth in income. The second elasticity, the relative medical price elasticity, reflects the sensitivity of consumers and purchasers in consuming health care to

---

<sup>85</sup>Resource-based productivity is defined as the real value of provider goods and services divided by the real value of the resources (inputs) used to produce the goods and services, whereas price changes are measured across constant products—that is, defined health services with a constant mix of inputs. Resource-based productivity is used for this decomposition, rather than outcomes-based productivity (which incorporates the estimated value of improvements in health resulting from the services), because Medicare and most other payers reimburse providers based on their resource use.

<sup>86</sup>A third factor, provider profit margins, is assumed to remain constant over the long range.

<sup>87</sup>Information on updated estimates of hospital productivity is available at <https://www.cms.gov/files/document/productivity-memo.pdf>; Fisher, Charles. "Multifactor Productivity in Physicians' Offices: An Exploratory Analysis." *Health Care Financing Review*, 29, no. 2 (2007): 15–32.

<sup>88</sup>Smith, Sheila, Newhouse, Joseph P., and Freeland, Mark S. "Income, Insurance, and Technology: Why Does Health Spending Outpace Economic Growth?" *Health Affairs*, 28, no. 5 (2009): 1276–1284.

<sup>89</sup>Additional information on the "factors contributing to growth" model is available in a memorandum by the CMS Office of the Actuary titled "A Conceptual View of the Long-Term Projection Methods for Medicare and Aggregate National Health Expenditures," available at <https://www.cms.gov/files/document/conceptual-view-long-term-projection-methods-medicare-and-aggregate-national-health-expenditures.pdf>.

### *Long-Range Assumptions*

changes in excess medical price inflation. The final key elasticity is the insurance elasticity, which reflects the change in demand for medical care as the level of insurance coverage changes.

For the income-technology elasticity, the Trustees developed a time-trend-based method for projecting the elasticity that reflects the historical declining trend, produces results consistent with the elasticity implied by the most recent short-range national health expenditure projections, and converges to 1.0 within a range of roughly 75 to 150 years. In the resulting projection, the income-technology elasticity is 1.23 in the 25th year of the projection period (2050) and declines at a slowing pace to 1.06 in the 75th year of the period (2100). This methodology results in an income-technology elasticity that reaches 1.0 in 2125. These are the same elasticity assumptions that were used for 2050 and 2100 in the 2025 report.

For the medical price elasticity, the Trustees assume a rising sensitivity of demand for health care to changes in relative medical price as the share of income devoted to health care rises. The medical price elasticity is determined for a given year by subtracting an income effect from a pure substitution effect. The income effect is determined by multiplying the share of income devoted to health care in that year by the estimated yearly income-technology elasticity. The substitution effect is assumed to be equal to  $-0.2$  and represents the change in demand in response to a change in the relative price of health care holding utility constant. For the 2026 report, the Trustees project the price elasticity to be  $-0.51$  for the 25th year of the projection (2050) and assume that it will follow a non-linear path until it reaches  $-0.57$  in the 75th year of the projection (2100). Based on the RAND Health Insurance Experiment, the insurance elasticity was estimated at  $-0.2$  and was assumed to be unchanged over the long range.<sup>90</sup>

Two additional assumptions are required to complete the factors model determination. First, relative medical price inflation must be estimated over the long-range projection period. As discussed previously, the Trustees assume a relative medical price growth rate of 0.75 percent per year. Second, insurance coverage is assumed to be unchanged over the long range in order to maintain consistency with

---

<sup>90</sup>Newhouse, Joseph P., and the Insurance Experiment Group. *Free for All? Lessons from the RAND Health Insurance Experiment*. Cambridge: Harvard University Press, 1993. The coefficient of this elasticity is negative because the level of insurance coverage is measured using individuals' cost-sharing requirements (such as deductibles and coinsurance).

### *Actuarial Methodology*

the concept of a Medicare projection in which the Medicare benefit package is not altered.

## **2. Long-Range Growth Assumptions for Medicare**

The Trustees have assumed since 2001 that it is reasonable to expect over the long range that the drivers of health spending will be similar for the overall health sector and for the Medicare program. This view was affirmed by the 2010–2011 Medicare Technical Review Panel, which recommended use of the same long-range assumptions for the increase in the volume and intensity of health care services for the total health sector and for Medicare. Therefore, the overall health sector long-range cost growth assumptions for volume and intensity are used as the starting point for developing the Medicare-specific assumptions.

Medicare payment rates for most non-physician provider categories are updated annually by the increase in providers' input prices for the market basket of employee wages and benefits, facility costs, medical supplies, energy and utility costs, professional liability insurance, and other inputs needed to produce the health care goods and services. These updates are then reduced by the 10-year moving average increase in economy-wide productivity, which the Trustees assume will be 1.0 percent per year over the long range. The Trustees assume that the full market basket increase will be approximately 3.2 percent annually, or about 0.4 percent greater than the net price increase of 2.8 percent per year described above for the total health sector. The different statutory provisions for updating payment rates require the development of separate long-range Medicare cost growth assumptions for five categories of health care provider services:

- (i) *All HI, and some SMI Part B, services that are updated annually by provider input price increases less the increase in economy-wide productivity.*

The annual increase in Medicare payment rates for these services is reduced by the 10-year moving average increase in economy-wide productivity. These gains are estimated to be 1.0 percent per year over the long-range projection period. Combined with an assumed market basket increase of 3.2 percent, the statutory price update for these services is 2.2 percent per year over the long range. The initial projected increase in the volume and intensity of these Medicare services is assumed to be equivalent to the average projected growth in the volume and intensity of services for the overall health sector. The Trustees believe that the use of a common baseline rate of volume and intensity growth across all

### *Long-Range Assumptions*

Medicare services is reasonable, as there would be only a small likelihood that one part of the health sector could continue to grow indefinitely at significantly faster rates of growth than do other parts.

Additionally, the Trustees assume that the growth in Medicare payment rates will reduce the volume and intensity growth of these services by 0.1 percent per year relative to the assumption from the factors model. The Trustees' assumption is based on the work of the 2010–2011 and 2016–2017 Medicare Technical Review Panels,<sup>91,92</sup> both of which concluded that there would likely be a small net negative impact on volume and intensity growth because of the following:

- Reduced incentives to develop new technologies: Medicare would pay lower fees than would otherwise be the case, and providers would be less likely to adopt new services and innovations, thereby lowering the demand for, and intensity of, the medical care provided.
- Fewer providers participating in Medicare: As fee-for-service fees decline relative to those assumed for private health insurance plans, providers—particularly facilities of marginal profitability—will become more likely to exit the Medicare market. Additionally, a more bifurcated health system may emerge in which only providers that could operate profitably under Medicare would offer services to Medicare beneficiaries, with a tendency to provide only the more basic services not associated with new medical technologies.
- Increased efficiencies associated with bundled payments and other innovations: As providers increase participation in innovations being tested for the Medicare program, such as bundled payments or accountable care organizations, there will be reduced incentives to adopt new cost-increasing technologies and increased incentives to adopt new cost-decreasing technologies. These innovations could contribute

---

<sup>91</sup>See Recommendation III-3 of the 2010–2011 Medicare Technical Review Panel and Finding 3-2 of the 2016–2017 Medicare Technical Review Panel.

<sup>92</sup>Other factors, such as reduced beneficiary cost-sharing requirements, would tend to increase the volume and intensity of services. The assumption of –0.1 percent reflects the Technical Panel's assessment that the overall impact would be a small net decrease in volume and intensity growth.

### *Actuarial Methodology*

to greater efforts to avoid services of limited or no value within the service bundle.

Reflecting all of these considerations, the year-by-year long-range cost growth rate assumption for these HI and SMI Part B services starts at 3.6 percent in 2050, or GDP plus 0.0 percent, and gradually declines to 3.4 percent by 2100, or GDP minus 0.3 percent.

#### (ii) *Physician services*

Payment rate updates are 0.75 percent per year for those qualified physicians assumed to be participating in advanced alternative payment models (advanced APMs) and 0.25 percent for those assumed to be participating in the merit-based incentive payment system (MIPS) in the long range. The year-by-year cost growth rates for physician payments are assumed to decline from 3.1 percent in 2050, or GDP minus 0.5 percent, to 2.8 percent in 2100, or GDP minus 0.9 percent.

#### (iii) *Certain SMI Part B services that are updated annually by the Consumer Price Index (CPI) increase less the increase in productivity.*

Such services include durable medical equipment (DME) that is not subject to competitive bidding,<sup>93</sup> care at ambulatory surgical centers, ambulance services, and medical supplies, which are updated by the CPI and reduced by the 10-year moving average increase in economy-wide productivity. For these services, the Trustees initially assume that the rate of per beneficiary volume and intensity growth is equivalent to that derived for the overall health sector using the factors model. This volume and intensity growth is assumed to be reduced by 0.1 percent per year, as described above. The volume and intensity assumption is combined with the long-range CPI assumption (2.4 percent) minus the productivity factor (1.0 percent) to produce a long-range growth assumption for these SMI Part B services. The corresponding year-by-year cost growth rates gradually decline from 2.8 percent in 2050, or GDP minus 0.8 percent, to 2.6 percent in 2100, or GDP minus 1.1 percent.

---

<sup>93</sup>The portion of DME that is subject to competitive bidding is included with all other Medicare services since the price is determined by a competitive bidding process.

### *Long-Range Assumptions*

- (iv) *The remaining Part B services, which consist mostly of physician-administered drugs, laboratory tests, and small facility services.*

The Trustees assume that per beneficiary costs for these other Part B services grow at the same rate as the overall health sector as determined from the factors model. The services are assumed to grow similarly because their payments are established through market processes. For physician-administered Part B drugs, the key inflation provisions in the Inflation Reduction Act of 2022 are not expected to affect such payments over the long range. The year-by-year cost growth rates gradually decline from 4.3 percent in 2050, or GDP plus 0.7 percent, to 4.1 percent by 2100, or GDP plus 0.4 percent.

- (v) *Prescription drugs provided through Part D.*

Medicare payments to Part D plans are based on a competitive-bidding process, and prior to the Inflation Reduction Act these payments were assumed to grow at the same rate as the overall health sector as determined from the factors model. While the negotiation provisions of this law are not anticipated to affect the long-range growth rates for Part D drugs, the inflation provisions would likely lower these trends relative to previous expectations. Analysis of Part D pricing trends in past years has consistently shown price growth in excess of the CPI, with a portion of these trends offset by increasing rebate percentages, and it was assumed, prior to this legislation, that such trends would continue over the long range.

The Inflation Reduction Act is expected to change this dynamic because it requires the change in prices (before rebate adjustments) to be limited to the rate of growth in the CPI. The inflation provisions would likely lower price trends, though it is anticipated that they would outpace the CPI because of certain manufacturer adaptations to the new law that may mitigate some of the pricing constraints, including new approaches regarding the development and release of new drugs. As a result, they are assumed to grow over the long range slightly more slowly than would be the case if they were determined strictly through market processes. The corresponding year-by-year cost growth rates decline from 4.1 percent in 2050, or GDP plus 0.5 percent, to 3.9 percent by 2100, or GDP plus 0.2 percent.

In addition, these long-range cost growth rates must be modified to reflect demographic impacts. Beginning with the 2020 report, these

### *Actuarial Methodology*

impacts reflect the changing distribution of Medicare enrollment by age, sex, and the beneficiary's proximity to death, which is referred to as a time-to-death adjustment. This adjustment reflects the fact that the closer an individual is to death, the higher his or her health care spending is. Thus, as mortality rates improve and a smaller portion of the Medicare population is likely to die at any given age, the effect of individuals getting older and spending more on health care is offset somewhat.<sup>94</sup>

After combining the rates of growth from the four long-range assumptions, the weighted average cost growth rate for Part B is 3.8 percent, or GDP plus 0.2 percent in 2050,<sup>95</sup> remaining at 3.8 percent, or GDP plus 0.1 percent by 2100. When Parts A, B, and D are combined, the weighted average cost growth rate is 3.8 percent in 2050, or GDP plus 0.2 percent, declining to 3.7 percent, or GDP plus 0.0 percent by 2100.

As in the past, the Trustees have established detailed growth rate assumptions for the initial 10 years of the projection period by individual type of service (for example, inpatient hospital care and physician services), reflecting recent trends and the impact of all applicable statutory provisions. For each of Parts A, B, and D, the assumed growth rates for years 11 through 25 of the projection period are set by interpolating between the rate at the end of the short-range period and the rate at the start of the final 50 years of the long-range period described above. The 2016–2017 Medicare Technical Review Panel concluded that both the current length of the transition period and the current approach to the transition are reasonable, and they recommended that the Trustees continue to use the same approach to transitions between short-range and long-range projections for both HI and SMI.<sup>96</sup>

---

<sup>94</sup>More information on the time-to-death adjustment is available at <https://www.cms.gov/files/document/incorporation-time-death-medicare-demographic-assumptions.pdf>.

<sup>95</sup>In 2050, the shares of Part B spending are 27 percent for services updated by input price indexes, 15 percent for physician services, 6 percent for services updated by the CPI, and 52 percent for the remaining Part B services.

<sup>96</sup>See Findings 6-2 and 6-3 and Recommendation 6-1.

## V. APPENDICES

### A. *MEDICARE AMENDMENTS SINCE THE 2025 REPORT*

Since Appendix V.A. for the 2025 annual report was written, and prior to this report's preparation, three laws have been enacted that have an effect on the Medicare trust funds. The more important provisions, from an actuarial standpoint, are described, in brief, in the following paragraphs. Certain provisions with a relatively minor financial impact, but which are important from a policy perspective, are briefly described as well.

1. **An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law 119-21, enacted on July 4, 2025), which is colloquially referred to as the "One Big Beautiful Bill Act" (OBBBA), included provisions that affect the HI and SMI programs.**

#### *Provision Affecting All Parts of Medicare*

- An individual is eligible for Medicare coverage only if the individual is (i) a United States citizen or national; (ii) an alien lawfully admitted for permanent residence; (iii) an alien who have been granted the status of Cuban and Haitian entrant (as defined in Public Law 96-422); or (iv) an individual from the Federated States of Micronesia, the Republic of the Marshall Islands, or the Republic of Palau who lawfully reside in the United States (in accordance with the Compact of Free Association referred to in Public Law 104-193). All other lawfully present non-citizens who were or would be eligible for Medicare under prior law are now excluded from coverage (regardless of how long they, or their spouse, have worked and paid into the system). This provision starts immediately for new enrollees; current Medicare beneficiaries who do not meet the new criteria will have their coverage end in January 2027.

- *Provision Affecting Part A*

- The lower ordinary income tax rates and adjusted tax brackets originally enacted under the 2017 Tax Cuts and Jobs Act are made permanent, and the larger standard deduction provided by the 2017 Act is increased and made permanent as well. Furthermore, a temporary additional standard deduction for taxpayers over age 65 is also added. As a result of these changes, taxable income for many Social Security beneficiaries

## *Appendices*

is reduced. Therefore, less income tax will be paid on Social Security benefits, and the HI trust fund will receive lower levels of revenue in the future from income taxation of Social Security benefits.

### ***Provision Affecting Both Part B and Part D of SMI***

- The exclusion for orphan drugs from the Medicare drug price negotiation program is modified in two ways. First, a drug or biologic approved to treat one or more rare diseases or conditions is now exempted from the negotiation program (whereas previously, only those drugs or biologics approved to treat a single rare disease or condition were exempted). Second, if a drug or biologic loses its orphan drug status, the price negotiation eligibility period begins on the first day after the date of non-orphan approval (for drugs) or non-orphan licensure (for biologics), rather than on the original approval or licensure date. These changes apply to initial price applicability years beginning on or after January 1, 2028.

### ***Provision Affecting Part B of SMI***

- In the formula for determining payment rates for services under the physician fee schedule, the updates to the conversion factors are temporarily increased, for 2026 only, by 2.5 percent. (That is, for 2026, the 0.75 percent update for physicians who are qualified participants in advanced alternative payment models and the 0.25 percent update for all other physicians are each multiplicatively combined with 2.5 percent.)

## **2. The Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37, enacted on November 12, 2025) included provisions that affect the HI and SMI programs.**

### ***Provisions Affecting All Parts of Medicare***

- The sequestration process that is in place should Congress fail to address the budget deficit by certain deadlines is extended by 1 month, through February 28, 2033. (In other words, the benefit payment reductions for the month of February 2033 are changed from 0 percent to 2 percent.) (Subsequent legislation further extended this provision; see Public Law 119-75, below.)

### *Medicare Amendments*

- Funding for the National Quality Forum from the HI and SMI trust funds is extended through September 30, 2026 (from September 30, 2025). (Subsequent legislation further extended this provision; see Public Law 119-75, below.)
- Funding from the HI and SMI trust funds for certain low-income outreach and assistance programs is extended through January 30, 2026 (from September 30, 2025). (Subsequent legislation further extended this provision; see Public Law 119-75, below.)

### ***Provision Affecting HI and Part B of SMI***

- Funding in the amount of \$1,403 million is provided to the Medicare Improvement Fund, from the HI and SMI trust funds in such proportion as is deemed appropriate by the Secretary of HHS, for services provided during and after fiscal year 2027. (Subsequent legislation changed the amount provided; see Public Law 119-75, below.)

### ***Provisions Affecting HI***

- For hospitals to qualify for low-volume add-on payments, the most recent criteria are extended through January 30, 2026 (from September 30, 2025). Specifically, hospitals must have fewer than 3,800 total discharges annually and be located 15 road miles or more from another acute care hospital. The most recent sliding scale used to determine the add-on percentages is also extended. (Subsequent legislation further extended this provision; see Public Law 119-75, below.)
- The Medicare-Dependent Hospital (MDH) program, which was scheduled to expire after September 30, 2025, is extended through January 30, 2026. (In addition, in most cases, MDH hospitals that had requested reclassification as sole community hospitals may decline this reclassification and reinstate their MDH status.) (Subsequent legislation further extended this provision; see Public Law 119-75, below.)
- The Acute Hospital Care at Home initiative is extended through January 30, 2026 (from September 30, 2025). (Subsequent legislation further extended this initiative; see Public Law 119-75, below.)
- For the standard hospice surveys required by the IMPACT Act of 2014 (Public Law 113-185), funding is extended through

## *Appendices*

January 30, 2026 (from September 30, 2025). (Subsequent legislation further extended this provision; see Public Law 119-75, below.)

### ***Provisions Affecting Part B of SMI***

- The 1.00 floor on the geographic index for physician work (which increases the work component for physicians who practice in locations where labor costs are lower than the national average) is extended through January 30, 2026 (from September 30, 2025). (Subsequent legislation further extended this provision; see Public Law 119-75, below.)
- Changes are made to the phase-in period for the market-based system intended to update the Medicare clinical laboratory fee schedule. (This fee schedule is used for determining payments for clinical diagnostic laboratory tests that are not categorized as advanced diagnostic laboratory tests). First, laboratories are exempted for one month from the requirement that they report private payer rates; that is, the next data-reporting period is now the 3-month period from February 1, 2026, through April 30, 2026 (instead of January 1, 2026, through March 31, 2026). Next, payment reductions are delayed a month, such that tests furnished during January 2026 (like those furnished during 2021–2025) are to be paid at the same rates as under the 2020 fee schedule. Payments for tests provided during February 1, 2026, through December 31, 2028 (rather than January 1, 2026, through December 31, 2028, as provided for under the previous statute) may not be reduced by more than 15 percent per year. (Subsequent legislation further extended these delays; see Public Law 119-75, below.)
- Certain ground ambulance add-on payments that had been extended through September 30, 2025 (under Public Law 119-4) are now extended through January 30, 2026. These add-on payments include a 3-percent bonus for services originating in rural areas, a 2-percent bonus for services originating in other locations, and a 22.6-percent super rural bonus for rural areas with the lowest population densities. (Subsequent legislation further extended this provision; see Public Law 119-75, below.)
- The telehealth flexibilities that were provided in response to the COVID-19 pandemic are extended through January 30, 2026 (from September 30, 2025). These flexibilities are

### *Medicare Amendments*

described in the 2021 report. (Subsequent legislation further extended this provision; see Public Law 119-75, below.)

#### ***Provision Affecting Part D of SMI***

- The temporary Part D coverage of certain prescription oral antiviral drugs used for the treatment of COVID-19 under an emergency authorization by the Food and Drug Administration (FDA) is extended through January 30, 2026 (from September 30, 2025). (Generally, products need to be fully approved or licensed by the FDA to be covered by Part D; these drugs have emergency use authorization only.) (Subsequent legislation further extended this provision; see Public Law 119-75, below.)

### **3. The Consolidated Appropriations Act, 2026 (Public Law 119-75, enacted on February 3, 2026) included provisions that affect the HI and SMI programs.**

#### ***Provisions Affecting All Parts of Medicare***

- The sequestration process that is in place should Congress fail to address the budget deficit by certain deadlines is extended through August 31, 2033. (In other words, the benefit payment reductions for the months of March 2033 through August 2033 are changed from 0 percent to 2 percent.)
- Funding for the National Quality Forum from the HI and SMI trust funds is extended through September 30, 2027 (from September 30, 2026).
- Funding from the HI and SMI trust funds for certain low-income outreach and assistance programs is extended through December 31, 2026 (from January 30, 2026).
- Medicare Advantage (MA) organizations are required to maintain directories of in-network providers on their websites and continually update these directories (not less than every 90 days) to ensure their accuracy, beginning with plan year 2028. In addition, if a provider is listed as in-network when a beneficiary selects and makes an appointment with the provider, but the provider is not actually in-network, the beneficiary is only responsible for the lesser of the in-network cost-sharing amounts or the amount of cost-sharing that would otherwise apply. MA organizations must also annually evaluate and report on the accuracy of their directories.

## *Appendices*

Moreover, the Government Accountability Office must report on the implementation of this provision.

### ***Provision Affecting HI and Part B of SMI***

- The funding amount of \$1,403 million that was previously provided to the Medicare Improvement Fund for services furnished during and after fiscal year 2027, as discussed under Public Law 119-37, is increased to \$2,062 million.

### ***Provisions Affecting HI***

- For hospitals to qualify for low-volume add-on payments, the most recent criteria are extended through December 31, 2026 (from January 30, 2026). Specifically, hospitals must have fewer than 3,800 total discharges annually and be located 15 road miles or more from another acute care hospital. The most recent sliding scale used to determine the add-on percentages is also extended. After December 31, 2026, the qualifying criteria and sliding scale will revert to their original parameters if this provision is not further extended.
- The Medicare-Dependent Hospital (MDH) program, which was scheduled to expire after January 30, 2026, is extended through December 31, 2026. (In addition, in most cases, MDH hospitals that had requested reclassification as sole community hospitals may decline this reclassification and reinstate their MDH status.)
- The Acute Hospital Care at Home initiative is extended through September 30, 2030 (from January 30, 2026).
- For the hospice aggregate cap, the change made by previous legislation—whereby a hospice payment update percentage is used for the annual updates for fiscal years 2017–2033 rather than the Consumer Price Index for All Urban Consumers—is extended through fiscal year 2035.
- For the standard hospice surveys required by the IMPACT Act of 2014 (Public Law 113-185), funding is extended through December 31, 2026 (from January 30, 2026).

### ***Provisions Affecting Part B of SMI***

- The 1.00 floor on the geographic index for physician work (which increases the work component for physicians who

### *Medicare Amendments*

practice in locations where labor costs are lower than the national average) is extended through December 31, 2026 (from January 30, 2026).

- For physicians who are qualified participants in advanced alternative payment models, incentive payment availability is reinstated for payment year 2028 (for performance year 2026). These incentive payments are to equal 3.1 percent of fee schedule payments (as compared with 5 percent for payment years 2019–2024; 3.5 percent for payment year 2025; 1.88 percent for payment year 2026; and 0 percent for payment year 2027). In addition, the lower participation thresholds that had been in place prior to payment year 2027, in order to qualify for the incentive payments, will apply in payment year 2028 (for performance year 2026); specifically, physicians must receive at least 50 percent of their Part B payments through the model (as opposed to at least 75 percent) or at least 35 percent of the patients they see must be through the model (as opposed to at least 50 percent). The more stringent thresholds will begin applying in payment year 2029.
- Changes are made to the phase-in period for the market-based system intended to update the Medicare clinical laboratory fee schedule. (This fee schedule is used for determining payments for clinical diagnostic laboratory tests that are not categorized as advanced diagnostic laboratory tests). First, laboratories are exempted for three months from the requirement that they report private payer rates; that is, the next data-reporting period is now May 1, 2026, through July 31, 2026 (instead of February 1, 2026, through April 30, 2026). The data collection period is revised as well, to January–June 2025 (from January–June 2019). Next, payment reductions are delayed, such that tests furnished during the last 11 months of 2026 (like those furnished during 2021–2025 and the first month of 2026) are to be paid at the same rates as under the 2020 fee schedule. Payments for tests provided during 2027 through 2029 (rather than February 1, 2026, through December 31, 2028, as provided for under the previous statute) may not be reduced by more than 15 percent per year.
- Certain ground ambulance add-on payments that had been extended through January 30, 2026, under Public Law 119-37, are now extended through December 31, 2027. These add-on payments include a 3-percent bonus for services originating in rural areas, a 2-percent bonus for services originating in other

## *Appendices*

locations, and a 22.6-percent super rural bonus for rural areas with the lowest population densities.

- The telehealth flexibilities that were provided in response to the COVID-19 pandemic are extended through December 31, 2027 (from January 30, 2026). These flexibilities are described in the 2021 report. In addition, the Secretary of HHS is required to establish unique billing codes or modifiers for instances when Medicare providers use any third-party platforms to deliver telehealth services.
- Within one year of enactment, the Secretary of Health and Human Services must issue guidance on furnishing services via telehealth to individuals with limited English proficiency. This guidance must be made in consultation with specified entities and must include best practices in a number of sub-areas.
- Outpatient cardiopulmonary rehabilitation furnished in-home through audio-visual real-time communications (excluding audio only) is covered by Medicare for service received on or after January 31, 2026, and before January 1, 2028. (These services must still be provided by a physician, physician assistant, nurse practitioner, or clinical nurse specialist.)
- Off-campus hospital outpatient departments must obtain and use a unique, location-specific National Provider Identifier (separate from that of their hospital or other parent facility) to receive Medicare reimbursement, effective January 1, 2028.
- Medicare coverage of external infusion pumps, drugs, and associated supplies used for home infusion therapy, under the durable medical equipment benefit, is amended to clarify that this coverage applies to drugs requiring administration or supervision by a professional (and not only to drugs that are self-administered), beginning April 1, 2027. (In addition, HHS must notify patients of cost sharing obligations for home infusion therapy compared to other applicable settings of care.)
- A Medicare coverage framework for blood-based multi-cancer early detection screening tests is defined. These tests must first be approved (by the Food and Drug Administration) and then must be determined to be reasonable and necessary for the prevention or early detection of illness or disability, and appropriate for individuals entitled to benefits under Part A or

### *Medicare Amendments*

enrolled in Part B (by the Secretary of HHS, through the usual national determination coverage process). If these conditions are met, coverage begins January 1, 2029, for individuals within specified lower and upper age limits.

- Digital health companies can participate in the Medicare diabetes prevention program (MDPP) as virtual suppliers through 2029. (Such participation had been approved under temporary authority during the COVID-19 pandemic and had been subsequently extended through 2027). Also, beneficiaries are now allowed to participate in the program multiple times. (The MDPP is a one-year health behavior change educational program that has demonstrated effectiveness in delaying or preventing the onset of type 2 diabetes among people with prediabetes.)
- No later than January 1, 2028, the Secretary of Health and Human Services must provide education and outreach to physicians and appropriate non-physician practitioners who participate in Medicare with respect to periodic screening for medication-induced movement disorders that are associated with the treatment of mental health disorders.
- Within 18 months of enactment, the Comptroller General must assess, and submit to Congress a report on, the capabilities and limitations of wearable medical devices used to support clinical decision-making.

### ***Provisions Affecting Part D of SMI***

- The temporary Part D coverage of certain prescription oral antiviral drugs used for the treatment of COVID-19 under an emergency authorization by the Food and Drug Administration (FDA) is extended through December 31, 2026 (from January 30, 2026). (Generally, products need to be fully approved or licensed by the FDA to be covered by Part D; these drugs have emergency use authorization only.)
- For low-income enrollees eligible for cost-sharing subsidies, the existing Part D copayment caps of \$1 for a generic or preferred multiple source drug and \$3 for a brand-name drug are maintained through 2027. In addition, beginning in 2028, the \$1 amount for generic drugs decreases to \$0, while the \$1 and \$3 amounts for preferred multiple source drugs and brand-

## *Appendices*

name drugs, respectively, will each be adjusted annually for inflation.

- For plan years beginning on or after January 1, 2029, Part D plans must allow any willing pharmacy that meets the plan's standard contract terms and conditions to participate in their networks (thereby reducing the ability of a Pharmacy Benefit Manager to steer patients to affiliated pharmacies). In addition, for plan years beginning on or after January 1, 2028, a special category of essential retail pharmacies is established. These pharmacies, which are primarily in rural and underserved areas, will be monitored by HHS regarding a number of defined metrics, to protect access to care.
- For plan years beginning on or after January 1, 2028, a Pharmacy Benefit Manager (PBM) acting on behalf of a Part D plan sponsor must agree to: (i) receive only bona fide service fees (as defined later in this paragraph); (ii) provide transparency to the plan sponsor related to guarantees and similar cost performance measures related to rebates, discounts, price concessions, and net costs; (iii) submit to the plan sponsor and to HHS, not later than July 1 of each year, a report with certain specific information on all drugs dispensed during the previous plan year; and (iv) at the request of the plan sponsor, allow for an audit of the PBM not less than once a year, to ensure compliance with all terms and conditions of the agreement. (Bona fide fees are flat, fair market value payments for itemized services rendered, as opposed to fees tied to drug prices, rebates, or volume.) Under this particular bona fide rule, rebates, discounts, and other price concessions received by the PBM from a manufacturer are not a violation if they are fully passed through to the PDP sponsor.

**B. TOTAL MEDICARE FINANCIAL PROJECTIONS**

Medicare is the nation's second largest social insurance program, exceeded only by Social Security (OASDI). Although Medicare's two components—Hospital Insurance (HI) and Supplementary Medical Insurance (SMI)—are very different from each other in many key respects, it is important to consider the overall cost of Medicare and its financing. By reviewing Medicare's total expenditures, readers can assess the financial obligation created by the program. Similarly, the sources and relative magnitudes of HI and SMI revenues are an important policy matter.

The issues of Medicare's total cost to society and the means of financing that cost are different from the question of the financial status of the Medicare trust funds. The latter focuses on whether a specific trust fund's income and expenditures are in balance. The separate HI and SMI financial projections prepared for this purpose, however, can be usefully combined for the broader purposes outlined above. To that end, this section presents information on combined HI and SMI costs and revenues. Sections III.B, III.C, and III.D of this report present detailed assessments of the financial status of the HI trust fund and the Part B and Part D accounts of the SMI trust fund, respectively.

**1. 10-Year Actuarial Estimates (2026–2035)**

Table V.B1 shows past and projected Medicare income, expenditures, and trust fund assets in dollar amounts for calendar years,<sup>97</sup> with projections shown under the intermediate set of assumptions for the short-range projection period 2026 through 2035.

---

<sup>97</sup>The table shows amounts on a *cash* basis, reflecting actual expenditures made during the year, even if the payments were for services performed in an earlier year. Similarly, income figures represent amounts actually received during the year, even if incurred in an earlier year.

Appendices

**Table V.B1.—Total Medicare Income, Expenditures, and Trust Fund Assets during Calendar Years 1970–2035**

[In billions]				
Calendar year	Total income	Total expenditures	Net change in assets	Assets at end of year
Historical data:				
1970	\$8.2	\$7.5	\$0.7	\$3.4
1975	17.7	16.3	1.3	12.0
1980	37.0	36.8	0.1	18.3
1985	76.5	72.3	4.2	31.4
1990	126.3	111.0	15.3	114.4
1995	175.3	184.2	-8.9	143.4
2000	257.1	221.8	35.3	221.5
2005	357.5	336.4	21.0	309.8
2010	486.1 <sup>1</sup>	522.9	-36.8	344.0
2015	644.4 <sup>1</sup>	647.6	-3.2	263.2
2016	710.2 <sup>1</sup>	678.7	31.5	294.7
2017	705.1	710.2	-5.0	289.6
2018	755.7	740.6	15.1	304.7
2019	794.7	796.1	-1.4	303.3
2020	899.9 <sup>1,2</sup>	925.8 <sup>3</sup>	-25.9	277.4
2021	887.7 <sup>1,2</sup>	839.4 <sup>3</sup>	48.3	325.7
2022	988.5 <sup>2</sup>	905.1 <sup>3</sup>	83.4	409.1
2023	1,024.3 <sup>2</sup>	1,036.7 <sup>3</sup>	-12.4	396.7
2024	1,133.3	1,122.0	11.2	407.9
2025	1,226.2	1,210.1	16.2	424.1
Intermediate estimates:				
2026	1,373.9 <sup>1</sup>	1,328.9	45.0	469.1
2027	1,424.6 <sup>1</sup>	1,440.9	-16.4	452.8
2028	1,561.5	1,567.1	-5.6	447.2
2029	1,665.5	1,682.9	-17.5	429.8
2030	1,780.6	1,807.2	-26.6	403.2
2031	1,896.0	1,935.8	-39.9	363.3
2032	2,008.9	2,058.0	-49.2	314.2
2033	2,152.0	2,212.9	-61.0	253.2
2034	2,299.2	2,387.9	-88.7	164.5
2035	2,439.0	2,543.1	-104.1	60.4

<sup>1</sup>Section 708 of the Social Security Act modifies the provisions for the payment of Social Security benefits when the regularly designated day falls on a Saturday, Sunday, or legal public holiday. Payment of those benefits normally due January 3, 2010, actually occurred on December 31, 2009, payment of benefits normally due January 3, 2016, occurred on December 31, 2015, and payment of benefits normally due January 3, 2021, occurred on December 31, 2020. Consequently, the Part B and Part D premiums withheld from these benefits and the associated Part B government contributions were added to the Part B or Part D account, as appropriate, on December 31, 2009 (about \$14.8 billion for Part B and about \$0.2 billion for Part D), December 31, 2015 (about \$7.5 billion for Part B and about \$0.1 billion for Part D), and December 31, 2020 (about \$10.0 billion for Part B and about \$0.1 billion for Part D), respectively. Similarly, the payment date for those benefits normally due January 3, 2027, will be on December 31, 2026. Accordingly, an estimated \$5.8 billion will be added to the Part B account, and an estimated \$0.2 billion will be added to the Part D account, on December 31, 2026.

<sup>2</sup>See footnote 9 of table III.C4.

<sup>3</sup>Includes net payments of \$100.5 billion made through the Medicare Accelerated and Advance Payments Program in calendar year 2020 and subsequent net repayments of \$47.9 billion, \$51.5 billion, and \$0.8 billion in calendar years 2021 through 2023, respectively.

Note: Totals do not necessarily equal the sums of rounded components.

As indicated in table V.B1, Medicare expenditures have increased rapidly during most of the program's history. From 1985 through 2025, expenditures grew at an average annual rate of 7.3 percent, and they are projected to increase at an average annual rate of 7.7 percent from 2026 through 2035.

### *Total Medicare Financial Projections*

Through most of Medicare's history, trust fund income has kept pace with increases in expenditures.<sup>98</sup> For this year's report, the Trustees estimate that, from 2026 through 2035, total Medicare income will increase at an average annual rate of 7.1 percent, which is slightly lower than the growth in expenditures.

The Department of the Treasury has invested past excesses of income over expenditures in special-issue U.S. Treasury securities, with total trust fund assets accumulating to \$424.1 billion at the end of calendar year 2025. Combined assets fluctuated over the recent historical period for various reasons, including transfers from the general fund of the Treasury required by enacted legislation. The change in assets continues to fluctuate slightly over the remainder of the short-range projection period because of the timing of premium collections, as described in footnote 1 of table V.B1, and the return of HI deficits.<sup>99</sup>

#### **2. 75-Year Actuarial Estimates (2026–2100)**

Table V.B2 shows past and projected Medicare expenditures expressed as a percentage of GDP.<sup>100</sup> This percentage provides a relative measure of the size of the Medicare program compared to the general economy and represents the portion of the nation's total production dedicated each year to providing health care services to beneficiaries through Medicare. Expenditures represented 0.7 percent of GDP in 1970 and had grown to 2.6 percent of GDP by 2005, reflecting rapid increases in the factors affecting health care cost growth. Starting in 2006, Medicare provided subsidized access to prescription drug coverage through Part D, which caused most of the increase in Medicare expenditures to 3.0 percent of GDP in the first year. The Trustees project much more moderate continuing growth in the long range, partially as a result of the lower price updates under current law, with total Medicare expenditures projected to reach about 7.5 percent of GDP by 2100.

The projections shown in table V.B2 for total Medicare as a share of GDP are higher than those in the 2025 report primarily as a result of

---

<sup>98</sup>This balance resulted from periodic increases in HI payroll tax rates and other HI financing, from annual increases in SMI premium rates and government contributions (to cover the following year's estimated expenditures), and from frequent legislation designed to slow the rate of growth in expenditures.

<sup>99</sup>See sections III.B, III.C, and III.D regarding the asset projections for HI and Part B and Part D of SMI, separately.

<sup>100</sup>In contrast to the expenditure amounts shown in table V.B1, table V.B2 shows historical and projected expenditures on an incurred basis. Incurred amounts relate to the expenditures for services performed in a given year, even if payment for those expenditures occurs in a later year.

*Appendices*

higher projected spending for prescription drugs and lower GDP projections.

**Table V.B2.—HI and SMI Incurred Expenditures as a Percentage of the Gross Domestic Product**

Calendar year	HI		SMI		Total
	Part A	Part B	Part C	Part D	
Historical data:					
1970	0.51%	0.21%	—	—	0.71%
1975	0.69	0.29	—	—	0.98
1980	0.91	0.40	—	—	1.31
1985	1.11	0.55	—	—	1.66
1990	1.12	0.74	—	—	1.86
1995	1.55	0.87	—	—	2.42
2000	1.28	0.91	—	—	2.19
2005	1.44	1.18	—	0.01%	2.62
2010	1.63	1.43	—	0.42	3.48
2015	1.52	1.54	—	0.49	3.55
2016	1.54	1.57	—	0.50	3.60
2017	1.53	1.60	—	0.48	3.61
2018	1.51	1.65	—	0.47	3.64
2019	1.54	1.73	—	0.48	3.74
2020	1.61	1.80	—	0.50	3.91
2021	1.51	1.81	—	0.46	3.78
2022	1.46	1.75	—	0.45	3.66
2023	1.46	1.81	—	0.46	3.73
2024	1.45	1.85	—	0.54	3.83
2025	1.45	1.90	—	0.59	3.94
Intermediate estimates:					
2026	1.50	1.96	—	0.68	4.14
2027	1.58	2.04	—	0.69	4.31
2028	1.63	2.15	—	0.73	4.51
2029	1.68	2.24	—	0.76	4.69
2030	1.73	2.36	—	0.76	4.84
2031	1.77	2.45	—	0.77	4.99
2032	1.80	2.54	—	0.75	5.10
2033	1.85	2.66	—	0.76	5.27
2034	1.91	2.80	—	0.76	5.46
2035	1.93	2.90	—	0.76	5.60
2040	2.01	3.33	—	0.76	6.10
2045	2.03	3.60	—	0.75	6.39
2050	2.03	3.73	—	0.77	6.53
2055	2.02	3.83	—	0.80	6.66
2060	2.03	3.96	—	0.84	6.83
2065	2.05	4.10	—	0.88	7.02
2070	2.09	4.22	—	0.91	7.22
2075	2.12	4.33	—	0.94	7.39
2080	2.13	4.42	—	0.97	7.51
2085	2.12	4.47	—	0.99	7.58
2090	2.10	4.49	—	1.00	7.59
2095	2.08	4.49	—	1.00	7.57
2100	2.04	4.48	—	1.01	7.53

Note: Percentages are affected by economic cycles.

The 75-year projection period fully allows for the presentation of anticipated future developments, such as the impact of a large increase in enrollees from 2010 through 2031. This increase in the number of beneficiaries will occur because the relatively large number of persons born during the period between the end of World War II and the mid-1960s (known as the baby boom generation) will reach eligibility

### *Total Medicare Financial Projections*

age and begin to receive benefits. Moreover, as this generation ages, these individuals will experience greater health care utilization and costs, thereby adding further to growth in program expenditures. Table V.B3 shows past and projected enrollment in the Medicare program.

As indicated in table V.B3, over the last 35 years the total number of Medicare beneficiaries approximately doubled, and the Trustees expect the total to increase by 35 percent over approximately the next 35 years. During this same historical period, the number of covered workers also increased rapidly (by about 39.3 percent), but the Trustees project this number to increase much more slowly (about 10 percent) over the next 35 years. This demographic shift and its implications for Medicare costs, relative to workers' earnings or to GDP, are fairly well known.

The enrollment data also show that the number of Medicare beneficiaries enrolled in private health plans under Part C has increased steadily in recent years. (Section IV.C of this report describes the changes in enrollment growth since 2005.) By 2025, about 51 percent of eligible Medicare beneficiaries were enrolled in private Part C health plans. The Trustees expect modest increases in private plan penetration rates between 2026 and 2035, with the estimated proportion of beneficiaries in such plans ultimately stabilizing at about 56 percent.

Appendices

**Table V.B3.—Medicare Enrollment**

Calendar year	[In thousands]					
	HI	SMI			Private health plans <sup>1</sup>	Total <sup>2</sup>
	Part A	Part B	Part D			
Historical data:						
1970	20,104	19,496	—	—	20,398	
1975	24,481	23,744	—	—	24,864	
1980	28,002	27,278	—	—	28,433	
1985	30,621	29,869	—	1,271	31,081	
1990	33,747	32,567	—	2,017	34,251	
1995	37,175	35,641	—	3,467	37,594	
2000	39,257	37,335	—	6,856	39,688	
2005	42,233	39,752	1,841	5,794	42,606	
2010	47,365	43,882	34,772	11,693	47,720	
2015	55,246	50,756	41,786	17,495	55,589	
2016	56,729	52,094	43,198	18,393	57,073	
2017	58,344	53,446	44,475	19,817	58,683	
2018	59,677	54,679	45,798	21,338	60,020	
2019	61,188	56,019	47,179	22,949	61,535	
2020	62,544	57,320	48,696	25,074	62,887	
2021	63,643	58,393	49,976	27,546	63,980	
2022	64,822	59,502	51,386	29,838	65,166	
2023	66,265	60,803	52,893	32,159	66,606	
2024	67,725	62,106	55,249	34,103	68,066	
2025	69,100	63,448	56,754	35,359	69,289	
Intermediate estimates:						
2026	70,351	64,802	57,973	36,171	70,743	
2027	71,910	66,399	59,700	37,327	72,322	
2028	73,596	68,110	61,448	38,719	74,026	
2029	74,989	69,537	62,975	39,983	75,436	
2030	76,135	70,742	64,201	41,088	76,598	
2031	77,044	71,746	65,224	42,056	77,521	
2032	77,838	72,642	66,111	42,927	78,327	
2033	78,558	73,463	66,899	43,721	79,058	
2034	79,315	74,300	67,661	44,480	79,827	
2035	80,109	75,144	68,416	45,164	80,632	
2040	82,046	77,405	70,471	46,908	82,606	
2045	83,066	78,566	71,528	47,625	83,648	
2050	84,810	80,148	72,969	<sup>3</sup>	85,413	
2055	87,304	82,427	75,043	<sup>3</sup>	87,929	
2060	90,272	85,249	77,612	<sup>3</sup>	90,916	
2065	92,947	87,965	80,085	<sup>3</sup>	93,612	
2070	95,946	90,919	82,775	<sup>3</sup>	96,634	
2075	98,871	93,799	85,396	<sup>3</sup>	99,585	
2080	100,754	95,789	87,208	<sup>3</sup>	101,485	
2085	101,920	97,078	88,382	<sup>3</sup>	102,662	
2090	102,074	97,459	88,728	<sup>3</sup>	102,816	
2095	102,109	97,587	88,845	<sup>3</sup>	102,848	
2100	102,393	97,861	89,095	<sup>3</sup>	103,133	

<sup>1</sup>Of Medicare beneficiaries enrolled in private plans, about 97 percent are in Medicare Advantage plans or Part C. The remainder are in certain holdover plans reimbursed on a cost basis rather than through capitation payments, in Program of All-Inclusive Care for the Elderly (PACE) plans, or in Medicare-Medicaid Plans (MMPs).

<sup>2</sup>Number of beneficiaries with HI and/or SMI coverage.

<sup>3</sup>The Trustees do not explicitly project enrollment in private health plans beyond 2045.

Table V.B4 shows the past and projected amounts of Medicare revenues as a percentage of total non-interest Medicare income, under the intermediate assumptions. The table excludes interest income, which would not be a significant part of program financing in the long range.

*Total Medicare Financial Projections*

**Table V.B4.—Medicare Sources of Income as a Percentage of Total Non-Interest Income**

Calendar year	Payroll taxes	Tax on benefits	Premiums <sup>1</sup>	Brand-name drug fees	State payments	Government contribution <sup>2</sup>
Historical data:						
1970	61.8%	—	13.7%	—	—	24.6%
1980	68.0	—	8.6	—	—	23.4
1990	62.2	—	9.8	—	—	27.9
2000	59.8	3.6%	9.1	—	—	27.6
2010	38.9	2.9	13.3	—	0.9%	44.0
2015	38.1	3.2	13.6	0.5%	1.4	43.2
2016	36.3	3.3	12.8	0.4	1.4	45.7
2017	37.7	3.5	14.6	0.6	1.6	42.0
2018	36.0	3.2	15.2	0.5	1.6	43.4
2019	36.4	3.0	15.3	0.4	1.6	43.4
2020	34.0	3.0	14.8	0.3	1.3	46.6
2021	34.4	2.8	15.1	0.3	1.4	46.1
2022	36.1	3.3	15.7	0.3	1.4	43.2
2023	36.3	3.4	15.3	0.3	1.6	43.2
2024	35.4	3.5	14.7	0.2	1.6	44.5
2025	33.3	3.4	14.2	0.2	1.6	47.3
Intermediate estimates:						
2030	29.1	3.8	17.3	0.2	1.4	48.2
2040	24.7	3.9	19.4	0.1	1.1	50.9
2050	23.3	3.9	19.9	0.1	1.0	51.8
2060	22.4	4.1	20.1	0.0	1.1	52.2
2070	21.6	4.2	20.3	0.0	1.1	52.7
2080	21.0	4.2	20.5	0.0	1.1	53.1
2090	20.9	4.2	20.6	0.0	1.1	53.2
2100	21.0	4.1	20.5	0.0	1.2	53.2

<sup>1</sup>Includes premium revenue from HI and both accounts in the SMI trust fund.

<sup>2</sup>Includes Part B repayment amounts in 2016–2025.

Note: Row sums may not exactly equal 100 percent because of rounding.

Transfers from the general fund of the Treasury (primarily those for SMI) represented 47 percent of total non-interest income to the Medicare program in 2025 and have constituted the largest share of Medicare financing since 2009. HI payroll taxes were the next largest source of overall financing at 33 percent. Beneficiary premiums (again, primarily for SMI) were third, at 14 percent.

Projected HI tax revenues fall short of projected HI expenditures in most future years. In contrast, SMI premium revenue and government contributions will keep pace with SMI expenditure growth, and State payments<sup>101</sup> (on behalf of Medicare beneficiaries who also qualify for full Medicaid benefits) will grow with Part D expenditures.

Government contributions to the Part B account increased significantly in 2016, as required by the Bipartisan Budget Act of 2015 to compensate for premium revenue that was not received in 2016 because of the hold-harmless provision. They increased again in 2020

<sup>101</sup>State payments to Part D amounted to 90 percent of their projected forgone Medicaid prescription drug costs in 2006, and this percentage phased down over a 10-year period to 75 percent in 2015.

## *Appendices*

and 2021, as required by the Continuing Appropriations Act, 2021 and Other Extensions Act to account for the outstanding balance of the Accelerated and Advance Payments (AAP) Program in 2020 and to compensate for premium revenue that was not received in 2021 because of the legislated specification of the aged actuarial rate calculation. Another source of Part B financing, from fees on manufacturers and importers of brand-name prescription drugs, increased from \$2.5 billion in 2011 to \$4.1 billion in 2018 but then decreased to \$2.8 billion for 2019 and later.


In the absence of legislation, HI tax income would represent a declining portion of total Medicare revenues. In 2033, for example, the projected year of depletion of the HI trust fund, currently scheduled HI payroll taxes would represent about 28 percent of total non-interest Medicare income. Government contributions and beneficiary premiums would equal about 49 and 18 percent, respectively.

The law requires an expanded analysis of the combined expenditures and dedicated revenues of the HI and SMI trust funds. In particular, the law requires a determination as to whether the difference between total Medicare expenditures and its dedicated financing sources is projected to exceed 45 percent of total expenditures within the next 7 fiscal years (2026–2032). Dedicated Medicare financing sources include the following: HI payroll taxes; income from taxation of Social Security benefits; State payments for the prescription drug benefit; premiums paid under Parts A, B, and D; fees on brand-name prescription drugs paid to Part B; and any gifts received by the Medicare trust funds. The test uses expenditures that are adjusted to avoid temporary distortions arising from the payment of Medicare Advantage and Part D capitation amounts in September when the normal October payment date is a Saturday or Sunday.

The Trustees made determinations of excess general revenue Medicare funding in each of the reports for 2006 through 2013 and in the 2017 through 2025 reports. Two consecutive such determinations trigger a Medicare funding warning. The 2007 through 2013 reports, and the 2018 through 2025 reports, thus prompted Medicare funding warnings. The law specifies that in response to such findings the President must submit to Congress, within 15 days after the date of the Budget submission for the succeeding year, proposed legislation to respond to the warning. The law also requires Congress to consider the legislation proposed in response to Medicare funding warnings on an expedited basis. To date, elected officials have not enacted legislation responding to these funding warnings.

### Total Medicare Financial Projections

Figure V.B1 displays, on a calendar-year basis, the historical and projected ratio of the difference between total Medicare expenditures and dedicated financing sources to total Medicare expenditures. As indicated, this ratio exceeded 45 percent at the end of calendar years 2009 through 2012, in calendar years 2020 and 2025, and it is expected to continue to exceed that level at the end of calendar year 2026, the first year of the projection. Therefore, the Board of Trustees is issuing a determination of excess general revenue Medicare funding in this report. Since this is the tenth consecutive such finding, a Medicare funding warning is again triggered.



As figure V.B1 also indicates, the Board projects that the difference between expenditures and dedicated funding sources will reach 53.9 percent of expenditures by 2050, will rise slowly to 54.6 percent by 2081, and then decline to 54.1 percent by the end of the 75-year period. This difference between expenditures and dedicated funding sources, which the law refers to as general revenue Medicare funding, includes the following:

- Financing specified portions of SMI Part B and SMI Part D expenditures;
- Reimbursing the HI trust fund for the costs of certain uninsured beneficiaries;

*Appendices*

- Paying interest on invested assets of the trust funds;
- Redeeming the special Treasury securities held as assets by the trust funds; and
- Financing the imbalance between HI expenditures and dedicated revenues after HI asset depletion.

Current law provides for the first four of these items. However, for the fifth—coverage of the HI shortfall—there is no provision under current law.

The law also requires a comparison of projected growth in the difference between expenditures and dedicated revenues with other health spending growth rates. Table V.B5 contains this comparison.

**Table V.B5.—Comparative Growth Rates of Medicare, Private Health Insurance, National Health Expenditures, and GDP**

Calendar year	Average annual growth in:				
	Incurred expenditures minus dedicated revenues	Incurred Medicare expenditures	GDP	National health expenditures <sup>1</sup>	Private health insurance <sup>1</sup>
2020	-0.1%	3.7%	-0.8%	10.5%	0.4%
2021	16.0	7.4	11.0	4.1	6.7
2022	-5.0	6.4	9.8	4.8	7.6
2023	15.7	8.6	6.7	7.4	11.2
2024	9.0	8.4	5.3	7.2	8.8
2025	14.8	8.1	5.1	7.1	7.6
2026	12.0	10.1	4.9	5.4	3.3
2027	9.1	7.9	3.7	5.7	4.5
2028	10.4	8.6	3.7	5.4	4.4
2029	9.5	7.9	3.8	5.5	4.3
2030	5.9	7.3	3.9	5.3	4.3
2031	7.9	7.1	4.0	5.2	4.5
2032	6.7	6.3	4.0	5.1	4.3
2033	8.8	7.6	4.0	5.6	4.3
2034	9.4	7.8	4.0	5.4	4.3
2035	7.3	6.5	4.0	5.0	4.3
2036–2050	5.2	4.9	3.9	4.6	—
2051–2075	4.3	4.3	3.7	4.4	—
2076–2100	3.8	3.8	3.7	4.2	—

<sup>1</sup>Based on a national health expenditure projections article published in July 2025 (*Health Affairs*, vol. 44, no. 7). Data through 2024 are considered historical, and years after 2033 were determined based on the methods described in section IV.D. The findings presented in this article, along with the paper outlining its methodology, are available at <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected>.

The COVID-19 pandemic had a significant effect on expenditures in 2020, but the impact on dedicated funding sources is delayed because program financing, which includes Part A payroll tax income and the Part B and Part D premiums, is set prospectively and is not able to be changed. This phenomenon results in the growth patterns shown in table V.B5. Beginning in 2026, the gap between expenditures and

### *Total Medicare Financial Projections*

dedicated revenues will increase faster than expenditures in many years through 2050 since the dedicated sources of income to the HI trust fund will generally cover a decreasing percentage of HI expenditures.

In addition to projected Medicare expenditure growth, table V.B5 shows projected growth in GDP, total national health expenditures in the U.S., and private health insurance expenditures. The Trustees expect each of the health expenditure categories to continue the longstanding trend of increasing more rapidly than GDP in most years. Private health insurance expenditures equal the total premiums earned by private health insurers, including benefits incurred and the net cost of insurance. The net cost of insurance includes administrative costs, additions to reserves, rate credits and dividends, premium taxes, and profits or losses.

Several factors affect comparisons between aggregate Medicare and private health insurance cost growth:

- The number of Medicare beneficiaries is currently increasing by about 2 percent per year, and this growth rate will continue as more of the post-World War II baby boom generation reaches eligibility age. The number of individuals with private health insurance is estimated to increase at slower rates than the growth in the number of Medicare beneficiaries.
- Certain current-law provisions, such as the limitation on maximum out-of-pocket costs in 2014 and later, will also affect the average actuarial value of private health insurance benefits.
- The use of health care services differs significantly between Medicare beneficiaries (who are generally over 65) and individuals with private health insurance (who are predominantly below age 65). The former group, for example, has a higher incidence of hospitalization, skilled nursing care, and home health care. For the latter group, physician services represent a greater proportion of their total health care needs. Different cost growth trends by type of service will affect overall growth rates and reflect the distribution of services for each category of people.
- There is some overlap between people with Medicare and those with private health insurance. For example, many Medicare beneficiaries have supplemental health insurance coverage through private Medigap insurance policies or employer-sponsored retiree health benefits, and private health insurance includes both

### *Appendices*

of these categories. About 10 million Medicare beneficiaries receive supplemental coverage through the Medicaid program; neither the growth rates for Medicare nor those for private health insurance reflect the Medicaid costs for these dual beneficiaries.

A number of research studies have attempted to control for some or all of these differences in comparing growth trends. Over long historical periods, average, demographically adjusted, per capita growth rates for common benefits have been somewhat lower for Medicare than for private health insurance. For shorter periods, however, the Medicare and private health insurance growth rates have often diverged substantially, and the differential has been negative in some years and positive in others. More information on past and projected national and private health expenditures, and on comparisons to Medicare growth rates, is available in the sources cited in table V.B5.

### **C. ILLUSTRATIVE ALTERNATIVE PROJECTIONS**

The Social Security Act requires the Trustees to evaluate the financial status of the Medicare trust funds. To comply with this mandate, the Trustees must assess whether the financing provided under current law is adequate to cover the benefit payments and other expenditures required under current law. Accordingly, the estimates shown in this report are based on all of the current statutory requirements, including (i) the reductions in payment updates by the increase in economy-wide productivity for most non-physician provider categories and (ii) the physician payment updates specified by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for all future years.

As discussed in the Introduction, there is substantial uncertainty regarding the adequacy of future Medicare payment rates under current law. This section illustrates the higher Medicare expenditures that would result if certain statutory Medicare payment provisions were not fully implemented in all future years. The assumptions that underlie the illustrative alternative and that transition from current law to the illustrative scenario are consistent with recommendations from the 2016–2017 Medicare Technical Review Panel.<sup>102</sup>

For all Part A services and some (non-physician) Part B services, payment updates have been reduced since 2012, and will be reduced in all future years, by the increase in economy-wide productivity.<sup>103</sup> In 2011, the Medicare payment rates for inpatient hospital services represented about 68 percent of those paid by private health insurance.<sup>104</sup> Based on price trends from the Bureau of Labor Statistics, this ratio fell to 55 percent in 2025.<sup>105</sup> If future improvements in productivity were to remain similar to what providers have achieved in the recent past (about 0.4 percent annually), then Medicare payment levels for inpatient hospital services at the end of the long-range projection period would be less than 40 percent of the corresponding level paid by private health insurance. This comparison assumes that private payer rate increases would continue to be set

---

<sup>102</sup>The 2016–2017 Medicare Technical Review Panel concluded that the ultimate assumptions underlying the illustrative alternative were reasonable (Finding 2-3) and recommended that they be implemented over a later time frame (Recommendation 2-4). These assumptions have been implemented since the 2018 report.

<sup>103</sup>In addition to the productivity adjustments, Medicare payments to providers will be affected by the sequestration of expenditures in April 2013 through October 2032.

<sup>104</sup>See <https://www.aha.org/system/files/media/file/2020/10/TrendwatchChartbook-2020-Appendix.pdf>. Private payer hospital payments are roughly 45 percent above costs while Medicare hospital payments are roughly 13 percent below costs.

<sup>105</sup>Based on the Producer Price Index for hospital inpatient care commodity prices by payer type. See <https://www.bls.gov/ppi/>.

## *Appendices*

through the same negotiation process used to date, independent of the Medicare reductions or other health system changes. Specifically, private payer rates would grow by 2.8 percent per year, or the increase in the price of inputs to the provision of health care (3.2 percent) less the assumed growth in hospital productivity (0.4 percent). By comparison, Medicare payment rates would grow by 2.2 percent per year, or 3.2 percent less the assumed growth in economy-wide productivity (1.0 percent).

Simulations that take into account the lower Medicare payment rates, other payment provisions, sequestration, changes to Medicare and Medicaid disproportionate share hospital payments, and coverage expansions collectively suggest a deterioration of facility margins for hospitals, skilled nursing facilities, and home health agencies, particularly over the long run. From 2024 through 2027, the simulations suggest that more hospitals would experience negative total facility margins and that roughly 5 percent more would experience negative Medicare margins. Other factors, such as efforts to improve efficiency in lower-performing hospitals, could mitigate some of the impact of the payment provisions under current law, though there is a wide range of uncertainty regarding these types of behavioral changes. By 2040, simulations suggest that about one-third of hospitals and roughly 50 percent of skilled nursing facilities and home health agencies would have negative total facility margins, raising the possibility of access and quality-of-care issues for Medicare beneficiaries. A memorandum on these provider margin simulations is available on the CMS website.<sup>106</sup>

Over time, unless providers could alter their use of inputs to reduce their cost per service correspondingly, Medicare's payments for health services would fall increasingly below providers' costs. Providers could not sustain continuing negative margins and would have to withdraw from serving Medicare beneficiaries or (if total facility margins remained positive) shift substantial portions of Medicare costs to their non-Medicare, non-Medicaid payers. Under such circumstances, lawmakers might feel substantial pressure to override the productivity adjustments, much as they did to prevent reductions in physician payment rates while the sustainable growth rate (SGR) system was in effect.

While the physician payment system put in place by MACRA avoided the significant short-range physician payment issues resulting from

---

<sup>106</sup>See <https://www.cms.gov/files/document/simulations-affordable-care-act-medicare-payment-update-provisions-part-provider-financial-margins.pdf>.

### *Alternative Projections*

the SGR system approach, it nevertheless raises important long-range concerns that will almost certainly need to be addressed by future legislation. The law specifies the physician payment updates for all years in the future, and these updates do not vary based on underlying economic conditions, nor are they expected to keep pace with the average rate of physician cost increases. The specified rate updates could be an issue in years when levels of inflation are high and would be problematic when the cumulative gap between the price updates and physician costs becomes large. Absent a change in the delivery system or level of update by subsequent legislation, the Trustees expect access to Medicare-participating physicians to become a significant issue in the long term.

A comparison with private rates provides some context. Medicare payment levels for physician services were roughly 82 percent of private health insurance rates in 2011. Medicare payment levels dropped to 68 percent of private rates by 2024<sup>107</sup> and are estimated to continue to fall to 64 percent of private rates by 2025. If Medicare rates continue to follow the prescribed current-law updates and private rates increase with Medicare Economic Index growth, then the Medicare rates will fall to 23 percent of private rates by the end of the 75-year projection period.

In view of these issues, it is important to note that the actual future costs for Medicare may exceed the projections shown in this report, possibly by substantial amounts. Use of an alternative projection can illustrate the potential magnitude of this difference.

It is conceivable that health care providers could improve their productivity, reduce wasteful expenditures, and take other steps to keep their cost growth within the bounds imposed by the Medicare price limitations. For such efforts to be successful in the long range, however, providers would have to generate and sustain unprecedented levels of productivity gains—a very challenging and uncertain prospect.

A transformation of health care in the U.S., affecting both the means of delivery and the method of paying for care, is also a possibility. Private health insurance and Medicare are taking important steps in this direction by initiating programs of research into innovative payment and service delivery models, such as accountable care organizations, patient-centered medical homes, improvement in care coordination for individuals with multiple chronic health conditions,

---

<sup>107</sup>MedPAC Report to the Congress: Medicare Payment Policy, March 2026.

## *Appendices*

better coordination of post-acute care, payment bundling, pay for performance, and assistance for individuals in making informed health choices. Such changes have the potential to reduce health care costs and cost growth rates and could, as a result, help lower health care spending to levels compatible with the lower price updates payable under current law.

The ability of new delivery and payment methods to lower cost growth rates is uncertain at this time. Preliminary indications are that some of these delivery reforms have had modest levels of success in lowering costs. It is too early to tell if these reductions in spending will continue or if they will grow to the magnitude needed to align with the statutory Medicare price updates. Given these uncertainties, it will be important for policymakers to monitor the adequacy of Medicare payment rates over time to ensure beneficiary access to high-quality care.

To help illustrate and quantify the potential magnitude of the cost understatement, a set of illustrative Medicare projections has been prepared under a hypothetical alternative.<sup>108</sup> The 2016–2017 Medicare Technical Review Panel recommended that the Trustees continue to prepare such a projection and that, under this illustrative alternative, Medicare spending reflect less than full implementation of the payment updates to providers specified under current law.<sup>109</sup>

There are multiple ways in which the law could be changed if these provider updates prove unsustainable. The illustrative scenario presented in this report is just one possibility among many that demonstrates the degree to which the current-law projections may be understated. While a particular set of illustrative alternative update assumptions for specific years is used, the transition from current law to the illustrative alternative ultimate assumptions over time is intended to reflect an increasing likelihood of modifications to current law rather than a specific forecast of when current law will cease to be


---

<sup>108</sup>The 2010–2011 Medicare Technical Review Panel supported the continued use of illustrative alternative projections for this purpose (Recommendation IV-3). In addition, the Panel recommended a graphical comparison of the current-law and alternative projections within the Medicare annual report, highlighting the potential effects of both the SGR system and productivity adjustments (Recommendation IV-4). The Panel's report, *Review of Assumptions and Methods of the Medicare Trustees' Financial Projections*, can be found at <http://aspe.hhs.gov/health/reports/2013/MedicareTech/TechnicalPanelReport2010-2011.pdf>. The text summarizes the specific assumptions chosen by the Trustees for the illustrative alternative projections.

<sup>109</sup>See Recommendation 2-3 of the 2016–2017 Medicare Technical Review Panel report, available at <https://aspe.hhs.gov/system/files/pdf/257821/MedicareTechPanelFinalReport2017.pdf>.

fully implemented. Figure V.C1 compares the illustrative alternative projection with the projections under current law.

**Figure V.C1.—Medicare Expenditures as a Percentage of the Gross Domestic Product under Current Law and Illustrative Alternative Projections**



Note: Percentages are affected by economic cycles.

The top curve in figure V.C1 shows the cost levels under the illustrative alternative. This scenario illustrates the impact that would occur if the payment updates that are affected by the productivity adjustments transition from current law to the payment updates assumed for private health plans over the period 2028–2042.<sup>110</sup> It also reflects physician payment updates that transition from current law to the increase in the Medicare Economic Index over the same period. Under this alternative, the average long-range per beneficiary growth rate for all Medicare services would be similar to the long-range growth rate assumed for the overall health sector.

Under the illustrative alternative scenario, Medicare costs as a percentage of GDP continue to increase rapidly throughout the projection period, reaching 7.0 percent of GDP in 2050 and 9.8 percent in 2100—considerably higher than under current law (6.5 percent of GDP in 2050 and 7.5 percent of GDP in 2100).

<sup>110</sup>Section IV.D of this report describes the price component of health care cost increases for the overall health sector.

*Appendices*

***D. AVERAGE MEDICARE EXPENDITURES PER  
BENEFICIARY***

Table V.D1 shows historical average per beneficiary expenditures for HI and SMI, as well as projected costs for calendar years 2026 through 2035 under the intermediate assumptions. Starting with the 2014 report, this section presents per beneficiary expenditures based on when the service is performed rather than when payment for the service is made.

For both HI and SMI Part B, costs increased very rapidly in the early years, in part because the availability of Medicare coverage enabled many beneficiaries to obtain the full range of health services they needed. The rapid inflation of the 1970s and early 1980s also contributed to rapid Medicare expenditure increases, and the cost-based reimbursement mechanisms in place provided relatively little incentive for efficiency in the provision of health care.

Growth in average HI expenditures moderated dramatically following the introduction of the inpatient hospital prospective payment system in fiscal year 1984, but it accelerated again in the late 1980s and early 1990s because of rapid growth in skilled nursing and home health expenditures. During this same period, SMI Part B average costs generally continued to increase at relatively fast rates, but cost growth slowed somewhat in the early 1990s with the implementation of physician fee reform legislation.

Expenditure growth moderated again during the late 1990s because of the effects of further legislation and efforts to control fraud and abuse. In addition, historically low levels of general and medical inflation helped reduce Medicare payment updates. The growth rates rebounded from 2001 through 2005 and then moderated somewhat for the remainder of the decade.

For 2010 through 2015, HI and Part B of SMI experienced the lowest 5-year per beneficiary growth rates in the program's history. This slow growth, which continued in 2016 and 2017 (and in 2018 for HI), was driven in part by legislated update reductions, low provider payment updates caused by the economic recession, and adjustments for documentation and coding that did not reflect changes in real case mix. In addition, increased enrollment resulting from eligibility of the baby boom generation has decreased the average age of Medicare beneficiaries, thereby reducing per beneficiary costs.

### *Per Beneficiary Cost*

The growth rates also reflect the impact of the sequestration process, which is required under current law and reduces Medicare expenditures by 2 percent per year beginning April 1, 2013, through August 31, 2033, with two exceptions: May 1, 2020, through March 31, 2022, when it was suspended and April 1, 2022, through June 30, 2022, when the reduction was 1 percent. Finally, growth in the volume and intensity of the services delivered has also been relatively low, highlighted by reductions in the number of hospital admissions over this period.

Although SMI Part D began in 2004, full prescription drug coverage did not start until 2006. Accordingly, this discussion includes only the per beneficiary expenditures for 2006 and later. Spending growth occurred in 2011 but was negative in 2012 because of the patent expiration of certain high-cost drugs. The large amount of growth in 2014 and 2015 was due to utilization of the new, expensive specialty drugs used to treat hepatitis C. Lower utilization of these drugs contributed to the decline in average spending growth in 2016. In 2017, larger rebates caused average per beneficiary costs to drop, but growth in spending rebounded in 2018 and 2019. It slowed again in 2020 and 2021 because the plan bids assumed higher direct and indirect remuneration and slow reinsurance growth. The Inflation Reduction Act of 2022 redesigned the standard Part D benefit to reduce beneficiary out-of-pocket costs while increasing Federal spending beginning in 2023, with the full effects of the benefit redesign implemented in 2025. Further, there was a significant increase in utilization of GLP-1 and expensive specialty drugs in 2025. The pattern of projected Part D expenditure growth reflects the impact of higher projected cost trends and lower projected direct and indirect remuneration, partially offset by the impact of drug price negotiations that lower growth after 2026.

Appendices

**Table V.D1.—HI and SMI Average Incurred per Beneficiary Costs**

Calendar year	Average per beneficiary costs				Average percent change <sup>1</sup>			
	HI	SMI		Total <sup>2</sup>	HI	SMI		Total
		Part B	Part D			Part B	Part D	
Historical data:								
1970	\$270	\$115	—	\$385	13.8%	13.8%	—	13.8%
1975	472	205	—	677	11.8	12.3	—	12.0
1980	929	423	—	1,352	14.5	15.6	—	14.8
1985	1,579	795	—	2,373	11.2	13.4	—	11.9
1990	1,979	1,355	—	3,334	4.6	11.3	—	7.0
1995	3,194	1,867	—	5,061	10.0	6.6	—	8.7
2000	3,348	2,496	—	5,844	0.9	6.0	—	2.9
2005	4,439	3,839	—	8,278	5.8	9.0	—	7.2
2010	5,193	4,901	\$1,808	11,902	3.2	5.0	—	7.5
2015	5,027	5,555	2,153	12,734	-0.6	2.5	3.6%	1.4
2016	5,094	5,672	2,156	12,922	1.3	2.1	0.2	1.5
2017	5,140	5,867	2,120	13,127	0.9	3.4	-1.7	1.6
2018	5,217	6,248	2,139	13,604	1.5	6.5	0.9	3.6
2019	5,409	6,644	2,171	14,224	3.7	6.3	1.5	4.6
2020	5,499	6,705	2,197	14,401	1.7	0.9	1.2	1.2
2021	5,621	7,344	2,206	15,170	2.2	9.5	0.4	5.3
2022	5,866	7,666	2,288	15,820	4.4	4.4	3.7	4.3
2023	6,108	8,271	2,430	16,809	4.1	7.9	6.2	6.3
2024	6,256	8,733	2,848	17,837	2.4	5.6	17.2	6.1
2025	6,470	9,232	3,192	18,894	3.4	5.7	12.1	5.9
Intermediate estimates:								
2026	6,880	9,776	3,774	20,430	6.3	5.9	18.3	8.1
2027	7,357	10,282	3,857	21,497	6.9	5.2	2.2	5.2
2028	7,704	10,961	4,118	22,783	4.7	6.6	6.8	6.0
2029	8,087	11,638	4,351	24,076	5.0	6.2	5.7	5.7
2030	8,496	12,474	4,432	25,401	5.0	7.2	1.9	5.5
2031	8,935	13,299	4,591	26,826	5.2	6.6	3.6	5.6
2032	9,387	14,157	4,626	28,169	5.1	6.4	0.8	5.0
2033	9,924	15,278	4,788	29,989	5.7	7.9	3.5	6.5
2034	10,532	16,516	4,919	31,967	6.1	8.1	2.7	6.6
2035	10,995	17,618	5,074	33,687	4.4	6.7	3.1	5.4

<sup>1</sup>Percent changes for 1970 represent the average annual increases from 1967 (the first full year of trust fund operations) through 1970. Similarly, percent changes shown for 1975, 1980, 1985, 1990, 1995, 2000, 2005, and 2010 represent the average annual increase over the 5-year period ending in the indicated year.

<sup>2</sup>Represents the sum of the HI and SMI per beneficiary costs.

On average, annual increases in per beneficiary costs have been greater for SMI Part B than for HI during the previous five decades—by approximately 1.0 percent, 4.5 percent, 1.0 percent, 2.5 percent, and 2.6 percent per year in the 1970s, 1980s, 1990s, 2000s, and 2010s, respectively. The HI increase remains lower than the SMI Part B increase for all of the next 10 years because of lower utilization growth of HI services.

Note that the rapid growth rates in the 1970s and 1980s are not expected to recur for either HI or SMI Part B because of more moderate inflation rates and the conversion of Medicare’s remaining cost-based reimbursement mechanisms to prospective payment systems. In addition, the reduction in Medicare price updates for most categories of providers that affected the growth rates over the last several years will continue to reduce growth rates throughout the projection period.

***E. MEDICARE COST-SHARING AND PREMIUM AMOUNTS***

HI beneficiaries who use covered services may be subject to deductible and coinsurance requirements. A beneficiary is responsible for an inpatient hospital deductible amount, which is deducted from the amount payable by the HI trust fund to the hospital, for inpatient hospital services furnished in a spell of illness. When a beneficiary receives such services for more than 60 days during a spell of illness, he or she is responsible for a coinsurance amount equal to one-fourth of the inpatient hospital deductible for each of days 61–90 in the hospital. After 90 days in a spell of illness, each individual has 60 lifetime reserve days of coverage, for which the coinsurance amount is equal to one-half of the inpatient hospital deductible. A beneficiary is responsible for a coinsurance amount equal to one-eighth of the inpatient hospital deductible for each of days 21–100 of skilled nursing facility services furnished during a spell of illness. No cost sharing is required for home health or hospice services.

Most persons aged 65 and older and many disabled individuals under age 65 are insured for HI benefits without payment of any premium. The Social Security Act provides that certain aged and disabled persons who are not insured may voluntarily enroll, subject to the payment of a monthly premium. In addition, since 1994, voluntary enrollees may qualify for a reduced premium if they have at least 30 quarters of covered employment.

Table V.E1 shows the historical levels of the HI deductible, coinsurance amounts, and premiums, as well as projected values for future years based on the intermediate set of assumptions used in estimating the operations of the trust funds. The values listed in the table for future years are estimates, and the actual amounts are likely to be somewhat different as experience emerges.

Appendices

**Table V.E1.—HI Cost-Sharing and Premium Amounts**

Year	Inpatient hospital deductible <sup>1</sup>	Inpatient daily coinsurance <sup>1</sup>			Monthly premium	
		Days 61–90	Lifetime reserve days	SNF daily coinsurance <sup>1</sup>	Standard <sup>2</sup>	Reduced <sup>1</sup>
Historical data:						
1970	\$52	\$13	\$26	\$6.50	—	—
1975	92	23	46	11.50	\$40	—
1980	180	45	90	22.50	78	—
1985	400	100	200	50.00	174	—
1990	592	148	296	74.00	175	—
1995	716	179	358	89.50	261	\$183
2000	776	194	388	97.00	301	166
2005	912	228	456	114.00	375	206
2010	1,100	275	550	137.50	461	254
2015	1,260	315	630	157.50	407	224
2016	1,288	322	644	161.00	411	226
2017	1,316	329	658	164.50	413	227
2018	1,340	335	670	167.50	422	232
2019	1,364	341	682	170.50	437	240
2020	1,408	352	704	176.00	458	252
2021	1,484	371	742	185.50	471	259
2022	1,556	389	778	194.50	499	274
2023	1,600	400	800	200.00	506	278
2024	1,632	408	816	204.00	505	278
2025	1,676	419	838	209.50	518	285
2026	1,736	434	868	217.00	565	311
Intermediate estimates:						
2027	1,788	447	894	223.50	600	330
2028	1,844	461	922	230.50	629	346
2029	1,900	475	950	237.50	660	363
2030	1,960	490	980	245.00	694	382
2031	2,028	507	1,014	253.50	730	402
2032	2,092	523	1,046	261.50	767	422
2033	2,160	540	1,080	270.00	812	447
2034	2,228	557	1,114	278.50	862	474
2035	2,296	574	1,148	287.00	900	495

<sup>1</sup>Amounts shown are effective for calendar years.

<sup>2</sup>Amounts shown for 1970–1980 are for the 12-month periods ending June 30; amounts shown for 1985 and later are for calendar years.

The *Federal Register* notice<sup>111</sup> announcing the HI deductible and coinsurance amounts for 2026 included an estimate of the aggregate cost to HI beneficiaries for the changes in the deductible and coinsurance amounts from 2025 to 2026. At the time of the notice’s publication, it was estimated that in 2026 there would be 5.63 million inpatient deductibles paid at \$1,736 each, 1.41 million inpatient days subject to coinsurance at \$434 per day (for hospital days 61 through 90), 0.72 million lifetime reserve days subject to coinsurance at \$868 per day, and 28.88 million extended care days subject to coinsurance at \$217.00 per day. Similarly, it was estimated that in 2025 there would be 55 million deductibles paid at \$1,676 each, 1.39 million days subject to coinsurance at \$419 per day (for hospital days 61 through 90), 0.71 million lifetime reserve days subject to coinsurance at \$838 per day, and 28.33 million extended care days subject to coinsurance at \$209.50 per day. The total increase in cost to

<sup>111</sup>See <https://www.govinfo.gov/content/pkg/FR-2025-11-19/pdf/2025-20249.pdf>.

*Cost Sharing and Premiums*

beneficiaries was estimated to be \$860 million as a result of the increase in the inpatient deductible and coinsurance amounts and the change in the number of deductibles and daily coinsurance amounts paid.

Table V.E2 displays the SMI cost-sharing and premium amounts for Parts B and D. The projected values for future years are based on the intermediate set of assumptions used in estimating the operations of the Part B and Part D accounts. As a result, these values are estimates, and the actual amounts are likely to be somewhat different as experience emerges.

The Part B premiums for 2010 and 2017 also reflect significant additional increases designed to offset the loss of revenues attributable to the hold-harmless provision, as described later in this appendix.

**Table V.E2.—SMI Cost-Sharing and Premium Amounts**

Calendar year	Part B		Base beneficiary premium	Part D		
	Standard monthly premium <sup>1</sup>	Annual deductible <sup>2</sup>		Deductible	Initial benefit limit <sup>3</sup>	Catastrophic threshold <sup>3</sup>
Historical data:						
1970	\$4.00	\$50	—	—	—	—
1975	6.70	60	—	—	—	—
1980	8.70	60	—	—	—	—
1985	15.50	75	—	—	—	—
1990	28.60	75	—	—	—	—
1995	46.10	100	—	—	—	—
2000	45.50	100	—	—	—	—
2005	78.20	110	—	—	—	—
2010	110.50	155	\$31.94	\$310	\$2,830	\$4,550
2015	104.90	147	33.13	320	2,960	4,700
2016	121.80	166	34.10	360	3,310	4,850
2017	134.00	183	35.63	400	3,700	4,950
2018	134.00	183	35.02	405	3,750	5,000
2019	135.50	185	33.19	415	3,820	5,100
2020	144.60	198	32.74	435	4,020	6,350
2021	148.50	203	33.06	445	4,130	6,550
2022	170.10	233	33.37	480	4,430	7,050
2023	164.90	226	32.74	505	4,660	7,400
2024	174.70	240	34.70	545	5,030	8,000
2025	185.00	257	36.78	590	—	2,000
2026	202.90	283	38.99	615	—	2,100
Intermediate estimates:						
2027	209.50	292	41.33	700 <sup>4</sup>	—	2,400 <sup>4</sup>
2028	224.50	313	43.81	685	—	2,350
2029	238.50	332	46.44	690	—	2,350
2030	255.50	356	68.93	710	—	2,400
2031	272.10	379	71.27	740	—	2,500
2032	290.20	404	71.59	765	—	2,600
2033	313.60	437	74.01	760	—	2,600
2034	338.50	472	75.48	760	—	2,600
2035	360.60	503	77.81	775	—	2,650

<sup>1</sup>Amounts shown for 1970–1980 are for the 12-month periods ending June 30; amounts shown for 1985 and later are for calendar years.

## *Appendices*

<sup>2</sup>The Part B deductible was fixed by statute through 2005 and is to be indexed by average per beneficiary Part B expenditures thereafter.

<sup>3</sup>As required by the provisions of the Inflation Reduction Act 2022, the initial benefit limit will end at the catastrophic threshold beginning in 2025, and the catastrophic threshold will be reduced to \$2,000 in that year. Thereafter, the catastrophic threshold will be indexed by program growth.

<sup>4</sup>This amount has already been finalized.

The Part B monthly premiums displayed in table V.E2 are the standard premium rates paid by most Part B enrollees. However, there are three provisions that alter the premium rate for certain Part B enrollees. First, there is a premium surcharge for those beneficiaries who enroll after their initial enrollment period.

Second, beginning in 2007, there is a higher income-related premium for those individuals whose modified adjusted gross income exceeds a specified threshold. Table V.E3 displays, for 2007 through 2035, the income-related premium adjustment amounts, the number of beneficiaries affected, and the aggregate additional premium amounts collected, based on the intermediate set of assumptions. In 2025, approximately 5.1 million beneficiaries paid a Part B income-related premium.

Cost Sharing and Premiums

**Table V.E3.—Part B Income-Related Premium Information**

Calendar year	Income-related monthly adjustment amount <sup>1</sup>					Beneficiaries affected (millions)	Aggregate premiums <sup>2</sup> (billions)
	35%	50%	65%	80%	85%		
Historical data:							
2007	\$12.30	\$30.90	\$49.40	\$67.90	—	1.7	\$0.7
2008	25.80	64.50	103.30	142.00	—	2.0	1.8
2009	38.50	96.30	154.10	211.90	—	2.2	2.9
2010	44.20	110.50	176.80	243.10	—	1.9	2.7
2011	46.10	115.30	184.50	253.70	—	1.6	2.3
2012	40.00	99.90	159.80	219.80	—	1.9	2.4
2013	42.00	104.90	167.80	230.80	—	2.2	2.9
2014	42.00	104.90	167.80	230.80	—	2.6	3.4
2015	42.00	104.90	167.80	230.80	—	2.9	3.8
2016	48.70	121.80	194.90	268.00	—	3.3	5.2
2017	53.50	133.90	214.30	294.60	—	3.5	6.0
2018	53.50	133.90	214.30	294.60	—	3.7	7.0
2019	54.10	135.40	216.70	297.90	\$325.00	4.3	8.4
2020	57.80	144.60	231.40	318.10	347.00	4.7	10.0
2021	59.40	148.50	237.60	326.70	356.40	4.8	10.5
2022	68.00	170.10	272.20	374.20	408.20	4.4	11.1
2023	65.90	164.80	263.70	362.60	395.60	5.3	13.4
2024	69.90	174.70	279.50	384.30	419.30	4.8	12.8
2025	74.00	184.90	295.80	406.90	443.90	5.1	14.1
2026	81.20	202.90	324.60	446.30	487.00	6.1	18.8
Intermediate estimates:							
2027	83.70	209.40	335.10	460.70	502.60	6.6	20.9
2028	89.80	224.50	359.20	493.90	538.80	7.0	24.1
2029	95.30	238.40	381.50	524.50	572.20	7.5	27.1
2030	102.10	255.40	408.70	561.90	613.00	8.0	30.8
2031	108.80	272.10	435.40	598.60	653.00	8.4	34.6
2032	116.00	290.10	464.20	638.30	696.30	8.8	38.8
2033	125.40	313.60	501.80	689.90	752.60	9.3	44.0
2034	135.30	338.40	541.50	744.50	812.20	9.7	49.9
2035	144.40	360.90	577.40	794.00	866.20	10.2	55.8

<sup>1</sup>Amount is based on the applicable percentage of program cost represented by the premium and also reflects the impact of the 3-year transition in 2007 and 2008. The Bipartisan Budget Act of 2018 created an additional premium level for 2019 and later.

<sup>2</sup>Represents the total amount paid by affected beneficiaries in excess of the Part B standard premium.

In 2026 the initial threshold is \$109,000 for an individual tax return and \$218,000 for a joint return. The thresholds were not indexed to inflation in the years 2011 through 2019 but are indexed thereafter. Individuals exceeding the threshold will pay premiums covering 35, 50, 65, 80, or, beginning in 2019, 85 percent of the average program cost for aged beneficiaries, depending on their income level, compared with the standard premium covering 25 percent.

Effective in 2018, the Medicare Access and CHIP Reauthorization Act of 2015 lowered certain income thresholds used for determining the income-related monthly adjustment amounts to be paid by beneficiaries, resulting in a greater number of beneficiaries paying the higher amounts. In addition, beginning in 2020, the legislation adjusted the methodology used to index the thresholds, and accordingly more beneficiaries will be subject to the income-related premiums. The Bipartisan Budget Act of 2018 (BBA 2018) established an additional premium level beginning in 2019 for individuals with

## *Appendices*

incomes at or above \$500,000 (and couples with incomes at or above \$750,000), and they will pay a premium covering 85 percent of the average program cost. These new thresholds will not be indexed until 2028 and later.

The third provision that may cause Part B premiums to vary from the standard rate is a hold-harmless provision that can lower the premium rate for individuals who have their premiums deducted from their Social Security benefits. On an individual basis, this provision limits the dollar increase in the Part B premium to the dollar increase in the individual's Social Security benefit. As a result, the person affected pays a lower Part B premium, and the net amount of the individual's Social Security benefit does not decrease despite the greater increase in the premium.

Most services under Part B are subject to an annual deductible and coinsurance. The annual deductible was set by statute through 2005. Thereafter, it increases with the increase in the Part B aged actuarial rate to approximate the growth in per capita Part B expenditures.<sup>112</sup> After meeting the deductible, the beneficiary pays an amount equal to the product of the coinsurance percentage and the remaining allowed charges.

The coinsurance percentage is 20 percent for most services. However, since the coinsurance payment for a service paid under the outpatient hospital prospective payment system is capped at the inpatient hospital deductible amount, the average coinsurance percentage for these services was about 18 percent in 2018 and is expected to gradually decline in the projection period. For those services not subject to the deductible or coinsurance (clinical laboratory tests, home health agency services, and most preventive care services), the beneficiary pays nothing.

The Part D average premiums displayed in table V.E2 are the estimated base beneficiary premiums. Starting in 2009, the national average monthly bid amount is based on the enrollment-weighted average. The actual premium that a beneficiary pays varies according to the plan in which the beneficiary enrolls. The average paid premium has always been lower than the base beneficiary premium. Since

---

<sup>112</sup>The current mechanism to index the Part B deductible has technical computational issues that are mainly attributable to the timing of the calculation. The Part B deductible for any given year is indexed by the increase in the monthly aged actuarial rate for that same year, which represents estimated monthly per capita expenditures. However, these expenditures are dependent on the Part B deductible, which is not known until the actuarial rate is determined. The result is circularity in the modeling process.

### *Cost Sharing and Premiums*

beneficiaries may switch plans each year once the premium rates become known, the Trustees assume that the estimated average premium rate paid by beneficiaries will continue to be somewhat less than the base beneficiary premium in future years. In 2025, the average paid premium was \$23.95, and it is projected to be \$27.22 in 2026. (The substantial percentage increase in 2026 is due to the smaller second-year impact from the 3-year voluntary Part D premium stabilization demonstration for prescription drug plans that started in 2025.)

Similar to Part B, there are two provisions that affect the premium rate for certain Part D beneficiaries. First, there is a Part D late enrollment penalty for those beneficiaries enrolling after their initial enrollment period. Second, starting in 2011, individuals whose modified adjusted gross income exceeds the same thresholds applicable to the Part B premium pay an income-related premium in addition to the premium charged by the plan in which the individual enrolled. The amount of the income-related premium adjustment is dependent on the individual's income level, and the extra premium amount is the difference between 35, 50, 65, 80, or 85 percent and 25.5 percent,<sup>113</sup> applied to the national average monthly bid amount adjusted for reinsurance. In addition, the changes to the income ranges and threshold methodology that were previously described for Part B also apply to Part D.

Table V.E4 displays, for 2011 through 2035, the Part D income-related premium adjustment amounts, the number of beneficiaries affected, and the aggregate additional premium amounts collected, based on the intermediate set of assumptions. In 2025, approximately 4.5 million beneficiaries paid a Part D income-related premium.

---

<sup>113</sup>Beginning in 2030, the base beneficiary premium percentage will be reset according to the specifications of the Inflation Reduction Act of 2022.

Appendices

**Table V.E4.—Part D Income-Related Premium Information**

Calendar year	Income-related monthly adjustment amount <sup>1</sup>					Beneficiaries affected (millions)	Aggregate premiums <sup>2</sup> (billions)
	35%	50%	65%	80%	85%		
Historical data:							
2011	\$12.00	\$31.10	\$50.10	\$69.10	—	0.9	\$0.3
2012	11.60	29.90	48.10	66.40	—	1.1	0.4
2013	11.60	29.90	48.30	66.60	—	1.5	0.5
2014	12.10	31.10	50.20	69.30	—	1.8	0.7
2015	12.30	31.80	51.30	70.80	—	2.1	0.9
2016	12.70	32.80	52.80	72.90	—	2.5	1.0
2017	13.30	34.20	55.20	76.20	—	2.7	1.2
2018	13.00	33.60	54.20	74.80	—	2.9	1.4
2019	12.40	31.90	51.40	70.90	\$77.40	3.4	1.6
2020	12.20	31.50	50.70	70.00	76.40	3.8	1.8
2021	12.30	31.80	51.20	70.70	77.10	3.9	1.8
2022	12.40	32.10	51.70	71.30	77.90	3.6	1.7
2023	12.20	31.50	50.70	70.00	76.40	4.4	2.2
2024	12.90	33.30	53.80	74.20	81.00	4.2	2.2
2025	13.70	35.30	57.00	78.60	85.80	4.5	2.4
2026	14.50	37.50	60.40	83.30	91.00	5.3	3.1
Intermediate estimates:							
2027	15.40	39.70	64.00	88.30	96.40	5.8	3.5
2028	16.30	42.10	67.90	93.60	102.20	6.2	4.0
2029	17.30	44.60	71.90	99.30	108.40	6.7	4.6
2030	51.70	103.40	155.10	206.80	224.00	7.1	10.8
2031	53.50	106.90	160.40	213.80	231.60	7.6	11.9
2032	53.70	107.40	161.10	214.80	232.70	8.0	12.6 <sup>3</sup>
2033	55.50	111.00	166.50	222.00	240.50	8.4	13.7
2034	56.60	113.20	169.80	226.40	245.30	8.8	14.7
2035	58.40	116.70	175.10	233.40	252.90	9.3	15.9

<sup>1</sup>Amount is based on the applicable percentage of program cost represented by the premium. The Bipartisan Budget Act of 2018 created an additional premium level for 2019 and later.

<sup>2</sup>Represents the total amount paid by affected beneficiaries in excess of the Part D plan premium.

<sup>3</sup>The income-related monthly adjustment amounts will increase more rapidly beginning in 2030 because of the new base beneficiary premium percentage specified by the Inflation Reduction Act of 2022.

In addition, there are Part D premium and cost-sharing subsidies for those beneficiaries with incomes less than 150 percent of the Federal poverty level and with assets, including burial expenses, in 2026 that amount to less than \$18,090 for an individual and \$36,100 for a couple. The asset thresholds are indexed in subsequent years by the Consumer Price Index (CPI-U). Under the current statutory adjustment formula, the asset figures for 2026 increase for both an individual and a couple as a result of increases in the CPI-U.

Under standard Part D coverage, there is an initial deductible. After meeting the deductible, beneficiaries pay 25 percent of the remaining costs up to the initial benefit limit. Beyond this limit, prior to 2011, beneficiaries paid all the drug costs until their total out-of-pocket expenditures reached the catastrophic threshold. (This total includes the deductible and coinsurance payments for expenses up to the initial benefit limit.) The coverage gap was to be gradually closed beginning in 2011 until 2020, and then BBA 2018 required the coverage gap for brand-name drugs to close 1 year earlier, in 2019. Starting in 2020, for all drugs, beneficiaries pay 25 percent of the costs between the

### *Cost Sharing and Premiums*

deductible and the catastrophic threshold under the standard coverage. Beginning in 2024, under the Inflation Reduction Act of 2022, there is no cost sharing for beneficiaries after they reach the catastrophic threshold.

Both the initial deductible amount and the catastrophic threshold under the standard benefit design are indexed annually by per enrollee Part D average costs. For 2027, the initial deductible and the catastrophic threshold will be set at \$700 and \$2,400 respectively. Beneficiaries qualifying for the Part D low-income subsidy pay substantially reduced premium and cost-sharing amounts. Many Part D plans offer alternative coverage that differs from the standard coverage described above. The majority of beneficiaries have not enrolled in the standard benefit design but rather in plans with low or no deductibles or flat copayments for covered drugs.

*Appendices*

***F. MEDICARE AND SOCIAL SECURITY TRUST FUNDS AND  
THE FEDERAL BUDGET***

One can view the financial operations of Medicare and Social Security in the context of the programs' trust funds or in the context of the overall Federal budget. The financial status of the trust funds differs fundamentally from the impact of these programs on the budget, and people often misunderstand the relationship between these two perspectives. Each perspective is appropriate and important for its intended purpose; this appendix attempts to clarify their roles and relationship.

By law, the annual reports of the Medicare and Social Security Boards of Trustees to Congress include a statement of the financial status of the programs' trust funds—that is, whether these funds have sufficient revenues and assets to enable the payment of benefits and administrative expenses. This trust fund perspective is important because the existence of trust fund assets provides the statutory authority to make such payments without the need for an appropriation from Congress. Under current law, Medicare and Social Security benefits can be paid only if the relevant trust fund has sufficient income or assets.

The trust fund perspective does not encompass the interrelationship between the Medicare and Social Security trust funds and the overall Federal budget. The budget is a comprehensive display of all Federal activities, whether financed through trust funds or from the general fund of the Treasury. This broader focus may appropriately be termed the budget perspective or government-wide perspective and is officially presented in the *Budget of the United States Government*<sup>114</sup> and in the *Financial Report of the United States Government*.<sup>115</sup>

Payroll taxes, income taxes on Social Security benefits, Medicare premiums, and special State payments to Medicare finance the majority of Medicare and Social Security costs. In addition to these earmarked receipts from workers, employers, beneficiaries, and States, and interest payments on their accumulated assets, the trust funds (principally the SMI trust fund) rely on Federal government contributions for some of their financing. The financial status of a trust fund appropriately considers all sources of financing provided for that

---

<sup>114</sup>See [https://www.whitehouse.gov/wp-content/uploads/2026/04/budget\\_fy2027.pdf](https://www.whitehouse.gov/wp-content/uploads/2026/04/budget_fy2027.pdf).

<sup>115</sup>See [https://fiscal.treasury.gov/system/files/2026-03/FY-2025-Financial-Report-3-19-2025\(Final\).pdf](https://fiscal.treasury.gov/system/files/2026-03/FY-2025-Financial-Report-3-19-2025(Final).pdf).

### *Trust Funds and Federal Budget*

fund, including the availability of trust fund assets that Medicare or Social Security can use to meet program expenditures.

From a budget perspective, however, government contributions represent a draw on other Federal resources for which there is no earmarked source of revenue from the public. For this appendix, interest payments to the trust funds and asset redemptions, both of which occur because of the postponed use of earmarked revenues, are classified as draws on other Federal resources, since they require payments from the Treasury general fund. The budget perspective does not reflect that publicly held debt and interest payments to the public are both lower because the trust funds hold some of the debt.

At the beginning of the Medicare program, government contributions and interest payments were relatively small. These amounts have been increasing, and the expected future growth of Medicare and Social Security will make their interaction with the Federal budget increasingly important. As the difference between earmarked and total trust fund revenues grows, the financial operations of Social Security and Medicare can appear markedly different depending on which of the two perspectives one uses.<sup>116</sup>

#### **Illustration with Actual Data for 2025**

Table V.F1 illustrates the trust fund and budget perspectives using actual data on Federal financial operations for fiscal year (FY) 2025. The first three columns show revenues and expenditures for HI, SMI, and OASDI, respectively, and the fourth (“Combined”) column is the sum of these three columns. The sixth (“Total”) column shows total revenues and expenditures for the total Federal budget, and the fifth (“Other”) column presents all other Federal programs (including the general fund account of the Treasury) and is calculated as the difference between the amounts in the “Total” column and the amounts in the “Combined” column. The table shows earmarked revenues from the public separately from revenues from other government accounts (government contributions and interest credits). Note that the

---

<sup>116</sup>A more complete treatment of this topic appears in a May 2009 Treasury report titled “Social Security and Medicare Trust Funds and the Federal Budget” at [https://home.treasury.gov/system/files/226/ep\\_budget\\_trust\\_fund\\_perspectives\\_2009.pdf](https://home.treasury.gov/system/files/226/ep_budget_trust_fund_perspectives_2009.pdf). Additional information is available in a *Health Care Financing Review* article titled “Medicare Financial Status, Budget Impact, and Sustainability: Which Concept Is Which?” at <http://www.cms.gov/Research-Statistics-Data-and-Systems/Research/HealthCareFinancingReview/Downloads/05-06Winpg127.pdf> and in a *Social Security Bulletin* article titled “Social Security Trust Fund Cash Flows and Reserves” at <https://www.ssa.gov/policy/docs/ssb/v75n1/v75n1p1.html>.

## Appendices

transfers and interest credits received by the trust funds are the key differences between the two perspectives.

**Table V.F1.—Annual Revenues and Expenditures  
for Medicare and Social Security Trust Funds and the Total Federal Budget,  
Fiscal Year 2025<sup>1</sup>**

Revenue and expenditures categories	Trust funds				Other	Total
	HI	SMI	OASDI	Combined		
[In billions]						
Revenues from public:						
Payroll and benefit taxes	\$442.4	—	\$1,367.9	\$1,810.3	—	\$1,810.3
Premiums <sup>2</sup>	5.7	\$163.9	—	169.7	—	169.7
Other taxes, fees, and payments <sup>3</sup>	1.2	22.3	—	23.5	\$3,233.0	23.5
<b>Total</b>	<b>449.3</b>	<b>186.3</b>	<b>1,367.9</b>	<b>2,003.5</b>	<b>3,233.0</b>	<b>5,236.4</b>
Total expenditures to public <sup>4</sup>	439.1	747.6	1,581.8	2,768.4	4,242.7	7,011.1
<b>Net Results for Budget Perspective</b>	<b>10.2</b>	<b>-561.3</b>	<b>-213.9</b>	<b>-765.0</b>	<b>-1,009.7</b>	<b>-1,774.7</b>
Revenues from other government accounts:						
Transfers	1.1	549.1	0.2	550.5	n/a	n/a
Interest credits	8.3	3.8	70.0	82.2	n/a	n/a
<b>Total</b>	<b>9.5</b>	<b>552.9</b>	<b>70.3</b>	<b>632.7</b>	<b>n/a</b>	<b>n/a</b>
<b>Net Results for Trust Fund Perspective</b>	<b>19.7</b>	<b>-8.4</b>	<b>-143.6</b>	<b>-132.3</b>	<b>n/a</b>	<b>n/a</b>

<sup>1</sup>The "Total" column presents revenues and expenditures for the total Federal budget in fiscal year 2025. The total revenue and expenditure amounts can be found in Historical Table 1.1 of the FY 2027 President's Budget, and the figure \$1,774.7 billion is the difference between these amounts and represents the estimated total Federal budget deficit for fiscal year 2025. Amounts reported for the "Trust funds" columns represent actual operations based on information in the Monthly Treasury Statement and are presented throughout the Trustees Reports. "Other" amounts are calculated as the difference between the amounts in the "Total" column and the amounts in the "Combined" column under "Trust funds."

<sup>2</sup>Includes Part D premiums paid directly to plans, which are not displayed on Treasury statements and are estimated.

<sup>3</sup>Includes Part D State payments, Part B drug fees, and other miscellaneous items.

<sup>4</sup>The OASDI figure includes \$5.9 billion transferred to the Railroad Retirement Board.

Notes: 1. For comparison, HI taxable payroll, OASDI taxable payroll, and GDP were \$13,277 billion, \$11,043 billion, and \$30,781 billion, respectively, in 2025.

2. Totals do not necessarily equal the sums of rounded components.

3. n/a indicates not applicable.

The trust fund perspective reflects both categories of revenues for each trust fund. For HI, revenues from the public plus transfers/credits from other government accounts were \$19.7 billion more than total expenditures in FY 2025, as shown at the bottom of the first column.<sup>117</sup> For the SMI trust fund, the statutory revenues from beneficiary premiums, State payments, government contributions, and interest earnings collectively were \$8.4 billion less than expenditures in FY 2025. Note that it is appropriate to view the government contributions as financial resources from the trust fund perspective

<sup>117</sup>The Department of the Treasury invests surplus revenues from the public over expenditures to the public in special Treasury securities, which thereby represent a loan from the trust funds to the general fund of the Federal Government. These loans reduce the amount that the general fund has to borrow from the public to finance a deficit (or likewise increase the amount of debt paid off if there is a surplus). Interest is credited to the trust funds while the securities are being held. Trust fund securities can be redeemed at any time if needed to help meet program expenditures.

### *Trust Funds and Federal Budget*

since they are available to help meet trust fund expenditures. For OASDI, total trust fund revenues from all sources (including \$70.0 billion in interest payments and \$0.2 billion in general fund reimbursements) were \$143.6 billion less than expenditures.

From the government-wide or budget perspective, only earmarked revenues received from the public—principally taxes on payroll and benefits, plus premiums—and expenditures made to the public are important for the final balance.<sup>118</sup> For HI, the difference between such revenues (\$449.3 billion) and total expenditures made to the public (\$439.1 billion) was \$10.2 billion in FY 2025, indicating that HI had a positive effect on the overall budget in FY 2025. For SMI, beneficiary premiums, fees on brand-name prescription drugs to Part B, and State payments to Part D of Medicare were the only sources of revenues from the public in FY 2025 and represented only about 27 percent of total expenditures. The remaining \$561.3 billion in FY 2025 expenditures represented a substantial net draw on the Federal budget in that year.<sup>119</sup>

For OASDI, the difference between revenues from the public (\$1,367.90 billion) and total expenditures (\$1,581.8 billion) was \$213.9 billion, indicating that OASDI also had a negative effect on the overall budget last year if the effects of past trust fund cash flows on interest payments from the Federal Government to the public are not taken into account.

Thus, from the trust fund perspective, HI had an annual surplus in FY 2025, and SMI and OASDI both had a deficit. From the budget perspective, HI had a surplus, and SMI and OASDI each required a net draw on the budget. HI, SMI, and OASDI collectively had a trust fund deficit of \$132.3 billion in FY 2025 and a net draw of \$765.0 billion on the budget.

It is important to recognize that each viewpoint is appropriate for its intended purpose but that one perspective cannot be used to answer questions related to the other. In the case of SMI, the trust fund will always be in balance and there will always be a net draw on the Federal budget. In the case of HI, trust fund surpluses in a given year may

---

<sup>118</sup>For this purpose, the public includes State governments since they are outside of the Federal Government.

<sup>119</sup>Three types of trust fund transactions constituted this net budget obligation: \$549.1 billion was drawn in the form of general revenue transfers, and another \$3.8 billion in interest payments, while \$8.4 billion was transferred from the general fund to the trust fund through the redemption of special-issue Treasury securities in an amount equal to the trust fund deficit for the year.

## Appendices

occur with either a positive or negative direct impact on the budget for that year. Conversely, a positive or negative budget impact from HI offers minimal insight into whether its trust fund has sufficient total revenues and assets to permit payment of benefits.

The next section illustrates the magnitude of the long-range difference between projected expenditures and revenues for Medicare and Social Security from both the trust fund and budget perspectives.

### Future Obligations of the Trust Funds and the Budget

Table V.F2 collects from the Medicare and OASDI Trustees Reports the present values of projected future revenues and expenditures over the next 75 years. For HI and OASDI, tax revenues from the public are projected to fall short of statutory expenditures by \$4.4 trillion and \$31.9 trillion, respectively, in present value terms.<sup>120</sup>

**Table V.F2.—Present Values of Projected Revenue and Cost Components of 75-Year Open-Group Obligations for HI, SMI, and OASDI**

[In trillions, as of January 1, 2026]

Revenue and expenditure categories	HI	SMI	OASDI	Combined
<b>Revenues from public:</b>				
Payroll and benefit taxes	\$32.0	—	\$91.9	\$123.9
Premiums	0.5	\$22.6	—	23.1
Other taxes and fees <sup>1</sup>	0.1	1.4	—	1.5
<b>Total</b>	<b>32.7</b>	<b>24.0</b>	<b>91.9</b>	<b>148.5</b>
Total expenditures to public	37.1	84.9	123.7	245.7
<b>Net Results for Budget Perspective</b>	<b>-4.4</b>	<b>-60.9</b>	<b>-31.9</b>	<b>-97.2</b>
<b>Revenues from other government accounts:</b>				
Transfers	0.0	60.8	0.0	60.8
Interest credits	n/a	n/a	n/a	n/a
<b>Total</b>	<b>0.0</b>	<b>60.8</b>	<b>0.0</b>	<b>60.8</b>
Trust fund assets on January 1, 2026	0.3	0.2	2.6	3.0
<b>Net Results for Trust Fund Perspective</b>	<b>-4.2</b>	<b>0.1</b>	<b>-29.3</b>	<b>-33.4</b>

<sup>1</sup>Includes Part B revenues from fees on manufacturers and importers of brand-name prescription drugs and Part D State payments.

- Notes: 1. For comparison, the present values of HI taxable payroll, OASDI taxable payroll, and GDP are \$810.5 trillion, \$690.4 trillion, and \$1,853.5 trillion, respectively, over the next 75 years. This present value of GDP is calculated using HI-specific interest discount factors and differs slightly from the corresponding amount shown in the OASDI Trustees Report.
2. Medicare present values are calculated using HI-specific discount factors, while OASDI amounts use OASDI-specific discount factors.
3. Totals do not necessarily equal the sums of rounded components.
4. n/a indicates not applicable.
5. 0.0 indicates an amount of less than \$50 billion.

From the budget perspective, these are the additional amounts that would be necessary in order to pay HI and OASDI benefits and other

<sup>120</sup>Interest income is not a factor in this table, as dollar amounts are in present value terms.

### *Trust Funds and Federal Budget*

costs at the level scheduled over the next 75 years. From the trust fund perspective, the amounts needed are smaller by the value of the accumulated assets in the respective trust funds—\$0.3 trillion for HI and \$2.6 trillion for OASDI—that could be drawn down to cover a part of the projected shortfall in tax revenues. Three points about this comparison in table V.F2 are important to note:

- The trust fund and budget perspectives differ in the treatment of the starting trust fund assets. Those accumulated reserves are credited to the trust fund programs under the trust fund perspective but are not under the budget perspective.
- The amounts shown in table V.F2 assume payment of full scheduled benefits, which is not permissible under current law after trust fund depletion. For both the budget and trust fund perspectives, the 75-year HI and OASDI deficits reflect the financial imbalance after trust fund depletion. By law, however, once assets are depleted, expenditures cannot be made except to the extent covered by ongoing tax receipts and other trust fund income.
- In practice, the long-range HI and OASDI deficits would likely be addressed by future legislation to reduce expenditures, increase payroll or other earmarked tax revenues, or some combination of such measures. For Medicare, in particular, lawmakers have frequently enacted legislation to slow the growth of expenditures.

The situation for SMI is somewhat different. SMI expenditures for Part B and Part D are projected to exceed premium and other dedicated revenues by \$60.9 trillion. To keep the SMI trust fund solvent for the next 75 years will require government contributions of this amount, and these amounts represent a formal budget requirement. From the trust fund perspective, the present value of projected total premiums and government contributions is about equal to the present value of future expenditures.

From the 75-year budget perspective, the present value of the additional resources that would be necessary to meet projected expenditures, for the three programs combined, is \$97.2 trillion.<sup>121</sup> To put this very large figure in perspective, it would represent 5.2 percent of the present value of projected GDP over the same period

---

<sup>121</sup>As noted previously, the long-range HI and OASDI financial imbalances could instead be partially addressed by expenditure reductions, thereby reducing the need for additional revenues. Similarly, SMI expenditure reductions would reduce the need for government contributions.

*Appendices*

(\$1,853 trillion). The components of the \$97.2 trillion total are as follows:

Unfunded Medicare and OASDI obligations (trust fund perspective) <sup>122</sup> .....	\$33.4 trillion	(1.8% of GDP)
HI, SMI, and OASDI asset redemptions.....	3.0 trillion	(0.2% of GDP)
SMI government contributions .....	60.8 trillion	(3.3% of GDP)

These resource needs would be in addition to the payroll taxes, benefit taxes, and premium payments. As noted, the asset redemptions and SMI government contributions represent formal budget commitments, but no provision exists for covering the HI and OASDI trust fund deficits once assets are depleted.

As discussed throughout this report, the Medicare projections shown here could be substantially understated as a result of other potentially unsustainable elements of current law. Although this issue does not affect the nature of the budget and trust fund perspectives described in this appendix, it is important to note that actual long-range present values for HI expenditures and SMI expenditures and revenues could exceed the amounts shown in table V.F2 by a substantial margin.

---

<sup>122</sup>Additional revenues and/or expenditure reductions totaling \$33.4 trillion, together with \$3.0 trillion in asset redemptions, would cover the projected financial imbalance but would leave the HI and OASDI trust funds depleted at the end of the 75-year period. The long-range actuarial deficits for HI and OASDI include a cost factor to allow for a normal level of fund assets. See section III.B3 in this report, and section IV.B4 in the OASDI Trustees Report, for the numerical relationship between the actuarial deficit and the unfunded obligations of each program.

### **G. INFINITE HORIZON PROJECTIONS**

Consistent with the practice of previous reports, this report focuses on the 75-year period 2026–2100 for the evaluation of the long-range financial status of the Medicare program. The estimates are for the open-group population—all persons, some of whom are not yet born, who will participate during the period as either taxpayers or beneficiaries, or both—and consist of payments from, and on behalf of, employees now in the workforce, as well as those who will enter the workforce over the next 75 years.

Experts have noted that limiting the projections to 75 years understates the magnitude of the long-range unfunded obligations because summary measures (such as the actuarial balance and *open-group unfunded obligations*) reflect the full amount of taxes paid by the next two or three generations of workers, but not the full amount of their benefits. One approach to addressing the limitations of 75-year summary measures is to extend the projection horizon indefinitely, so that the overall results reflect the projected costs and revenues after the first 75 years.<sup>123</sup> Such extended projections can also help indicate whether the financial imbalance would be improving or continuing to worsen beyond the normal 75-year period.

Table V.G1 presents estimates of HI unfunded obligations that extend to the infinite horizon. The extension assumes that the HI program and the demographic and economic trends used for the 75-year projection continue indefinitely except that average HI expenditures per beneficiary increase at the same rate as GDP per capita less the productivity adjustments after 2100. If the slower HI price updates under current law were able to continue indefinitely, then the HI financial imbalance would actually improve beyond the 75-year period.<sup>124</sup> Specifically, under these assumptions, extending the calculations beyond 2100 *subtracts* \$11.9 trillion in unfunded obligations from the amount estimated through 2100. Over the infinite horizon, the HI program thus has a projected surplus of \$7.7 trillion.

---

<sup>123</sup>The calculation of present values, in effect, applies successively less weight to future amounts over time, through the process of interest discounting. For example, the weights associated with the 25th, 75th, and 200th years of the projection would be about 34.3 percent, 3.5 percent, and 0.01110 percent, respectively, of the weight for the first year. In this way, it is possible to calculate a finite summary measure for an infinite projection period.

<sup>124</sup>It is important to note that the actual future costs for Medicare may exceed the projections shown in this report, possibly by substantial amounts. See section V.C for details on the illustrative alternative projections.

Appendices

**Table V.G1.—Unfunded HI Obligations from Program Inception through the Infinite Horizon**

[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of:	
		HI taxable payroll	GDP
Unfunded obligations through the infinite horizon <sup>1</sup>	-\$7.7	-0.5%	-0.2%
Unfunded obligations from program inception through 2100 <sup>1</sup>	4.2	0.5	0.2

<sup>1</sup>Present value of future expenditures less income, reduced by the amount of trust fund assets at the beginning of the period.

- Notes: 1. The present values of future HI taxable payroll for 2026–2100 and for 2026 through the infinite horizon are \$810.5 trillion and \$1,523.0 trillion, respectively.  
 2. The present values of GDP for 2026–2100 and for 2026 through the infinite horizon are \$1,853.5 trillion and \$3,818.2 trillion, respectively. (These present values differ slightly from the corresponding amounts shown in the OASDI Trustees Report because of the use of HI-specific interest discount factors.)

It is possible to separate the projected HI unfunded obligation over the infinite horizon into the portions associated with current participants versus future participants. The first line of table V.G2 shows the present value of future expenditures less future taxes for current participants, including both beneficiaries and covered workers. Subtracting the current value of the HI trust fund (the accumulated value of past HI taxes less expenditures) results in a closed-group unfunded obligation of \$15.2 trillion. In contrast, the projected difference between taxes and expenditures for future participants is a surplus of \$22.9 trillion.

The year-by-year HI deficits described in section III.B have shown that HI taxes will not be adequate to finance the program on a pay-as-you-go basis (whereby payroll taxes from today’s workers provide benefits to today’s beneficiaries).<sup>125</sup> The unfunded obligations shown in table V.G2 for current participants further indicate that their HI taxes are not adequate to cover their own future costs when they become eligible for HI benefits—and that this situation has also occurred for workers in the past. For future workers, however, the compounding effects of the lower HI price updates would, if they were able to continue indefinitely, lower costs to the point that scheduled HI taxes would be more than sufficient.

In practice, lawmakers could address the projected aggregate HI deficits by raising additional revenue or reducing benefits (or some combination of these actions). The impact of such changes on the unfunded obligation amounts for current versus future participants would depend on the specific policies selected.

<sup>125</sup>As noted previously, the HI trust fund also receives small amounts of income in the form of income taxes on OASDI benefits, interest, and general fund reimbursements for certain uninsured beneficiaries.

*Infinite horizon projections*

**Table V.G2.—Unfunded HI Obligations for Current and Future Program Participants through the Infinite Horizon**

[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of:	
		HI taxable payroll	GDP
Future expenditures less income for current participants.....	\$15.4	1.0%	0.4%
Less current trust fund (income minus expenditures to date for past and current participants).....	0.3	0.0	0.0
Equals unfunded obligations for past and current participants <sup>1</sup> .....	15.2	1.0	0.4
Plus expenditures less income for future participants for the infinite horizon	-22.9	-1.5	-0.6
<u>Equals unfunded obligations for all participants for the infinite future.....</u>	<u>-7.7</u>	<u>-0.5</u>	<u>-0.2</u>

<sup>1</sup>This concept is also referred to as the closed-group unfunded obligation.

- Notes: 1. The estimated present value of future HI taxable payroll for 2026 through the infinite horizon is \$1,523.0 trillion.  
 2. The estimated present value of GDP for 2026 through the infinite horizon is \$3,818.2 trillion. See note 2 in table V.G1.  
 3. Totals do not necessarily equal the sums of rounded components.

Tables V.G3 and V.G4 show the infinite horizon estimates for Part B. The extension assumes that the demographic and economic trends used for the 75-year projection continue indefinitely and that the productivity adjustments to payment updates for some providers remain unchanged. To simplify and stabilize the modeling for the infinite horizon, the Trustees project that average Part B expenditures per beneficiary will increase at about the same rate as GDP per capita minus 0.3 percentage point in every year, reflecting the mix of costs by provider category after 2100 and the payment rate updates applicable to each category.

Table V.G3 shows an estimated present value of Part B expenditures through the infinite horizon of \$143.2 trillion, of which \$69.1 trillion would occur during the first 75 years. Because such amounts, calculated over extremely long horizons, can be difficult to interpret, they are also shown as percentages of the present value of future GDP. So expressed, the corresponding figures are 3.8 percent and 3.7 percent, respectively. The table also indicates that beneficiary premiums will finance approximately 29 percent of expenditures for each time period and that fees related to brand-name prescription drugs will finance about 0.1 percent. Government contributions pay for the remaining 71 percent.

*Appendices*

**Table V.G3.—Unfunded Part B Obligations from Program Inception through the Infinite Horizon**

[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of GDP
Unfunded obligations through the infinite horizon <sup>1</sup>	\$0.0	0.0%
Expenditures	143.2	3.8
Income	143.2	3.8
Beneficiary premiums	40.9	1.1
Government contributions	102.2	2.7
Fees related to brand-name prescription drugs	0.1	0.0
Unfunded obligations from program inception through 2100 <sup>1</sup>	0.0	0.0
Expenditures	69.1	3.7
Income	69.1	3.7
Beneficiary premiums	19.7	1.1
Government contributions	49.4	2.7
Fees related to brand-name prescription drugs	0.1	0.0

<sup>1</sup>Present value of future expenditures less income, reduced by the amount of trust fund assets at the beginning of the period.

Notes: 1. The present values of GDP for 2026–2100 and for 2026 through the infinite horizon are \$1,853.5 trillion and \$3,818.2 trillion, respectively. See note 2 of table V.G1.

2. Totals do not necessarily equal the sums of rounded components.

Table V.G4 shows corresponding present values separately for current versus future beneficiaries. As indicated, about 40 percent of the projected total, infinite-horizon cost is attributable to current beneficiaries, with the remaining 60 percent attributable to beneficiaries becoming eligible for Part B benefits after January 1, 2026.

*Infinite horizon projections*

**Table V.G4.—Unfunded Part B Obligations  
for Current and Future Program Participants through the Infinite Horizon**  
[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of GDP
Future expenditures less income for current participants.....	\$0.0	0.0%
Expenditures .....	57.4	1.5
Income .....	57.4	1.5
Beneficiary premiums .....	16.4	0.4
Government contributions .....	41.0	1.1
Fees related to brand-name prescription drugs .....	0.0	0.0
Less current trust fund (Income minus expenditures to date for past and current participants) .....	0.1	0.0
Equals unfunded obligations for past and current participants <sup>1</sup> .....	-0.1	0.0
Expenditures .....	57.3	1.5
Income .....	57.3	1.5
Beneficiary premiums .....	16.3	0.4
Government contributions .....	40.8	1.1
Fees related to brand-name prescription drugs .....	-0.1	0.0
Plus expenditures less income for future participants for the infinite horizon ..	0.0	0.0
Expenditures .....	85.8	2.2
Income .....	85.8	2.2
Beneficiary premiums .....	24.5	0.6
Government contributions .....	61.2	1.6
Fees related to brand-name prescription drugs .....	0.0	0.0
Equals unfunded obligations for all participants for the infinite future .....	-0.1	0.0
Expenditures .....	143.1	3.7
Income .....	143.1	3.7
Beneficiary premiums .....	40.8	1.1
Government contributions .....	102.1	2.7
Fees related to brand-name prescription drugs .....	-0.1	0.0

<sup>1</sup>This concept is also referred to as the closed-group unfunded obligation.

Notes: 1. The estimated present value of GDP for 2026 through the infinite horizon is \$3,818.2 trillion. See note 2 of table V.G1.

2. Totals do not necessarily equal the sums of rounded components.

Tables V.G5 and V.G6 present revenue and expenditure estimates for Part D that extend to the infinite horizon. The extension assumes that the demographic and economic trends used for the 75-year projection continue indefinitely except that average Part D expenditures per beneficiary would increase at the same rate as GDP per capita minus 0.1 percentage point in every year after 2100.

Table V.G5 shows an estimated present value of Part D expenditures through the infinite horizon of \$35.9 trillion, of which \$15.7 trillion would occur during the first 75 years. To put the estimates in perspective, they are also shown as percentages of the present value of future GDP. Expressed in this way, the corresponding figures are 0.9 percent and 0.8 percent, respectively. The table also indicates that, for each time period, beneficiary premiums would finance approximately 18 percent of expenditures and State payments would finance about 9 percent, with government contributions paying for the remaining 73 percent.

Appendices

**Table V.G5.—Unfunded Part D Obligations from Program Inception through the Infinite Horizon**

[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of GDP
Unfunded obligations through the infinite horizon <sup>1</sup>	\$0.0	0.0%
Expenditures	35.9	0.9
Income	35.9	0.9
Beneficiary premiums	6.7	0.2
State payments	3.1	0.1
Government contributions	26.2	0.7
Unfunded obligations from program inception through 2100 <sup>1</sup>	0.0	0.0
Expenditures	15.7	0.8
Income	15.7	0.8
Beneficiary premiums	2.9	0.2
State payments	1.3	0.1
Government contributions	11.5	0.6

<sup>1</sup>Present value of future expenditures less income, reduced by the amount of trust fund assets at the beginning of the period.

Notes: 1. The present values of GDP for 2026–2100 and for 2026 through the infinite horizon are \$1,853.5 trillion and \$3,818.2 trillion, respectively. See note 2 of table V.G1.

2. Totals do not necessarily equal the sums of rounded components.

Table V.G6 shows corresponding projections separately for current versus future beneficiaries. As indicated, about 34 percent of the projected total, infinite-horizon cost is attributable to current beneficiaries, with the remaining 66 percent attributable to beneficiaries becoming eligible for Part D benefits after January 1, 2026.

*Infinite horizon projections*

**Table V.G6.—Unfunded Part D Obligations  
for Current and Future Program Participants through the Infinite Horizon**  
[Present values as of January 1, 2026; dollar amounts in trillions]

	Present value	As a percentage of GDP
Future expenditures less income for current participants.....	\$0.0	0.0%
Expenditures .....	12.3	0.3
Income .....	12.3	0.3
Beneficiary premiums .....	2.3	0.1
State payments.....	1.0	0.0
Government contributions .....	9.0	0.2
Less current trust fund (Income minus expenditures to date for past and current participants) .....	0.0	0.0
Equals unfunded obligations for past and current participants <sup>1</sup> .....	0.0	0.0
Expenditures .....	12.3	0.3
Income .....	12.3	0.3
Beneficiary premiums .....	2.3	0.1
State payments.....	1.0	0.0
Government contributions .....	9.0	0.2
Plus expenditures less income for future participants for the infinite horizon ..	0.0	0.0
Expenditures .....	23.6	0.6
Income .....	23.6	0.6
Beneficiary premiums .....	4.4	0.1
State payments.....	2.0	0.1
Government contributions .....	17.2	0.5
Equals unfunded obligations for all participants for the infinite future.....	0.0	0.0
Expenditures .....	35.9	0.9
Income .....	35.9	0.9
Beneficiary premiums .....	6.7	0.2
State payments.....	3.0	0.1
Government contributions .....	26.2	0.7

<sup>1</sup>This concept is also referred to as the closed-group unfunded obligation.

Notes: 1. The estimated present value of GDP for 2026 through the infinite horizon is \$3,818.2 trillion.  
See note 2 of table V.G1.

2. Totals do not necessarily equal the sums of rounded components.

Appendices

**H. FISCAL YEAR HISTORICAL DATA AND PROJECTIONS  
THROUGH 2035**

Tables V.H1, V.H2, and V.H3 present detailed operations of the HI trust fund, along with Part B and Part D of the SMI trust fund, for fiscal year 2025. These tables are similar to the calendar-year operation tables displayed in sections III.B, III.C, and III.D.

**Table V.H1.—Statement of Operations of the HI Trust Fund during Fiscal Year 2025**  
[In thousands]

Total assets of the trust fund, beginning of period .....	\$234,693,606
Revenue:	
Payroll taxes .....	\$400,622,160
Income from taxation of OASDI benefits .....	41,054,000
Interest on investments .....	8,318,868
Premiums collected from voluntary participants .....	5,481,315
Premiums collected from Medicare Advantage participants .....	248,001
ACA Medicare shared savings program receipts .....	503,563
Transfer from Railroad Retirement account .....	686,200
Reimbursement, transitional uninsured coverage .....	44,000
Interfund interest payments to OASDI <sup>1</sup> .....	-1,712
Interest on reimbursements, Railroad Retirement .....	30,092
Other .....	612
Reimbursement, union activity .....	1,263
General fund transfer, program management .....	573,403
Fraud and abuse control receipts:	
Criminal fines .....	10,523
Civil monetary penalties .....	28,070
Civil penalties and damages, Department of Justice .....	479,581
Asset forfeitures, Department of Justice .....	161,588
3% administrative expense reimbursement, Department of Justice .....	22,528
General fund appropriation fraud and abuse, FBI .....	173,565
General fund transfer, discretionary .....	334,977
Total revenue .....	<u>\$458,772,597</u>
Expenditures:	
Net benefit payments .....	\$432,938,641
Administrative expenses:	
Treasury administrative expenses .....	152,154
Salaries and expenses, SSA <sup>2</sup> .....	1,347,264
Salaries and expenses, CMS <sup>3</sup> .....	1,739,258
Salaries and expenses, Office of the Secretary, HHS .....	84,389
Medicare Payment Advisory Commission .....	8,294
Medicare Access Children's Health Insurance Program (CHIP) .....	-352
Fraud and abuse control expenses:	
HHS Medicare integrity program .....	1,156,476
HHS Office of Inspector General .....	292,630
Department of Justice .....	176,899
FBI .....	159,652
HCFAC Discretionary, CMS .....	933,186
HCFAC Department of Justice Discretionary, CMS .....	69,930
HCFAC Office of Inspector General Discretionary, CMS .....	35,342
Total administrative expenses .....	6,155,123
Total expenditures .....	<u>\$439,093,764</u>
Net addition to the trust fund .....	19,678,833
Total assets of the trust fund, end of period .....	<u>\$254,372,439</u>

*FY Operations and Projections*

<sup>1</sup>Reflects interest adjustments on the reallocation of administrative expenses among the Medicare trust funds, the OASDI trust funds, and the general fund of the Treasury. Estimated payments are made from the trust funds and then are reconciled, with interest, the next year when the actual costs are known. A positive figure represents a transfer to the HI trust fund from the other trust funds. A negative figure represents a transfer from the HI trust fund to the other funds.

<sup>2</sup>For facilities, goods, and services provided by SSA.

<sup>3</sup>Includes expenses of the Medicare Administrative Contractors.

Note: Totals do not necessarily equal the sums of rounded components.

**Table V.H2.—Statement of Operations of the Part B Account  
in the SMI Trust Fund during Fiscal Year 2025**

[In thousands]	
Total assets of the Part B account in the trust fund, beginning of period	\$154,536,461
Revenue:	
Premiums from enrollees:	
Enrollees aged 65 and over .....	\$132,993,962
Disabled enrollees under age 65 .....	14,615,960
Total premiums .....	147,609,922
Premiums collected from Medicare Advantage participants .....	378,472
Government contributions:	
Enrollees aged 65 and over .....	356,431,584
Disabled enrollees under age 65 .....	62,451,399
Repayment amount <sup>1</sup> .....	-485,780
Adjustment for exempted amounts <sup>2</sup> .....	-3,917,454
Repayment of the Medicare Accelerated and Advance Payments (AAP) Program transfer <sup>3</sup> .....	-24,115
Union activity .....	1,849
Total government contributions .....	414,457,484
Other .....	311
Interest on investments .....	3,522,313
Interfund interest receipts & payments <sup>4</sup> .....	-5,646
Annual fees—branded Rx manufacturers and importers .....	2,795,039
ACA Medicare shared savings program receipts .....	615,885
Total revenue .....	\$569,373,780
Expenditures:	
Net Part B benefit payments .....	\$568,600,375
Administrative expenses:	
Transfer to Medicaid <sup>5</sup> .....	1,370,746
Treasury administrative expenses .....	343
Salaries and expenses, CMS <sup>6</sup> .....	2,401,431
Salaries and expenses, Office of the Secretary, HHS .....	84,389
Salaries and expenses, SSA .....	1,995,240
Medicare Payment Advisory Commission .....	5,530
Railroad Retirement administrative expenses .....	13,268
Railroad Retirement administrative expenses, OIG .....	286
Railroad Retirement administrative expenses, SMAC .....	11,439
MACRA <sup>7</sup> .....	-338
Total administrative expenses .....	5,882,334
Total expenditures .....	\$574,482,709
Net addition to the trust fund .....	-5,108,929
Total assets of the Part B account in the trust fund, end of period .....	\$149,427,533

<sup>1</sup>Represents transfers from Part B to the general fund of the Treasury of amounts collected from beneficiaries for repayment of (i) the 2016 and 2021 transfers for the premium income lost and (ii) the forgone income-related premium income in those years as a result of the specification of the aged actuarial rate. The repayment amounts reflect the \$3.00 that is added to the Part B premium otherwise determined. This addition will continue until the total amount of the forgone income-related premium income plus transfers is fully repaid.

<sup>2</sup>The additional premium repayment amounts (footnote 1 repayment amounts) are not to be matched by general revenue contributions; however, since CMS is not able to separate the additional repayment premium amounts from the standard premium amounts, the additional repayment premium amounts are matched. An adjustment for exempted amounts is therefore necessary to transfer these erroneous Federal matching amounts back to the general fund.

*Appendices*

<sup>3</sup>Represents transfers from Part B to the general fund of the Treasury of amounts recovered from providers for repayment of AAP program payments.

<sup>4</sup>Reflects interest adjustments on the reallocation of administrative expenses among the Medicare trust funds, the OASDI trust funds, and the general fund of the Treasury. Estimated payments are made from the trust funds and then are reconciled, with interest, the next year when the actual costs are known. A positive figure represents a transfer to the Part B account of the SMI trust fund from the other trust funds. A negative figure represents a transfer from the Part B account in the SMI trust fund to the other funds.

<sup>5</sup>Represents amount transferred from the Part B account in the SMI trust fund to Medicaid to pay the Part B premium for certain qualified individuals.

<sup>6</sup>Includes expenses of the Medicare Administrative Contractors.

<sup>7</sup>Represents amounts transferred from the Part B account of the SMI trust fund for administration of provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

Note: Totals do not necessarily equal the sums of rounded components.

**Table V.H3—Statement of Operations of the Part D Account  
in the SMI Trust Fund during Fiscal Year 2025**

[In thousands]

Total assets of the Part D account in the trust fund, beginning of period		\$12,552,567
Revenue:		
Premiums from enrollees		
Premiums deducted from Social Security benefits .....	\$5,930,714	
Premiums paid directly to plans <sup>1</sup> .....	10,020,619	
Total premiums .....		15,951,333
Government contributions:		
Prescription drug benefits .....	134,404,839	
Prescription drug administrative expenses .....	279,387	
Total government contributions .....		134,684,226
Payments from States .....		18,644,904
Interest on investments .....		275,611
DOJ/OIG/MA settlements <sup>2</sup> .....		268,620
Total revenue .....		<u>\$169,824,694</u>
Expenditures:		
Part D benefit payments <sup>1</sup> .....	\$172,584,261	
Part D administrative expenses .....	518,931	
Total expenditures .....		<u>\$173,103,193</u>
Net addition to the trust fund .....		-3,278,499
Total assets of the Part D account in the trust fund, end of period .....		<u>\$9,274,068</u>

<sup>1</sup>Premiums paid directly to plans are not displayed on Treasury statements and are estimated. These premiums have been added to the benefit payments reported on the Treasury statement to obtain an estimate of total Part D benefits. Direct data on such benefit amounts are not yet available.

<sup>2</sup>Reflects amounts transferred to the Part D account for settlements related to Department of Justice (DOJ) civil and criminal court cases, Office of the Inspector General (OIG) civil monetary penalties, and Medicare Advantage (MA) civil monetary penalties.

Note: Totals do not necessarily equal the sums of rounded components.

Tables V.H4, V.H5, V.H6, V.H7, and V.H8 present estimates of the fiscal-year operations of total Medicare, the HI trust fund, the SMI trust fund, the Part B account in the SMI trust fund, and the Part D account in the SMI trust fund, respectively. These tables correspond to the calendar-year trust fund operation tables shown in section V.B and in section III.

*FY Operations and Projections*

**Table V.H4.—Total Medicare Income, Expenditures, and Trust Fund Assets during Fiscal Years 1970–2035**

[In billions]				
Fiscal year	Total income	Total expenditures	Net change in assets	Assets at end of year
Historical data:				
1970	\$7.5	\$7.1	\$0.3	\$2.7
1975	16.9	14.8	2.1	11.3
1980	35.7	35.0	0.7	19.0
1985	75.5	71.4	4.1	31.9
1990	125.7	109.7	16.0	110.2
1995	173.0	180.1	-7.1	143.4
2000	248.9	219.3	29.6	214.0
2005	349.4	336.9	12.5	294.6
2010	500.7	521.2	-20.5	350.9
2015	629.9	638.1	-8.3	265.3
2016	687.7	694.5	-6.8	258.6
2017	721.0	707.4	13.6	272.1
2018	744.4	711.3	33.1	305.3
2019	782.8	782.1	0.7	306.0
2020	833.7	915.4 <sup>1</sup>	-81.7	224.3
2021	928.6 <sup>2</sup>	843.0 <sup>1</sup>	85.6	309.9
2022	957.4 <sup>2</sup>	918.2 <sup>1</sup>	39.2	349.1
2023	1,021.5 <sup>2</sup>	1,017.7 <sup>1</sup>	3.8	352.9
2024	1,103.8	1,055.0	48.9	401.8
2025	1,198.0	1,186.7	11.3	413.1
Intermediate estimates:				
2026	1,330.5	1,296.5	34.0	447.1
2027	1,422.9	1,425.3	-2.3	444.8
2028	1,534.4	1,607.3	-72.9	371.9
2029	1,640.8	1,586.0	54.8	426.7
2030	1,751.9	1,777.1	-25.3	401.4
2031	1,868.4	1,904.5	-36.0	365.4
2032	1,979.5	2,027.5	-48.0	317.4
2033	2,119.7	2,273.4	-153.7	163.6
2034	2,264.5	2,358.6	-94.1	69.5
2035	2,407.4	2,394.7	12.7	82.2

<sup>1</sup>Includes net payments of \$103.8 billion made through the Medicare Accelerated and Advance Payments (AAP) Program in fiscal year 2020 and subsequent net repayments of \$36.4 billion, \$62.4 billion, and \$4.8 billion in fiscal years 2021 through 2023, respectively.

<sup>2</sup>Includes (i) a transfer of \$37.8 billion in fiscal year 2021 from the general fund of the Treasury to Part B, which occurred in November 2020 for the outstanding balance of the AAP program, as required by the Continuing Appropriations Act, 2021 and Other Extensions Act, and (ii) subsequent recoveries from providers that were transferred from Part B to the general fund of the Treasury in the amounts of \$8.5 billion, \$26.5 billion, and \$2.7 billion in fiscal years 2021 through 2023, respectively.

Note: Totals do not necessarily equal the sums of rounded components.

Table V.H5.—Operations of the HI Trust Fund during Fiscal Years 1970–2035

[In billions]

Fiscal year <sup>1</sup>	Income								Expenditures			Trust fund	
	Payroll taxes	Income from taxation of benefits	Railroad Retirement account transfers	Reimbursement for uninsured persons	Premiums from voluntary enrollees	Payments for military wage credits	Interest and other <sup>2,3</sup>	Total	Benefit payments <sup>3,4</sup>	Administrative expenses <sup>5</sup>	Total	Net change	Balance at end of year
Historical data:													
1970	\$4.8	—	\$0.1	\$0.6	—	\$0.0	\$0.1	\$5.6	\$4.8	\$0.1	\$5.0	\$0.7	\$2.7
1975	11.3	—	0.1	0.5	\$0.0	0.0	0.6	12.6	10.4	0.3	10.6	2.0	9.9
1980	23.2	—	0.2	0.7	0.0	0.1	1.1	25.4	23.8	0.5	24.3	1.1	14.5
1985	46.5	—	0.4	0.8	0.0	0.1	3.2	50.9	47.8	0.8	48.7	4.1 <sup>6</sup>	21.3
1990	70.7	—	0.4	0.4	0.1	0.1	7.9	79.6	65.9	0.8	66.7	12.9	95.6
1995	98.1	\$3.9	0.4	0.5	1.0	0.1	11.0	114.8	113.6	1.3	114.9	0.0	129.5
2000	137.7	8.8	0.5	0.5	1.4	0.0	10.8	159.7	127.9 <sup>7</sup>	2.4	130.3	29.4	168.1
2005	169.0	8.8	0.4	0.3	2.3	0.0	16.2	196.9	181.3	2.9	184.1	12.8	277.7
2010	183.6	13.8	0.5	-0.1	3.3	0.0	16.9	218.0	245.6	3.3	249.0	-31.0	278.9
2015	237.7	20.2	0.6	0.2	3.3	0.0	10.4	272.4	273.2	5.5	278.7	-6.4	195.9
2016	250.5	23.0	0.7	0.2	3.2	0.0	9.6	287.1	285.6	5.1	290.6	-3.5	192.4
2017	259.7	24.2	0.6	0.1	3.5	0.0	10.3	298.5	290.3	3.0 <sup>8</sup>	293.3	5.3	197.6
2018	264.6	24.2	0.6	0.1	3.5	0.0	9.8	302.8	292.1	5.1	297.2	5.7	203.3
2019	281.4	23.8	0.6	0.1	3.8	0.0	9.5	319.3	318.4	5.4	323.7	-4.5	198.8
2020	295.9	26.9	0.6	0.1	4.0	0.0	8.6	336.1	395.8 <sup>9</sup>	4.8	400.6	-64.5	134.3
2021	299.1	25.0	0.6	0.1	4.1	0.0	4.8	333.7	326.8 <sup>9</sup>	5.1	331.9	1.8	136.1
2022	343.7	32.8	0.5	0.1	4.5	0.0	5.1	386.6	339.6 <sup>9</sup>	5.2	344.7	41.9	178.0
2023	362.5	35.0	0.6	0.1	4.7	0.0	7.3	410.1	390.7 <sup>9</sup>	5.6	396.3	13.8	191.7
2024	391.9	39.8	0.7	0.0	4.7	0.0	8.4	445.5	396.6	6.0	402.6	43.0	234.7
2025	400.6	41.1	0.7	0.0	5.5	0.0	10.9	458.8	432.9	6.2	439.1	19.7	254.4
Intermediate estimates:													
2026	414.9	47.0	0.7	0.0	6.6	0.0	11.7	480.9	466.1	6.1	472.3	8.6	263.0
2027	434.5	52.1	0.7	0.0	7.3	0.0	12.6	507.3	507.7	6.5	514.1	-6.8	256.2
2028	460.6	56.8	0.7	0.0	7.8	0.0	12.5	538.5	569.3	6.8	576.1	-37.6	218.6
2029	481.5	61.6	0.8	0.0	8.3	0.0	12.1	564.3	565.2	7.1	572.3	-8.0	210.5
2030	505.9	66.6	0.8	0.0	8.9	0.0	11.2	593.4	626.4	7.5	633.9	-40.5	170.1
2031	530.8	71.6	0.8	0.0	9.5	0.0	9.7	622.4	667.5	7.8	675.3	-52.8	117.2
2032	555.4	76.9	0.8	0.0	10.1	0.0	7.3	650.6	709.2	8.1	717.3	-66.7	50.5
2033 <sup>10</sup>	587.4	83.0	0.8	0.0	10.9	0.0	4.6	686.7	784.8	8.6	793.4	-106.7	-56.3
2034 <sup>10</sup>	610.6	89.0	0.9	0.0	11.7	0.0	2.2	714.2	812.9	9.2	822.1	-107.8	-164.1
2035 <sup>10</sup>	637.1	94.9	0.9	0.0	12.4	0.0	-1.2	744.2	822.7	9.7	832.4	-88.3	-252.3

<sup>1</sup>Fiscal years 1970 and 1975 consist of the 12 months ending on June 30 of each year; fiscal years 1980 and later consist of the 12 months ending on September 30 of each year.

<sup>2</sup>Other income includes recoveries of amounts reimbursed from the trust fund that are not obligations of the trust fund, receipts from the fraud and abuse control program, and a small amount of miscellaneous income.

<sup>3</sup>See footnote 2 of table III.B4.

<sup>4</sup>Includes costs of Peer Review Organizations from 1983 through 2001 (beginning with the implementation of the prospective payment system on October 1, 1983) and costs of Quality Improvement Organizations beginning in 2002.

<sup>5</sup>Includes costs of experiments and demonstration projects. Beginning in 1997, includes fraud and abuse control expenses.

<sup>6</sup>Includes repayment of loan principal, from the OASI trust fund, of \$1.8 billion.

<sup>7</sup>For 1998 through 2003, includes monies transferred to the SMI trust fund for home health agency costs.

<sup>8</sup>Reflects a larger-than-usual downward adjustment of \$1.8 billion for prior-year allocations among Part A, Part B, and Part D.

<sup>9</sup>Includes net payments of \$65.5 billion made through the Medicare Accelerated and Advance Payments Program in fiscal year 2020 and subsequent net repayments of \$21.9 billion, \$40.4 billion, and \$3.0 billion in fiscal years 2021 through 2023, respectively.

<sup>10</sup>Estimates for 2033 and later are hypothetical since the HI trust fund would be depleted in those years.

Note: Totals do not necessarily equal the sums of rounded components.

Appendices

**Table V.H6.—Operations of the SMI Trust Fund (Cash Basis)  
during Fiscal Years 1970–2035**

[In billions]

Fiscal year <sup>1</sup>	Income				Expenditures			Trust fund		
	Premium income	Government contribution <sup>2</sup>	Payments from States	Interest and other <sup>3,4</sup>	Total	Benefit payments <sup>4,5</sup>	Administrative expense	Total	Net change	Balance at end of year <sup>6</sup>
Historical data:										
1970	\$0.9	\$0.9	—	\$0.0	\$1.9	\$2.0	\$0.2	\$2.2	-\$0.3	\$0.1
1975	1.9	2.3	—	0.1	4.3	3.8	0.4	4.2	0.2	1.4
1980	2.9	6.9	—	0.4	10.3	10.1	0.6	10.7	-0.5	4.5
1985	5.5	17.9	—	1.2	24.6	21.8	0.9	22.7	1.8	10.6
1990	11.5 <sup>7</sup>	33.2	—	1.4 <sup>7</sup>	46.1 <sup>7</sup>	41.5	1.5 <sup>7</sup>	43.0 <sup>7</sup>	3.1 <sup>7</sup>	14.5 <sup>7</sup>
1995	19.2	37.0	—	1.9	58.2	63.5	1.7	65.2	-7.0	13.9
2000	20.5	65.6	—	3.2	89.2	87.2 <sup>8</sup>	1.8	89.0	0.2	45.9
2005	35.9	115.2	—	1.4	152.5	149.8	2.9	152.7	-0.2	16.9
2010	61.4	213.7	\$4.5	3.2	282.7	268.7	3.5	272.2	10.5	72.0
2015	79.4	263.5	8.8	5.9	357.5	355.8	3.6	359.4	-1.9	69.4
2016	86.1	299.5	9.8	5.3	400.6	399.5	4.4	403.9	-3.3	66.2
2017	94.8	309.6	11.1	6.9	422.4	409.3	4.9 <sup>9</sup>	414.1	8.3	74.5
2018	106.2	316.7	11.7	7.0	441.6	409.4	4.7	414.1	27.5	102.0
2019	113.5	331.8	12.2	6.1	463.6	453.5	4.9	458.4	5.2	107.2
2020	122.0	357.5	11.7	6.4	497.6	509.6 <sup>10</sup>	5.2	514.8	-17.2	90.0
2021	129.2	448.2 <sup>11</sup>	11.9	5.7	594.9	505.7 <sup>10</sup>	5.3	511.1	83.8	173.8
2022	144.3	406.4 <sup>11</sup>	13.3	6.8	570.8	567.8 <sup>10</sup>	5.7	573.4	-2.6	171.2
2023	149.1	439.0 <sup>11</sup>	15.1	8.2	611.4	615.4 <sup>10</sup>	5.9	621.4	-10.0	161.2
2024	156.7	476.1	17.8	7.7	658.3	646.3	6.1	652.4	5.9	167.1
2025	163.6	548.6	18.6	8.4	739.2	741.2	6.4	747.6	-8.4	158.7
Intermediate estimates:										
2026	186.4	633.9	20.3	9.1	849.6	817.0	7.3	824.2	25.4	184.1
2027	205.9	676.4	22.5	10.8	915.7	903.4	7.8	911.1	4.5	188.6
2028	227.1	733.8	23.7	11.4	996.0	1,023.0	8.3	1,031.3	-35.3	153.3
2029	247.8	792.7	24.0	12.1	1,076.5	1,005.0	8.8	1,013.7	62.8	216.1
2030	284.6	836.0	25.0	12.9	1,158.5	1,133.9	9.3	1,143.2	15.2	231.3
2031	313.2	892.8	26.3	13.7	1,246.0	1,219.3	9.8	1,229.2	16.8	248.2
2032	337.2	949.6	27.5	14.5	1,328.9	1,299.8	10.4	1,310.2	18.7	266.9
2033	366.8	1,022.5	28.1	15.5	1,433.0	1,469.0	11.0	1,480.0	-47.0	219.9
2034	399.7	1,105.5	28.4	16.6	1,550.2	1,524.9	11.6	1,536.5	13.7	233.6
2035	432.3	1,184.0	29.1	17.9	1,663.3	1,550.0	12.3	1,562.3	101.0	334.6

<sup>1</sup>Fiscal years 1970 and 1975 consist of the 12 months ending on June 30 of each year; fiscal years 1980 and later consist of the 12 months ending on September 30 of each year.

<sup>2</sup>Includes Part B general fund matching payments, Part D subsidy costs, and certain interest-adjustment items.

<sup>3</sup>Other income includes recoveries of amounts reimbursed from the trust fund that are not obligations of the trust fund and other miscellaneous income. In 2008, includes an adjustment of \$0.8 billion for interest inadvertently earned as a result of Part A hospice costs that were misallocated to the Part B trust fund account.

<sup>4</sup>See footnote 2 of table III.B4.

<sup>5</sup>See footnote 3 of table III.B4.

<sup>6</sup>The financial status of SMI depends on both the assets and the liabilities of the trust fund (see table III.C8).

<sup>7</sup>Includes the impact of the Medicare Catastrophic Coverage Act of 1988.

<sup>8</sup>Benefit payments less monies transferred from the HI trust fund for home health agency costs.

<sup>9</sup>Reflects a larger-than-usual upward adjustment of \$1.4 billion for prior-year allocations among Part A, Part B, and Part D.

<sup>10</sup>Includes net Part B payments of \$38.3 billion made through the Medicare Accelerated and Advance Payments (AAP) Program in fiscal year 2020 and subsequent net repayments of \$14.5 billion, \$22.0 billion, and \$1.7 billion in fiscal years 2021–2023, respectively.

<sup>11</sup>Includes (i) a transfer of \$37.8 billion in fiscal year 2021 from the general fund of the Treasury to Part B, which occurred in November 2020 for the outstanding balance of the AAP program, as required by the Continuing Appropriations Act, 2021 and Other Extensions Act, and (ii) subsequent recoveries from providers that were transferred from Part B to the general fund of the Treasury in the amounts of \$8.5 billion, \$26.5 billion, and \$2.7 billion in fiscal years 2021–2023, respectively.

Note: Totals do not necessarily equal the sums of rounded components.

*FY Operations and Projections*

**Table V.H7.—Operations of the Part B Account in the SMI Trust Fund (Cash Basis) during Fiscal Years 1970–2035**

[In billions]

Fiscal year <sup>1</sup>	Income				Expenditures			Account	
	Premium income	Government contribution <sup>2</sup>	Interest and other <sup>3,4</sup>	Total	Benefit payments <sup>4,5</sup>	Administrative expense	Total	Net change	Balance at end of year <sup>6</sup>
Historical data:									
1970	\$0.9	\$0.9	\$0.0	\$1.9	\$2.0	\$0.2	\$2.2	-\$0.3	\$0.1
1975	1.9	2.3	0.1	4.3	3.8	0.4	4.2	0.2	1.4
1980	2.9	6.9	0.4	10.3	10.1	0.6	10.7	-0.5	4.5
1985	5.5	17.9	1.2	24.6	21.8	0.9	22.7	1.8	10.6
1990	11.5 <sup>7</sup>	33.2	1.4 <sup>7</sup>	46.1 <sup>7</sup>	41.5	1.5 <sup>7</sup>	43.0 <sup>7</sup>	3.1 <sup>7</sup>	14.5 <sup>7</sup>
1995	19.2	37.0	1.9	58.2	63.5	1.7	65.2	-7.0	13.9
2000	20.5	65.6	3.2	89.2	87.2 <sup>8</sup>	1.8	89.0	0.2	45.9
2005	35.9	114.0	1.4	151.3	148.6	2.9	151.5	-0.2	16.9
2010	54.8	161.1	3.2	219.0	205.1	3.3	208.4	10.7	71.3
2015	67.1	195.8	5.8	268.8	272.0	3.2	275.2	-6.4	63.9
2016	72.5	223.1	5.3	300.8	295.1	4.0	299.1	1.7	65.6
2017	79.7	231.0	6.9	317.5	304.1	5.0 <sup>9</sup>	309.1	8.5	74.1
2018	90.4	244.3	6.9	341.7	316.8	4.2	321.0	20.7	94.8
2019	97.8	263.9	5.7	367.4	358.2	4.4	362.6	4.7	99.5
2020	106.3	285.2	5.9	397.3	409.9 <sup>10</sup>	4.8	414.6	-17.3	82.2
2021	112.4	366.1 <sup>11</sup>	5.4	483.9	396.1 <sup>10</sup>	4.8	400.9	82.9	165.1
2022	126.8	313.7 <sup>11</sup>	6.4	447.0	438.3 <sup>10</sup>	5.2	443.4	3.5	168.7
2023	131.0	342.8 <sup>11</sup>	7.5	481.2	486.6 <sup>10</sup>	5.4	492.0	-10.8	157.9
2024	137.7	373.7	7.4	518.9	516.6	5.6	522.2	-3.4	154.5
2025	147.6	413.9	7.9	569.4	568.6	5.9	574.5	-5.1	149.4
Intermediate estimates:									
2026	167.7	462.1	8.5	638.3	610.2	6.7	616.9	21.5	170.9
2027	181.6	480.9	10.2	672.7	662.7	7.1	669.8	2.9	173.8
2028	199.1	527.8	10.8	737.7	752.8	7.6	760.4	-22.8	151.0
2029	217.7	576.4	11.4	805.5	751.0	8.1	759.0	46.4	197.4
2030	238.2	626.2	12.2	876.6	852.8	8.6	861.3	15.2	212.7
2031	259.1	676.7	12.9	948.8	924.2	9.1	933.3	15.5	228.2
2032	281.3	729.4	13.8	1,024.4	997.4	9.6	1,006.9	17.5	245.7
2033	308.1	793.2	14.7	1,116.1	1,134.5	10.1	1,144.7	-28.6	217.1
2034	338.3	864.0	15.8	1,218.2	1,193.8	10.8	1,204.6	13.6	230.6
2035	367.8	932.4	17.0	1,317.3	1,226.1	11.4	1,237.5	79.8	310.4

<sup>1</sup>Fiscal years 1970 and 1975 consist of the 12 months ending on June 30 of each year; fiscal years 1980 and later consist of the 12 months ending on September 30 of each year.

<sup>2</sup>General fund matching payments, plus certain interest-adjustment items.

<sup>3</sup>Other income includes recoveries of amounts reimbursed from the trust fund that are not obligations of the trust fund and other miscellaneous income. In 2008, includes an adjustment of \$0.8 billion for interest earned as a result of Part A hospice costs that were misallocated to the Part B trust fund account.

<sup>4</sup>See footnote 2 of table III.B4.

<sup>5</sup>See footnote 3 of table III.B4.

<sup>6</sup>The financial status of Part B depends on both the assets and the liabilities of the trust fund (see table III.C8).

<sup>7</sup>Includes the impact of the Medicare Catastrophic Coverage Act of 1988.

<sup>8</sup>Benefit payments less monies transferred from the HI trust fund for home health agency costs.

<sup>9</sup>Reflects a larger-than-usual upward adjustment of \$1.7 billion for prior-year allocations among Part A, Part B, and Part D.

<sup>10</sup>See footnote 10 of table V.H6.

<sup>11</sup>See footnote 11 of table V.H6.

Note: Totals do not necessarily equal the sums of rounded components.

Appendices

**Table V.H8.—Operations of the Part D Account in the SMI Trust Fund (Cash Basis) during Fiscal Years 2004–2035**

[In billions]

Fiscal year	Income				Expenditures			Account		
	Premium income	Government contribution <sup>1</sup>	Payments from States <sup>2</sup>	Interest and other	Total	Benefit payments <sup>3</sup>	Administrative expense	Total	Net change	Balance at end of year <sup>4</sup>
Historical data:										
2004	—	\$0.2	—	—	\$0.2	\$0.2	—	\$0.2	—	—
2005	—	1.2	—	—	1.2	1.2	—	1.2	—	—
2006	\$2.6	28.3	\$3.6	\$0.0	34.6	33.7	\$0.2	33.9	\$0.7	\$0.7
2007	3.9	41.4	7.0	0.0	52.3	51.4	1.0	52.4	-0.1	0.6
2008	4.8	35.5	7.0	0.0	47.4	46.8	0.4	47.2	0.2	0.8
2009	5.8	43.5	7.5	0.0	56.9	56.6	0.2	56.8	0.0	0.9
2010	6.6	52.6	4.5	0.0	63.7	63.6	0.3	63.8	-0.2	0.7
2011	7.5	56.3	6.5	0.0	70.4	70.6	0.4	71.0	-0.7	0.0
2012	8.2	45.3	8.3	0.0	61.8	60.6	0.4	61.0	0.8	0.8
2013	9.5	50.3	8.7	0.0	68.5	68.0	0.4	68.3	0.1	1.0
2014	11.0	52.9	8.7	0.0	72.7	72.2	0.4	72.6	0.1	1.1
2015	12.3	67.6	8.8	0.0	88.7	83.8	0.4	84.2	4.5	5.6
2016	13.6	76.4	9.8	0.0	99.8	104.4	0.4	104.8	-5.0	0.6
2017	15.1	78.7	11.1	0.1	104.9	105.2	-0.1 <sup>5</sup>	105.1	-0.2	0.4
2018	15.8	72.4	11.7	0.1	99.9	92.6	0.5	93.1	6.8	7.2
2019	15.7	67.9	12.2	0.4	96.2	95.3	0.5	95.7	0.5	7.7
2020	15.7	72.3	11.7	0.6	100.3	99.7	0.4	100.2	0.1	7.8
2021	16.8	82.1	11.9	0.3	111.0	109.6	0.5	110.2	0.9	8.7
2022	17.5	92.7	13.3	0.3	123.8	129.5	0.5	130.0	-6.2	2.5
2023	18.1	96.2	15.1	0.8	130.2	128.8	0.5	129.4	0.8	3.3
2024	19.0	102.4	17.8	0.3	139.5	129.7	0.5	130.2	9.3	12.6
2025	16.0	134.7	18.6	0.5	169.8	172.6	0.5	173.1	-3.3	9.3
Intermediate estimates:										
2026	18.7	171.8	20.3	0.6	211.3	206.7	0.6	207.4	3.9	13.2
2027	24.3	195.6	22.5	0.6	243.0	240.7	0.6	241.3	1.6	14.8
2028	28.0	206.0	23.7	0.7	258.3	270.1	0.7	270.8	-12.5	2.3
2029	30.1	216.3	24.0	0.7	271.1	254.0	0.7	254.7	16.4	18.7
2030	46.4	209.8	25.0	0.7	281.9	281.2	0.7	281.9	-0.0	18.6
2031	54.1	216.1	26.3	0.7	297.2	295.1	0.8	295.9	1.3	20.0
2032	56.0	220.2	27.5	0.8	304.4	302.4	0.8	303.2	1.2	21.2
2033	58.7	229.3	28.1	0.8	316.9	334.5	0.8	335.3	-18.4	2.8
2034	61.4	241.4	28.4	0.8	332.1	331.0	0.9	331.9	0.2	3.0
2035	64.4	251.6	29.1	0.8	346.0	323.9	0.9	324.8	21.2	24.2

<sup>1</sup>Includes, net of payments from States, all government transfers required to fund benefit payments, inflation rebates as specified under the Inflation Reduction Act of 2022, administrative expenses, and State expenses for making low-income eligibility determinations.

<sup>2</sup>Payments from States with respect to the Federal assumption of Medicaid responsibility for drug expenditures for full-benefit dually eligible individuals.

<sup>3</sup>Includes payments to Part D plans, government subsidies corresponding to both the Inflation Reduction Act of 2022 and demonstration program costs, payments to retiree drug subsidy plans, payments to States for making low-income eligibility determinations, Part D drug premiums collected from beneficiaries, and transfers to Medicare Advantage plans and stand-alone prescription drug plans. Includes amounts for the Transitional Assistance program of \$0.2, \$1.1, and \$0.2 billion in 2004–2006, respectively.

<sup>4</sup>As noted in section III.D.2, a new policy was developed in 2015 under which amounts from the Treasury are transferred into the Part D account 5 business days before the benefit payments to the plans, rather than on the day the benefit payments are due—typically the first business day of a month—as had previously been the case. Accordingly, for any year in which October 1 does not occur on a weekend, the Part D account includes a balance at the end of the previous fiscal year that is more substantial than it would have been prior to implementation of the new policy. In addition, the balances since 2019 have also included an accumulated reserve for the administrative costs incurred by the Social Security Administration on behalf of Medicare.

<sup>5</sup>Reflects a larger-than-usual downward adjustment of \$0.3 billion for prior-year allocations among Part A, Part B, and Part D.

Note: Totals do not necessarily equal the sums of rounded components.

*FY Operations and Projections*

Table V.H9 shows the total assets of the HI trust fund and their distribution by interest rate and maturity date at the end of fiscal years 2024 and 2025. The assets at the end of fiscal year 2025 totaled \$254.4 billion: \$252.9 billion in the form of U.S. Government obligations and an undisbursed balance of \$1.5 billion.

**Table V.H9.—Assets of the HI Trust Fund, by Type,  
at the End of Fiscal Years 2024 and 2025<sup>1</sup>**

	September 30, 2024	September 30, 2025
Investments in public-debt obligations sold only to the trust funds (special issues):		
Certificates of indebtedness:		
4.000 percent, 2025.....	\$26,962,033,000.00	—
4.250 percent, 2026.....	—	\$19,288,999,000.00
Bonds:		
1.875 percent, 2026.....	278,171,000.00	—
2.250 percent, 2026–2029.....	45,482,280,000.00	—
2.250 percent, 2028–2029.....	—	28,063,928,000.00
2.875 percent, 2027–2028.....	17,524,027,000.00	11,984,582,000.00
3.000 percent, 2029–2031.....	46,145,100,000.00	46,145,100,000.00
3.875 percent, 2031–2032.....	30,470,818,000.00	30,470,818,000.00
4.500 percent, 2036–2038.....	—	48,855,869,000.00
4.625 percent, 2032–2036.....	68,097,148,000.00	68,097,148,000.00
Total investments.....	\$234,959,577,000.00	\$252,906,444,000.00
Undisbursed balance <sup>2</sup> .....	-265,970,920.80	1,465,994,703.26
<b>Total assets.....</b>	<b>\$234,693,606,079.20</b>	<b>\$254,372,438,703.26</b>

<sup>1</sup>Certificates of indebtedness and bonds are carried at par value, which is the same as book value.

<sup>2</sup>Negative figures represent an extension of credit against securities to be redeemed within the following few days.

The effective annual rate of interest earned by the assets of the HI trust fund during the 12 months ending on December 31, 2025, was 3.8 percent. Interest on special issues is paid semiannually on June 30 and December 31. The interest rate on public-debt obligations issued for purchase by the trust fund in June 2025 was 4.5 percent, payable semiannually.

Table V.H10 shows a comparison of the total assets of the SMI trust fund, Parts B and D combined, and their distribution at the end of fiscal years 2024 and 2025. At the end of 2025, assets totaled \$158.7 billion: \$153.8 billion in the form of U.S. Government obligations and an undisbursed balance of \$4.9 billion.

Appendices

**Table V.H10.—Assets of the SMI Trust Fund, by Type,  
at the End of Fiscal Years 2024 and 2025<sup>1</sup>**

	September 30, 2024	September 30, 2025
Investments in public-debt obligations sold only to the trust funds (special issues):		
Certificates of indebtedness:		
4.000 percent, 2025.....	\$30,726,291.000.00	—
4.125 percent, 2025.....	1,016,723,000.00	—
4.250 percent, 2026.....	—	\$29,068,837,000.00
4.500 percent, 2026.....	—	2,278,136,000.00
4.625 percent, 2025.....	2,737,286.000.00	—
Bonds:		
1.500 percent, 2029–2036.....	—	49,906,022,000.00
1.500 percent, 2028–2036.....	54,508,024,000.00	—
1.875 percent, 2029–2031.....	13,543,136,000.00	13,543,136,000.00
2.250 percent, 2027–2034.....	27,519,069,000.00	—
2.250 percent, 2029–2034.....	—	18,651,758,000.00
2.875 percent, 2027–2033.....	7,289,354,000.00	—
2.875 percent, 2029–2033.....	—	7,075,115,000.00
3.000 percent, 2027–2037.....	26,404,358,000.00	—
3.000 percent, 2028–2037.....	—	23,676,776,000.00
4.500 percent, 2028.....	—	1,239,834,000.00
4.500 percent, 2038.....	—	7,736,306,000.00
4.625 percent, 2028–2038.....	667,977,000.00	667,977,000.00
Total investments.....	\$164,412,218,000.00	\$153,843,897,000.00
Undisbursed balance.....	2,676,810,210.39	4,857,703,910.07
<b>Total assets.....</b>	<b>\$167,089,028,210.39</b>	<b>\$158,701,600,910.07</b>

<sup>1</sup>Certificates of indebtedness and bonds are carried at par value, which is the same as book value.

The effective annual rate of interest earned by the assets of the SMI trust fund for the 12 months ending on December 31, 2025, was 2.2 percent. Interest on special issues is paid semiannually on June 30 and December 31. The interest rate on special issues purchased by the account in June 2025 was 4.5 percent, payable semiannually.

## I. GLOSSARY

**Accelerated and Advance Payments (AAP) Program.** A Medicare loan program that allows the Centers for Medicare & Medicaid Services (CMS) to make accelerated payments to Part A and Part B providers, and advance payments to Part B suppliers, when there is a disruption in claims submission and/or claims processing. CMS can also offer these payments in circumstances such as national emergencies or natural disasters in order to accelerate cash flow to the affected health care providers and suppliers.

**Accountable care organizations (ACOs).** Groups of clinicians, hospitals, and other health care providers that choose to come together to deliver coordinated, high-quality care to the Medicare patients they serve.

**Actuarial balance.** The difference between the summarized income rate and the summarized cost rate over a given valuation period.

**Actuarial deficit.** A negative actuarial balance.

**Actuarial rates.** One-half of the Part B expected monthly benefit and administrative costs for each aged enrollee adjusted for interest earned on the Part B account assets attributable to aged enrollees and a contingency margin (for the aged actuarial rate), and one-half of the expected monthly benefit and administrative costs for each disabled enrollee adjusted for interest earned on the Part B account assets attributable to disabled enrollees and a contingency margin (for the disabled actuarial rate), for the duration the rate is in effect.

**Actuarial status.** A measure of the adequacy of the financing as determined by the difference between assets and liabilities at the end of the periods for which financing was established.

**Administrative expenses.** Expenses incurred by the Department of Health and Human Services and the Department of the Treasury in administering HI and SMI and the provisions of the Internal Revenue Code relating to the collection of contributions. Such administrative expenses, which are paid from the HI and SMI trust funds, include expenditures for contractors to determine costs of, and make payments to, providers, as well as salaries and expenses of CMS.

**Advanced alternative payment model (advanced APM).** An APM that meets certain standards for risk-bearing, use of health information technology, and quality.

## *Appendices*

**Aged enrollee.** An individual, aged 65 or over, who is enrolled in HI or SMI.

**Allowed charge.** Individual charge determined by a Medicare Administrative Contractor for a covered Part B medical service or supply.

**Alternative payment model (APM).** A program or model (except for a health care innovation award model) implemented by the Center for Medicare and Medicaid Innovation at CMS; a demonstration under the Health Care Quality Demonstration Program; an ACO model participating in the Medicare shared savings program; or a Medicare demonstration required by law.

**Annual out-of-pocket threshold.** The amount of out-of-pocket expenses that must be paid for prescription drugs before significantly reduced Part D beneficiary cost sharing is effective. Amounts paid by a third-party insurer are not included in testing this threshold, but amounts paid by State or Federal assistance programs are included.

**Assets.** Treasury notes and bonds guaranteed by the Federal Government, and cash held by the trust funds for investment purposes.

**Assumptions.** Values relating to future trends in certain key factors that affect the balance in the trust funds. Demographic assumptions include fertility, mortality, net immigration, marriage, divorce, retirement patterns, disability incidence and termination rates, and changes in the labor force. Economic assumptions include unemployment, average earnings, inflation, interest rates, and productivity. Three sets of economic assumptions are presented in the Trustees Report:

- (1) The low-cost alternative, with relatively rapid economic growth, low inflation, and favorable (from the standpoint of program financing) demographic conditions;
- (2) The intermediate assumptions, which represent the Trustees' best estimates of likely future economic and demographic conditions; and
- (3) The high-cost alternative, with slow economic growth, more rapid inflation, and financially disadvantageous demographic conditions.

See also *Hospital assumptions*.

**Average market yield.** A computation that is made on all marketable interest-bearing obligations of the United States. It is computed on the

basis of market quotations as of the end of the calendar month immediately preceding the date of such issue.

**Baby boom.** The period from the end of World War II through the mid-1960s marked by unusually high birth rates.

**Base estimate.** The updated estimate of the most recent historical year.

**Beneficiary.** A person enrolled in HI or SMI. See also *Aged enrollee* and *Disabled enrollee*.

**Benefit payments.** The amounts disbursed for covered services after the deductible and coinsurance amounts have been deducted.

**Benefit period.** An alternate name for spell of illness.

**Board of Trustees.** The Social Security Act established separate boards to oversee the financial operations of the Federal Hospital Insurance Trust Fund and the Federal Supplementary Medical Insurance Trust Fund. Both boards have the same membership comprised of six members, four of whom serve automatically by virtue of their positions in the Federal Government: the Secretary of the Treasury, who is the Managing Trustee; the Secretary of Labor; the Secretary of Health and Human Services; and the Commissioner of Social Security. Two other members are public representatives whom the President appoints and the Senate confirms. These positions are currently vacant. The Administrator of CMS serves as Secretary of the Board of Trustees.

**Bond.** A certificate of ownership of a specified portion of a debt due by the Federal Government to holders, bearing a fixed rate of interest.

**Callable.** Subject to redemption upon notice, as is a bond.

**Capitated payment.** A predetermined amount paid to a health care provider or organization to provide specified services to enrollees over a period of time.

**Case mix index.** A relative weight that captures the average complexity of certain Medicare services.

**Cash basis.** The costs of the service when payment was made rather than when the service was performed.

## *Appendices*

**Certificate of indebtedness.** A short-term certificate of ownership (12 months or less) of a specified portion of a debt due by the Federal Government to individual holders, bearing a fixed rate of interest.

**Closed-group population.** Includes all persons currently participating in the program as either taxpayers or beneficiaries, or both. See also *Open-group population*.

**Coinsurance.** Portion of the costs for covered services paid by the beneficiary after meeting the annual deductible. See also *Hospital coinsurance* and *SNF coinsurance*.

**Consumer Price Index (CPI).** A measure of the average change in prices over time in a fixed group of goods and services. In this report, references to the CPI relate to the CPI for Urban Wage Earners and Clerical Workers (CPI-W), except for those cases in which the CPI for All Urban Consumers—all items (CPI-U) is indicated.

**Contingency.** Funds included in the SMI Part B trust fund account to serve as a cushion in case actual expenditures are higher than those projected at the time financing was established. Since the financing is set prospectively, actual experience may be different from the estimates used in setting the financing.

**Contingency margin.** An amount included in the actuarial rates to provide for changes in the contingency level in the SMI Part B trust fund account. Positive margins increase the contingency level, and negative margins decrease it.

**Contribution base.** See *Maximum tax base*.

**Contributions.** See *Payroll taxes*.

**Cost rate.** The ratio of HI cost (or expenditures) on an incurred basis during a given year to the taxable payroll for the year.

**Covered earnings.** Earnings in employment covered by HI.

**Covered employment.** All employment and self-employment creditable for Social Security purposes. Almost every kind of employment and self-employment is covered under HI. In a few employment situations—for example, religious orders under a vow of poverty, foreign affiliates of American employers, or State and local governments—coverage must be elected by the employer. However, effective July 1991, coverage is mandatory for State and local employees who are not participating in a public employee retirement

system. All new State and local employees have been covered since April 1986. In a few situations—for instance, ministers or self-employed members of certain religious groups—workers can opt out of coverage. Covered employment for HI includes all Federal employees (whereas covered employment for OASDI includes some, but not all, Federal employees).

**Covered Part D drugs.** Prescription drugs covered under the Medicaid program plus insulin-related supplies and smoking cessation agents. Drugs covered in Parts A and B of Medicare will continue to be covered there, rather than in Part D.

**Covered services.** Services for which HI or SMI pays, as defined and limited by statute. Covered HI services are provided by hospitals (inpatient care), skilled nursing facilities, home health agencies, and hospices. Covered SMI Part B services include most physician services, care in outpatient departments of hospitals, diagnostic tests, durable medical equipment, ambulance services, and other health services that are not covered by HI. See *Covered Part D drugs* for SMI Part D.

**Covered worker.** A person who has earnings creditable for Social Security purposes on the basis of services for wages in covered employment and/or on the basis of income from covered self-employment. The number of HI covered workers is slightly larger than the number of OASDI covered workers because of different coverage status for Federal employment. See *Covered employment*.

**Creditable prescription drug coverage.** Prescription drug coverage that meets or exceeds the actuarial value of Part D coverage provided through a group health plan or otherwise.

**Dedicated financing sources.** The sum of HI payroll taxes, HI share of income taxes on Social Security benefits, Part D State payments, Part B drug fees, and beneficiary premiums. This amount is used in the test of excess general revenue Medicare funding.

**Deductible.** The annual amount payable by the beneficiary for covered services before Medicare makes reimbursement. See also *Inpatient hospital deductible*.

**Deemed wage credit.** See *Non-contributory or deemed wage credits*.

**Demographic assumptions.** See *Assumptions*.

**Diagnosis-related groups (DRGs).** A classification system that groups patients according to diagnosis, type of treatment, age, and

## *Appendices*

other relevant criteria. Under the inpatient hospital prospective payment system, hospitals are paid a set fee for treating patients in a single DRG category, regardless of the actual cost of care for the individual.

**Direct and indirect remuneration (DIR).** Payments primarily consisting of drug manufacturer rebates and pharmacy rebates that Part D plans negotiate.

**Direct subsidy.** The amount paid to the prescription drug plans representing the difference between the plan's risk-adjusted bid and the beneficiary premium for basic coverage.

**Disability.** For Social Security purposes, the inability to engage in substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or to last for a continuous period of not less than 12 months. Special rules apply for workers aged 55 or older whose disability is based on blindness. The law generally requires that a person be disabled continuously for 5 months before he or she can qualify for a disabled-worker cash benefit. An additional 24 months is necessary to qualify for benefits under Medicare.

**Disability Insurance (DI).** See *Old-Age, Survivors, and Disability Insurance (OASDI)*.

**Disabled enrollee.** An individual under age 65 who has been entitled to disability benefits under Title II of the Social Security Act or the Railroad Retirement system for at least 2 years and who is enrolled in HI or SMI.

**Disproportionate share hospital (DSH).** A hospital that serves a significantly disproportionate number of low-income patients and receives payments from Medicare to cover the costs of providing care to uninsured patients.

**DRG Coding.** The DRG categories used by hospitals on discharge billing. See also *Diagnosis-related groups (DRGs)*.

**Dual beneficiary.** An individual who is eligible for both Medicare and Medicaid.

**Durable medical equipment (DME).** Items such as iron lungs, oxygen tents, hospital beds, wheelchairs, and seat lift mechanisms that are used in the patient's home and are either purchased or rented.

**Earnings.** Unless otherwise qualified, all wages from employment and net earnings from self-employment, whether or not taxable or covered.

**Economic assumptions.** See *Assumptions*.

**Economy-wide private nonfarm business total factor productivity.** A measure of real output per combined unit of labor and capital, reflecting the contributions of all factors of production for the private nonfarm business sector of the economy.

**End-stage renal disease (ESRD).** Permanent kidney failure.

**Excess general revenue Medicare funding.** A determination that occurs when the difference between expenditures and dedicated funding sources exceeds or is projected to exceed 45 percent of expenditures.

**Extended care services.** In the context of this report, an alternate name for skilled nursing facility services.

**Federal Insurance Contributions Act (FICA).** Provision authorizing taxes on the wages of employed persons to provide for OASDI and HI. The tax is paid in equal amounts by covered workers and their employers.

**Financial interchange.** Provisions of the Railroad Retirement Act providing for transfers between the trust funds and the Social Security Equivalent Benefit Account of the Railroad Retirement program in order to place each trust fund in the same position as if railroad employment had always been covered under Social Security.

**Fiscal year.** The accounting year of the U.S. Government. Since 1976, each fiscal year has begun October 1 of the prior calendar year and ended the following September 30. For example, fiscal year 2026 began October 1, 2025 and will end September 30, 2026.

**Fixed capital assets.** The net worth of facilities and other resources.

**Frequency distribution.** An exhaustive list of possible outcomes for a variable, and the associated probability of each outcome. The sum of the probabilities of all possible outcomes from a frequency distribution is 100 percent.

**General fund of the Treasury.** Funds held by the U.S. Treasury, other than revenue collected for a specific trust fund (such as HI or SMI) and maintained in a separate account for that purpose. The

## *Appendices*

majority of this fund is derived from individual and business income taxes.

**GLP-1.** Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily utilized to treat Type 2 diabetes and obesity.

**Government contributions.** Contributions of the Federal Government that the law authorizes to be appropriated and transferred from the general fund of the Treasury to the Part B and Part D accounts of the SMI trust fund. For both parts separately, beneficiary premiums and government contributions are established annually to cover the expected costs for the upcoming year, with both parts primarily financed by government contributions.

**Gross Domestic Product (GDP).** The total dollar value of all goods and services produced in a year in the United States, regardless of who supplies the labor or property.

**High-cost alternative.** See *Assumptions*.

**Hold-harmless provision.** A provision limiting the dollar increase in the Part B premium to the dollar increase in an individual's Social Security benefit. As a result, the person affected pays a lower Part B premium, and the net amount of the individual's Social Security benefit does not decrease despite the greater increase in the premium.

**Home health agency (HHA).** A public agency or private organization that is primarily engaged in providing the following services in the home: skilled nursing services, other therapeutic services (such as physical, occupational, or speech therapy), and home health aide services.

**Hospice.** A provider of care for the terminally ill; delivered services generally include home health care, nursing care, physician services, medical supplies, and short-term inpatient hospital care.

**Hospital assumptions.** These include differentials between hospital labor and non-labor indices compared with general economy labor and non-labor indices; rates of admission incidence; the trend toward treating less complicated cases in outpatient settings; and continued improvement in DRG coding.

**Hospital coinsurance.** For the 61st through 90th day of hospitalization in a benefit period, a daily amount for which the beneficiary is responsible, equal to one-fourth of the inpatient hospital deductible; for lifetime reserve days, a daily amount for which the

beneficiary is responsible, equal to one-half of the inpatient hospital deductible (see *Lifetime reserve days*).

**Hospital input price index.** An alternate name for hospital market basket.

**Hospital Insurance (HI).** The Medicare trust fund that covers specified inpatient hospital services, posthospital skilled nursing care, home health services, and hospice care for aged and disabled individuals who meet the eligibility requirements. Also known as Medicare Part A.

**Hospital market basket.** The cost of the mix of goods and services (including personnel costs but excluding nonoperating costs) comprising routine, ancillary, and special care unit inpatient hospital services.

**Income rate.** The ratio of HI income (including payroll taxes, income from taxation of Social Security benefits, premiums, general fund transfers for uninsured beneficiaries, and monies from fraud and abuse control activities, but excluding interest income) to taxable payroll for the year.

**Incurred basis.** The costs based on when the service was performed rather than when the payment was made.

**Infinite horizon.** The period extending into the indefinite future.

**Independent laboratory.** A free-standing clinical laboratory meeting conditions for participation in the Medicare program.

**Initial coverage limit.** The amount up to which the coinsurance applies under the standard prescription drug benefit.

**Inpatient hospital deductible.** An amount of money that is deducted from the amount payable by Medicare Part A for inpatient hospital services furnished to a beneficiary during a spell of illness.

**Inpatient hospital services.** These services include bed and board, nursing services, diagnostic or therapeutic services, and medical or surgical services.

**Interest.** A payment for the use of money during a specified period.

**Intermediate assumptions.** See *Assumptions*.

## *Appendices*

**Late enrollment penalty.** Additional beneficiary premium amounts for those who either do not enroll in Part D at the first opportunity or fail to maintain other creditable coverage for more than 63 days.

**Lifetime reserve days.** Under HI, each beneficiary has 60 lifetime reserve days that he or she may opt to use when regular inpatient hospital benefits are exhausted. The beneficiary pays one-half of the inpatient hospital deductible for each lifetime reserve day used.

**Long range.** The next 75 years.

**Low-cost alternative.** See *Assumptions*.

**Low-income beneficiaries.** Individuals meeting income and assets tests who are eligible for prescription drug coverage subsidies to help finance premiums and out-of-pocket payments.

**Managed care.** See *Private Health Plans*.

**Market basket.** See *Hospital market basket*.

**Maximum tax base.** Annual dollar amount above which earnings in employment covered under HI are not taxable. In 1994, the maximum tax base was eliminated under HI.

**Maximum taxable amount of annual earnings.** See *Maximum tax base*.

**Medicare.** A nationwide, federally administered health insurance program authorized in 1965 under Title XVIII of the Social Security Act to cover the cost of hospitalization, medical care, and some related services for most people aged 65 and over. In 1972, lawmakers extended coverage to people receiving Social Security Disability Insurance payments for 2 years and people with end-stage renal disease. (For beneficiaries whose primary or secondary diagnosis is Amyotrophic Lateral Sclerosis, the 2-year waiting period is waived.) In 2010, people exposed to environmental health hazards within areas under a corresponding emergency declaration became Medicare-eligible. In 2006, prescription drug coverage was added as well. Medicare consists of two separate but coordinated trust funds: Hospital Insurance (HI, or Part A) and Supplementary Medical Insurance (SMI). The SMI trust fund comprises two separate accounts: the Part B account and the Part D account. Almost all persons who are aged 65 and over or disabled and who are entitled to HI are eligible to enroll in Part B and Part D on a voluntary basis by paying monthly premiums.

**Medicare Administrative Contractor (MAC).** A private health care insurer that processes Part A and Part B medical claims or DME claims for fee-for-service beneficiaries.

**Medicare Advantage (formerly called Medicare+Choice).** An expanded set of options, established in 2006, for the delivery of health care under Medicare. Most Medicare beneficiaries can choose to receive benefits through the original fee-for-service program or through one of the following Medicare Advantage plans: (i) coordinated care plans (such as health maintenance organizations, provider-sponsored organizations, and preferred provider organizations); (ii) medical savings account (MSA)/high-deductible plans; (iii) private fee-for-service plans; or (iv) special needs plans.

**Medicare Advantage Prescription Drug Plan (MA-PD).** Prescription drug coverage provided by Medicare Advantage plans.

**Medicare Advantage ratebook.** A set of statutory capitation payment rates, by county, originally used directly to establish payments to private health insurance plans contracting with Medicare. Under current law, the ratebook amounts are used as benchmarks, against which plan costs are compared in the calculation of plan payments.

**Medicare Economic Index (MEI).** An index often used in the calculation of the increases in the prevailing charge levels that help to determine allowed charges for physician services. In 1992 and later, this index is considered in connection with the update factor for the physician fee schedule.

**Medicare funding warning.** A warning triggered when a determination of excess general revenue Medicare funding has occurred in 2 consecutive years. Such a warning requires the President to submit to Congress, within 15 days after the date of the Budget submission for the succeeding year, proposed legislation to respond to the warning. The law also requires Congress to consider the legislation proposed in response to Medicare funding warnings on an expedited basis. See also *Excess general revenue Medicare funding*.

**Medicare Payment Advisory Commission (MedPAC).** A commission established by Congress in 1997 to replace the Prospective Payment Assessment Commission and the Physician Payment Review Commission. MedPAC is directed to provide the Congress with advice and recommendations on policies affecting the Medicare program.

## *Appendices*

**Medicare Prescription Drug Account.** The separate account within the SMI trust fund to manage revenues and expenditures of the Part D drug benefit.

**Medicare severity diagnosis-related groups (MS-DRGs).** A refinement of the diagnosis-related group classification system that groups patients according to diagnosis, type of treatment, age, and other relevant criteria. Under the inpatient hospital prospective payment system, hospitals are paid a set fee for treating patients in a single MS-DRG category, regardless of the actual cost of care for the individual.

**Merit-based incentive payment system (MIPS).** A system for adjusting payments under the Medicare physician fee schedule to non-advanced APM providers based on metrics assessing provider quality, resource use, meaningful use of electronic health records, and clinical practice improvement activities.

**Military service wage credits.** Credits recognizing that military personnel receive other cash payments and wages in kind (such as food and shelter) in addition to their basic pay. Noncontributory wage credits of \$160 were provided for each month of active military service from September 16, 1940 through December 31, 1956. For years after 1956, the basic pay of military personnel is covered under the Social Security program on a contributory basis. In addition to contributory credits for basic pay, noncontributory wage credits of \$300 were granted for each calendar quarter in which a person received pay for military service from January 1957 through December 1977. Deemed wage credits of \$100 were granted for each \$300 of military wages, up to a maximum of \$1,200 per calendar year, from January 1978 through December 2001. See also *Quinquennial military service determinations and adjustments*.

**National average monthly bid.** The weighted average of all Part D drug bids including all of the bids from Prescription Drug Plans (PDPs) and the drug portion of bids from MA-PDs.

**Noncontributory or deemed wage credits.** Wages and wages in kind that were not subject to the HI tax but are deemed as having been. Deemed wage credits exist for the purposes of (i) determining HI eligibility for individuals who might not be eligible for HI coverage without payment of a premium were it not for the deemed wage credits and (ii) calculating reimbursement due the HI trust fund from the general fund of the Treasury. The first purpose applies in the case of providing coverage to persons during the transitional periods when HI

began and when it was expanded to cover Federal employees; both purposes apply in the cases of military service wage credits and deemed wage credits granted for the internment of persons of Japanese ancestry during World War II.

**Old-Age, Survivors, and Disability Insurance (OASDI).** The Social Security programs that pay for (i) monthly cash benefits to retired-worker (old-age) beneficiaries, their spouses and children, and survivors of deceased insured workers (OASI); and (ii) monthly cash benefits to disabled-worker beneficiaries and their spouses and children, and for providing rehabilitation services to the disabled (DI).

**Open-group population.** Includes all persons who will ever participate in the program as either taxpayers or beneficiaries, or both. See also *Closed-group population*.

**Open-group unfunded obligation.** See *Unfunded obligation*.

**Original Medicare.** Also referred to as fee-for-service Medicare. Provides health insurance coverage that is administered by the federal government as compared to Medicare Advantage, which is administered by private insurers. Allows beneficiaries to use any provider that accepts Medicare.

**Outpatient hospital.** Part of the hospital providing services covered by SMI Part B, including, for example, services in an emergency room or outpatient clinic, ambulatory surgical procedures, medical supplies such as splints, and laboratory tests billed by the hospital.

**Part A.** The Medicare Hospital Insurance trust fund.

**Part A premium.** A monthly premium paid by or on behalf of individuals who wish for and are entitled to voluntary enrollment in Medicare HI. These individuals are those who are aged 65 and older, are uninsured for Social Security or Railroad Retirement, and do not otherwise meet the requirements for entitlement to Part A. Disabled individuals who have exhausted other entitlement are also qualified. These individuals are those not now entitled but who have been entitled under section 226(b) of the Social Security Act, who continue to have the disabling impairment upon which their entitlement was based, and whose entitlement ended solely because the individuals had earnings that exceeded the substantial gainful activity amount (as defined in section 223(d)(4) of the Social Security Act).

**Part B.** The account within the Medicare Supplementary Medical Insurance trust fund that pays for a portion of the costs of physician

## *Appendices*

services, outpatient hospital services, and other related medical and health services for voluntarily enrolled aged and disabled individuals.

**Part B premium.** The monthly amount paid by those individuals who have voluntarily enrolled in Part B. Most enrollees pay the standard premium amount, which currently represents approximately 25 percent of the average program costs for an aged beneficiary. Beneficiaries with high income are also required to pay an income-related monthly adjustment amount starting in 2007, and those individuals who meet the definition of a late enrollee are required to pay a penalty. In addition, beneficiaries who are affected by the hold-harmless provision pay a lower premium. See section V.E for more details about the Part B premium.

**Part C.** See *Private health plans*.

**Part D.** The account within the Medicare Supplementary Medical Insurance trust fund that pays private plans to provide prescription drug coverage.

**Part D premium.** The monthly amount paid by those individuals who have voluntarily enrolled in Part D. Premiums are to represent, on average, 25.5 percent of the cost of standard coverage. The actual premium that a beneficiary pays varies according to the plan in which the beneficiary enrolls. Beneficiaries with high income are also required to pay an income-related monthly adjustment amount starting in 2011, and those who enroll late may be required to pay a penalty. In addition, there are premium subsidies for those beneficiaries with income and resources under specified amounts. See section V.E for more details about the Part D premium.

**Pay-as-you-go financing.** A financing scheme in which taxes are scheduled to produce just as much income as required to pay current benefits, with trust fund assets built up only to the extent needed to prevent depletion of the fund by random fluctuations.

**Payroll taxes.** Taxes levied on the gross wages of employees and net earnings of self-employed workers.

**Peer Review Organization (PRO).** A group of practicing physicians and other health care professionals paid by the Federal Government to review the care given to Medicare patients. Starting in 2002, these organizations are called Quality Improvement Organizations.

**Percentile.** A number that corresponds to one of the equal divisions of the range of a variable in a given sample and that characterizes a

value of the variable as not exceeded by a specified percentage of all the values in the sample. For example, a score higher than 97 percent of those attained is said to be in the 97th percentile.

**Prescription Drug Plans (PDPs).** Stand-alone prescription drug plans offered to beneficiaries in traditional fee-for-service Medicare and to beneficiaries in Medicare Advantage plans that do not offer a prescription drug benefit.

**Present value.** The present value of a future stream of payments is the lump-sum amount that, if invested today, together with interest earnings would be just enough to meet each of the payments as it fell due. At the time of the last payment, the invested fund would be exactly zero.

**Private health plans.** Plans offered by private companies that contract with Medicare to provide coverage for Part A and Part B services. Medicare Advantage plans, cost plans, and Program of All-Inclusive Care for the Elderly (PACE) plans are all private health plans.

**Projection error.** Degree of variation between estimated and actual amounts.

**Prospective payment system (PPS).** A method of reimbursement in which Medicare payment is made based on a predetermined, fixed amount. The payment amount for a particular service is derived based on the classification system of that service (for example, DRGs for inpatient hospital services).

**Provider.** Any organization, institution, or individual who provides health care services to Medicare beneficiaries. Hospitals (inpatient services), skilled nursing facilities, home health agencies, and hospices are the providers of services covered under Medicare Part A. Physicians, ambulatory surgical centers, and outpatient clinics are some of the providers of services covered under Medicare Part B.

**Quality Improvement Organization (QIO).** See *Peer Review Organization*.

**Quinquennial military service determination and adjustments.** Prior to the Social Security Amendments of 1983, quinquennial determinations (that is, estimates made once every 5 years) were made of the costs arising from the granting of deemed wage credits for military service prior to 1957; annual reimbursements were made from the general fund of the Treasury to the HI trust fund for these costs.

## *Appendices*

The Social Security Amendments of 1983 provided for (i) a lump-sum transfer in 1983 for (a) the costs arising from the pre-1957 wage credits and (b) amounts equivalent to the HI taxes that would have been paid on the deemed wage credits for military service for 1966 through 1983, inclusive, if such credits had been counted as covered earnings; (ii) quinquennial adjustments to the pre-1957 portion of the 1983 lump-sum transfer; (iii) general fund transfers equivalent to HI taxes on military deemed wage credits for 1984 and later, to be credited to the fund on July 1 of each year; and (iv) adjustments as deemed necessary to any previously transferred amounts representing HI taxes on military deemed wage credits.

**Railroad Retirement.** A Federal insurance program similar to Social Security designed for workers in the railroad industry. The provisions of the Railroad Retirement Act provide for a system of coordination and financial interchange between the Railroad Retirement program and the Social Security program.

**Ratebook.** See *Medicare Advantage ratebook*.

**Real-wage growth.** The annual percentage change in average covered wages adjusted for the average percentage change in the CPI.

**Reasonable-cost basis.** The calculation to determine the reasonable cost incurred by individual providers when furnishing covered services to beneficiaries. The reasonable cost is based on the actual cost of providing such services, including direct and indirect costs of providers, and excluding any costs that are unnecessary in the efficient delivery of services covered by a health insurance program.

**Reinsurance subsidy.** Payments to the prescription drug plans in the amount of 80 percent of drug expenses that exceed the annual out-of-pocket threshold.

**Residual factors.** Factors other than price, including volume of services, intensity of services, and age/sex changes.

**Risk corridor.** Triggers that are set to protect Part D prescription drug plans from unexpected losses and that allow the government to share in unexpected gains.

**Self-employment.** Operation of a trade or business by an individual or by a partnership in which an individual is a member.

**Self-Employment Contributions Act (SECA).** Provision authorizing taxes on the net income of most self-employed persons to provide for OASDI and HI.

**Sequestration.** The process of applying automatic reductions to certain Federal funding, which was required by the Budget Control Act of 2011.

**Short range.** The next 10 years.

**Skilled nursing facility (SNF).** An institution that is primarily engaged in providing skilled nursing care and related services for residents who require medical or nursing care or that is engaged in the rehabilitation of injured, disabled, or sick persons.

**SNF coinsurance.** For the 21st through 100th day of extended care services in a benefit period, a daily amount for which the beneficiary is responsible, equal to one-eighth of the inpatient hospital deductible.

**Social Security Act.** Public Law 74-271, enacted on August 14, 1935, with subsequent amendments. The Social Security Act consists of 20 titles, four of which have been repealed. The HI and SMI trust funds are authorized by Title XVIII of the Social Security Act.

**Special public-debt obligation.** Securities of the U.S. Government issued exclusively to the OASI, DI, HI, and SMI trust funds and other Federal trust funds. Sections 1817(c) and 1841(a) of the Social Security Act provide that the public-debt obligations issued for purchase by the HI and SMI trust funds, respectively, shall have maturities fixed with due regard for the needs of the funds. The usual practice in the past has been to spread the holdings of special issues, as of every June 30, so that the amounts maturing in each of the next 15 years are approximately equal. Special public-debt obligations are redeemable at par at any time.

**Spell of illness.** A period of consecutive days, beginning with the first day on which a beneficiary is furnished inpatient hospital or extended care services, and ending with the close of the first period of 60 consecutive days thereafter in which the beneficiary is in neither a hospital nor a skilled nursing facility.

**Standard prescription drug coverage.** Part D prescription drug coverage that includes a deductible, coinsurance up to an initial coverage limit, and protection against high out-of-pocket expenditures by having reduced coinsurance provisions for individuals exceeding the out-of-pocket threshold.

## *Appendices*

**Stochastic model.** An analysis involving a random variable. For example, a stochastic model may include a frequency distribution for one assumption. From the frequency distribution, possible outcomes for the assumption are selected randomly for use in an illustration.

**Summarized cost rate.** The ratio of the present value of expenditures to the present value of the taxable payroll for the years in a given period. The summarized cost rate includes the cost of reaching and maintaining a target trust fund level, known as a contingency fund ratio. Because a trust fund level of about 1 year's expenditures is considered to be an adequate reserve for unforeseen contingencies, the targeted contingency fund ratio used in determining summarized cost rates is 100 percent of annual expenditures. Accordingly, the summarized cost rate is equal to the ratio of (i) the sum of the present value of the expenditures during the period, plus the present value of the targeted ending trust fund level, plus the beginning trust fund amount, to (ii) the present value of the taxable payroll during the period.

**Summarized income rate.** The ratio of the present value of HI income (including payroll taxes, income from taxation of Social Security benefits, premiums, general fund transfers for uninsured beneficiaries, and monies from fraud and abuse control activities, but excluding interest income) incurred during a given period to the present value of the taxable payroll for the years in the period.

**Supplemental prescription drug coverage.** Coverage in excess of the standard prescription drug coverage.

**Supplementary Medical Insurance (SMI).** The Medicare trust fund comprising the Part B account, the Part D account, and the Transitional Assistance Account. The Part B account pays for a portion of the costs of physician services, outpatient hospital services, and other related medical and health services for voluntarily enrolled aged and disabled individuals. The Part D account pays private plans to provide prescription drug coverage, beginning in 2006. The Transitional Assistance Account paid for transitional assistance under the prescription drug card program in 2004 and 2005.

**Sustainable growth rate (SGR).** A system for establishing goals for the rate of growth in Medicare Part B expenditures for physician services. The Medicare Access and CHIP Reauthorization Act of 2015 permanently repealed the SGR formula.

**Tax rate.** The percentage of taxable earnings, up to the maximum tax base, that is paid for the HI tax. Currently, the percentages are 1.45 for employees and employers, each. The self-employed pay 2.9 percent. There is an additional 0.9-percent tax on earnings above \$200,000 (for those who file an individual tax return) or \$250,000 (for those who file a joint income tax return).

**Taxable earnings.** Taxable wages and/or self-employment income under the prevailing annual maximum taxable limit.

**Taxable payroll.** A weighted average of taxable wages and taxable self-employment income. When multiplied by the combined employee-employer tax rate, it yields the total amount of taxes incurred by employees, employers, and the self-employed for work during the period.

**Taxable self-employment income.** Net earnings from self-employment—generally above \$400 and below the annual maximum taxable amount for a calendar or other taxable year—less any taxable wages in the same taxable year.

**Taxable wages.** Wages paid for services rendered in covered employment up to the annual maximum taxable amount.

**Taxation of benefits.** Beginning in 1994, up to 85 percent of an individual's or a couple's OASDI benefits are potentially subject to Federal income taxation under certain circumstances. The revenue derived from taxation of benefits in excess of 50 percent, up to 85 percent, is allocated to the HI trust fund.

**Taxes.** See *Payroll taxes*.

**Term insurance.** A type of insurance that is in force for a specified period of time.

**Test of Long-Range Close Actuarial Balance.** The conditions required to meet this test are as follows: (i) The trust fund satisfies the short-range test of financial adequacy; and (ii) the trust fund ratios stay above zero throughout the 75-year projection period, such that benefits would be payable in a timely manner throughout the period. This test is applied to HI trust fund projections made under the intermediate assumptions.

**Test of Short-Range Financial Adequacy.** The conditions required to meet this test are as follows: (i) If the trust fund ratio for a fund exceeds 100 percent at the beginning of the projection period, then it

## *Appendices*

must be projected to remain at or above 100 percent throughout the 10-year projection period; (ii) alternatively, if the fund ratio is initially less than 100 percent, it must be projected to reach a level of at least 100 percent within 5 years (and not be depleted at any time during this period), and then remain at or above 100 percent throughout the rest of the 10-year period. This test is applied to HI trust fund projections made under the intermediate assumptions.

**Transitional assistance.** An interim benefit for 2004 and 2005 that provided up to \$600 per year to assist low-income beneficiaries who had no drug insurance coverage with prescription drug purchases. This benefit also paid the enrollment fee in the Medicare Prescription Drug Discount Card program.

**Transitional Assistance Account.** The separate account within the SMI trust fund that managed revenues and expenditures for the transitional assistance drug benefit in 2004 and 2005.

**Trust fund.** Separate accounts in the U.S. Treasury, mandated by Congress, whose assets may be used only for a specified purpose. For the HI and SMI trust funds, monies not withdrawn for current benefit payments and administrative expenses are invested in interest-bearing Federal securities, as required by law; the interest earned is also deposited in the trust funds.

**Trust fund ratio.** A short-range measure of the adequacy of the HI and SMI trust fund level; defined as the assets at the beginning of the year expressed as a percentage of the costs during the year.

**Unfunded obligation.** A measure of the shortfall of trust fund income to fully cover program cost over a specified time period after depletion of trust fund asset reserves. This measure can be expressed in present value dollars, discounted to the beginning of the valuation period, by computing the excess of the present value of the projected cost of the program over the sum of (i) the value of trust fund reserves at the beginning of the valuation period and (ii) the present value of the projected non-interest income of the program, assuming scheduled tax rates and benefit levels. This measure can apply for all participants over a specified time period—that is, the *open-group population*—or be limited to a specified subgroup of participants, referred to as the *closed-group population*.

**Uninsured beneficiaries.** HI beneficiaries who do not have 40 quarters of covered earnings but are entitled to HI coverage either because (i) they were deemed additional wage credits during the

## *Glossary*

transitional periods when the HI program began or when it was expanded to cover Federal employees, or because (ii) they pay a monthly premium that is intended to cover their full cost. See *Part A premium*.

**Unit input intensity allowance.** The amount added to, or subtracted from, the hospital input price index to yield the prospective payment system update factor.

**Valuation period.** A period of years that is considered as a unit for purposes of calculating the status of a trust fund.

**Voluntary enrollees.** Certain individuals, aged 65 or older or disabled, who are not otherwise entitled to Medicare and who opt to obtain coverage under Part A by paying a monthly premium.

**Year of depletion.** The first year in which a trust fund is unable to pay full benefits when due because the assets of the fund are depleted.

*List of Tables*

**TABLES**

II.A1.— HI Key Results .....	8
II.A2.— SMI Key Results.....	10
II.B1.— Medicare Data for Calendar Year 2025 .....	12
II.C1.— Key Assumptions, 2050–2100 .....	15
II.D1.— Components of Increase in Medicare Incurred Expenditures by Part .....	23
II.E1.— Estimated Operations of the HI Trust Fund under Intermediate Assumptions, Calendar Years 2025–2035....	28
II.F1.— Estimated Operations of the SMI Trust Fund under Intermediate Assumptions, Calendar Years 2025–2035....	35
II.F2.— Average Annual Rates of Growth in SMI and the Economy.....	39
II.F3.— SMI Government Contributions as a Percentage of Personal and Corporate Federal Income Taxes .....	43
III.B1.— Statement of Operations of the HI Trust Fund during Calendar Year 2025 .....	49
III.B2.— Tax Rates and Maximum Tax Bases .....	50
III.B3.— Comparison of Actual and Estimated Operations of the HI Trust Fund, Calendar Year 2025.....	53
III.B4.— Operations of the HI Trust Fund during Calendar Years 1970–2035.....	58
III.B5.— Estimated Operations of the HI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions .....	60
III.B6.— Ratio of Assets at the Beginning of the Year to Expenditures during the Year for the HI Trust Fund.....	62
III.B7.— HI Cost and Income Rates .....	65
III.B8.— HI Actuarial Balances under Three Sets of Assumptions..	70
III.B9.— Components of 75-Year HI Actuarial Balance under Intermediate Assumptions (2026–2100).....	71
III.B10.— Change in the 75-Year Actuarial Balance since the 2025 Report.....	75
III.B11.— Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various Real-Wage Growth Assumptions .....	76
III.B12.— Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various CPI-Increase Assumptions .....	77
III.B13.— Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various Real-Interest Assumptions .....	78
III.B14.— Estimated HI Income Rates, Cost Rates, and Actuarial Balances, Based on Intermediate Estimates with Various Health Care Cost Growth Rate Assumptions .....	79
III.C1.— Statement of Operations of the Part B Account in the SMI Trust Fund during Calendar Year 2025.....	81

*List of Tables*

III.C2.— Standard Part B Monthly Premium Rates, Actuarial Rates, and Premium Rates as a Percentage of Part B Cost .....	83
III.C3.— Comparison of Actual and Estimated Operations of the Part B Account in the SMI Trust Fund, Calendar Year 2025.....	86
III.C4.— Operations of the Part B Account in the SMI Trust Fund (Cash Basis) during Calendar Years 1970–2035 .....	90
III.C5.— Growth in Part B Benefits (Cash Basis) through December 31, 2035 .....	92
III.C6.— Estimated Operations of the Part B Account in the SMI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions.....	93
III.C7.— Estimated Part B Income and Expenditures (Incurred Basis) for Financing Periods through December 31, 2026.....	96
III.C8.— Summary of Estimated Part B Assets and Liabilities as of the End of the Financing Period, for Periods through December 31, 2026 .....	97
III.C9.— Actuarial Status of the Part B Account in the SMI Trust Fund under Three Cost Sensitivity Scenarios for Financing Periods through December 31, 2026 .....	99
III.C10.— Part B Expenditures (Incurred Basis) as a Percentage of the Gross Domestic Product .....	100
III.D1.— Statement of Operations of the Part D Account in the SMI Trust Fund during Calendar Year 2025.....	103
III.D2.— Comparison of Actual and Estimated Operations of the Part D Account in the SMI Trust Fund, Calendar Year 2025 .....	106
III.D3.— Operations of the Part D Account in the SMI Trust Fund (Cash Basis) during Calendar Years 2005–2035 ....	110
III.D4.— Growth in Part D Benefits (Cash Basis) through December 31, 2035 .....	112
III.D5.— Estimated Operations of the Part D Account in the SMI Trust Fund during Calendar Years 2025–2035, under Alternative Sets of Assumptions.....	114
III.D6.— Part D Expenditures (Incurred Basis) as a Percentage of the Gross Domestic Product .....	117
IV.A1.— Components of Historical and Projected Increases in HI Inpatient Hospital Payments .....	121
IV.A2.— Comparison of Increases in HI Expenditures and Increases in Taxable Payroll .....	125
IV.A3.— Aggregate Part A Reimbursement Amounts on an Incurred Basis .....	128
IV.A4.— Summary of HI Alternative Projections .....	129
IV.B1.— Increases in Total Allowed Charges per Fee-for-Service Enrollee for Practitioner Services .....	134
IV.B2.— Incurred Reimbursement Amounts per Fee-for-Service Enrollee for Practitioner Services .....	135

*List of Tables*

IV.B3.— Increases Costs per Fee-for-Service Enrollee for Institutional Services .....	139
IV.B4.— Incurred Reimbursement Amounts per Fee-for-Service Enrollee for Institutional Services .....	140
IV.B5.— Fee-for-Service Enrollment and Incurred Reimbursement for Beneficiaries under Age 65 with End-Stage Renal Disease.....	141
IV.B6.— Aggregate Part B Reimbursement Amounts on an Incurred Basis .....	143
IV.B7.— Part D Enrollment .....	147
IV.B8.— Key Factors for Part D Expenditure Estimates .....	150
IV.B9.— Incurred Reimbursement Amounts per Enrollee for Part D Expenditures .....	152
IV.B10.— Aggregate Part D Reimbursements on an Incurred Basis .....	153
IV.B11.— Part D Assumptions under Alternative Scenarios for Calendar Years 2025–2035.....	154
IV.C1.— Private Health Plan Enrollment .....	158
IV.C2.— Medicare Payments to Private Health Plans, by Trust Fund .....	163
IV.C3.— Incurred Expenditures per Private Health Plan Enrollee.....	163
IV.C4.— Key Factors for Medicare Advantage Expenditure Estimates .....	165
V.B1.— Total Medicare Income, Expenditures, and Trust Fund Assets during Calendar Years 1970–2035.....	186
V.B2.— HI and SMI Incurred Expenditures as a Percentage of the Gross Domestic Product .....	188
V.B3.— Medicare Enrollment .....	190
V.B4.— Medicare Sources of Income as a Percentage of Total Non-Interest Income .....	191
V.B5.— Comparative Growth Rates of Medicare, Private Health Insurance, National Health Expenditures, and GDP .....	194
V.D1.— HI and SMI Average Incurred per Beneficiary Costs.....	204
V.E1.— HI Cost-Sharing and Premium Amounts .....	206
V.E2.— SMI Cost-Sharing and Premium Amounts .....	207
V.E3.— Part B Income-Related Premium Information.....	209
V.E4.— Part D Income-Related Premium Information.....	212
V.F1.— Annual Revenues and Expenditures for Medicare and Social Security Trust Funds and the Total Federal Budget, Fiscal Year 2025.....	216
V.F2.— Present Values of Projected Revenue and Cost Components of 75-Year Open-Group Obligations for HI, SMI, and OASDI .....	218
V.G1.— Unfunded HI Obligations from Program Inception through the Infinite Horizon .....	222
V.G2.— Unfunded HI Obligations for Current and Future Program Participants through the Infinite Horizon.....	223

*List of Tables*

V.G3.—	Unfunded Part B Obligations from Program Inception through the Infinite Horizon .....	224
V.G4.—	Unfunded Part B Obligations for Current and Future Program Participants through the Infinite Horizon.....	225
V.G5.—	Unfunded Part D Obligations from Program Inception through the Infinite Horizon .....	226
V.G6.—	Unfunded Part D Obligations for Current and Future Program Participants through the Infinite Horizon.....	227
V.H1.—	Statement of Operations of the HI Trust Fund during Fiscal Year 2025.....	228
V.H2.—	Statement of Operations of the Part B Account in the SMI Trust Fund during Fiscal Year 2025 .....	229
V.H3.—	Statement of Operations of the Part D Account in the SMI Trust Fund during Fiscal Year 2025 .....	230
V.H4.—	Total Medicare Income, Expenditures, and Trust Fund Assets during Fiscal Years 1970–2035 .....	231
V.H5.—	Operations of the HI Trust Fund during Fiscal Years 1970–2035.....	232
V.H6.—	Operations of the SMI Trust Fund (Cash Basis) during Fiscal Years 1970–2035 .....	234
V.H7.—	Operations of the Part B Account in the SMI Trust Fund (Cash Basis) during Fiscal Years 1970–2035 .....	235
V.H8.—	Operations of the Part D Account in the SMI Trust Fund (Cash Basis) during Fiscal Years 2004–2035 .....	236
V.H9.—	Assets of the HI Trust Fund, by Type, at the End of Fiscal Years 2024 and 2025.....	237
V.H10.—	Assets of the SMI Trust Fund, by Type, at the End of Fiscal Years 2024 and 2025.....	238

*List of Figures*

**FIGURES**

I.1.— Medicare Expenditures as a Percentage of the Gross Domestic Product under Current Law and Illustrative Alternative Projections .....	4
II.D1.— Medicare Expenditures as a Percentage of the Gross Domestic Product .....	22
II.D2.— Medicare Sources of Non-Interest Income and Expenditures as a Percentage of the Gross Domestic Product.....	24
II.E1.— HI Trust Fund Balance at Beginning of Year as a Percentage of Annual Expenditures .....	29
II.E2.— Long-Range HI Non-Interest Income and Cost as a Percentage of Taxable Payroll, Intermediate Assumptions .....	32
II.F1.— SMI Expenditures and Premiums as a Percentage of the Gross Domestic Product.....	38
II.F2.— Comparison of Average Monthly SMI Benefits, Premiums, and Cost Sharing to the Average Monthly Social Security Benefit.....	41
III.B1.— HI Expenditures and Income .....	55
III.B2.— HI Trust Fund Balance at the Beginning of the Year as a Percentage of Annual Expenditures .....	63
III.B3.— Estimated HI Cost and Income Rates as a Percentage of Taxable Payroll .....	66
III.B4.— Workers per HI Beneficiary.....	68
III.B5.— Present Value of Cumulative HI Taxes Less Expenditures through Year Shown, Evaluated under Current-Law Tax Rates and Legislated Expenditures.....	72
III.B6.— Comparison of HI Cost and Income Rate Projections: Current versus Prior Year's Reports .....	73
III.C1.— Part B Aged and Disabled Monthly Per Capita Income .....	84
III.C2.— Premium Income as a Percentage of Part B Expenditures .....	91
III.C3.— Actuarial Status of the Part B Account in the SMI Trust Fund through Calendar Year 2026 .....	99
III.C4.— Comparison of Part B Projections as a Percentage of the Gross Domestic Product: Current versus Prior Year's Reports.....	101
III.D1.— Comparison of Part D Projections as a Percentage of the Gross Domestic Product: Current versus Prior Year's Reports .....	118
V.B1.— Projected Difference between Total Medicare Expenditures and Dedicated Financing Sources, as a Percentage of Total Expenditures.....	193
V.C1.— Medicare Expenditures as a Percentage of the Gross Domestic Product under Current Law and Illustrative Alternative Projections .....	201

**STATEMENT OF ACTUARIAL OPINION**

It is my opinion that (1) the techniques and methodology used in this report to evaluate the financial status of the Federal Hospital Insurance Trust Fund and the Federal Supplementary Medical Insurance Trust Fund are based upon sound principles of actuarial practice and are generally accepted within the actuarial profession; and (2) with the important caveats noted below, the principal assumptions used and the resulting actuarial estimates are, individually and in combination, reasonable for the purpose of evaluating the financial status of the trust funds under current law, taking into consideration the past experience and future expectations for the population, the economy, and the program. I am a member of the American Academy of Actuaries and I meet the Qualification Standards of the American Academy of Actuaries to render the actuarial opinion contained herein.

There remains continued uncertainty regarding adherence to current-law payment updates, particularly in the long range. This concern is more immediate for physician services, for which payment rate updates have been low or even negative for a number of years and are projected to be below the rate of inflation in all future years. Should payment rates prove to be inadequate for any service, beneficiaries' access to and the quality of Medicare benefits would deteriorate over time, or future legislation would need to be enacted that would likely increase program costs beyond those projected under current law in this report.

For more information, I encourage readers to review the illustrative alternative projection, which provides the potential magnitude of the understatement of Medicare costs relative to the current-law projections.<sup>126</sup>

Paul Spitalnic  
Associate, Society of Actuaries  
Member, American Academy of Actuaries  
Chief Actuary, Centers for Medicare & Medicaid Services

---

<sup>126</sup>See <https://www.cms.gov/files/document/illustrative-alternative-scenario-2026.pdf>.